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Screening for large deletions in the CFTR gene by quantitative
multiplex PCR Amplification of Short Fluorescent Fragments (QMPSF)
and denaturing HPLC
M.P. Audrezet , O. Raguenes , J.M.Chen , F. Sangiuolo , G. Novelli , A.1 1 1 2 2
Ulgenalp , T. McDevitt , D. Barton , K. Giteau , C. Le Marechal , I. Quere , C.3 4 4 1 1 1
Ferec1
INSERM 0115, Genetique Moleculaire et Genetique Epidemiologique, Brest,1 ´ ´ ´ ´ ´ ´
France, Dipartimento di Biopatologica e Diagnostica per Immagini, Universita di2
Roma Tor, Roma, Italy, Department of Pediatric Genetics, Dokuz Eylul University3
Faculty of Medicine, Izmir, Turkey, National Center for Medical Genetics, Dublin,4
Ireland
Fifteen years after the discovery of the CFTR gene and the identification of more
than 1000 mutations and polymorphisms, up to 30% of the CFTR alleles remain
unidentified in some populations. The large majority of the mutations reported
throughout the 27 exons of the gene are point mutations, large deletions represent
only 1% of the mutated alleles. As they are not detectable by conventional PCR-
based techniques (the currently reported large CFTR gene deletions were identified
fortuitously either by noting an uniparental inheritance pattern or through failure to
PCR amplify target sequences), it has been suggested that such mutations could
account for a significant number of remaining unidentified alleles. We report in this
study the first systematic screening of the 27 exons of the CFTR gene for large
genomic rearrangements, by quantitative multiplex polymerase chain reaction of
short fluorescent fragments (QMPSF) and quantitative Denaturing high-perform-
ance liquid chromatography (DHPLC). A cohort of 39 CF French CF patients, 6
Italian CF patients, 40 Turkisch CF patients and 40 Irish CF patients carrying at
least one unidentified allele, after extensive and complete screening of the CFTR
gene by DHPLC, participated in this study. Using this strategy, we have been able
to characterise up to 16% of the previously unidentified CF mutant alleles, and we
report the identification and the determination of the brackpoints for six novel large
deletions in the CFTR gene.
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Searching for a Cystic Fibrosis-related gene expression pattern:
preliminary data from small-scale microarrays
L.A. Clarke , L. da Sousa , M.D. Amaral1 2 1
Department of Chemistry and Biochemistry, University of Lisbon, Lisbon, Portu-1
gal, Department of Statistics, University of Lisbon, Lisbon, Portugal2
Our aim is to identify marker genes showing robust differential expression across
a range of human Cystic Fibrosis (CF) cell lines and native tissues. We used human
starter arrays (MWG-Biotech, UK) containing 400 probes for 160 genes, to measure
differential expression in three pairs of human cell lines with one member of each
pair derived from a CF patient: CFTE-14yHBE-16 (bronchialytracheal epithelial),
6CF-SMEyCalu-3 (both bronchial sub-mucosal epithelial) and CFPACyCAPAN
(both pancreatic duct). RNA was extracted from cells and ds-DNA transcribed using
an oligo dT primer incorporating a T7 promoter site, which was then used to ampli-
fy cRNAs incorporating Cy3y5-UTPs. Labelled cRNA pairs were then mixed and
hybridized to arrays. For each cell line pair, six arrays were used (Cy3yCy5s3
arrays; Cy5yCy3s3 arrays) for statistical analysis of log ratios with a Bayesian
method using the Normal distribution. Several significantly regulated genes were
identified for each paired CF cell line, some with known roles in CF pathology.
Regulated genes common to two cell line pairs included myc, rpI29, rpI35, pcna,
tmsb10 (all up-regulated), s100a9, anxa2, asah, cd44 and mgst1 (all down-regu-
lated). Repetition of these hybridizations on genome-wide 40 K arrays is underway
and is expected to generate a short (;10–20) list of very strongly regulated genes
that may be relevant to CF pathophysiology or as markers for CF. These will ulti-
mately be used to design oligonucleotide probes for a novel magnetic sensor-based
microchip array for high throughput CF diagnosis. (Funded by EU Grant QLK3-
CT-2001-01982: ‘CF-CHIP’)
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Validation of a new line probe assay for the simultaneous detection of
36 CFTR gene mutations and the Tn variants
A. Verhelst , G. Matthijs , Ch. Verellen-Dumoulin , S. Adamis , K. De Vreese , M.1 2 3 3 1
Blaser , F. Hulstaert , I. Azzuz , J. Van Crombruggen , G. Verpooten , C. Van1 1 1 1 1¨
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The performance of the INNO-LiPA CFTR19 and the INNO-LiPA CFTR17qTn
Update for the detection and identification of 36 specified CFTR mutations and
their wild-type sequences, including the identification of a CBAVD-related poly-
morphism, was validated externally in two Belgian human genetics laboratories.
Each center selected approximately 50 samples with a known mutation profile to
be tested with the INNO-LiPA CFTR assays. Inter-lab reproducibility was evaluated
both in the centers and in-house with an identical 5-sample panel of known reac-
tivity. Concordance with conventional genotyping methods, performed manually or
using Auto-LiPA on 100 samples was 100%. Tn polymorphisms could be compared
for 51 samples, with all results identical. Interlab reproducibility at the three testing
sites was also similar. Development of the assays has aimed at avoiding cross-
reactivity with other than the specified mutations or polymorphisms in the CFTR
gene. For instance, the R117C, R347H mutations, and F508C polymorphism,
known to be present in the test samples at the centers, did not interfere or cross-
react with probes present on the strip, that detect R117H, R347P, and F508dely
I507del, respectively. Other mutations not available at the centers were evaluated
internally. All samples were correctly genotyped. In addition, DNA extracted from
a limited number of buccal brushes was successfully genotyped. In conclusion, this
study showed that the INNO-LiPA CFTR19 and INNO-LiPA CFTR17qTn Update
detect and reliably identify 36 of the most frequent CF-related mutations, as well
as the CBAVD-related Tn polymorphism in the CFTR gene region.
4*
Rapid genotyping of CFTR mutations using a primer extensionyDHPLC
assay
I. Quere, M.P. Audrezet, C. Le Marechal, C. Ferec
Laboratoire de Genetique Moleculaire, Brest, France´ ´ ´
More than 1000 mutations have now been described throughout the CFTR gene,
the majority of them being point mutations. Several commercial kits are available
to screen for the most common mutations, and technologies such as DHPLC have
been developed to identify common and new mutations. Nevertheless, laboratories
have to include in their screening strategy a second technique to confirm the muta-
tions, particularly when screening methods such as DHPLC are used. Sequencing
is the most common reference technique used, but it is time consuming and expen-
sive. In this work we described the technical conditions that we have set up to
identify the 32 most common CFTR mutations. We have combined DHPLC and
microsequencing for each point mutation. The technique was evaluated on previ-
ously genotyped samples carrying the 32 mutations and intra-laboratory reproduc-
ibility assay was performed. This technique is fast, accurate and can distinguish
between homozygotes and heterozygotes for all the mutations tested. This assay
can easily be developed to allow analysis of new mutations. The cost of the assay
and the time spend to get the results have been compared with other techniques.
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Using real-time (Taqman) RT-PCR to measure gene expression – a
core facility of the UK Cystic Fibrosis Gene Therapy Consortium
R.L. Smith, H. Painter, D.R. Gill, S.C. Hyde
GeneMedicine Research Group, NDCLS John Radcliffe Hospital, University of1
Oxford, Oxford, United Kingdom, The United Kingdom Cystic Fibrosis Gene Ther-2
apy Consortium, Oxford, United Kingdom
Gene therapy for cystic fibrosis has been predominantly aimed at correcting the
chloride ion transport defects in the lung epithelia. Mouse and sheep lung models
are widely used to assess the effectiveness of a variety of gene transfer vectors and
to test delivery methods to be used in the clinic (e.g. bronchoscopy, aerosolization,
etc.). Testing in these animal models requires a sensitive, fast and accurate way of
measuring gene transfer. Routine protein expression studies using reporter genes
have proved of limited use due to the sensitivity required to detect low levels of
expression that may still be therapeutic. At the John Radcliffe Hospital in Oxford,
we have established a Core Testing Service using the ABI7700 Sequence Detector
(Taqman) to quantify vector delivery (DNA) and gene expression (mRNA).
Measurement of gene transfer using the reverse transcriptase polymerase chain reac-
tion (RT-PCR) in real time with the Taqman can be performed in a range of pre-
clinical and patient samples including blood, tissue biopsies, airway brushings and
bronchial washings. Samples are collected in RNAlater stabilization solution
(Ambion), transported to the core facility and the RNA extracted using the
RNEasy mini kit (Qiagen). A reverse transcriptase step is performed, and the
resultant cDNA amplified using the Taqman instrument. An endogenous gene is
analyzed simultaneously and the quantitative result normalized to the endogenous
expression level. The sensitivity of the assay is 10 target RNA molecules in 100ng2
of RNA, with intra-assay variability typically less than 2%. RT-PCR in real time is
a reliable and sensitive method to assess gene transfer efficiency and is recom-
mended as an end-point assay for clinical assessment of gene transfer.
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The role of insertion sequences in the genomic plasticity of the
Burkholderia cepacia complex
D.T. Kenna , H. Yesilkaya , K.J. Forbes , V.A. Barcus , J.R.W. Govan1 2 2 1 1
University of Edinburgh, Edinburgh, United Kingdom, University of Aberdeen,1 2
Aberdeen, United Kingdom
The Burkholderia cepacia complex (Bcc) currently comprises nine genomic species
(genomovars). Although strains from each of these genomovars have been isolated
from patients, the majority of infections in CF patients are caused by B. cenocepacia
and B. multivorans. The reasons for this disparity are unclear and knowledge about
virulence factors of the Bcc is limited. Little work has been done on the potential
contribution insertion sequences (IS) might have on the pathogenicity and diversity
of these bacteria, particularly following the recent species expansion. This project
aimed to establish the prevalence of three IS (IS402, IS407 and IS1416) which
possess the ability to activate transcription, and hence influence gene expression.
Resulting data revealed that all three IS are prevalent across the genomovars,
although IS402 was absent from the seventeen B. ambifaria strains tested. Likewise
IS1416 was more prevalent in genomovars VII to IX, and rare in isolates from
genomovars I to VI. IS407 was absent from the nine B. pyrrocinia isolates tested.
Heminested inverse PCR was used to determine the genomic insertion sites of IS407
in seven strains (two B. cenocepacia strains, one strain each of B. multivorans, B.
stabilis, B. vietnamiensis and B. anthina, and one from the potential tenth geno-
movar, B. ubonensis). Comparisons between IS407 flanking sequence and the San-
ger Centre J2315 whole genome sequence revealed considerable DNA sequence
variability in some of these strains, while others remained highly conserved. This
study suggests that the abundance and distribution of these IS is likely to affect
diversity, and potentially gene transcription and virulence.
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Differential expression of the multidrug resistance-associated protein 1
in isogenic CF and non-CF human bronchial epithelial cells
C. Cigana , M. Pasetto , E. Nicolis , B.M. Assael , P. Melotti1 2 1 1 2
Cystic Fibrosis Center-Azienda Ospedaliera di Verona, Verona, Italy, Italian Cys-1 2
tic Fibrosis Research Foundation, Verona, Italy
Homologous proteins share related functions eventually supporting functional com-
plementations. Multidrug Resistance Protein 1 (MDR1) is a member of the ATP
binding cassette superfamily which includes CFTR. Co-ordinate regulation of CFTR
and MDR1 genes in CF knockout mice has been described as well as complemen-
tary patterns of epithelial expression in a large variety of human tissues. Focusing
on closer members of this superfamily as multidrug resistance-associated protein 1
(MRP1) and CFTR we hypothesized that the former could be up-regulated in the
presence of a CFTR defect. This work was aimed to determine whether MRP1 is
differentially expressed in isogenic CF versus non-CF cells. To address this question
we utilized human bronchial epithelial IB3-1 cells derived from a CF patient and
C38 cells, the corrected cell line. We determined MRP1 mRNA levels by quanti-
tative real-time PCR. MRP-1 protein expression was analyzed by flow cytometry.
We found that CF cells express higher levels of MRP1 mRNA than non-CF. A 2.5
fold of induction has been detected in CF versus non-CF cells (ns7, Ps0.0084).
In order to investigate the functional relevance of this regulation we analyzedMRP1
protein levels: no differences of MRP1 protein expression levels were detected
between the two isogenic cell lines. We concluded that higher MRP1 mRNA levels
in CF versus non-CF cells may not be sufficient for induction of protein expression
levels. Investigating endogenous mechanisms responsible for the described up-reg-
ulation of MRP1 mRNA in CF cells as well as the mechanisms of MRP1 transla-
tional regulation might suggest strategies for inducing functional MRP1 able to
compensate CFTR defect. Supported by Italian Cystic Fibrosis Research Foundation
and Azienda Ospedaliera di Verona-Italy.
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Modulating genes in CF and COPD disease
J. Yarden , D. Radojkovic , R. Vlietinck , A. Vankeerberghen , H. Nuytten , C. De1 1 1 1 1
Boeck , C. Nackaerts , M. Jr Milan , V. Vavrova , D. Zemkova , O. Scudiero , F.2 3 4 4 4 5
Salvatore , J.-J. Cassiman , H. Cuppens5 1 1
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Pediatrics, UZ Gasthuisberg, Leuven, Belgium, Department of Pulmonology, UZ3
Gasthuisberg, Leuven, Belgium, School of Medicine, Charles University, Prague,4
Czech Republic, University of Naples Frederico II, Naples, Italy5
CF patients display a wide range of disease severity, which cannot be attributed to
the CFTR genotype alone. So far, MBL, GSTM1, GSTM3, GSTP1, TNFa,
TGFb , nitric oxide synthase, and angiotensin I converting enzyme have been1
claimed to modulate CF disease. In order to conclude that a gene is a true CF
modulator, it is a prerequisite to confirm the modulator effect of each gene in at
least one different population. Moreover, it would be of interest to study the effect
of the different CF modulators in a single ethnic population. The association study
described here was performed in Belgian and Czech F508delyF508del CF patients.
Also Belgian COPD patients, with a special focus on emphysema, were studied.
Apart from the genes mentioned above, hBD1, hBD2, hBD3, hBD4, the a-ENaC
subunit, the b-ENaC subunit, the g-ENaC subunit, surfactant proteins A1 and A2,
the b2-adrenergic receptor, IL8, IL10, syntaxin 1A, syntaxin 8, NHERF1, NHERF2,
CAP70, the a1-subunit of AMPK and the a2-subunit of AMPK were studied. In
COPD patients, an involvement was found for MBL, SP-A2, TNFa and TGFb1.
Preliminary statistical analysis shows an involvement of MBL, SP-A2, TNFa,
TGFb1, GSTM1, and possibly interleukin 8 and interleukin 10 in CF disease. For
many genes that have been reported to modulate CF disease, no association could
be confirmed in this study. No modulating effect was seen in CF patients for pro-
teins that directly interact with CFTR. For MBL and TNFa, which both were found
to be involved in CF and emphysema, opposite effects were seen. Altogether, the
modulator effect of genes in CF and COPD disease is very complex. Apart from
the finding of modulating genes, this study provides a framework for future asso-
ciation studies of modulating genes in genetic diseases such as CF.
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CD14 C-159T and age at first isolation of Pseudomonas aeruginosa in
children with cystic fibrosis
A.C. Martin , S. Brennan , I.A. Laing , M.L. Cox , S.-K. Khoo , J. Goldblatt , P.N.1 2 1 1 1 1
LeSouef1
School of Paediatrics and Child Health, University of Western Australia, Perth,1
Australia, Institute of Child Health Research, Perth, Australia2
Introduction: Cystic fibrosis (CF) is a single gene disorder that exhibits considerable
phenotypic variability, not entirely explained by allelic heterogeneity of CFTR
mutations. It is hypothesised that this phenotypic diversity is largely due to epistatic
factors. CD14 is a receptor for lipopolysaccharide, a constitutive element of the
P.aeruginosa cell wall. The C allele of a promoter polymorphism (C-159T) was
associated with lower levels of soluble CD14 in healthy children. We hypothesise
that children with the –159CC genotype will acquire P.aeruginosa at an earlier age.
Aim: To identify potential associations of CD14 C-159T with age of first isolation
of P.aeruginosa in children with CF. Methods: Population: Children with CF aged
¯less than 7 years, who have undergone annual bronchoscopy and bronchoalveolar
lavage. Genotyping: DNA was extracted from whole blood. Ava II restriction digest
of PCR products spanning the CD14 C-159T polymorphism was performed.
Results: Thirty-nine children (16 male), aged 0.5-6.3 years (mean 3.0 years) were
studied. CD14 genotype frequencies at position -159 were: CC 23%, CT 49%, TT
28%. There was no significant difference in CFTR genotype frequencies between
C-159T genotype groups. P.aeruginosa was isolated from nine children (23%). The
mean age of first isolation was 2.0 yrs. The mean age of first isolation of
P.aeruginosa for children with –159TT and CT was 2.81 yrs (95%CI 1.65-3.97,
ns6), whereas those with –159CC had a mean age at first isolation of 0.80 yrs
(95%CI 0.49–1.09, ns3, Ps0.017). CD14 –159CC was associated with earlier
first isolation of P.aeruginosa in this population of children with CF. Conclusion:
The CD14 C-159T polymorphism may play an important role in determining the
age of first isolation of P.aeruginosa.
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The CFTR 3849H10kbC-)TyDeltaF508 genotype is usually associated
with a milder phenotype
I. Dugueperoux , G. Bellis , M. De Braekeleer1 2 1´ ´
Faculte de Medecine & CHU Morvan, Brest, France, Institut d’Etudes Demo-1 2´ ´ ´
graphiques, Paris, France
Since 1992, 40 patients carrying at least one copy of the 3849q10kbC-)T muta-
tion have been registered in the French cystic fibrosis (CF) registry. Among them,
27 were 3849q10kbC-)TyDeltaF508. Sixteen, seen in 2000, were matched on
sex, age and CF care centre to DeltaF508 homozygotes. Mean age in both groups
was 19.6 years wrange: 7–47x; 10 were older than 15 years. Mean age at diagnosis
was 12.7 years versus 3.1 years (Ps0.02). All 3849q10kbC-)TyDeltaF508
patients, but one, had respiratory problems at diagnosis (Ps0.01), but only one
had diarrhoea (Ps0.03) and none meconium ileus (Ps0.03). The mean sweat test
chloride values was close to normal in the (mean: 67.9 versus 110.4; P-0.0001).
The anthropometric values were similar in both groups. Although only borderline
significant, the lung function was better in the 3849q10kbC-)TyDeltaF508 group
(FEV1 83.0% and FVC 91.6% of predicted values) than in the DeltaF508 homo-
zygotes group (FEV1s59.9% and FVC 77.0% of predicted values). DeltaF508y
3849q10kbC-)T had a lower morbidity than their matched homozygotes (Ps
0.01). No compound heterozygote had liver cirrhosis, nor mellitus diabetes, and
only 2 had nasal polyposis. Enzymatic intake was required for 46.6% of the 3849q
10kbC-)Ty DeltaF508 versus 100% of the DeltaF508yDeltaF508 patients (Ps
0.002). Since 1994, 5 of the 16 compound heterozygotes had had children.
Although the prevalence of pathogens was similar in both groups, the 3849q
10kbC-)T allele confers a milder CF phenotype. We thank the participating centres
to the French CF Registry. Ingrid Dugueperoux is the recipient of a post-doctoral´ ´
fellowship from ‘Vaincre la Mucoviscidose’. This research was supported by ‘Vain-
cre la Mucoviscidose’.
11*
Are the Y1092X and R1162X stop mutations, both located in the
transmembrane segment 11, associated with different phenotypes?
I. Dugueperoux , G. Bellis , M. De Braekeleer1 2 1´ ´
Faculte de Medecine & CHU Morvan, Brest, France, Institut National d’Etudes1 2´ ´
Demographiques, Paris, France´
The localisation and nature of the CFTR mutations are known to be determining
in the cystic fibrosis (CF) phenotype. As part of a genotypeyphenotype study, we
were interested in 2 stop mutations (Y1092X, R1162X) located in the membrane
spanning domain 11. Thirteen patients carrying the R1162XyDeltaF508 genotype
and 14 the Y1092XyDeltaF508 genotype were seen in a CF care centre in 2000
(mean age: 12.5 and 12 years respectively, Ps0.88). Mean age at diagnosis was
13.0 and 24.6 months respectively. A higher proportion of patients carrying the
R1162X allele than those with the Y1092X mutation were diagnosed because of
respiratory problems (46.2% versus 28.6%). All 14 Y1092XyDeltaF508 and 11 of
13 R1162Xy DeltaF508 patients were pancreatic insufficient. Anthropometric val-
ues of R1162Xy DeltaF508 patients were higher than those of Y1092XyDeltaF508
patients (including a BMI of 18.0 compared to 16.4, Ps0.054). Lung function was
also better: FEV1s77.2% and FVCs84.9% for the R1162XyDeltaF508 patients
compared to FEV1s57.8% and FVCs67.3% for the Y1092XyDeltaF508 patients.
Two Y1092XyDeltaF508 patients had liver cirrhosis. A lower proportion of patients
carrying the R1162X allele than those with the Y1092X mutation had intravenous
antibiotics (23.1% versus 64.3%, Ps0.03). Although some of the differences were
large, none reached statistical significance (P)0.05), possibly because of the small
series analysed. More patients need to be studied to determine whether these 2 stop
mutations located in the same membrane spanning segment lead to somewhat dif-
ferent phenotypes. We thank the participating centres to the French CF Registry.
Ingrid Dugueperoux is the recipient of a post-doctoral fellowship from ‘Vaincre la´ ´
Mucoviscidose’. This research was supported by ‘Vaincre la Mucoviscidose’.
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A novel CFTR gene mutation P1290S in a Portuguese patient with
congenital bilateral absence of the vas deferens
A. Grangeia , F. Carvalho , S. Fernande , J. Silva , M. Sousa , A. Barros1 1 1 2 3 1
Dept Genetics, Fac Medicine, Univ Porto, Porto, Portugal, Centre Reproductive1 2
Genetics A Barros, Porto, Portugal, Lab Cell Biol, Inst Biomed Sci Abel Salazar,3
Porto, Portugal
Aim: We report a novel cystic fibrosis transmembrane conductance regulator
(CFTR) gene missense mutation in a Portuguese compound heterozygote patient
without cystic fibrosis (CF) and infertile due to congenital bilateral absence of the
vas deferens (CBAVD). Methods: Screening of 31 frequent CFTR gene mutations
was performed with a commercial kit. The whole CFTR gene analysis was per-
formed by Denaturing Gradient Gel Electrophoresis (DGGE), followed by direct
sequencing. The poly-T variants of intron 8 (IVS8-T) were also analysed. Results:
A novel CFTR gene mutation was identified by DGGE and direct sequencing in a
CBAVD heterozygote patient for 3272-26A™G mutation (7Ty9T for IVS8-T). The
novel mutation, P1290S, leads to the nucleotide change C to T at position 4000 in
exon 20 and results in an amino acid substitution. The mutations were identified
in the parents, revealing that they are located on different chromosomes of the
patient. To rule out the possibility of P1290S being a polymorphism, 218 normal
chromosomes from healthy Portuguese males, 10 from classical CF patients, 30
from carrier of a CFTR mutation and 64 from CBAVD patients were analysed and
the T allele was not detected. Conclusion: The P1290S missense mutation resides
in the NBD2 of CFTR protein. Since ATP hydrolysis at NBD2 terminates a burst
of activities associated with opening of the channel, the alteration in amino acid
sequence might change the ATP-dependent regulation, confering a loss of the gating
control. Furthermore, as the 1290 codon occurs in a highly conserved CFTR region,
the P1290S missense mutation might have a deleterious effect on protein function
and thus be pathogenic. In the present patient the CBAVD phenotype can thus be
explained by the association of both mutations.
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Isolated severe nasal polyposis in a CF patient carrying a complex
CFTR genotype
M.N. Feuillet-Fieux , G. Lenoir , I. Sermet , M. Ferrec , L. Thuillier , J.P.1 2 2 1 1
Bonnefont3
Hopital Necker-Enfants Malades, Laboratorie de Biochemie B, Paris, France,1 ˆ
Hopital Necker-Enfants Malades, Service de Pediatrie Generale, Paris, France,2 ˆ ´ ´ ´
Hopital Necker-Enfants Malades, Service de Genetique Medicale, Paris, France3 ˆ ´ ´ ´
The wide range of CF clinical symptoms frequently involved the sinonasal cavity.
Usual manifestations include chronic and recurrent sinusitis, and nasal polyposis of
varying degrees. Prevalence of nasal polyposis has been estimated to be 20 to 30%
in a CF paediatric group (Triglia JM, et al. Laryngoscope 1997;107:963–6), and
about 18% of European CF patients require medical or surgical therapies on such
a clinical context (Di Cicco M et al. 25th CF conference, Vienne, 2001 Abs. 138).
Few genotype-phenotype correlations are available, compared to those involving
lung and pancreatic disease. We report on the case of a 19-year-old man from South
of France, whose massive severe nasal polyposis was the only symptom of CF and
required 3 surgical operations. CF was confirmed by a positive sweat test (70
mmolyl). The CFTR gene was entirely screened for mutations by DGGE-sequenc-
ing of all exons and flanking intronic regions. This patient was shown to carry a
complex genotype consisting of 4 heterozygous mutations, namely: (i) 1609C)T
(exon 10, Q493X), previously reported in 2 homozygous CF patients with pancre-
atic insufficiency, mild lung disease, and high sweat chloride; (ii) 3149C)A (exon
17a, A1006E) already reported in one CF chromosome; (iii) 1816G)A (exon 12,
V562I) the deleterious effect of which on CFTR function is still a matter of debate;
and (iv) IVS8 5T associated in cis with the last two mutations on the maternal
chromosome. Such a haplotype associating 5T in cis with a second mutation has
previously been reported in patients with non classic CF. Two additional polymor-
phisms were present at homozygous state in exons 14a (2694T)G, T854T) and
24 (4521G)A, Q1463Q). This report suggests that other genetic andyor environ-
mental factors could be involved in the protection against multi-organ involvement
in this individual. This study was supported by Association Mucoviscidose ‘ABCF
proteins’.
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Mutations of the cystic fibrosis gene in children with chronic
pancreatitis
G. Oracz , B. Oralewska , A. Sobczynska-Tomaszewska , K. Czerska , M.1 1 2 2
Teisseyre , J. Socha , J. Bal1 1 1
Gastroenterology, Hepatology and Immunol; Children’s Memorial Health Institute,1
Warsaw, Poland, Department of Medical Genetics, National Research Institute of2
Mother and Child, Warsaw, Poland
Objectives: Recently an association between chronic pancreatitis and gene muta-
tions, i.e. PRSS1, CFTR and SPINK1, was identified. The aim of our study was to
assess prevalence of CFTR gene mutations in children with chronic pancreatitis y
CPy. Methods: All children with chronic pancreatitis (CP) hospitalized since 1998
to 2003 were enrolled into the study. Clinical and epidemiological data were record-
ed and analyzed. All children were screened for the 30 most common CFTR gene
mutations and for the 5T allele in intron 8 of the CFTR gene. Results: 80 children
(36 boys and 44 girls) with CP were hospitalized. Mean age was 10.4 years (range:
3 to 19 years). 9 CFTR gene mutations were found in 8 children: delF – 4 alleles,
5T variant – 4 alleles, dele2,3 (21 kb) – 1 allele. In 3 patients were found CFTR
and coexisting SPINK1 or PRSS1 gene defects: 2 patients with delFy- (CFTR) and
N34Sy- (SPINK1) genotype, 1 patient with 5Ty- (CFTR) and R122Cy- (PRSS1)
genotype. Family history was positive in 2 cases (20%). In two patients with delFy
- we found pancreas divisum. Conclusions: Our data demonstrate the need for
genetic testing in children with idiopathic chronic pancreatitis In the CP group
deltaF508 mutation is 2.5 times more frequent then in normal population.
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The CFTR 2789H5G-)A allele: a mutation associated with a milder
cystic fibrosis phenotype
I. Dugueperoux , G. Bellis , M. De Braekeleer1 2 1´ ´
Faculte de Medecine & CHU Morvan, Brest, France, Institut National d’Etudes1 2´ ´
Demographiques, Paris, France´
Most of the CFTR mutations are rare. The French cystic fibrosis (CF) registry
offers an opportunity to study the genotype-phenotype relationship of these rare
alleles. Since 1992, 88 patients carrying one copy of the 2789q5G-)A mutation
have been seen at least once in a CF care centre. Among them, 61 were 2789q
5G-)Ay DeltaF508. Thirty-four, seen in 2000, were matched on sex, age and CF
care centre to DeltaF508 homozygotes. Mean age in both groups was 26.3 years.
Mean age at diagnosis was 16.6 years versus 4.5 years (Ps0.0001). No 2789q
5G-)Ay DeltaF508 patient had meconium ileus (Ps0.01). At diagnosis, com-
pound heterozygotes had less often diarrhoea (Ps0.001) or growth retardation (Ps
0.03), but more often nasal polyposis (Ps0.02). 59.4% of the 2789q5G-)Ay
DeltaF508 patients were pancreatic insufficient versus 96.9% of the DeltaF508y
DeltaF508 (Ps0.0002). The body mass index was higher, although not signifi-
cantly, among compound heterozygotes than DeltaF508 homozygotes (20.2 versus
18.8). Mean FEV1 was significantly higher (75.4 vs. 59.1% of predicted value,
Ps0.03). 2789q5G-)Ay DeltaF508 patients were less colonised by Pseudomonas
aeruginosa (P-0.0001), but had more Staphylococcus aureus (Ps0.003). None
has had cirrhosis (Ps0.01) or mellitus diabetes since 1994. In conclusion, the
2789q5G-)A allele is associated with a milder CF phenotype including delayed
diagnosis, less gastrointestinal involvement, better anthropometric and pulmonary
measures and life expectancy. We thank the participating centres to the French CF
Registry. Ingrid Dugueperoux is the recipient of a post-doctoral fellowship from´ ´
‘Vaincre la Mucoviscidose’. This research was supported by ‘Vaincre la
Mucoviscidose’.
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Genotypeyphenotype correlation in a family with complex genotype
T. Repetto , C. Centrone , E. Pelo , G. Taccetti , S. Farina , F. Torricelli1 2 2 1 1 2
Cystic Fibrosis Centre of Tuscany,Meyer Hospital,University of Florence, Florence,1
Italy, Cytogenetic and Genetics Unit,Careggi Hospital, Florence, Italy2
We were asked by a 36-year-old brother of a CF patient to detect his carrier status.
We studied his genotype and found he is compound hetrozigous for 3659delCy
L997F. The sweat test was borderline (chloride 66 mEqyL). He has been suffering
of chronic sinusitis and had ‘primary’ spontaneous pneumothorax at age of 35, no
other respiratory symptoms. Tc lung scanner showed apical pleural blebs, no other
abnormalities and lung function tests are normal. He has pancreatic sufficiency and
normal seminal fluid. His CF brother genotype is F508 dely3659delC; he is 33 and
has a classical CF phenotype with pancreatic insufficiency, Ps lung infection and
liver disease. They have a sister who also presented spontaneous pneumothorax.
Their mother died at the age of 43 because of undefined chronic respiratory prob-
lems. We studied the family genotype: the father is a carrier for F508del; and the
sister is compound heterozigous for 3659delCyL997F. The polymorphisms to obtain
the family aplotype are: M470V in the exon 10, 3121-92A12y13, 3123 GyC in the
exon 17a. The results of this study allowed us to define the mutations present in
the brother and in the sister as a TRANS mutation, and to detect the mother gen-
otype as a F508delyL997F compound heterozigous. The 3659delC is a frameshift
mutation in the exon 19 identified in in a pancreatic insufficient patient. The L997F
is a missense mutation with G-)C substitution at 3123 in the exon 17a. The muta-
tion was observed in 1996 in a 5-year-old North Indian boy, with a borderline sweat
chloride value. The presence in this family of 4 subjects with heterozigous com-
pound genotype, one with F508dely3659delC, two with 3659delCyL997F, and one
with F508dely3659delC genotype, can explain the diversity of the phenotype.
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CFTR mutations in a heterogeneous Cystic Fibrosis (CF) population in
Minas Gerais, Brazil
P.V.T. Vidigal, F.J.C. Reis, L.A.C. de Marco, M.B.M. Bedran, G. Brasileiro Filho
Federal University of Minas Gerais-UFMG, Belo Horizonte, Brazil
Introduction: A three base-pair deletion (CTT) of codon 508 (phenylalanine) of
CFTR gene is the most prevalent mutation associated with Cystic Fibrosis (CF),
its prevalence varying from 26% among Turkish patients to 88% in Denmark and
53% among Caucasian Brazilian CF patients. Objectives: Evaluate the prevalence
of DF508 in an ethnically heterogeneous CF patients diagnosed in Minas Gerais
(Brazil). Methods: Blood DNA samples from 94 patients of different ethnical
groups were amplified by polimerase chain reaction method (PCR) using specific
primers to exon 10 of the CFTR gene. The PCR product was then analyzed by
automatic sequencing. Results: Among the 94 patients, 68 did not show DF508
mutation in exon 10 and 22(23.4%) presented DF508 (13 of them were homozy-
gous for DF508), with an allelic frequency of 0.19. Four patients have shown a
three base-pair deletion (TTT) of codon 508, mutation described for the first time,
which confers to these patients the same phenotype of DF508, with a different
genotype. Conclusion: The low prevalence of DF508 described here may be
explained by the Amerindian, Caucasian and Black admixture that ocurred in this
population that will, probably, show other rare mutations. Knowing the mutation
pattern of the Brazilian population is important to improve CF screening and molec-
ular diagnosis, which could contribute to the early diagnosis, adequate treatment
and to enhance life expectancy of CF patients.
19*
Frequency of ocurring of the 3849H10kb C)T mutation in Polish CF
patients is significantly higher than in most of other populations
K. Czerska, A. Sobczynska-Tomaszewska, J. Bal
National Research Institute of Mother and Child, Warsaw, Poland
The 3849q10kb C)T mutation belongs to the group of splicing CFTR gene
defects. It creates a partially active splice site in intron 19 that can lead to the
insertion of a new 84-bp cryptic exon containing an in-frame stop codon. This
mutation has been found to be associated with a milder form of disease manifes-
tation. Patients carrying this mutation in one allele are characterised by: better
nutritional status, older age of onset, normal or slightly elevated chloride values (in
comparison to homozygotes for delF508 mutation). Till now there have been 30
CF patients genotyped in our laboratory who have 3849q10kb C)T mutation in
at least one allele of CFTR gene. There are 26 patients in this group with genotype:
3849q10kb C)T y delF508. There are also two patients who are homozygotes
for 3849q10kb C)T mutation, whose clinical data are being currently collected.
They are members of two unrelated families. This genotype is very rare in Poland
and in the world. In case of the other patients second mutation has been also
identified. 5 patients are carriers of this mutation in one allele and any other muta-
tion in second allele has not been found. Mutation 3849q10kb C)T is found in
Polish population with frequency of 3,9% of CF alleles which places this mutation
at second position after delF508 (53%). In comparison to the frequency in world
population (0,2%) it‘s significantly higher score. That is why the identification of
this mutation is a part of the routine diagnostics provided by our laboratory.
20*
Preimplantation Genetic Diagnosis in couples with a " or $ risk for a
child with Cystic Fibrosis
K. Keymolen , M. De Rijcke , V. Goossens , K. Boelaert , M. Bonduelle , A. Van1 1 1 1 1
Steirteghem , P. Devroey , I. Liebaers2 2 1
Center for Medical Genetics AZ VUB, Brussels, Belgium, Center reproductive1 2
Medicine Az VUB, Brussels, Belgium
Preimplantation genetic diagnosis (PGD) is an early form of prenatal diagnosis,
designed to prevent the birth of an affected child without the burden of a termination
of pregnancy. After in vitro fertilization, genetic analysis with simplex or duplex
polymerase chain reaction (PCR) is done on one or two blastomeres, obtained by
embryo biopsy and only ‘healthy’ embryos are transferred. Between January 1992
and December 2002 our Center performed 90 PGD cycles for 47 couples with an
increased risk for a child with CF. In 11 couples the man had congenital bilateral
absence of vas deferens (CBAVD) and the wife was healthy carrier of one CFTR
mutation; in 33 couples both partners were healthy carriers and in 3 couples one
partner was CF patient while the other was a healthy carrier. In the 90 cycles 1127
Cumulus Oocyte Complexes (COC) were retrieved and for 921 COC’s intracyto-
plasmatic sperm injection (ICSI) was performed, resulting in 461 biopsied embry-
o’s. In 72 cycles an embryo transfer was done leading to 23 positive HCG
screenings, 27 fetal sacs (6 twins and 15 singletons) and 25 positive fetal heart
beats (5 twins and 15 singletons). Fifteen singleton and 5 twin pregnancies ended
in the delivery of 25 liveborn children. This gives a delivery rate of 22.2% per
cycle; 27.8% per embryotransfer and 42.5% per couple. For 16 children PGD was
confirmed by pre- or postnatal DNA analysis or sweat test. Conclusion: PGD is an
option for couples at increased risk for having a child with CF, giving them the
opportunity to have a healthy child. PGD can be offered to couples of healthy
carriers as well as to couples with a CBAVD or CF patient. Success rates of PGD
in CF are comparable with those for other monogenic diseases.
21*
Detection of CF heterozygosity in echogenic bowel: should we be
concerned?
M.J. Schwarz, G.M. Malone, H. Shaw, J. Hinks, E. Inglis
Molecular Genetics, Royal Manchester Children’s Hospital, Manchester, United
Kingdom
The presence of echogenic bowel detected on ultrasound investigation during preg-
nancy can be associated with cystic fibrosis, as well as a number of other disorders
such as chromosome aneuploidy. An increased frequency of heterozygotes has also
been observed, although no explanation for this has been offered. We have inves-
tigated over 150 cases of echogenic bowel and have detected cystic fibrosis (2
mutant alleles) in four of these. In addition, F508del heterozygosity has been
observed in 7 instances; heterozygosity for I148T and R117H has also been
observed. An unsuspected finding was the presence of particular polymorphisms:
5 instances of 1716G)A and 2 of G576A. Since both of these are known CFTR
splicing variants and are seen in certain CFTR-related disorders, this was an intrigu-
ing discovery, suggesting that their presence in echogenic bowel is significant. Fur-
thermore, as these polymorphisms do not give rise to classical cystic fibrosis, their
presence has profound implications for genetic counselling. If they can provide an
explanation for echogenic bowel, while not causing cystic fibrosis, their presence
would actually reduce the risk of CF. We suggest, therefore, that echogenic bowel
pregnancies should not only be tested for common cystic fibrosis mutations, but
also known associated variants.
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A database for knowledge of pedigrees and genotypes of CF patients
and their parents in France
L. Gueganton , G. Bellis , A. Chaventre , G. Rault1 2 3 1´ ´
Centre of Perharidy, Roscoff, France, Institut National d’Etudes Demographiques,1 2 ´
Paris, France, Laboratoire d’anthropologie et de demographie genetiques, Univ.3 ´ ´ ´
Victor Segalen, Bordeaux, France
‘To give years to life and life to years’, the CF health network in western regions
of France gave itself the means to implement an action plan. The 1 plan involvedst
about 15 projects around 3 themes: screening, diagnosis and therapeutic evaluation
for young children; care and public health; epidemiology, anthropology and impact
studies. Our database will be used to support actions included in these themes. It
will enable us to improve: the contents of a patient’s medical file; the duty of
personalized genetic council; the methods of information and psychological support;
the knowledge about populations concerned with CF. Collected data relate to a
patient’s identity; his date and place of birth, marriage and death; his parents’
identities; mutations transmitted by his 2 parents; links between all individuals
listed. Elements that can be extracted from data are: family reconstitutions of 1st
generations (for medical file and genetic council); ascending pedigrees (for fami-
lies); anonymized family trees (for informative support); other bases of indirectly
personal coded data (basic material for research). Sources of data are (after patient’s
information and consent): interview with a patient; research in his medical file;
investigation of laboratories in charge of blood analysis; information contained in
his family record book; consultation of the civil status registers. Any recorded
individual has a right of access, correction and opposition on his family tree and
on his genetic data. Safety measures guarantee data protection. We were granted an
authorization from the Computer and Liberty National Committee in January 2004,
therefore we are starting data exploitation now. Our database concerns only patients
of western regions of France. Nevertheless, it should be widened to all french
patients.
CFTR / Cell
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Three-dimensional architecture of human CFTR as deduced from
sequenceystructure analysis
I. Callebaut , R. Eudes , J.P. Mornon , P. Lehn1 1 1 2
CNRS UMR7590, Paris, France, INSERM U458, Paris, France1 2
We have recently proposed a three-dimensional (3D) model at the atomic level of
the NBD1yNBD2 heterodimer formed by the human CFTR nucleotide-binding
domains (NDB) . Our approach was based on a detailed and sensitive sequencey1
structure analysis of NBDs from several ABC proteins of known 3D structure. The
model highlights the specific features of the CFTR asymmetric active sites located
at the interface between the two NBDs. Moreover, additional CFTR-specific features
could be identified at the subunit interface, which may play critical roles in the
active site interdependence and are uncommon in other NBD dimers. Our model is
also in good agreement with recent experimental data, in particular the very recently
solved structure of the NBD1 subunit of mouse CFTR . We have also used the2
same sensitive methods of sequence analysis, especially Hydrophobic Cluster Anal-
ysis (HCA), to investigate the membrane spanning and R domains for which no
structural data is yet available. Altogether, our work may allow to better understand
the normal functioning of CFTR, to get new insights into the phenotypeygenotype
relationships of some mutations and, eventually, also permit the rational design of
CFTR-specific drugs for pharmacological treatment of CF.
1. Callebaut I, Eudes R, Mornon JP, Lehn P. Cell. Mol. Life Sci 2004; 61:230-42.
2. Lewis HA et al. EMBO J 2004 23:282-93.
Work supported by the association ‘‘Vaincre La Mucoviscidose‘‘ (Paris, France).
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CFTR is present in membrane microdomain lipid rafts
S. Huang , T. Dudez , L. Wiszniewski , S. Suter , B. Stanton , M. Chanson1 1 1 1 2 1
Geneva University Hospitals, Geneva, Switzerland, Dartmouth Medical School,1 2
Hanover, United States
In addition to function as a Cl channel, CFTR exhibits a variety of pleiotropic
effects. We have recently shown that CFTR is required for c-Src dependent regu-
lation of gap junction channels in airway epithelial cells exposed to TNF-alpha. To
understand the molecular mechanisms that link CFTR to gap junctions, we inves-
tigated whether CFTR is present in cholesterol-enriched membrane microdomain
lipid rafts. Lipid rafts, which serve as platforms for efficient signal transduction in
a number of systems, have been shown to contain c-Src. Soluble and microdomain-
containing non-soluble fractions of proteins were extracted from MDCK cells
expressing GFP-tagged CFTR and subjected to Western blots. CFTR was detected
in non-soluble fractions using antibodies against CFTR or GFP. Quality of the
preparation was confirmed by the detection of lipid raft markers, such as caveolin-
1, flottilin-1, and the tyrosine kinases c-Src and c-Yes. Biotinylation experiment
showed that most of the glycosylated CFTR is localized in lipid rafts. The amount
of CFTR in lipid rafts was reduced by extraction of cell surface cholesterol with
cyclodextrin and increased by depolymerization of actin filaments with latrunculin.
This suggests that CFTR-containing lipid rafts are dynamic structures stabilized by
the cytoskeleton. Finally, the presence of CFTR in lipid rafts was also confirmed
in primary cultures of human airway epithelial cells. These data indicate that CFTR
is localized in specialized, higher order of membrane structures, the lipid rafts,
which may represent a molecular basis for the pleiotropic effects of CFTR in epi-
thelial cells. Supported by Vaincre la Mucoviscidose and the Swiss National Science
Foundation.
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Relationship between CFTR Cl channel function in native humanI
colon, genotype and phenotype in cystic fibrosis
T. Gonska , S. Hirtz , H.H. Seydewitz , J. Thomas , P. Greiner , J. Kuehr , M.1 1 1 1 1 1
Brandis , I. Eichler , H. Rocha , A.I. Lopes , C. Barreto , M.D. Amaral , K.1 2 3 4 4 5
Kunzelmann , M. Mall6 7
Department of Pediatrics and Adolescent Medicine, Albert Ludwigs University,1
Freiburg, Germany, Department of Pediatrics and Adolescent Medicine, University2
of Vienna, Vienna, Austria, Hospital Maria Pia, Porto, Portugal, Department of3 4
Pediatrics, Hospital de Santa Maria, Lisboa, Portugal, Department of Chemistry5
and Biochemistry,University of Lisboa, Lisboa, Portugal, Institute of Physiology,6
University of Regensburg, Regensburg, Germany, Cystic Fibrosis Research and7
Treatment Center, University of North Carolina, Chapel Hill, United States
Background & Aims: Cystic fibrosis (CF) is caused by over 1000 mutations in the
CFTR gene and presents with a widely variable phenotype. Genotype-phenotype
studies identified CFTR mutations that were associated with pancreatic sufficiency
(PS). Residual Cl channel function was demonstrated for selected PS mutationsy
in heterologous cells. However, the functional consequences of most CFTR muta-
tions in native epithelia are not well established. Methods: To elucidate the rela-
tionships between epithelial CFTR function, CFTR genotype, and patient
phenotype, we measured cAMP-mediated Cl secretion in rectal biopsies from 45y
non-deltaF508 homozygous CF patients carrying a wide spectrum of CFTR muta-
tions. We compared CFTR genotypes and clinical manifestations of CF patients
who expressed residual CFTR-mediated Cl secretion with CF patients in whomy
Cl secretion was absent. Results: Residual anion secretion was detected in 40%y
of CF patients who carried at least one missense or splice mutation, and was asso-
ciated with later disease onset (P-0.0001), higher frequency of PS (P-0.0001)
and less severe lung disease (P-0.05). Clinical outcomes correlated with the mag-
nitude of residual CFTR activity, which was in the range of;12–54% of controls.
Conclusions: Specific CFTR mutations confer residual CFTR function to rectal
epithelia, which is closely related to a mild disease phenotype. Conversely, our data
give no evidence for intestinal Ca -activated Cl channels as disease modifiers2q y
in CF. Quantification of rectal CFTR-mediated Cl secretion may be a sensitivey
test to predict the prognosis of CF disease and identify CF patients who may benefit
from therapeutic strategies that increase residual CFTR activity.
28*
Rescue of functional CFTR-DF508 protein by overexpression of the
NHE-RF protein in A549 cells
Amal Robay, Gilles Toumaniantz, Jean Merot, Chanta Gauthier´
INSERM U533, Nantes, France
In cystic fibrosis (CF), the anterograde trafficking of CFTR-DF508 (DF508) from
the endoplasmic reticulum to the plasma membrane is inefficient. Identification of
strategies for increasing delivery of DF508 to the apical membrane is important for
the treatment of CF. Recent studies have demonstrated that PDZ domains play an
essential role in determining protein trafficking and polarised targeting. The NHE-
RF protein, which contains two PDZ domains, can bind the C-terminus of CFTR.
In our study, we have hypothesised that overexpression of NHE-RF protein might
increase apical membrane expression of DF508. For this, the plasmids encoding
DF508 and NHE-RF were intranuclearly co-injected in A549 cells. DF508 activity
was functionally assayed using SPQ fluorescent probe. The DF508 stimulation was
performed by the application of 10 mM forskolin (Fsk). Cells injected with DF508
alone presented very low chloride permeability. Conversely, the overexpresion of
NHE-RF protein increased the basal DF508 permeability to halides by two-folds.
The activation of DF508 by Fsk was also increased by six-folds (ns19, P-0.001).
Activation of DF508 by Fsk was abolished by injection of antisens oligonucleotides
of NHE-RF mRNA. The specificity of this antisens was checked by the use of a
sens oligonuclotide of NHE-RF mRNA that didn’t affected the stimulation of
DF508 activity by Fsk in the presence of an overexpression of NHE-RF. Similar
results were obtained in polarised cells, MDCK. These studies showed that a mod-
ification in expression level of CFTR proteins partners, like NHE-RF, resulted in a
rescue of DF508 activity.
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Rme-1 Regulates CFTR Recycling
J.A. Picciano, N. Ameen, B.D. Grant, N.A.
Bradbury University of Pittsburgh School of Medicine, Pittsburgh, United States
Endocytic motifs in the carboxyl terminus of CFTR direct its internalization from
the plasmalemma clathrin mediated endocytosis. However, the fate of internalized
CFTR has remained unknown. Internalized membrane proteins can be either tar-
geted for degradation or recycled back to the plasma membrane. We show that
CFTR undergoes constitutive endocytosis and recycling back to the plasma
membrane. Expression of dominant-negative Rme-1 (a protein which regulates exit
from the endosomal recycling compartment) in CFTR expressing cells results in
the expansion of recycling compartments. Transferrin, a marker for the endosomal
recycling compartment, and CFTR, accumulate in these enlarged recycling endo-
somes. Such accumulation leads to a loss of cell surface CFTR as it is prevented
from being recycled back to the cell surface. In contrast, traffic of the LDL is
unaffected by the expression of dominant negative Rme-1. In addition, chimeras
containing the extracellular domain of the transferrin receptor and the carboxyl
terminal tail of CFTR also enter Rme-1 regulated recycling compartments and accu-
mulate in these compartments containing dominant negative Rme-1, suggesting that
in addition to endocytic signals, the carboxyl terminal tail of CFTR also contains
intracellular trafficking information. In contrast to wt CFTR, DF508 CFTR does
not enter recycling compartments. Thus the cell surface stability of ‘‘corrected
DF508 CFTR may be compromised by its inability to recycle following endocytosis
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The identification of surrogate gene markers of CFTR activity and CF
lung inflammation using microarrays
V. Ogilvie , S. Webb , J.R. Dorin , A.C. Boyd , D.J. Porteous2,3 1 1 2,3 2,3
MRC Human Genetics Unit, University of Edinburgh, Edinburgh, United Kingdom,1
Medical Genetics Section, University of Edinburgh, Edinburgh, United Kingdom,2
UK Cystic Fibrosis Gene Therapy Consortium, United Kingdom3
The development of surrogate assays for measuring both CFTR functionality and
the inflammatory status of the CF lung is important for validation of CF gene
therapy (CFGT) procedures. The aim of this work is therefore to identify genes
expressed differentially between CF and healthy respiratory tissue, as these genes
are most likely to be affected by CFTR activity. In this study, we used the G480C
mouse model of CF as this mutation shares several characteristics with DF508.
Microarray analysis was performed on lung tissue isolated from 5 age-matched
normal and G480C mice using a 5000 gene mouse developmental cDNA array. The
data generated were analysed by GenePix and Acuity software. Log-normalised data
revealed that 30 genes were significantly differentially expressed by more than 1.5-
fold in the CF lung; including several relevant cytokines and ion channels, such as
TGF-beta 1, voltage-gated sodium channel and TIMP3. Interestingly, Thrombos-
pondin 1 expression appears to be switched off in G480C mouse lung tissue. This
protein is required for wound repair and resolution of inflammation. QRT-PCR and
protein assays are being carried out to validate these results and further microarray
analysis is proposed for gene transfer studies in the mouse to correlate the expres-
sion of these genes with WT CFTR expression. Assays will be developed for select-
ed markers and used to complement the more established assays used in pre-clinical
and clinical CFGT studies. We hope, thereby, to be able to monitor the efficacy of
CFGT more accurately and sensitively.
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Glycosylation and Calnexin in the ER Quality Control of CFTR
C.M. Farinha , L. Reis , D. Penque , M.D. Amaral1 1 2 1
Department of Chemistry and Biochemistry, Faculty of Sciences, University of1
Lisboa, Lisboa, Portugal, Centre of Human Genetics, National Institute of Health,2
Lisboa, Portugal
Calnexin (CNX), described to form complexes with both wt- and F508del-CFTR,
has been the most often implicated in endoplasmic reticulum (ER) retention and
degradation (ERAD) of F508del-CFTR. We have looked at the effect of glucosy-
lation and of CNX binding on the turnover and processing of CFTR. Pulse-chase
assays followed by CFTR immunoprecipitation were performed in cells after treat-
ment with castanospermin (CAS) that prevents interaction with CNX or 1-deoxy-
mannojirimycin (DMM) an inhibitor of mannosidases, prevents trimming of outer
mannose residues thus enhancing CNX binding. For wt-CFTR, the proportion of
band B observed after treatment with these compounds is significantly higher than
the proportion of mature protein observed without treatment, indicating that each
of these compounds is effectively stabilizing wt-CFTR. However, for F508del-
CFTR only a slight stabilization was observed after treatment with DMM. Results
were also confirmed by using the mannosidase inhibitors swainsonine and kifunen-
sine. CNX downregulation, by an RNAi approach, only impaired wt-CFTR proc-
essing, with no effect on F508del-CFTR. Studies with in vitro mutagenized CFTR
lacking the consensus glycosylation sites are in progress. Our results suggest that
CNX-mediated ERAD occurs for both wt- and F508del-CFTR, but it seems that
F508del-CFTR also undergoes ERAD through an alternative degradative pathway
or at an earlier (pre-CNX) point of the same pathway. The enhancing alpha-man-
nosidase-like protein (EDEM) is probably involved in this process as suggested by
co-IP experiments.
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Cx30, a newly detected gap junction protein expressed in the ciliated
human airway epithelium
L. Wiszniewski , J. Sanz , L. Jornot , I. Scerri , T. Dudez , S. Lacroix , S. Suter ,1 2 1 1 1 1 1
S. Gallati , M. Chanson2 1
Geneva University Hospitals, Geneva, Switzerland, Children’s Hospitals, Bern,1 2
Switzerland
Gap junctions play key roles for tissue homeostasis, differentiation and response to
the environment. The functional expression of gap junction proteins (connexins,
Cx) was investigated in primary cultures of human airway epithelial cells. In sub-
merged cultures, the expression of Cx26, Cx30 and Cx43 was detected by immu-
nofluorescence and Western blots. Microinjection of the fluorescent dye Lucifer
Yellow revealed extensive gap junctional communication (GJC). Exposing the cul-
tures to air induced differentiation to a pseudostratified epithelium. This was asso-
ciated with virtually loss of Cx43 expression and marked decrease in the extent of
dye coupling. Whereas weak transfer of Lucifer Yellow was observed between basal
cells, no diffusion of the fluorescent dye was detected in ciliated cells. In contrast,
neurobiotin, a tracer of lower MW, diffused extensively between ciliated cells. To
evaluate whether Cx expression in primary cultures was comparable to that observed
in vivo, quantitative RT-PCR was performed on samples from human nasal mucosa
brushes. Again, mRNAs for Cx26, Cx30 and Cx43 were detected. Finally, confocal
microscopy of immunolabeled mouse airways revealed a basal localisation of Cx26,
a broader distribution of Cx30 and absence of Cx43. Because Cx30 allows cell-cell
diffusion of neurobiotin but not Lucifer Yellow, we suggest that Cx30 is a newly
detected gap junction protein expressed in ciliated airway epithelial cells. The data
also indicate that connexins are differentially regulated during the differentiation of
human airway epithelial cells, leading to the establishment of compartments of GJC
within the respiratory mucosa. Supported by Vaincre la Mucoviscidose and the
Swiss National Science Foundation.
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A new model of polarized human airway epithelium in primary culture
L. Wiszniewski , L. Jornot , T. Dudez , A. Pagano , S. Suter , S. Lacroix , T.1 1 1 2 1 1
Rochat , M. Chanson1 1
Geneva University Hospitals, Geneva, Switzerland, Geneva Medical School,1 2
Geneva, Switzerland
We have established a new model of polarised human airway epithelium. Airway
cells were isolated from nasal biopsies and seeded onto 24-mm diameter micro-
porous membranes carrying on their undersurface a preformed feeder layer of post-
mitotic human airway fibroblasts. Under submerged conditions, the feeder layer
stimulated proliferation of epithelial cells, as confirmed by Ki67 immunolabeling,
allowing the expansion of the cell pool with successive passages. Cells were then
seeded onto 6.5-mm porous supports undercoated with fibroblasts for 48 hours
before the apical surface was exposed to air. Under these conditions, proliferation
ceased and differentiation occurred. A pseudostratified epithelium characterized by
the presence of basal, secreting and columnar ciliated cells was obtained within
20–30 days, as revealed by electron microscopy. The epithelium was polarized, as
indicated by confocal immunodetection of occludin at the tight junctions, apical
CFTR, basolateral Na, K-ATPase and basal AQP3. Differentiated ciliated cultures,
as visualized by immunolabeled tubulin, were maintained for up to 3 months. Uss-
ing chamber measurements indicated bioelectric properties of a tight epitheliumwith
characteristics of both Na absorption and Cl secretion. These properties were
observed in epithelia generated from passage 0 to 4 airway cells. Thus, airway
fibroblasts support the expansion and differentiation of respiratory epithelial cells,
permitting to generate cultures from starting material with low yield of cells such
as nasal scraping or bronchial brushing. This new model is therefore suitable for
studies aimed at investigating dysfunction of the CF airway epithelium. Supported
by Vaincre la Mucoviscidose and the Swiss National Science Foundation.
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Levels of normal CFTR mRNA in non-CF individuals and CF patients
with mild disease
A.S. Ramalho , C. Barreto , H. Rocha , V. Serra , D. Penque , P. Pacheco , P.1 2 3 3 1 1
Loureiro , M. Mall , M.D. Amaral1 4 5
Centre of Human Genetics, National Institute of Health, Lisboa, Portugal, Hos-1 2
pital de Santa Maria, Lisboa, Portugal, Hospital Maria Pia, Porto, Portugal,3
Universitats-Kinderklinik Freiburg, Freiburg, Germany, Department of Chemistry4 5¨
and Biochemistry, Faculty of Sciences, University of Lisboa, Lisboa, Portugal
Cystic Fibrosis (CF) can be caused by a class of CFTR mutations that result in
reduction of the levels of normal CFTR transcripts (previously class V, now class
I). For CF therapies aimed at restoring lung function by increasing these levels
(e.g. gene therapy), it is important to determine the threshold of normal CFTR
mRNA levels that is sufficient to avoid CF. The objective of the current study is
to determine this threshold, namely in individuals who carry a polymorphismy
mutation causing substantial reduction of normal CFTR mRNA levels, but still do
not have CF. By using a recently developed method (1), CFTR transcripts from
nasal and colonic epithelia were quantitatively analysed in a group of non-CF indi-
viduals and CF patients with mild disease, carrying polymorphismsygene variants
that result in skipping of exons 9 or 12, namely: T5 in intron 8 (ns4) or the
missense mutation G576A (ns5), respectively (2,3). In one CF individual with
T5, the percentage of full-length transcripts is ;6%, and a carrier (father of a CF
child) it is ;10%. The latter figure should be very close to the threshold of normal
CFTR transcripts level necessary and sufficient to avoid CF. Transepithelial cAMP-
and carbachol-induced Cl secretion was also determined in rectal biopsies fromy
some of these patients, using a perfused micro Ussing chamber. Ramalho et al
(2002) Am J Resp Cell Mol Biol 27, 619–627; Chu et al (1991) EMBO J 10 1355–
1363; Pagani et al (2003) Hum Mol Genetics 12, 1111–1120. Supported by POC-
TIy1999yMGIy35737 and ASR is a recipient of PhD fellowship SFRHyBDy3085y
2000.
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Rescue of cystic fibrosis mutations in the first nucleotide-binding
domain by mutation of arginine-framed ER retention signals
M. Roxo-Rosa , C.M. Soares , Z. Cai , D.N. Sheppard , D. Penque , M.D.1 3 4 4 1
Amaral2
Centro de Genetica Humana, Instituto Nacional de Saude Dr Ricardo Jorge, Lis-1 ´ ´
boa, Portugal, Department of Quımica e Bioquımica, Faculdade de Ciencias,2 ´ ´ ˆ
Universidade de Lisboa, Lisboa, Portugal, Instituto de Tecnologia Quımica e Biol-3 ´
ogica, Universidade Nova de Lisboa, Oeiras, Portugal, Department of Physiology,4´
School of Medical Sciences, University of Bristol, Bristol, United Kingdom
R560T, A561E and V562I are CF mutations, located within the first nucleotide-
binding domain (NBD1) of CFTR, between the signature and Walker C motifs, at
a region that constitutes a hotspot for CF mutations . Using biochemical assays, we1
demonstrated that R560T and A561E disrupt the processing of CFTR protein. In
contrast, V562I seems to be more efficiently processed than wild-type CFTR.
Simultaneous mutation to lysines of the endoplasmic reticulum (ER) retention sig-
nals (RXR triplets) present in CFTR (R29, R516, R555 and R766; designated 4RK)
promotes the maturation of F508del-CFTR . Based on these data, we tested whether2
the 4RK mutant rescues the trafficking of the above processing mutations. Like
F508del, A561E-CFTR is reverted, whereas R560T-CFTR is apparently not. Inter-
estingly, V562I-CFTR seems to be stabilised even further by the 4RK mutant. To
learn how mutation of arginine-framed ER retention signals alters CFTR processing,
we are analysing our data using a comparative model for the NBD1-NBD2 dimer.
In this model, R560, A561 and V562 span the lower half of the D8 a-helix of
NBD1, not far from the ATP binding site of NBD2. In other studies, we are inves-
tigating the role of V562I as a chloride channel, as well as how the 4RK revertants
affect the function of these CFTR processing mutants. The results of our studies
might suggest new approaches to therapy for CF patients. 1 http:yy
www.genet.sickkids.on.caycftry; 2 Chang, et al (1999) Molecular Cell, 4, 137–
142. Supported by POCTIy1999yMGIy35737, POCTIyMGIy47382y2002 and CF
Trust grants and PRAXIS BDy19869y99 doctoral fellowship (MRR).
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Differential sensitivity of the CF mutants G551D and G1349D to CFTR
potentiators
Z. Cai , A. Taddei , D.N. Sheppard1 2 1
Department of Physiology, University of Bristol, Bristol, United Kingdom, Labor-1 2
atorio Genetica Molecolare, Istituto Gaslini, Genoa, Italy
The fluorescein derivative phloxine B potentiates wild-type and DF508 CFTR
Cl channels by prolonging channel open-time. To learn whether phloxine B poten-y
tiates other CF mutants, we studied G551D and G1349D, two identical missense
mutations found in NBD1 and NBD2, respectively. As a control, we studied pyro-
phosphate (PP ), an inorganic phosphate analogue that robustly potentiates wild-i
type CFTR Cl channels. We used excised inside-out membrane patches with they
external solution containing 10 mM Cl and internal solution containing 147 mMy
Cl , 1 mM ATP and 75 nM PKA at 37 8C; voltage was y50 mV. G551D andy
G1349D Cl channels were characterised by prolonged closures separating shorty
bursts of channel openings (ns6–12). Both phloxine B (1 mM) and PP (5 mM)i
potentiated strongly the activity of G551D by 284"61 and 295"42%, respectively,
(ns5; P-0.05). In contrast, at these concentrations phloxine B and PP were with-i
out effect on G1349D (ns3–8). Different from the stimulatory effects of phloxine
B on G551D (ns5), the increase in burst duration only accounted partially for
PP potentiation of G551D (control, MBDs65"21 ms; PP (5 mM), MBDsi i
81"21 ms; ns5; P-0.05). Interestingly, the stimulatory effects of PP and phlox-i
ine B on G551D were additive (ns3), suggesting that they might act at different
sites. Our results indicate that G551D and G1349D have distinct pharmacological
profiles. They also suggest that future therapy for CF is likely to be mutation
specific. (Supported by the CF Trust (UK) and TeleThon (Italy)).
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Acidic pH regulates the ATP-dependence of CFTR channel gating
J.H. Chen, Z. Cai, D.N. Sheppard
Department of Physiology, University of Bristol, Bristol, United Kingdom
Gating of the cystic fibrosis transmembrane conductance regulator (CFTR) is pri-
marily controlled by ATP binding and hydrolysis at two nucleotide-binding domains
(NBDs). We previously demonstrated that acidic intracellular pH (pHi) alters CFTR
gating to increase open probability (Po). To investigate this effect of acidic pHi,
we studied wild-type and mutant CFTR using excised membrane patches. The
pipette (external) solution contained 10 mM Cl at pH 7.3. The bath (internal)y
solution contained 147 mM Cl at either pH 6.3 or 7.3, PKA (75 nM) and MgATPy
(0–10 mM) at 37 8C. At each pHi, the relationship between Po and wMgATPxi
(ns6–7) was best fit by a Michaelis-Menten function. However, at pH 6.3 the Km
value was decreased compared with that at pH 7.3 (pH 6.3, Kms36 mM; pH 7.3,
Kms90 mM), while the maximum Po (Pomax) was increased (pH 6.3, Pomaxs
0.71; pH 7.3, Pomaxs0.61). These data suggest that acidic pHi might alter both
the ATP affinity and ATPase activity of the NBDs. To study ATP binding, we used
Mg2q-free solutions that abolish ATPase activity. Under these conditions, Po was
greatly decreased at pH 7.3, but less reduced at pH 6.3 (ns5–6; P-0.05). More-
over, acidic pHi failed to enhance the activity of the CFTR mutant K1250M, which
disrupts the ATPase function of NBD2 (pH 7.3, Pos0.32"0.05; pH 6.3, Pos
0.21"0.02; ns5; P-0.05). These data suggest that acidic pHi might enhance
channel gating by promoting ATP binding to the NBDs. They also suggest that the
ATP binding sites of CFTR likely contain pH-sensitive amino acid residues. Sup-
ported by the CF Trust and the University of Bristol.
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The effect of artificial anion transporters on transepithelial ion
transport
L.K. Hughes , H. Li , J.-B. Joos , J.P. Clare , A.L. Sisson , A.V. Koulov , T.N.1 1 2 2 2 3
Lambert , R. Shukla , M. Jain , J.M. Boon , D.N. Sheppard , B.D. Smith , A.P.3 3 3 3 1 3
Davis2
Department of Physiology, University of Bristol, Bristol, United Kingdom, School1 2
of Chemistry, University of Bristol, Bristol, United Kingdom, Department of Chem-3
istry & Biochemistry & Walther Cancer Research Center, University Notre Dame,
Notre Dame, United States
One strategy to bypass the loss of cystic fibrosis transmembrane conductance reg-
ulator (CFTR) function in cystic fibrosis is to stimulate alternative Cl channelsy
already present in epithelial tissues. Another possibility is to insert artificial Cly
transporters into the apical membrane to mimic the role of CFTR. In previous work,
we demonstrated that a novel family of steroid-based anion receptors termed ‘cho-
lapods’ are capable of Cl efflux across phospholipid membranes in artificial lipo-y
somes (Angew. Chem. Int. Ed. 42, 4931; 2003). To test the effects of cholapods on
transepithelial ion transport, we studied MDCK epithelia expressing endogenous
CFTR and FRT epithelia expressing recombinant wild-type human CFTR as model
systems. We used the Ussing chamber technique to study transepithelial ion trans-
port imposing a Cl gradient across epithelia (wCl x , 148 mM andy y basolateral
wCl x , 14.8 mM). Addition of cholapod RS1 (80 mM) to the apical membraney apical
of epithelia activated an increase in short-circuit current (I ) in both cell linessc
without any other stimulation and without causing a large fall in transepithelial
resistance (MDCK, DI 7.1"1.8 mAycm ; ns4; P-0.05; similar results obtained2sc
for FRT epithelia). The peak of the RS1 response was transient, but RS1 generated
a sustained I . The cholapod-generated current was Cl dependent and was distinctysc
from that induced by activators of native Cl channels. We interpret our data toy
suggest that RS1 generates Cl dependent transepithelial ion transport. Supportedy
by the CF Trust, EPSRC and Royal Society.
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The effect of S-nitrosoglutathione on chloride transport in cystic
fibrosis airway cells
Z. Servetnyk , B. Gaston , G.M. Roomans , A. Dragomir1 2 1 1
Department of Medical Cell Biology, University of Uppsala, Uppsala, Sweden,1
Department of Pediatrics, University of Virginia School of Medicine, Charlottes-2
ville, VA, United States
S-nitrosoglutathione (GSNO) is an endogenous NO donor levels of which are
decreased in the airways of cystic fibrosis (CF) patients. GSNO has been shown
to increase maturation of CFTR in CF cell lines. The effect of GSNO on mutated
CFTR was investigated in the bronchial epithelial cell line CFBE (homozygous for
DF508) and in the submucosal airway gland cell line CFSME (heterozygous for
DF508). Immunocytochemistry and confocal microscopy of CFTR showed that
GSNO treatment (60 mM for 4 h, with changes of GSNO every 30 min) increased
the amount of apically localized protein. Studies of chloride transport by X-ray
microanalysis showed that GSNO treatment significantly increased both basal chlo-
ride efflux and efflux in the presence of the CFTR activators forskolin and IBMX.
Chloride transport studies with the fluorescent dye N-(ethoxycarbonylmethyl)-6-
methoxyquinolinium bromide (MQAE) showed that GSNO treatment increased the
cAMP-dependent efflux rate from 0.26"0.04 to 1.1"0.15 mMys in CFBE cells
and from 0.25"0.06 to 0.6"0.18 mMys in CFSME cells. After GSNO treatment,
basal efflux increased proportionally with cAMP-activated chloride efflux. Basal
efflux was sensitive to both DIDS (unspecific blocker of chloride channels other
than CFTR) and glibenclamide (specific blocker of CFTR), consistent with the idea
that GSNO can both correct the trafficking defect and activate the DF508-CFTR
protein. Taken together, our data and the fact that endogenous GSNO levels are
lower in the airways of CF patients make GSNO an interesting candidate for phar-
macological treatment of CF.
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Inhibition of proliferation and apoptosis in response to oxidative stress
in normal and CF airway epithelial cells
E. Boncoeur, A. Clement, J. Jacquot, A. Henrion-Caude
INSERM E213, Hopital St-Antoine, Paris, France, Hopital Trousseau, Paris,1 2ˆ ˆ
France
Cystic fibrosis is associated with an imbalance in the concentrations of lung oxi-
dants and antioxidants. Evidence of increased oxidative stress in CF airways sug-
gests that reactive oxygen species may overwhelm antioxidant defences. This work
was done to document the regulation of proliferation and susceptibility to apoptosis
in response to oxidative stress in normal (Beas-2B) and CF airway epithelial cells
(IB3-1). Exposure of both cell lines to hyperoxia (95%O y5%CO ) for 24 and 482 2
h revealed increasing amount of intracellular production of reactive oxygen species
as assessed by a dual fluorescent staining approach using MitoTracker and dihy-
drorhodamine. In normal and in CF cells, we could observe a similar inhibition of
proliferation evaluated by cell count that was further documented as an arrest in S
phase by FACS analysis (50% of cells in S phase after 48 hours of exposure). In
Beas-2B cells, this growth arrest was associated with the induction of the cyclin
dependent kinase inhibitor 1A, CDKN1A, which was unexpectedly down-regulated
in IB3-1 cells. Since CDKN1A is also implicated in apoptosis, we sought to char-
acterize apoptosis in response to hyperoxia both in Beas-2B and IB3-1 cells. After
48 h of hyperoxic exposure, we observed apoptosis in Beas-2B cells with a char-
acteristic DNA ladder and an increased immunostaining of active caspase 3. In
contrast, IB3-1 cells appeared to be less sensitive to oxidative stress-induced apop-
tosis than Beas-2B. These results indicate that CF airway epithelial cells are less
prone to undergo apoptosis after injury by oxidative stress and implicate CDKN1A
in this increased resistance. This work was supported by a grant and a scholarship
to EB from Vaincre La Mucoviscidose.
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Proteome analysis of human nasal cells
M. Roxo-Rosa , G. da Costa , T. Luider , B.J. Scholte , A.V. Coelho , M.D.1 3 4 5 3
Amaral , D. Penque2 1
Centro de Genetica Humana, Instituto Nacional de Saude Dr Ricardo Jorge, Lis-1 ´ ´
boa, Portugal, Department of Quımica e Bioquımica, Faculdade de Ciencias,2 ´ ´ ˆ
Universidade de Lisboa, Lisboa, Portugal, Instituto de Tecnologia Quımica e Biol-3 ´
ogica, Universidade Nova de Lisboa, Oeiras, Portugal, Biomics Center, Erasmus4´
University Rotterdam, Rotterdam, Netherlands, Department of Cell Biology, Eras-5
mus University Rotterdam, Rotterdam, Netherlands
In order to identify proteins that are differentially expressed by respiratory cells of
CF patients and non-CF controls, we are analyzed total protein extracts of nasal
cells from those individuals by two-dimensional (2D) electrophoresis. Nasal brush-
ing is a non-invasive method that allows the easy sampling of numerous, well
preserved and dissociated cells from the superficial respiratory mucosa that is rep-
resentative of the respiratory epithelium . The 2D-maps of nasal brushing samples1
isolated from non-CF individuals (ns9) were found to be reproducible and con-
sistent, thus allowing the generation of a 2D reference map that can be used as
control for 2D-maps of CF patients. The most representative proteins in these 2D-
maps were identified by mass spectrometry: some are ubiquous proteins, such as
a- and b-tubulin, b-actin, and Hsc 70. Additionally, proteins exclusively expressed
in epithelial cells were identified in these samples. Examples are: cytokeratins 8
and 19, SCCA1 (Squamous cell carcinoma antigen 1) and Plunc protein (with a
described role in the airway inflammatory response to exposure to irritants). Com-
parison of these 2D-maps with those from CF patients (F508delyF508del) is cur-
rently underway. Changes in 2D-gel patterns may suggest the involvement of novel
proteins in CF pathophysiology and potential therapeutic targets.
Penque D et al (2000) Lab Invest 80, 857-868.
Work supported by POCTIy1999yMGIy35737 and POCTIyMGIy40848y2001
research grants. MRR is a recipient of PRAXIS BDy19869y99 doctoral fellowship.
GC is a recipient of FCTyFEDER doctoral fellowship.
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Nasal airway ion secretion and lung function in patients with cystic
fibrosis: preliminary results
T. Leal , I. Fajac , P. Lebecque , C. Knoop , J. Dall’ Ava , D. Dusser , D.1 2 1 3 2 2
Hubert , J. Cumps , P. Wallemacq2 1 1
Universite Catholique de Louvain, Brussels, Belgium, Rene Descartes University,1 2´ ´
Paris, France, Universite Libre de Bruxelles, Brussels, Belgium3 ´
The aim of this work was to examine the correlation between airway ion transport
abnormality, as determined by nasal transepithelial potential difference (PD), and
severity of CF. Nasal PD was measured under the inferior turbinate in a group of
50 CF patients (26 males: 24 females; mean age 25.6 year, range 15–39) homo-
zygous for DF508. The stable maximal baseline PD (PDmax) was lower in patients
scoring above average FEV for their age (y46.5"2.1; n: 13) than in those scoring1
below average FEV (y54.9"3.9; n: 17; P: 0.05). Patients without Pseudomonas1
aeruginosa (PA) colonization (n: 18) revealed a significant difference in the mag-
nitude of chloride efflux across the cell after perfusion with a zero chloride solution
containing 10 M amiloride and 10 M isoprenaline when compared with thosey4 y5
patients colonized by PA (n: 32; SDCl: y4.4"0.8 and y1.2"1.1; P: 0.028). A
significantly lower PDmax and a more preserved chloride conductance was seen in
patients displaying body mass index (BMI) higher than 18.5 kgym (n: 34) in2
comparison to those displaying BMI below 18.5 kgym (n: 15). A positive corre-2
lation between lung function, as represented by FEV %pred, and the degree of1
chloride conductance was seen in more severely affected patients displaying both
FEV below average for age and PA colonization (r: 0.5; P: 0.04 on Pearson’s1
correlation). We can conclude that the measurements of nasal PD may give an
insight into CF prognosis. Nevertheless, other factors may influence the degree of
respiratory involvement in CF. This study was supported by the French CF Asso-
ciation, Vaincre la Mucovisidose, and the Belgian CF Association.
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X-ray microanalysis of apical surface liquid in cystic fibrosis and
normal bronchial epithelial cell cultures
I. Kozlova, H. Nilsson, G.M. Roomans
Department of Medical Cell Biology, University of Uppsala, Uppsala, Sweden
The ionic composition of the ASL in cystic fibrosis (CF) patients and under normal
conditions has been debated. Two techniques were developed to measure the ele-
mental composition of the surface liquid in cell cultures. CFBE41o andy
16HBE14o cell lines were grown on membrane inserts in both a liquid–liquidy
interface culture system for 7 days, and in air–liquid interface culture system for
one month. The liquid-liquid culture was then covered with a 200 mm thick layer
of phosphate-buffered saline (PBS), which was left for 24 h. The culture on the
membrane insert, including the liquid layer covering it, was then rapidly frozen,
transferred in the frozen state to a scanning electron microscope (SEM) equipped
with a cold stage and analysed by X-ray microanalysis. Alternatively, both for the
liquid–liquid interface and the air–liquid interface cultures, dextran beads were
placed on the apical surface of the cells and left to equilibrate with the surface
liquid for 20 min. The beads were dried and then subjected to X-ray microanalysis
in the SEM. Both techniques showed that the apical fluid in the cell culture was
hypotonic and that Na and Cl concentrations in the fluid were about half those in
PBS. X-ray microanalysis also showed that the apical fluid in CF cell cultures had
a significantly higher concentration of Na, Cl and K than the control. This agrees
with the notion that the cells investigated have ion-absorptive properties, but that
absorption in CF cells is deficient.
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Composition of airway surface liquid in mouse trachea
I. Kozlova, H. Nilsson, M. Phillipson, G.M. Roomans
Department of Medical Cell Biology, University of Uppsala, Uppsala, Sweden
The ionic composition of airway surface liquid (ASL) has been debated. In partic-
ular, for the mouse, a wide range of values has been published. Two techniques
were developed to measure the elemental composition of the ASL. In the first
technique, mouse trachea was rapidly frozen, transferred to the cold stage of a
scanning electron microscope, and analyzed by X-ray microanalysis in the frozen
state. In the second technique, dextran beads (Sephadex) were placed on top of the
epithelium, left to equilibrate with the AS, dried and subjected to X-ray microa-
nalysis. Both techniques showed that mouse ASL has significantly lower concen-
trations of Na and Cl (approx. 60–80 mM) than serum. Analysis of frozen hydrated
trachea gave higher values for P, S and K than analysis of dextran beads, because
the former method analyzes the entire mucus layer including mucus and cell debris
(rich in P, S and K), whereas the latter analyzes the watery component of the ASL.
Pilocarpine stimulation significantly reduces the ion concentrations in the ASL. X-
ray microanalysis of frozen-hydrated trachea showed that CFTR (yyy) mice have
significantly higher concentrations of Na, Cl, K and Ca in their ASL, but no dif-
ference in Mg, P and S compared to control. The hypotonic composition of mouse
ASL is in contradiction to our earlier results in the pig, where ASL was shown to
be isotonic. The difference may be related to the well-known differences in airway
wall histology and physiology between these two species, mice having fewer sub-
mucosal glands than pigs.
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In vivo immunodetection of human CFTR in human, ovine and mouse
epithelial cells
H.E. Davidson, A. Wilson, G. McLachlan, C. Payne, G. MacGregor, A. Doherty,
T. Wodehouse, D. Collie, A.C. Boyd, D.J. Porteous
Medical Genetics Section, University of Edinburgh, Edinburgh, United Kingdom,1
Comparative Respiratory Medicine, University of Edinburgh, Edinburgh, United2
Kingdom, Department of Gene Therapy, Imperial College, London, United3
Kingdom
Reliable immunodetection of human CFTR (hCFTR) in primary airway cells
remains challenging. However, optimisation of the technique is crucial to our pro-
gramme of developing endpoint assays for gene therapy trials. We report progress
in optimising hCFTR immunodetection in human, sheep and mouse backgrounds.
Human: Freshly brushed (;60% viability) and fixed HNE cells were stained for
apically localised hCFTR protein with 11 antibodies (Abs). Of the 11 Abs, the
polyclonal G449 and the monoclonal (mAb) MATG1061 were the most reliable.
The percentages of cells with detectable apical localisation of CFTR were, according
to genotype, 50–60% (qyq), 11–25%(DFyDF), and 27% (DFyA455E). In dou-
ble labelling experiments, using G449 and MATG1061 Abs (raised to different
CFTR domains), results indicate that the same cells are positive for both antibodies.
This gives us confidence that we are not scoring false positives. Sheep: Two anti-
bodies, G449 and the mAb MATG1104, did not cross react with sheep CFTR.
Studies on mixtures of human and sheep nasal epithelial cells showed that detection
of apical hCFTR was possible even at a 1% proportion of HNE cells. We delivered
hCFTR by in vivo transfection (efficiency;0.088%) to a sheep trachea and detect-
ed hCFTR with G449 in a blinded experiment. Mouse: Out of three polyclonal Abs
tested in mice transgenic for a human genomic CFTR PAC construct, Lis1 Ab
detected hCFTR protein in embryos, lung, intestine, ovary and testes. Conclusion:
We now have the basis for developing optimal hCFTR immunohistochemical assays
for each of the three species.
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Pseudomonas aeruginosa adherence to murine nasal epithelium
T. Wodehouse , R. Farley , B. Wainwright , D.M. Geddes , J.C. Davies , E.W.F.W.1 1 2 1 1
Alton1
Department of Gene Therapy at Imperial College London, UK CFGT Consortium,1
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Much of the morbidity and mortality seen in cystic fibrosis (CF) is related to
chronic infection of the respiratory tract with Pseudomonas aeruginosa (Pa). Some
studies have attributed this to the presence of increased numbers of specific cell-
surface receptors on the CF respiratory epithelium. Pa adherence is increased in CF
as compared to non-CF human nasal epithelium and is reduced after CFTR gene
therapy. Murine nasal epithelium is often used for the assessment of novel thera-
peutic agents including gene therapy. We therefore investigated whether Pa adher-
ence is also increased in the CF murine nose. Nasal epithelial cells from G551D
(ns6) and wild-type (WT) littermates (ns6) were obtained by dissection of the
nasal passages. Tissue was separated into respiratory and olfactory regions, disso-
ciated for 26 h with trypsin and incubated with a non-mucoid strain of Pa (PA
serotype O1). Adherence of bacteria to the ciliated epithelial cells was quantified
using scanning electron microscopy. There were significant differences in Pa adher-
ence between CF and WT mice for epithelium from both the respiratory region
(10.9(SEM 0.85)y10 cells and 3.69 (0.6)y10 cells respectively; P-0.001) and the
olfactory region (11.9 (0.8)y10 cells and 3.26 (0.78)y10 cells; P-0.001). We
conclude that G551D mice show increased binding of Pa to nasal epithelial cells.
This has important implications both for the further investigation of pathogenesis
in CF and for the assessment of novel therapeutics.
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The single-channel properties of human-murine CFTR chimeras
-p)T.S. Scott-Ward , E.S. Dawson , A. Doherty , H. Davidson , D.J. Porteous ,1 2 2 2 2
D.N. Sheppard , A.C. Boyd1 2
Department of Physiology, University of Bristol, Bristol, United Kingdom, Med-1 2
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The gating behaviour of murine CFTR (mCFTR) is distinct from that of human
CFTR (hCFTR; J Physiol 508, 379–392, 1998). To determine the protein regions
responsible for this difference, we constructed the human-murine CFTR chimeras
hmNBD1, hmNBD2 and hmRD by replacing nucleotide-binding domain 1 (NBD1),
NBD2 and the R domain of hCFTR with the equivalent regions of mCFTR and
studied Cl channels in excised membrane patches. The external solution containedy
10 mM Cl and the internal solution contained 147 mM Cl , 0.3–1 mM ATP andy y
75 nM PKA at 37 8C; voltage was y50 mV. At negative voltages, the single-
channel conductances of CFTR chimeras were comparable to that of hCFTR. Chan-
nel gating of hmRD and hCFTR were similar (ns3–5; P)0.05). In contrast, the
duration of bursts of openings of hmNBD1 (176"6 ms; mean"S.E.M.; ns3) and
hmNBD2 (243"11 ms; ns4) exceeded those of hCFTR (137"7 ms; ns5; P-
0.05). Moreover, long closures separating bursts of openings of hmNBD1 and
hmNBD2 were prolonged compared with those of hCFTR (ns3–5; P-0.01). The
opposing nature of these differences in burst duration and interburst interval explain
why the open probabilities of hmNBD1 (0.40"0.03; ns3) and hmNBD2
(0.47"0.02; ns4) are similar to that of hCFTR (0.44"0.02; ns5). Our results
suggest that while hmRD gating is comparable to that of hCFTR, the gating behav-
iour of hmNBD1 and hmNBD2 are different from that of hCFTR. Supported by
the CF Trust.
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Histology of the mouse nose as a new model in cystic fibrosis
T.N. Hilliard , J. Williams , B.J. Wainwright , A. Bush , J.C. Davies , E.W.F.W.1 1 2 3 1
Alton1
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Introduction: The CF mouse has been a disappointing model of human airway
disease. The CF mouse and human nose share similar bioelectrical properties. We
hypothesised that there might be histological abnormalities in CF murine nasal
epithelium. Methods: Mice used were G551D CF and wild type littermates (8–13
weeks) and gut corrected CF, (FABP-CFTR) (12–16 weeks). Nasal lavage was
performed in the left nasal cavity in G551D and WT. From all 3 groups, heads
were embedded in paraffin and serial coronal sections obtained. At 3 distinct depths
on the right side, thickness and cell density of the olfactory epithelium (OE), and
number of goblet cells in septal respiratory epithelium (RE) were measured.Results:
RE and OE began at similar levels in the 3 types of mice (1600 mm and 3200
mm). OE in the CF mice was abnormal compared to that in WT animals, with
reduced thickness and lower cell density. There was goblet cell hyperplasia in CF
mice compared to WT. In addition, inflammatory cell clusters below RE were seen
in 11y12 G551D heads, 2y6 FABP and 0y12 WT (P-0.001, xs20.8). There was
no difference in cell counts, total bacterial concentration or MIP-2 levels in nasal
lavage.
n OE thickness OE cell density Goblet cells
(mm, mean (SEM)) (cellsy1000 mm )2 (cellsymm)
WT 12 50.8 (0.6) 37.6 (1.0) 47.8 (2.3)
G551D 12 32.7 (1.2) 27.0 (1.2) 81.7 (2.2)
FABP 6 38.9 (1.9) 28.2 (1.5) 82.7 (2.7)
P (WT vs G551D) -0.001 -0.001 -0.001
P (WT vs FABP) -0.001 -0.001 -0.001
Conclusion: These data support the hypothesis that CFTR may be involved in
cellular development either as a primary effect or in response to secondary changes.
In addition, the data suggest that histology of the CF mouse nose may provide a
better model than the lung for investigating the pathogenesis of, and new therapies
for, structural airway changes in CF.
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A cystic fibrosis rat produced by transient in utero knockout (TIUKO) of
CFTR
J.C. Cohen , D. Broussard , J.E. Larson1 2 2
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Clinic Foundation, New Orleans, United States
In utero transfer of genes to epithelial stem cells in the developing mouse and rat
lungs is highly efficient. A method (TIUKO) for the transfer and transient expres-
sion of antisense genes in an adenovirus vector was produced to characterize devel-
opmentally important genes in the lungs and intestines. This method was applied
to the Sprague–Dawley rat to evaluate developmental aspects of the CF phenotype.
Treatment of rat fetuses at 15, 16, or 17 days gestation with an adenovirus-antisense
CFTR yielded different phenotypes. Animals treated at 15 days gestation died short-
ly after birth and showed significant pathology in their intestines. Treatment later
in gestation did not result in a lethal intestinal phenotype, although some changes
in histology were noted immediately after birth. The lungs from rats treated at 16–
17 days gestation exhibited many of the characteristics seen in CF. Airway fibrosis
and parenchymal thickening with monocytic infiltrates were present as early as 90
days of age. An increase in airway reactivity to methylcholine was also documented.
CF antigen (MRP8y14) expression was induced in utero. Because the TIUKO CF
rats mimic human lung disease, it was used to evaluate genes that could modulate
the CF phenotype. Rats deficient in CF antigen expression were treated at 16 days
gestation with the adenovirus-antisense CFTR recombinant. Evaluation of airway
reactivity and cell type populations in the lung demonstrated that CF antigen is
involved developmentally in the lung. Its absence results in a lung phenotype dif-
ferent from that observed in CF antigen expressing animal. Upon treatment with
antisense, a unique phenotype was observed. Thus, CF antigen is involved in normal
lung development and its absence affects the CF disease phenotype.
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Binding of Pseudomonas aeruginosa to cystic fibrosis human nasal
epithelium
T. Wodehouse, L.A. Collins, D.M. Geddes, J.C. Davies, E.W.F.W. Alton
Department of Gene Therapy, Imperial College; UK CFGT Consortium, London,
United Kingdom
Pseudomonas aeruginosa (Pa) is the major pathogen in the cystic fibrosis (CF)
lung. Binding of Pa to CF respiratory epithelium is increased and this is related to
an increased number specific cell surface receptors. We have previously shown that
CFTR gene transfer can reduce the excess binding of Pa to CF nasal epithelium.
In preparation for further human clinical trials we have undertaken optimisation
studies of this assay. Nasal epithelial cells were obtained from patients who were
homozygous for DF508 and incubated with a non-mucoid strain of Pa (PA serotype
O1) for 30, 60 and 90 min (ns6ygroup) and three concentrations of Pa
(2.5=10 , 10 and 10 in 50 ml ns6ygroup). Adherence was assessed by scanning7 8 9
electron microscopy. Only adherence to the apical surface was assessed and binding
to mucus was excluded. Adherence of Pa to epithelial cells at an incubation times
of 30 minutes demonstrated bacterial adherence to be 9.76y10 cells (S.E.M.s0.39);
at 60 min, 10.11(0.33)y10 cells and at 90 min to be 6.18(0.53)y10 cells. There
was no significant difference between Pa adherence at the following concentrations
2.5=10 s9.76(0.96)y10 cells; and 10 s8.3(0.86)y10 cells, however 2.5=107 9 8
was significant at 10.14(0.29)y10 cells therefore demonstrating the lowest variation.
We can conclude that an incubation time of 30 minutes and Pa concentration of
10 provides optimal discrimination between bacterial adherence to CF and non-8
CF epithelial cells. This assay provides a measure of CFTR molecular function for
gene therapy and other therapeutic studies.
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Evidence for normal CFTR function in diffuse pan-bronchiolitis
A. Jaffe , C. Anzai , E.W.F.W. Alton , K. Yoshimura1 2 3 2
Portex Unit, Institute of Child Health and Great Ormond St Hospital for Children,1
London, United Kingdom, Department of Respiratory Medicine, Toranomon Hos-2
pital, Tokyo, Japan, Department of Gene Therapy, Imperial College, London, Unit-3
ed Kingdom
Introduction: There are many similarities between diffuse pan-bronchiolitis (DPB),
a disease of the Japanese and cystic fibrosis (CF). Successful macrolide treatment
in DPB has led to the introduction of therapy in CF. We have previously shown an
increased prevalence of cystic fibrosis transmembrane conductance regulator
(CFTR) mutations in DPB, raising the speculation that DPB is a mild variant of
CF. Aim: To investigate CFTR function in patients with DPB. Methods: Nasal poten-
tial differences were undertaken in 13 DPB subjects, 16 CF subjects and 9 healthy
controls (C) (2 Japanese). The following perfusion protocol was used: Krebsy
Hepes, 100 mM Amiloride, Low chloride (LC) and 100 mM Isoprenaline. Results:
Subjects with DPB had significantly different ion transport compared to CF (Table).
No difference was seen between DPB and controls.
DPB (mV) CF (mV) Controls (mV) P value
Mean Mean Mean DPB v CF
(SEM) (SEM) (SEM) DPB v C
Baseline 17.8 (1.8) 33.9 (2.5) 12.7 (1.3) -0.001 NS
D Amiloride 3.2 (0.6) 17.1 (1.8) 4.5 (0.9) -0.001 NS
D LC 7.4 (2.1) y0.7 (1.0) 12.3 (2.7) -0.01 NS
D Iso 8.3 (2.3) 1.5 (0.6) 7.2 (0.9) -0.01 NS
D LCyIso 15.8 (4.2) 0.8 (1.5) 19.5 (2.6) -0.01 NS
NSsnot significant.
Conclusions: Despite a similar clinical phenotype to CF, and an increased prevalence
of CFTR mutations, patients with DPB have normal CFTR function. This may have
implications in understanding the mechanisms by which macrolides exert their
effects in CF.
Acknowledgement: This work is supported by a grant from Pfizer Ltd.
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Hsp90 modulates ClC-2 currents
A. Hinzpeter, J. Lipecka, J. Fritsch, A. Edelman
INSERM U467, Paris, France
ClC-2 is activated by voltage and intracellular chloride, wClx . I kinetics andi ClC-2
threshold potential vary depending on the tissues and the expression system. The
aim of this study is to gain insight into the factors modulating these parameters by
identifying proteins interacting with ClC-2. A FLAG sequence was inserted into a
ClC-2 loop to maintain the intracellular domains of the protein accessible. HEK
cells were stably transfected with ClC-2 WT, ClC-2 FLAG, or mock plasmid. ClC-
2 was immunoprecipitated with an anti-FLAG antibody or an antibody raised
against a C-ter epitope. Co-immunoprecipitated proteins were identified by mass
spectrometry. Protein expression was measured by immunoprecipitation followed
by immunoblotting. Membrane expression was quantified by biotinylation ClC-2
current was measured using the whole cell patch-clamp configuration. Mass spec-
trometry shows that Hsp90 co-immunoprecipitates with ClC-2. Hsp90 also co-
immunoprecipitates with ClC-2 in mouse brain homogenates. Geldanamycin and
radicicol, two Hsp90 inhibitors, affect neither ClC-2 expression even after 24-h
treatment, nor CIC-2 membrane expression, suggesting that inhibition of Hsp90
does not modify ClC-2 degradation and assembly. Measurements of I indicateClC-2
that both drugs decrease I . The percentage of inhibition is wClx dependant: 95%ClC-2 i
at wClx s35 mM, 50% at wClx s64 mM, and 20% at wClx s80 mM. Currenti i i
inhibition is associated with a shift in the relative open-probability (Po) curve to
more hyperpolarized potentials and with a decrease in maximal conductance and
with changes in activation and deactivation kinetics. Moreover, inhibition leads to
important changes in the relationship between the midpoint of activation and wC1x.
We suggest that interaction between Hsp90 and ClC-2 leads to conformational
changes of CIC-2 thus drastically modifying conductance, activation threshold and
wC1x regulation.
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Proteomic analysis of distal colon crypts from cftr cystic fibrosistm1Unc
and normal mouse
N. Ben-Salem , A.P. Ventura , B. Vallee , J. Lipecka , N. Davezac , D. Tondelier ,1 2 1 1 1 1´
F. Halgand , O. Laprevote , A. Edelman2 2 1´
Inserm U467, Paris, France, ICSN CNRS, Gif sur Yvette, France1 2
Clinical studies suggest that the symptomatology of Cystic Fibrosis (CF) is not
only due to the abnormal CFTR-related fluid transport, but may also involve pol-
ymorphism of modifier genes and epigenetic factors that remain to be identified.
Global proteomic analysis coupled to mass spectrometry provides an important
approach to search for proteins involved in the altered condition of cells in CF
tissues. Within this framework, the aim of the present study was to identify the
differentially expressed proteins in distal colon crypts from two types of mice hav-
ing the same genetic background: cftr cystic fibrosis mice (KO cftr) vs. controltm1Unc
mice (C57BL6). We analysed the proteins from colon crypts, since this is the major
site of the functional defect of CFTR in these KO mice. The crypts were isolated
and the total proteins were solubilized in SDS-containing buffer and separated by
2D gel electrophoresis (pH 6–11, 10% SDS-PAGE, at least 3 gels per mouse).
Proteins were detected by silver staining. The proteins from 4 mice of each genotype
were analysed. Under our experimental conditions, only one difference in protein
patterns was observed. The protein spot (PI 7, MW 97 kDa) was down-regulated
in KO mice and was not a high abundance protein. The identification of this protein
by MS (MALDI-TOF) required optimisation of the tryptic digestion protocol. The
protein was identified as Annexin 1 (A1). The immunohistochemistry experiments
on mouse colon, lung, and muscle using anti-A1 antibodies showed that diminished
expression of A1 is limited to CFTR-expressing tissues (lung and colon). Since it
is known that A1 is an anti-inflammatory protein (Perretti M. and al.), we suggest
that decreased expression of A1 contributes to the worsening of the CF phenotype
in KO mice.
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Mass spectrometric analysis of distal bronchial epithelium from normal
and mutant (F508del) mice
I. Carvalho-Oliveira , T. Luider , D. Penque , B.J. Scholte1 2 1 3
Centro de Genetica Humana, Instituto Nacional de Saude Dr Ricardo Jorge, Lis-1 ´ ´
bon, Portugal, Biomics Center, Erasmus University Rotterdam, Rotterdam, Neth-2
erlands, Department of Cell Biology, Erasmus University Rotterdam, Rotterdam,3
Netherlands
Proteome analysis of CF mutant cells compared to normal is an important tool in
the study of CF pathology. So far, 2D gel electrophoresis is the most widely used
technique. However, this approach has serious limitations. Firstly, not all proteins
are suitable for this method. Further, a considerable amount of protein is required,
compared to the amount that can be acquired from biopsies or brushed airway cells.
In an attempt to develop a gel-free alternative we apply Laser Micro-dissection of
cryosections followed by Mass Spectrometry (MALDI) analysis of tryptic digests.
As a model of CF lung disease, we compare distal lung epithelial cells of normal
and F508del mice. The Laser Micro-dissection of cryosections permits us to select
the cells of interest without disturbing the tissue. After digestion of the collected
material with trypsin in RapiGest, the complex peptide mixtures are analyzed by
Mass Spectrometry. To reduce the complexity of the analysis we propose to perform
a subtractive comparison of two data sets (F508del vs control), and identify peptides
that are unique to either. For this we use a combination of database searches and
peptide sequencing using a LC-QTOF device. We have initially optimized the tech-
nique by comparing spectra obtained from dissected normal mouse lung epithelial
cells to connective tissue. In the MALDI spectra analysis we indeed found differ-
ently expressed peptides. We are now collecting data from normal and F508del
mice to identify differently expressed peptides, and corresponding proteins, that may
be used as genotypic markers and potential therapeutic targets. ICO is a recipient
of FCT doctoral fellowship.
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Detection of endogenous CFTR expression in laser captured
respiratory epithelial cells from the mouse nasal cavity
E. Fox , B. Stevenson , T. Hilliard , S. Collishaw , V. Mann , A.C.1, 4 1, 4 2, 4 3 3
Boyd , D.J. Porteous1, 4 1, 4
Department of Medical Genetics, The University of Edinburgh, Edinburgh, United1
Kingdom, Department of Gene Therapy, Imperial College, London, United King-2
dom, Scottish Mechanotransduction Consortium, The University of Edinburgh,3
Edinburgh, United Kingdom, UK CF Gene Therapy Consortium, United Kingdom4
Gene transfer is often assessed in mouse nasal airways as the delivery and contact
time can be controlled. Furthermore, CFTR function can be assessed by measuring
changes in potential difference across the nasal epithelium in the CF mouse. The
mouse nasal cavity lining is composed of several types of epithelium, including
squamous, respiratory and olfactory; however, only the respiratory epithelium (RE)
is a satisfactory model for human airway ciliated epithelium. Assessing gene transfer
in homogenates of nasal tissue will not indicate the respiratory epithelial cell trans-
fection efficiency but only reflect an average expression from the various epithelial
types. Therefore, we have used laser dissection microscopy to selectively harvest
RE from the mouse nasal cavity. We developed a technique that allows sections to
be cut through freshly frozen mouse heads (which is more favourable for down-
stream mRNA analysis than fixation and decalcification protocols) and the epithe-
lium to be laser captured at precise depths along the septum to ensure only
respiratory cells are harvested. Endogenous mCFTR mRNA has been successfully
detected in as few as 20 respiratory epithelial cells using Southern analysis (mCFTR
mRNA was detected in 4 out of 6 wild-type C57yBL6 mice). Therefore, we have
demonstrated that the RE can be isolated from the mouse nasal cavity and CFTR
expression can be detected in a small number of laser captured cells. This technique
will now be used with RT-PCR and TaqMan analysis to quantitatively assess CFTR
gene transfer to the RE in the mouse nasal cavity.
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Embryonic stem cells generate airway epithelial tissue
C. Coraux , B. Nawrocki-Raby , J. Hinnrasky , C. Kileztky , D. Gaillard , C.1 1 1 1 1
Dani , E. Puchelle2 1
INSERM UMR S514, Reims, France, CNRS UMR 6543, Nice, France1 2
In airway diseases, and particularly in cystic fibrosis, the airway epithelium is fre-
quently injured and must be regenerated. Embryonic stem (ES) cells, derived from
the inner cell mass of the blastocyst stage embryo, are pluripotent cells, which are
investigated increasingly to obtain specific cell lineages for therapeutic treatments
and tissue engineering. The aim of our study was to determine the ability of murine
ES cells to differentiate into airway epithelial cells and to generate mature airway
epithelium. We first demonstrate by immunocytochemistry and RT-PCR of a spe-
cific Clara cell marker CC10, that ES cells grown as embryonic bodies (EB) were
able to differentiate into Clara cells after 15 days of culture. Moreover RT-PCR
analysis demonstrated that only ES cells grown as monolayer on type I collagen
(Coll-I) differentiated into Clara cells as early as day 8 of culture, whereas CC10
expression was seen in ES cell cultures on Coll-I or plastic after 15 days, suggesting
an inductive effect of Coll-I on Clara cell differentiation. In order to promote airway
epithelium differentiation, Coll-I-induced ES cells were cultured at the air–liquid
interface on a Coll-I-coated acellular substratum. After two weeks, examination of
the cultures revealed the generation of a mature airway epithelium composed of
basal cells, Clara cells and ciliated cells, and similar to those of native mouse airway
and human bronchiolar epithelia. The ES-derived airway epithelium exhibited
ultrastructural junctional complexes observed in native airway epithelia, as well as
CC10 protein secretion, characteristic of airway epithelial tissues. These results open
new perspectives for cell therapy of injured epithelium in airway diseases, such as
bronchopulmonary dysplasia, cystic fibrosis or bronchiolitis obliterans Supported
by INSERM, Association Vaincre la Mucoviscidose and INSERM ATC 2002: ‘Cel-
lules souches a finalite therapeutique’.` ´ ´
Infl ammation
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Measurement of enzymatically active elastase, protease 3 and
cathepsin G from neutrophils primary granules in sputum of CF
patients
B. Korkmaz, E. Hazouard, S. Attucci, F. Gauthier
INSERM U618, Tours, France, University Francois Rabelais, Tours, France1 2 ¸
Human neutrophil elastase (HNE) remains so far the main protease target in bron-
chial secretions for an anti-inflammatory CF therapy. Synthetic inhibitors have been
designed based on their anti elastase properties notwithstanding the presence in
neutrophil primary granules of similar concentation of protease 3 and cathepsin G.
The fate of these proteases once released from activated neutrophils is not yet
elucidated. It could be that their activity is differently regulated by natural inhibitors
or other factors that modulate protease activities in bronchial secretions of CF
patients. We have designed new synthetic substrates that allow complete discrimi-
nation between the activities of HNE, protease 3 and cathepsin G. Those allow
specific measurement of individual proteolytic activities in a complex medium such
as CF sputum. All three proteases are present in an active form and in similar
amounts in supernatants of expectorations of CF patients and may therefore partic-
ipate to the overall proteolytic activity that leads to chronic inflammation and ulti-
mately to lung destruction. We conclude that all three neutral proteases from
neutrophil primary granules should be considered as putative targets for an antiin-
flammatory therapy based on the use of protease inhibitors.
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Analysis of tumor necrosis factor-a (TNFA) and lymphotoxin-a (LTA)
polymorphisms in cystic fibrosis patients
G.F. Korytina, D.G. Yanbaeva, T.V. Victorova
Institute of Biochemistry and Genetics, Ufa Scientific Center, Russian Academy o,
Ufa, Russia
Cystic fibrosis (CF) is an autosomal recessive lethal disease characterized by pro-
gressive obstructive lung disease, pancreatic dysfunction and elevated sweat elec-
trolytes. Some of clinical variations may be explained by the type of mutations in
the CFTR gene, but the severity of lung disease in CF modified by secondary
genetic and environmental factors. Inflammation of the airway wall is a principal
feature of the airway disease and it may therefore be of interest to identify factors
that could directly influence the intensity of airway inflammation. Tumour necrosis
factor (TNF) is an inflammatory cytokine that is found in increased concentrations
in chronic respiratory patients airways. The TNF and LTA genes are located within
the human major histocompatibility (MHC) locus on chromosome 6p. Polymor-
phisms in genes within the MHC have been of primary interest in relation to dis-
eases involving inflammatory disorders. In order to investigate the possible roles of
gene polymorphisms in the development and progression of CF we genotyped 62
patients with CF and 216 control subjects for both TNFA and LTA polymorphisms.
No association between CF and TNFA polymorphic status was found. The rarer
LTA GG genotype was found in 10.2% of CF subjects versus 2.7% in control (x2s
4.42, P-0.03; ORs3.96 CI 1.07–14.58). We observed association of CF with
TNFA-LTA (GG-AG) combination (36.6% vs. 22.4% in control; ORs2.00 CI
1.00–3.91, Ps0.04). Our results suggest that TNFA and LTA polymorphisms may
be important in the pathogenesis of severe lung disease at CF patients.
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Cytokine production in whole blood and lipoproteins in cystic fibrosis
V. Hippe , S. Schmitt-Grohe , M. Igel , K.v. Bergmann , D. Posselt , A Krahl , C1 1 2 2 3 3´
Smaczny , T Wagner , W Nikolaizik , S Zielen4 4 5 3
Children’s Hospital Medical Center, Bonn, Germany, Department of Clinical1 2
Pharmacology, Bonn, Germany, Department of Pediatric Pulmonary, University3
Hospital, Frankfurt, Germany, Pulmonary Department, University Hospital,4
Frankfurt, Germany, Department of Pediatrics, University Hospital, Essen,5
Germany
According to the endotoxin lipoprotein hypothesis lipoproteins may down regulate
proinflammatory cytokines by neutralizing lipopolysaccharide (LPS)yLPS binding
protein (LBP) complexes. The aim of this study was to assess the correlation
between lipoproteins and ex vivo cytokine production in patients with the Delta F
508 (homozygous) mutation. Patients with mild disease (Shwachman score 71–
100 pts, group A, ns22, median FEV1 80%) were compared with those with more
severe disease (Shwachman score 41–55 pts, group B, ns22, median FEV1 59%)
and age matched controls (group C, ns22). The following tests were performed:
Interleukin-8 (IL-8 median AyByC 15y25.1y8.0 pgyml, P-0.006), LBP (median
AyByC 4.3y7.2y4.0, P-0.022), tumor necrosis factor alpha (TNF alpha median
AyByC 43y56y30 pgyml, P-0.0001) using a chemiluminescent immunometric
assay (DPC Bad Nauheim, Germany) and serum triglycerides (TRG median AyBy
C 106y90y76 pgyml, P-0.11), LDL (median AyByC 51.5y56y91 pgyml, P-
0.0001) and HDL (median AyByC 43.5y45.5y55 pgyml, P-0.09) were measured
as well. Though TRG levels were higher and TNF alpha levels were lower in mild
disease, we could not provide evidence of a correlation (rsy0.32, P-0.032)
between TRG and TNF alpha in CF pts (AqB), but there was almost a negative
correlation for TNF-alpha and TRG (rsy0.42, P-0.055) in subanalysis of group
B. Conclusion: The endotoxin lipoprotein hypothesis may apply in more advanced
disease states of CF.
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Consequences of CFTRDF508 mutation on eicosanoıd production and¨
sPLA2-IIA expression in pulmonary epithelial cells
S. Medjane, Y. WU, L. Touqui
Institut Pasteur, Paris, France
The aim of this study was to study the impact of CFTR on eicosanoıd production¨
and secreted phospholipase A2 (sPLA2) expression in pulmonary epithelial cell.
Increased levels of arachidonic acid (AA) metabolites have been observed in the
sputum from CF patient. Prostaglandin E (PGE ), an AA-derived metabolite, has2 2
been shown to modulate the sPLA2 expression in various cell types. Previous stud-
ies show an increased AA release from epithelial cell and skin fibroblasts from CF
patients, as well as CF epithelial cell line (CFT-2: DF508 homozygote). This led
us to study sPLA2-IIA expression in CFT-2. We showed that CFT-2 cells released
higher PGE level than control cell line NT-1 cells. RT-PCR analysis revealed higher2
expression of cyclooxygenase-2 (COX-2) in resting CFT-2 cell than in NT-1 cell.
Moreover, the CFTR re-trafficking by thapsigargin and low-temperature culture
induced a decrease of PGE production in CFT-2 cell line. We showed that CFT-22
cells constitutively expressed higher level of sPLA-IIA compared to NT-1 cells.
LPS and PGE increased this expression in both cell lines. This expression was2
correlated with sPLA2-IIA activity assay using LY311727, a sPLA2-IIA specific
inhibitor. These results suggest a relationship between deficiency of CFTR, AA
metabolism and sPLA2-IIA expression in epithelial cells. Because sPLA2-IIA is
known to play a role in inflammatory lipid mediator and to exhibit antibacterial
activities, the regulation of their expression might have an important physiopath-
ological relevance in the context of CF.
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Incidence of the interleukin 8 -251 gene polymorphism in the Northern
Ireland Cystic Fibrosis population
A.P. Watt , OA Ross , D. Middleton , J. Courtney , J.S. Elborn , M. Ennis1 3 2 1 1 1
Respiratory research group, The Queens University of Belfast, Belfast, United1
Kingdom, Northern Ireland Regional Histocompatibility and Immunogenetics Lab-2
oratory, Belfast, United Kingdom, School of Biology and Biochemistry The Queens3
University of Belfast, Belfast, United Kingdom
Interleukin 8 (IL-8) is a pro-inflammatory cytokine thought to play a key role in
promoting neutrophil dominated inflammation in CF. The IL-8 -251 polymorphism
is found in the promoter region of the IL-8 gene, the A allele being associated with
increased IL-8 production (Hull et al. Thorax; 2000; 55 1023-1027).Frequency of
the IL-8 polymorphism was analysed to investigate potential CF related association
in the Northern Ireland (NI) CF population. 100 control samples (59% female, 41%
male, 19–45 years) were chosen at random from the NI population (Ross et al.,
Mech Age Dev; 2003; 124 199–206). 103 CF DNA samples (46.6% female and
53.4% male, 15–50 years) from the NI population were also studied. Analysis of
the IL-8 polymorphism was carried out using PCR followed by sequence specific
oligonucleotide probes. Genotyping of the IL-8 -251 polymorphism revealed that
in the CF population 24 (23.2%) individuals were AA, (high producers), 53
(51.5%) were AT (intermediate producers) and 26 (25.3%) were TT (low produc-
ers). In the control population 25 (25%) individuals were AA, 45 (45%) were AT
and 30 (30%) were TT. Statistical analysis was performed employing the Chi square
test. There was no significant variation between the two groups studied (Ps0.926).
IL-8 is a potent neutrophil chemoattractant found in increased levels in sputum,
bronchoalveolar lavage fluid and serum of CF patients, even during clinical stability
which may suggest IL-8 is an important factor in the pathogenesis of CF. These
findings demonstrate no difference in polymorphism frequency in the NI CF pop-
ulation. Further studies are required to investigate any potential association of the
IL-8 polymorphism with clinical markers of disease severity in CF.
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Inhibitory effects of azithromycin on interleukin 8 expression by CF
airway epithelial cells
M. Pasetto , E. Nicolis , C. Cigana , B.M. Assael , P. Melotti1 2 2 2 1
Italian Cystic Fibrosis Research Foundation, Verona, Italy, Cystic Fibrosis Center-1 2
Azienda Ospedaliera di Verona, Verona, Italy
Progressive lung damage in CF is a consequence of exaggerated and chronic pro-
inflammatory processes which are considered intrinsic in this disorder. Azithro-
mycin (AZM) has been reported to ameliorate airway inflammation in CF patients.
Properties relevant for therapy other than bactericidal activity have been proposed
for this macrolide, including anti-inflammatory effects. Interleukin 8 (IL-8), the
major polymorphonuclear chemokine in the lung, has been reported to be expressed
at higher levels in CF than in non-CF cells. We investigated whether AZM is
capable of reducing the expression of IL-8 in CF cells. We utilized 2CFSMEo-
cells, an airway epithelial cell line derived from a CF patient. IL-8 mRNA levels
were determined by quantitative real-time PCR based analysis. Amounts of secreted
IL-8 were detected in supernatants by ELISA. We have shown the ability of AZM
to reduce constitutive IL-8 mRNA expression as well as protein secretion in CF
cells. AZM caused an about 3 fold reduction of IL-8 mRNA expression levels (ns
6, P-0.05). An inhibition of about 70% of IL-8 secretion was determined in the
presence of AZM (ns3, P-0.01). The mechanisms of clinical benefits induced
by AZM are still unclear: the results of our study support the anti-inflammatory
properties of this macrolide, since we have demonstrated that it is capable of reduc-
ing the production of a pro-inflammatory chemokine by airway epithelial cells. Our
study identify a molecule very relevant for pathogenesis of CF as target of AZM.
The molecular mechanisms by which AZM inhibits IL-8 production are under
investigation. Supported by the Italian Cystic Fibrosis Research Foundation and
Azienda Ospedaliera di Verona-Italy.
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Effect of clarithromycin on inflammatory markers in bronchoalveolar
lavage fluid in cystic fibrosis: a randomised, placebo-controlled
crossover trial
D. Dogru , F. Dalgic , N. Kiper , U. Ozcelik , E. Yalcin , A.T. Aslan , A.1 1 1 1 1 1
Gozacan , N. Gurcan2 1
Hacettepe University Faculty of Medicine Pediatric Chest Disease Unit, Ankara,1
Turkey, Hacettepe University Faculty of Medicine Department of Anesthesiology,2
Ankara, Turkey
Macrolide antibiotics have antiinflammatory effects which are potentially useful in
cystic fibrosis (CF). The aim of this study was to evaluate the effects of clarith-
romycin on inflammatory markers in bronchoalveolar lavage fluid (BALF) as well
as on body mass index (BMI), pulmonary function tests (PFTs) and life quality of
CF patients. Twelve children with CF aged 3–14 years who were clinically stable
were randomised to receive either clarithromycin (15 mg kg day in two dividedy1 y1
doses) (Group I) or placebo (Group II) for 3 months. After 15 days of washout
period, the treatments were crossed over. BALF was obtained in the beginning of
the study and at the end of each treatment period for measurement of interleukin
(IL)-8, IL-6, IL-1 beta, tumor necrosis factor (TNF) and neutrophil elastase (NE).
Modified NIH score, BMI and PFTs were recorded in the same periods. Only IL-
1 beta and NE were reduced with clarithromycin in BALF in both groups; IL-8,
IL-6 and TNF alpha were not decreased. The total number of acute pulmonary
exacerbations were 3 while on clarithromycin and 7 while on placebo. BMIs were
increased only in Group II at the end of active treatment period. NIH scores and
forced expiratory volume in 1 s were improved with clarithromycin in both groups
when compared to placebo. Clarithromycin was well tolerated in all patients. A 3-
month treatment of clarithromycin can reduce IL-1 beta and NE in BALF and may
improve the symptoms of CF patients.
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Mast cells play a keyrole in the pathophysiology of lung destruction in
cystic fibrosis
P.O. Schiotz, H.V. Olesen, H.B. Andersen, M. Holm
CF-centre West, Aarhus University Hospital, Skejby Sygehus, Aarhus, Denmark
Mast cell mediators are known to cause bronchoconstriction and they also produce
fibrosis. Both are important factors in CF lung pathophysiology. In 1984 Eggelston,
P.A. et al showed that human lung mast cells were hyperreactive to IgE mediated
stimuli when stimulation occurred in a hypertonic solution (Am. Rev. Resp. Dis.
1984;130:86). A situation that probably occurs in CF lungs as well. (Guggino W.B.
Cell 1999;96:607). We have therefore cultured human mast cells from cord blood
stem cells (CD133 ) (Dahl, C., JIM 2002; 262:137) and obtain a 100% pureq
culture of mature mast cells that have been stimulated with anti-IgE as well as
CON-A. The stimulation was carried out in buffer solutions with 300–400–500
and 600 mOSmol and resulted in a significantly increased histamine release when
the osmolarity was 400 or above. It is our conclusion that excessive mast cell
leakage in a hypertonic extracellular fluid in the lung or in the airway surface liquid
in CF can explain a lot of the cystic fibrosis pulmonary pathology. This means that
mast cell mediated inflammation may be the most important factor in lung destruc-
tion and explains the increased prevalence of ‘astma’ in CF. Infections would thus
be secondary events and when treated sufficiently no more can be obtained by
antibiotics. Advocates of profylactic or aggressive early antibiotic treatment have
failed to show that this can influence survival rate-and this is not surprising if the
primary defect initiates an ongoing inflammation independent of antibiotics.
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PMN tolerance of Pseudomonas aeruginosa biofilms is Quorum
Sensing dependent
P. Jensen , T. Bjarnsholt , M. Hentzer , C. Moser , N. Hoiby , M. Givskov1 2 2 1 1 2
Rigshospitalet, Copenhagen, Denmark, BioCentrum, Techincal Univesity of Den-1 2
mark, Copenhagen, Denmark
In the majority of patients with cystic fibrosis (CF) the disease is complicated by
chronic lung infections with Pseudomonas aeruginosa. This infection is dominated
by P. aeruginosa forming biofilm structures in the alveoli. In the biofilm mode of
growth the bacteria are highly tolerant to otherwise lethal doses of antibiotics, and
protected from bactericidal activity of polymorphonuclear leukocytes (PMNs). P.
aeruginosa control expression of virulence factors by means of the quorum sensing
(QS) communication systems. In this study we have investigated the effect of QS
deficiency during interactions between PMNs and biofilm in vitro. QS deficient P.
aeruginosa strains (lasI and rhlI or lasR and rhlR) were grown in vitro in contin-
uous-culture once-through flow chambers. 3 day old biofilms were treated with
human PMNs and the activation of PMNs was estimated by 123-dihydrorhodamine
which is oxidized to fluorescent 123-rhodamine by H O produced during the res-2 2
piratory burst. When incubated on a QS deficient biofilm, more activation of the
PMNs and a faster degradation of GFP tagged biofilms was observed by confocal
laser scanning microscopy. These result indicate that if the bacteria are unable to
communicate by the QS system, the biofilm becomes sensitive to the PMNs.
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Asymmetric chemokine release from murine cystic fibrosis airway
epithelial cells after Pseudomonas infection
L. Hogue, Y. You, T. Joseph, R. Medina-Garcia, K. Akers, S. Brody, T. Ferkol
Washington University School of Medicine, St Louis, United States
Introduction: The marked inflammatory response accompany airway infection great-
ly contributes to the morbidity of patients with cystic fibrosis (CF). We have pre-
viously shown, using a well-characterized, murine model of lung infection, that
concentrations of inflammatory cells and mediators was markedly elevated in CF
mice compared to normal littermates. We hypothesized that the exaggerated inflam-
matory response observed in the CF lung was a result of epithelium-directed signals.
Methods: Differentiated airway epithelial cells isolated from isogenic (C57Bly6)
CF (DF508) or wild type mice grown in primary culture on semipermeable supports
at an air-liquid interface were treated for 1 hour with P. aeruginosa (PAO1). CXC
chemokine secretion was measured in the apical and basolateral compartment 1 and
2 days later using specific enzyme-linked immunoassays. Results: Chemokine
(MIP-2 and KC) secretion as markedly induced following infection with Pseudo-
monas, and MIP-2 secretion was significantly higher in CF airway epithelial cells
grown in primary culture as compared to wild-type cells. The release of both che-
mokines from the epithelium was polarized, with higher amounts secreted basola-
terally that became more pronounced after infection. Conclusion: Polarized CXC
chemokine secretion suggest that airway epithelium contributes to the inflammatory
response induced by P. aeruginosa, by attracting cells from the circulation through
a vectoral chemokine signal, and this response is exaggerated in CF epithelia. Sup-
ported by grants from the National Institutes of Health (HL64044), March of
Dimes, and Cystic Fibrosis Foundation
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Improved biomarkers of cystic fibrosis lung disease in bronchoalveolar
lavage fluid identified using SELDI-TOF mass spectrometry
G. MacGregor , T.H. Hilliard , M. Imrie , J.A. Innes , A.C. Boyd , E. Alton , J.1 2 1 1 1 2
Davies , A. Bush , D. Porteous , A.P. Greening2 2 1 1
Medical Genetics Unit, University of Edinburgh, Edinburgh, United Kingdom,1
Department of Gene Therapy, Imperial College, London, United Kingdom, United2 3
Kingdom Cystic Fibrosis Gene Therapy Consortium, Edinburgh, Oxford, London,
United Kingdom
Introduction: There is a need for biomarkers of CFTR function and of inflammation
for use in CF gene therapy trials. These should be CF specific and sensitive enough
to detect subtle changes resulting from CF gene transfer. The preferred technique
to sample airway surface liquid (ASL) is by bronchoalveolar lavage (BAL). Estab-
lished endpoint assays such as differential cell counts and interleukin-8 are not
disease specific and therefore may not validly report on CFTR function. Addition-
ally, some gene transfer agents have the potential to cause inflammation perse. We
hypothesised that more sensitive and specific markers of CFTR function and inflam-
mation would be detectable in ASL. SELDI-TOF mass spectrometry is able to
separate a complex mixture of proteins in a sample according to molecular weights
with attomolar sensitivity. SELDI-TOF was therefore used to compare BAL fluid
between children with and without CF. Methods: BAL was performed in 26 children
with CF and 24 non CF children (Primary Ciliary Dyskinesia or Lower Respiratory
Tract Infection). BAL was applied to cationic exchange and metal affinity SELDI
TOF chromatographic chip surfaces. Differential analysis of proteins was performed
and p values calculated with Mann–Whitney. Results: 27 proteins (5–70 kDa) were
revealed as being markedly different between CF and non-CF subjects (P-0.001).
Some of the proteins showed )95% sensitivity and specificity for CF compared
to non-CF respiratory disease. Protein identification is ongoing. Conclusion: Using
a proteomics approach, we have identified in CF BAL a panel of possible biom-
arkers of CFTR function and inflammation. The most discriminatory of these will
form the basis of secondary assays for CFTR function for use in gene therapy trials.
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Anti-neutrophil cytoplasmic antibodies (ANCA) against bactericidaly
permeability increasing (BPI) protein in serum and bronchoalveolar
lavage fluids of CF children
U. Ozcelik , A. Bakkaloglu , I. Cetin , E. Yalcin , D. Dogru , N. Kiper1 2 3 1 1 1
Hacettepe University Faculty of Medicine, Pediatric Chest Diseases Unit, Ankara,1
Turkey, Hacettepe University Faculty of Medicine, Pediatric Nephrology Depart-2
ment, Ankara, Turkey, Baskent University Faculty of Medicine, Pediatric Cardi-3
ology Department, Ankara, Turkey
The presence of ANCA has previously been observed in the sera of patients with
CF and BPI is the major ANCA antigen in CF. BPI is a protein found in neutrophil,
which has specific bactericidal activity for gram (y) bacteria. Aim: The aim was
to investigate the role of BPI in CF lung disease and to identify the relation between
BPI-ANCA and microorganisms in the lung. Method: We searched the IIF-ANCA
and BPI-ANCA in bronchoalveolar lavage fluid (BALF) and serum samples of 19
CF children, control group consisted of 8 children whom bronchoscopy was applied
due to other than infection and 7 children with bronchiectasis (BE) other than CF.
Results: In serum, IIF-ANCA was positive in 13y19 of CF patients, none of the
control group and 2y7 of the BE group. In BALF, IIF-ANCA was positive in 10y
19 of the CF patients, 2y8 of the control group and none of the BE group. In serum,
BPI-ANCA was positive in 3y19 of the CF patients, none of the control group and
2y7 of the BE patients. BPI-ANCA was positive in 1y19 of the CF patients and
none of the control and BE patients in BALF. BALF culture positivity was higher
in CF patients who had IIF-ANCA (q) in serum than CF patients who had IIF-
ANCA (y). BALF culture positivity was higher in CF patients who had IIF-ANCA
(q) patients in BALF than CF patients who had IIF-ANCA (y). P. aeruginosae
was not detected from BALF in all patients. Conclusion: In serum and BALF
samples, ANCA positivity other than BPI is very high in children with CF in our
patients. The reason of the low BPI positivity may be related to the lack of P.
aeruginosa existence in our CF group.
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Neutrophils isolated from cystic fibrosis delta F508 homozygotes do
not demonstrate a primary defect in superoxide anion production
D.J. McKeon , K. Cadwallader , E.R. Chilvers , D. Bilton , A.M. Condliffe1 2 1 2 1
Papworth Hospital, Papworth Everard, United Kingdom, University of Cam-1 2
bridge, Cambridge, United Kingdom
Introduction: The inflammation in cystic fibrosis is neutrophil mediated. Previous
studies have demonstrated excess superoxide anion production in CF neutrophils,
however these studies involved patients with mixed ages and genotypes and unre-
corded inflammatory status. We examined this hypothesis in an adult delta F508
homozygote CF population who were clinically stable. Method: Ten subjects were
selected from adult CF clinics, all colonised with Pseudomonas aeruginosa. Neu-
trophils were purified from peripheral blood by discontinuous Percoll gradients.
Neutrophils were isolated in parallel from age and sex matched healthy controls.
Inflammatory status was measured by C-reactive protein (CRP, mgyl). Chemilu-
minesence (CL) was performed using the probe lucigenin (0.25 mM-extracellular
reactive-oxygen species wROSx) or luminol (1 mM-intrayq extracellular ROS) in
freshly isolated neutrophils under the following conditions; GM-CSF (100 ngyml,
30 min), GM-CSF followed by fMLP (100 nM), fMLP or PMA (1 ngyml). Results:
Data were analysed using the Mann–Whitney test. With lucigenin CL signal was
identical in all conditions for CF and control. With luminol CL signal was identical
between CF and control in all conditions for median integral (AUC) and mean peak
height (MPH) except MPH with PMA (2.25"0.47 relative light units wRLUx and
126"0.49 RLU, P-0.05 respectively). Mean CRP levels were 5.6"1.5 in CF
subjects and 1.19"0.42 in controls, (P)0.05). Conclusion: These data suggest that
circulating neutrophils from delta F508 CF patients have normal fMLP-stimulated
respiratory burst responses under both primed and basal conditions. The minor
increase in PMA-stimulated superoxide anion responses is of uncertain significance
but concurs with the reported enhanced elastolytic capacity of CF neutrophils.
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Proteolysis of surfactant protein D (SP-D) in children with CF
N.G. Henderson, A.D. Postle, A. George, J.O. Warner
University of Southampton, Southampton, United Kingdom
Surfactant protein D (SP-D) is an important component of the innate host defence
of the lung but is susceptible to enzymatic degradation in the lung. In this study
we examined whether the reduced concentrations of SP-D seen in patients with CF
are caused by proteolysis of the protein by host cell-derived andyor bacterially-
derived enzymes. Proteolysis of SP-D in bronchoalveolar lavage fluid (BALF) from
children with CF (ns29) was determined by immunoblotting. Additionally native
human SP-D purified from amniotic fluid and a recombinant SP-D fragment were
treated with neutrophil and bacterial proteases with and without their specific inhib-
itors in an attempt to determine which proteases might cause the patterns of protein
degradation seen in the patient samples. At least 10 different sized products of SP-
D proteolysis below approximately 50 kDa (the size of normally reduced SP-D)
were detected in BALF fluid by immunoblotting. Proteolysis of native SP-D by
neutrophil elastase, proteinase 3 and Pseudomonas aeruginosa elastase generated
only one breakdown fragment while cathepsin G generated the same and one addi-
tional breakdown fragment. Quantification of SP-D blots by densitometry showed
a negative correlation between the proportion of neutrophils in BALF as determined
by differential cell count and the concentration of BALF SP-D. Initial indications
showed that the recombinant fragment of SP-D is also digested by these proteases.
This research demonstrates that SP-D is susceptible to degradation by a variety of
host and bacterially important CF proteases and has implications for the inclusion
of SP-D in proposed surfactant replacement therapies in CF.
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Adhesion and survival of CF airway neutrophils are increased on CFTR-
deficient respiratory cells
O. Tabary, H. Corvol, K. Chadelat, C. Fitting, J.M. Cavaillon, A. Clement, J. Jacquot
Inserm E213, Paris, France, Institut Pasteur, Paris, France1 2
Persistent presence and activation of polymorphonuclear neutrophils (PMNs) in
airways is the hallmark of cystic fibrosis (CF) disease. To assess whether there is
a CF-related anomaly of PMNs adherence, the rate of apoptosis and cytokine
responses when PMNs interact with airway epithelial cells, we examinated cocul-
tures of airway and blood PMNs with bronchial epithelial cells bearing mutated
CFTR (IB3-1) compared to corrected (C38) and normal (Beas2B) cell lines. Puri-
fied sputum and blood PMNs were collected from young children with CF and
other lung diseases compared to healthy adults. By FACS analysis, we showed that
spontaneous apoptosis of airway PMNs of CF patients was significantly greater to
that observed from CF blood PMNs (45% and 10%, respectively). In coculture, we
observed a significant increase of blood (by a 3.0 fold factor) and airway (by a
4.5 fold factor) PMNs adhesion on IB3-1 cells as compared to C38 and Beas2B
cells. We observed a significantly higher IL-6 and IL-8 production normalized to
adhered CF blood and airway PMNs with IB3-1 cells as compared to cocultures
with C38 and Beas2B cells. Apoptotic rate of adhered blood PMNs was signifi-
cantly higher in CF (45%) compared to healthy blood PMNs (10%) cocultured to
either IB3-1 or C38 or Beas2B cells. Interestingly, apoptotic rate of CF airway
PMNs adhered to IB3-1 was significantly lower (8%) as compared to that observed
with C38 (22%) and Beas2B (39%) cells. Our study shows that CFTR-deficient
airway cells limit CF airway PMNs apoptosis whereas CFTR-corrected and normal
airway cells did not. We speculate that prolonged survival of PMNs adhered to CF
airway epithelium may contribute to the airway inflammation in CF patients.
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Staphylococcus aureus-stimulated airway epithelial cells induce
human T lymphocyte chemotaxis through chemokines and chemokine
receptors modulation
S. Escotte , R. Le Naour , M. Merten , E. Puchelle , M. Guenounou , S.C.1 1 2 3 1
Gangloff1
REIMS, France, EMI INSERM 0014, Laboratoire de Pathologie Cellulaire et1
Moleculaire en Nutritio, REIMS, France, INSERM UMRS 514, IFR 532´
The airway epithelium is one of the first line of defense in the organism as it
provides a physical and immunological barrier against microorganisms and toxic
substances. In response to injuries like bacterial infections, the airway epithelium
is able to release pro-inflammatory cytokines leading to immune cell efflux involved
in the immune response, like neutrophils, macrophages or T cells. The aim of our
study is to analyze the effect of apical and basolateral airway epithelial cell culture
supernatants, stimulated by S. aureus (3 h), on T cells chemotaxis. Apical and
basolateral airway epithelial cell cultures supernatants induce a 1.6 and 2.3-fold
increase, respectively, on lymphocyte migration as compared to non-stimulated air-
way epithelial cell culture supernatants. The CD3q T cells and more specifically
the CD3qyCD4q T cell subset exhibited the highest chemotaxis capacity. These
chemotactic effect can be explained by an increase in polarized secretion of IL-8
and Eotaxin (5 to 12 fold) among other, in the apical and basolateral epithelial cell
culture supernatants. It can also be explained by the upregulation of CXCR1 and
CCR3 expression on the T cell subsets after contact with S. aureus-stimulated air-
way epithelial cell culture supernatants. Altogether, these results suggest that bac-
terial (S. aureus) infection induces rapidly the establishment of a chemical gradient
for lymphocyte chemotaxis as well as a modulation of the chemokine receptors
expression on T cell and as a consequence exacerbates their migration toward infect-
ed bronchial epithelial sites. This work was supported by Association Francaise¸
Vaincre la Mucoviscidose.
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Inflammatory markers in breath condensate in patients with cystic
fibrosis
M. Hofer, T. Rechsteiner, E.W. Russi, A. Boehler
Pulmonary Medicine, Adult Cystic Fibrosis Program, University Hospital, Zurich,¨
Switzerland
Background: TNF-alpha and IL-6 are two of the key cytokines in acute inflam-
matory response. Analysis of exhaled breath condensate (eBC) is a non-invasive
tool to measure inflammatory markers of the lung. Aim: To evaluate if TNF-alpha
and IL-6 is detectable in eBC in stable, ambulatory patients with cystic fibrosis
without and with lung transplantation (LTx) and in healthy individuals. Methods:
Exhaled breath condensate was collected over a 10 minute period with a tidal
volume of 1000 ml. TNF-alpha and IL-6 concentrations were measured using EIA.
Statistical comparisons were done with unpaired t-test. Results: 11 healthy controls
(mean age 42"13 years) and 11 patients with cystic fibrosis (mean age 36"10
years) were evaluated: 4 stable patients without LTx (mean FEV1 1.5"0.4L,
44"18% predicted) and 7 stable patients after LTx (mean time after LTx 3.4"1.9
years; mean FEV1 2.8"0.9, 83"19% predicted). TNF-alpha was measurable in 8
of the 11 patients (mean concentration 0.30"0.12 pgyml) and in 10 of the 11
healthy controls (mean concentration 0.35"0.17 pgyml). On the other hand IL-6
was only measurable in 2 of the 11 patients (mean concentration 0.12"0.02 pgy
ml) and in 5 of the 11 healthy controls (mean concentration 0.05"0.01 pgyml).
There was no statistically significant difference between the three groups. Conclu-
sions: TNF-alpha is measurable in eBC in healthy controls and in stable patients
with cystic fibrosis. We found no significant differences in concentration in the
control group and in patients with cystic fibrosis without and with LTx. On the
other hand IL-6 was only measurable in 2 of the 11 patients (in no patient without
LTx) and in 5 of the 11 healthy controls. TNF-alpha in eBC may serve as a marker
of inflammation.
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Inhibition of p38 mitogen-activated-protein-kinase controls neutrophil
migration and IL-8 production in human cystic fibrosis nasal polyps
explants
V. Raia , L. Maiuri , I. Ricciardelli , L. Vacca , S. Auricchio , M. Cimmino , A.1 2 2 1 1 3
Cesaro , M. Cavaliere , M. Nardone , C. Ciacci , J. Malcolm , S. Quaratino , M.3 3 3 4 2 5
Londei2
Department of Pediatrics, University of Naples Federico II, Naples, Italy, Institute1 2
of Child Health, University College London, London, United Kingdom, Department3
of Otolaryngology, University of Naples Federico II, Naples, Italy, Department of4
Gastroenterology, University of Naples Federico II, Naples, Italy, Cancer Research5
UK, University of Southampton, Southampton, United Kingdom
A chronic inflammatory response, characterized by increased IL-8 secretion, neu-
trophil migration and degranulation is a characteristic trait of Cystic Fibrosis (CF)
respiratory airways. This inflammatory response is a main concern for the treatment
of CF patients as it is the principal factor of morbidity and ultimately mortality in
these patients. The correct management of the chronic inflammatory response is
therefore at the core of basic and clinical CF research. A few reports have been
dealing with strategies to manage airways inflammation in CF patients. An attractive
therapeutic target to control inflammation in CF is the inhibition of the p38-MAP-
kinase pathway. In the present study we have explored whether inhibition of the
p38-MAP-kinase can control IL-8 secretion, neutrophil activation and migration, in
ex-vivo cultures of nasal polyps explants from CF patients and controls. The results
we obtained indicate that inhibition of the p38-MAP-kinase pathway is extremely
effective in blocking IL-8 release, neutralizing neutrophil migration and degranu-
lation as well as other signs of inflammation. With this study, in which human
respiratory CF tissue has been used to test our hypothesis, we provide the rationale
and proof-of-principle for the potential clinical use of p38-MAP-kinase inhibitors
to control inflammation in CF patients.
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Preservation of the inhibitory capacity of EPI-hNE4, a potent neutrophil
elastase inhibitor, in the presence of oxidants and CF sputum-
associated proteases
S. Attucci, B. Korkmaz, E. Hazouard, F. Saudubray, F. Gauthier
INSERM U618, Tours, France, Debiopharm SA, Lausanne, Switzerland1 2
The proteaseyantiprotease imbalance is a key feature of cystic fibrosis. A number
of elastase inhibitors have been designed for an aerosol-based, anti-inflammatory
therapy. Resistance to the physical constraints of nebulization and to the adverse
environment found in CF sputum are the main features for such therapeutic inhib-
itors. We have further characterized the physicochemical properties of EPI-hNE4,
a potent inhibitor of human neutrophil elastase (HNE) engineered by phage display
from the second Kunitz domain of the light chain of the natural inter-a-trypsin
inhibitor (ITI). We studied its resistance to oxidation and to proteolysis in com-
parison with a1-PI. The serine and metalloproteases (protease 3, cathepsin G,
MMP-8 and MMP-9), that are secreted by activated neutrophils or released from
dead cells at inflammatory sites, were assayed for this purpose, as well as MMP-
7, a matrix metalloprotease released from epithelial lung cells, and the bacterial
metalloproteases pseudolysin and aeruginolysin produced by Pseudomonas aeru-
ginosa. We also tested the ability of EPI-hNE4 to inhibit membrane-bound HNE
and whole-sputum HNE. Since CF patients also suffer from digestive disorders and
part of aerosolized HNE rapidly reaches the digestive tractus, we also checked that
EPI-hNE 4 did nor interfere with the activity of pepsin and pancreatic elastase. The
results show that EPI-hNE4 is more resistant than a1-PI to oxidation and proteol-
ysis. It inhibits membrane-bound HNE, and remains fully active in whole CF spu-
tum. EPI-hNE4 appears therefore as an efficient inhibitor of HNE potentially able
to control HNE activity in CF patients with Pseudomonas infection upon aerosol
administration.
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Airway inflammation and remodelling in children with cystic fibrosis
T.N. Hilliard , N. Madden , A.G. Nicholson , J. Shute , E.W.F.W. Alton , J.C.1 2 2 3 1
Davies , A. Bush1 2
Imperial College, London, United Kingdom, Royal Brompton Hospital, London,1 2
United Kingdom, University of Portsmouth, Portsmouth, United Kingdom3
Introduction: The airway inflammatory response is exaggerated in cystic fibrosis
(CF), but there is little information on the relationship between inflammation and
structural airway changes in early stage disease. We aimed to compare this rela-
tionship between CF and other inflammatory lung diseases. Methods: Flexible bron-
choscopy was performed for clinical reasons in 3 groups of children: (i) CF, (ii)
Primary ciliary dyskinesia (PCD), and (iii) recurrent respiratory tract infections
(RTI). Bronchoalveolar lavage (BAL) and endobronchial biopsy were performed
under standardised conditions. Results: 53 children underwent bronchoscopy (27
CF, 6 PCD, 20 RTI). 49 biopsies were available, of which 33 allowed measurement
of reticular basement membrane (RBM) thickness (67%; 16 CF, 5 PCD, 12 RTI).
Both CF and PCD groups had raised neutrophil and Interleukin 8 (IL-8) concen-
trations compared to the RTI group (Table 1). RBM was thickened in the CF group
but this was not predicted by age, bacterial count, or cell counts.
Table 1. Data are expressed as median and wrangex
Age years Neu 10 yml6 IL-8 pgyml RBM mm
CF 6.6 0.7 1150 6.1
w0.3–14.3x w0–24.0x w16–11 600x w3.9–9.1x
PCD 9.8 2.3 1075 5.2
w5.7–14.8x w0.1–13.8x w360–21 100x w3.4–9.8x
RTI 4.6 0.01 122 4.4
w0.9–13.6x w0–0.2x w15–1796x w3.2–8.4x
p (CF vs RTI) ns -0.001 -0.01 -0.05
Conclusions: This study provides evidence of remodelling within the airways of
children with cystic fibrosis. There are similar levels of BAL inflammatory markers
in CF and PCD. There is however no clear relationship between RBM thickening
and inflammation within the airway lumen.
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Treatment with montelukast sodium in CF patients
I. Stelmach, A. Korzeniewska, T. Grzelewski, P. Majak
Department of Pediatrics and Allergy, M. Curie Hospital, Zgierz, Poland
The purpose of this study was to define the effect of treatment with montelukast
on lung function and inflammatory markers in CF patients. Material and methods:
It was 20 week, randomized, double blind, placebo-controlled, cross-over trial. We
examined 14 CF patients, aged 6–29. Patients received montelukast (5 or 10 mg
once daily oral tablet, according to age) or placebo for 8 weeks and then, after a
washout 4-week period, crossed over to receive the alternative treatment. FEV1 (%
of predicted value) and sputum and serum levels of ECP (mgyl), IL-8 (pgyml),
IL-10 (pgyml) and MPO (ngyml) were measured on first and last days of each
treatment block. Results: All 14 patients completed the study. Compared with pla-
cebo montelukast significantly improved FEV1 (Ps0.0021); serum (P1) and spu-
tum (P2) concentration of ECP (P1, P2-0.0001), IL-8 (P1, P2-0.0001), MPO
(P1s0.0010, P2-0.0001) significantly decreased; concentration of IL-10 (P1s
0.0001, P2-0.0001) significantly increased. Montelukast resulted in within-group
decrease in concentrations of serum markers (mean"SD): ECP (21.7"12.1 before
and 4.9"2.7 after treatment, Ps0.0010), IL-8 (9.57"3.95 vs. 4.39"3.17, Ps
0.0019), increase in concentration of IL-10 (10.39"1.59 vs. 16.9"4.4, Ps0.0019)
and improvement in FEV1 (55.6"22.6 vs. 61.0"19.0, Ps0.0142) after treatment.
Sputum markers measurements showed decreased concentrations of ECP
(159.9"51.1 vs. 57.2"49.4, Ps0.0010), IL-8 (564.71"383.06 vs.
287.22"318.45, Ps0.0010), MPO (4.54"2.69 vs. 3.59"2.10, Ps0.0010) and
increased concentrations of IL-10 (9.27"3.26 vs. 23.94"9.71, Ps0.0010) within
montelukast group. Conclusion: These results indicate that montelukast improved
lung function and has measurable anti-inflammatory properties in CF patients.
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Evaluating pulmonary inflammation with radiolabeled
fluorodeoxyglucose and positron emission tomography in patients with
cystic fibrosis
D. Chen, J. Pittman, D. Rosenbluth, T. Ferkol, S. Schuster
Washington University School of Medicine, St Louis, United States
Introduction: Currently, few effective, non-invasive methods exist to monitor dis-
ease activity in cystic fibrosis (CF), particularly neutrophilic inflammation. Positron
emission tomography (PET) imaging with radiolabeled fluorodeoxyglucose (FDG)
has recently been used to detect acute neutrophilic inflammation in a variety of
settings, including lung disease. This study was designed to evaluate if FDG-PET
imaging could be used to monitor lung inflammation in CF. Methods: We studied
6 stable CF patients (ages 19–50 years). Patients with diabetes were excluded.
FDG (;10 mCi) was administered intravenously, followed by 66 min of dynamic
image acquisition. The influx constant (K ), a measure of net FDG uptake in thei
tissue, was calculated by Patlak graphical analysis. The tissueyplasma activity ratio
(TPR), a correlate of the K , was also calculated at the end of the scan. Results:i
Mean forced expiratory volume in 1 s (FEV-1) at the time of study was 2.39"0.10
l (64"21% predicted). The mean K for all lung regions was 15"9=10 mly4i
bloodyml lung tissueymin (normal range: 3–8=10 ). Mean TPR was 0.36"0.12y4
ml bloodyml lung and correlated strongly with K (R s0.72). Mean neutrophil2i
count from BAL was 4.6"7.8=10 cellsymm (67"20% of total cell count) and3 3
was also positively correlated with K and TPR (R s0.83 and 0.79, respectively).2i
The annual rate of FEV-1 decline also correlated with K (R s0.72). Conclusion:2i
PET imaging may be an useful, non-invasive alternative to BAL to measure pul-
monary neutrophilic inflammation in CF. The TPR may be a simple and effective
alternative to dynamic imaging. Supported by grants from the National Institutes
of Health (HL64044) and Cystic Fibrosis Foundation.
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Polymorphisms of TGF-b1 in CF patients
J. Brazova , K. Sismova , O. Cinek , J. Bartosova , A. Sediva1 2 3 4 5
Institute of Immunology, University Hospital Motol, Prague, Czech Republic,1
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Clinic, University Hospital Motol, Prague, Czech Republic, Institute of Immunol-5
ogy, University Hospital Motol, Prague, Czech Republic
Introduction: CF patients present with large phenotypic variance. Due to the role
of TGF-b1 in fibrotic processes we therefore investigated possible influence of
TGF-b1 gene polymorphisms on the phenotype of CF. Methods: TGF-b1 codons
10 and 25 genotypes were determined in 118 CF patients and 268 controls by PCR-
ARMS. Production of TGF-b1 was measured in 40 CF patients and 10 controls in
the supernatants of whole blood cell cultures. Corresponding TGF-b polymorphism1
and production were compared with lung functions (LF) and clinical status (CS).
Results: The CF patients showed similar pattern of polymorphisms as controls, with
the exception of lower frequency of TyT homozygotes on codon 10 (CF 29%,
controls 42%, P Yates 0.02, 95% CI 0.35–0.89, OR 0.56) and higher frequency of
GyC heterozygotes on codon 25 (CF 16%, controls 8%, P Yates 0.03, 95% CI
1.11–4.14, OR 2.15). Range of TGF-b production, wide in controls, appeared even1
broader in CF. The highest levels of TGF- were found in patients chronically1
colonized with P. aeruginosa, impaired LF and CS. However patients with very
low levels of TGF-b1 presented with worse LF too. Conclusion: None of the tested
polymorphisms was associated with impaired TGF-b1 production. Independently
of the genetic pattern, the CF patients differ widely in the production of the cyto-
kine. Both extreme ends, high or low TGF-b1 production, are associated with
impaired LF. Supported by MZCR IGA: 00000064203; NIy7468-3.
New Therapies
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A long duration ß2-adrenergic receptor agonist increases cAMP-
induced chloride secretion in human normal and CF-corrected airway
epithelial cells
N. Castillon , A. Avril-Delplanque , J.M. Zahm , M. Merten , O. Danos , T.1 2 1 3 2
Chinet , E. Puchelle4 1
INSERM UMRS 514, CHU Maison Blanche, Reims, France, GENETHON, CNRS,1 2
UMR 8115, Evry, France, INSERM 00-14, Faculte de Medecine, Nancy, France,3 ´ ´
UPRES EA 220, UFR Paris Ile de France Ouest, Boulogne, France4
We have earlier shown that CFTR protein expression is increased by exposure to
a long duration b -adrenergic agonist– salmeterol – in non-CF human airway epi-2
thelial cells (Taouil et al., J. Biol. Chem., 2003, 278, 17 320–7). We address the
question of whether cAMP-induced chloride secretion could be increased by a 24
h pre-incubation with salmeterol (2=10 M) in human airway glandular epithelialy7
cell lines, either normal, CF airway cells-DF508 homozygous-(MM-39 and KM4
respectively) or CF cells transduced by a lentiviral vector encoding the cDNA-
CFTR and pseudotyped with the vesicular virus glycoprotein (VSV-G). The effi-
cient CFTR lentiviral transduction of CF airway cells was assessed by RT-PCR and
Western blotting. Chloride secretion was assessed by image analysis using the flu-
orescent SPQ probe and by measuring the changes of fluorescence (DFyDt) after
amiloride (10 mM) and forskolin (25 mM) sequential stimulation. Compared to
non pre-treated airway cells, salmeterol induced, in non-CF airway and CF corrected
airway cells, an almost two-fold significant (Ps0.005) increase in chloride secre-
tion. No significant increase was observed in non-corrected CF airway cells with
salmeterol pre-treatment. These results demonstrate that salmeterol increases cAMP-
induced chloride secretion in non-CF but not CF airway epithelial cells and that
the transduction of CF airway cells with cDNA-CFTR lentiviral vector, associated
with salmeterol treatment, exerts a synergistic effect allowing restoration of a
cAMP-chloride secretion in CF airway cells. This work was supported by
INSERMyAFM, GlaxoSmithKline and Association Vaincre la Mucoviscidose.
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Heparin inhibits neutrophil transendothelial migration with the same
potency as the PDE-4 inhibitor cilomilast
V.J. Broughton-Head, J.K. Shute
School of Pharmacy and Biomedical Sciences, Institute of Biomedical and Miom-
lecular Sciences, University of Portsmouth, Portsmouth, United Kingdom
An over-exaggerated, self-amplifying, neutrophilic inflammatory response to chron-
ic infection in the CF airways, leads to neutrophil elastase-mediated tissue damage,
bronchiectasis and respiratory failure. Heparin has been suggested to inhibit airway
inflammation and since the endothelium is the primary barrier to IL-8-dependent
neutrophil recruitment to the CF lung we compared the effect of heparin with the
PDE-4 inhibitor, cilomilast, on neutrophil transendothelial migration. HUVECs
were grown to confluence on collagen-IV coated Transwells. IL-8 (10 M) wasy8
added to the lower well for 1 hour at 37 8C. Normal neutrophils were isolated by
dextran sedimentation and separation on Lymphoprepand resuspended in HBSS,
20 mM Hepes, 2.5 % FCS at 2=10 cellsyml. Neutrophils and HUVECs were6
treated with heparin (0.1–100 mgyml) or cilomilast (10 –10 M) for 30 miny8 y6
prior to addition of neutrophils (300 ml) to the upper well. Transwells were incu-
bated at 37 8C for 4 h. Transmigrated neutrophils were quantified using a myelo-
peroxidase assay. Heparin and cilomilast inhibited neutrophil migration in a
dose-dependent manner.
Heparin (mgyml) Response (%) Cilomilast (Log M) Response (%)
0 100 0 100
0.1 72.3"7.5 y8 108.6"14.1
1 51.9"4.1 y7.5 61.0"14.7
10 46.71"9.8 y7 44.6"5.9
100 23.7"1.9 y6 29.1"7.4
The IC for heparin (99.5"44.1 nM) was not significantly different to 117.2"42.550
nM for cilomilast. Inhibition of neutrophil transendothelial migration by heparin
indicates that non-anticoagulant forms of heparin may prove useful inhibitors of the
excessive neutrophil-mediated inflammatory response in cystic fibrosis. Supported
by a University of Portsmouth studentship.
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Effect of charged oligosaccharides on drug delivery through DNA
networks in CF sputum
J. Shur, V. Broughton-Head, J.R. Smith, J.K. Shute
University of Portsmouth, Portsmouth, United Kingdom
Oligosaccharides are reported to decrease mucus viscoelasticity by disrupting inter-
actions between DNA, actin and mucin polymers present in CF sputum. We inves-
tigated the effects of oligosaccharides on DNA networks using atomic force
microscopy (AFM) and their ability to improve transport of FITC-dexamethasone
through DNA barriers and CF sputum. DNA (0.1 mgyml) was treated with oli-
gosaccharides (unfractionated heparin (UFH), low-molecular weight heparin
(LMWH), dextran and dextran sulphate) in the concentration range 0.1 mgyml–1
mgyml, at 37 8C for 1 h. Samples were dialysed and analysed using AFM. In the
barrier assay, DNA (5 mgyml) was added into the upper wells of a microBoyden
chamber and over-layered with oligosaccharide solutions. CF sputum was pre-incu-
bated with oligosaccharides for 2 h at 37 8C and added to the upper well. Barriers
were over-layered with FITC-dexamethasone and incubated for 1 h at 37 8C after
which fluorescence in the lower wells was analysed. Pore size of the DNA network
(0.38"0.03 mm) was significantly (P-0.05) increased by UFH and LMWH at all
concentrations. Dextran sulphate was only effective at 0.1–1 mgyml, while, dextran
significantly (P-0.05) reduced pore size. UFH and LMWH (10 mgyml) signifi-
cantly (P-0.05) increased drug transport through DNA barriers, while dextran
sulphate had no significant effect. However, dextran significantly (P-0.05) reduced
transport through the DNA barrier. Importantly, UFH (0.1–1 mgyml) significantly
(P-0.05) increased drug transport through CF sputum. Therefore, UFH may be
an effective mucoactive agent, improving drug delivery in CF. Supported by a
University of Portsmouth studentship.
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Sildenafil (Viagra) increases trafficking ofDF508-CFTR in nasal
epithelial cells from CF patients
C.M. Harris , Z.E. Clark , M.M.C. Pereira , I.J.M. Doull , C. Norez , F. Becq ,1 1 1 2 3 3
M.A. McPherson , R.L. Dormer1 1
University of Wales College of Medicine, Cardiff, United Kingdom, University1 2
Hospital of Wales, Cardiff, United Kingdom, Universite de Poitiers, Poitiers,3 ´
France
The most common mutation in CFTR (DF508) results in abnormal location of
DF508-CFTR within the cell, rather than at the apical membrane. The aim is to
identify pharmacological agents that move DF508-CFTR to the apical membrane
in native cells from CF patients. Nasal epithelial cells were obtained by brushing
from four DF508yDF508 CF individuals and incubated in the presence or absence
of sildenafil for 2 h at 37 8C. CFTR location was determined by immunofluoresc-
ence and confocal imaging. The effect of sildenafil treatment on CFTR Cl trans-y
port was measured in CF15 cells using an I efflux assay. In non-CF cells, CFTR125
showed an apical location whereas in CF cells, DF508-CFTR was abnormally locat-
ed, close to the nucleus. Sildenafil had no effect on the location of wild type CFTR
but caused a dramatic relocation of DF508-CFTR in CF cells. Thus following sil-
denafil (150mM) treatment, the number of CF cells having DF508-CFTR at an
apical location was increased from 10"1% to 32"5% (P-0.05) and the number
having an abnormal intracellular location was decreased from 65"8% to 34"2%
(P-0.05). Sildenafil treatment also resulted in the appearance of CFTR Cl trans-y
port. Thus pretreatment of CF15 cells with sildenafil restored stimulation of I125
efflux in response to the CFTR agonists forskolin and genistein. Sildenafil did not
affect the location of other normal cell proteins, indicating selectivity of action. The
data suggest direct interaction of sildenafil with DF508-CFTR causing rescue of the
mutant protein. The finding that a drug in clinical use, Viagra, corrects DF508-
CFTR location provides a major step towards developing a drug treatment for CF.
We are grateful to WORD, Pfizer Pharmaceuticals, VLM, and the CF Trust for
financial support.
s28 Journal of Cystic Fibrosis 3 (2004) S27–S31
94
Exploration of bronchoalveolar lavage (BAL) constituents before and
after the inhalation of glutathione (GSH) in cystic fibrosis
M. Griese , D. Hartl , V. Starostov , C. Rebhan , K. Maier , I. Beck-Speier , B.1 1 1 1 5 5
Becker , J. Ramakers , P. Latzin , S. van Koenigsbruggen , R. Huber , F. Ratjen ,6 1 1 2 3 4
S. Kraus-Etschmann , E. Rietschel1 2
Department of Paediatrics, Ludwig Maximilians University, Munich, Germany,1
Department of Paediatrics, University of Cologne, Cologne, Germany, Depart-2 3
ment of Internal Medicine, Ludwig Maximilians University, Munich, Germany,
Department of Paediatrics, University of Essen, Essen, Germany, GSF, Neuher-4 5
berg, Germany, Department of Physiology, Munich, Germany6
GSH is a major antioxidant and involved in redox regulated signal transduction,
cell proliferation, remodeling of extracellular matrix, apoptosis, and the conservation
of the anti-protease capacity of the lungs. Optimized inhalation of GSH for 14 days
in CF patients increased the level of GSH up to 12 h later (AJRCCM 2004, in
press). In 17 pairs of lavages from our previous study, secondary outcome variables
were explored. The number and percentage of CD4q and of CD8q lymphocytes
was increased 7–10-fold in BAL, whereas there was no change in peripheral blood.
Also the expression of CCR5 on both lymphocyte subclasses was increased 7–10-
fold with GSH treatment. Various other lymphocyte markers did not change. The
lavage levels of IL-1, IL-2, IL-4, IL-6, IL-10, TNFa, INFg, G-CSF, MCP-1 and
MIP-1 did not differ with treatment. Overall oxidation of lavage proteins, assessed
as protein carbonylation, of the lavage lipids (8-isoprostanes), PGE -concentrations,2
and the level of uric and ascorbic acid were not significantly changed. In urine, 8-
isoprostanes, corrected for creatinine were not different before and after the inha-
lation of GSH. Despite a significant increase of reduced GSH in BAL, the oxidation
of lavage proteins was not reduced by GSH. The increases in CD4q and of CD8q
lymphocytes and their CCR5 receptors was not associated with changes of a broad
range of cytokines and chemokines. These unexpected effects of inhaled GSH sup-
port its immunoregulatory role in patients with CF, known from in vitro studies and
necessitates further comprehensive evaluation. Supported by Mukoviszidose e.V.,
Bonn and CF-Selbsthilfe.
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Inducing immunological tolerance to allow repeated administration of
recombinant Sendai virus vector to the murine airways
U. Griesenbach , R. Boyton , L. Somerton , S. Escudero Garcia , S. Ferrari , T.1 2 1 1 1
Owaki , Z. Ya-Fen , D.M. Geddes , M. Hasegawa , D. Altman , E.W.F.W. Alton1 3 3 3 4 1
Department of Gene Therapy, NHLI, Imperial College, London, United Kingdom,1
Lung Immunology Group, Department of Biological Sciences, NHLI, Imperial Col-2
lege, London, United Kingdom, DNAVEC Research Inc., Tsukuba, Japan, Human3 4
Disease Immunogenetics Group, Department of Infectious Diseases, NHLI,, Lon-
don, United Kingdom, UK Cystic Fibrosis Consortium, London, United Kingdom5
Sendai virus (SeV) is currently the only viral vector that transfects airway epithelial
cells efficiently in vivo. However, as for any other viral vector repeated adminis-
tration, leads to a significant drop in gene expression. Induction of immunological
tolerance may permit repeated administration of the SeV vector. To achieve this we
investigated the induction of immunological tolerance using CD4q and CD8q T
cell immunodominant epitopes of SeV. These peptides (100 mgymouse) or a control
peptide were administered to the lungs of C57Bly6 mice (female, 6–8 weeks) via
‘‘sniffing’’ 10 days before the first virus administration (dFySeV-GFP 10 pfuy6
mouse). 21 days after the first virus administration, mice were repeatedly transfected
with dFySeV. To avoid interference from anti-GFP antibodies, the second transfec-
tion was carried out with dFySeV-lacZ (10 pfuymouse). Two days after dFySeV-7
lacZ administration all animals were culled. The lungs were harvested for bgal
quantification and T-cell proliferation in response to the immunodominant epitopes
was assessed to determine immunological tolerance. In addition serum was collected
to measure anti-SeV neutralising antibodies. Administration of peptide 1 or 2 and
1q2 reduced CD4 and CD8 T-cell proliferation ex vivo after re-challenge with the
respective protein by )60%. bgal expression following a second administration of
SeV in mice receiving no peptide or the control peptide was 40–50% lower com-
pared to mice that only had a single administration. Administration of the peptides
did not elevate expression levels over levels measured in these control groups. This
result indicates either that T cell responses need to be further reduced or that
immune mechanisms other than T cells play a major role in eliminating SeV.
U. Griesenbach and R. Boyton both contributed equally to the above work.
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Transendothelial transport studies of polymer-based gene delivery
systems
E. Mennesson , P. Sandrin , C. Kieda , P. Erbacher , P. Midoux , C. Pichon1 1 1 2 1 1
Centre de Biophysique Moleculaire, CNRS UPR4301, Orleans, France, Polyplus1 2´ ´
transfection SA, Strasbourg, France
These last decade, efforts have been made to design polymer-based gene delivery
systems that incorporate viral-like features for powerful transfection. Efficient sys-
temic administration of these systems will be achieved when DNA-polymer com-
plexes (polyplexes) can get over endothelium barrier to reach the underlying target
cells. Our goal is to investigate the transendothelial passage of polyplexes made
either with histidylated polylysine (His-pLK) or polyethyleneimine (PEI). We have
optimized culture conditions to get highly polarized monolayers of a human lung
microvascular endothelial cell line (HLMEC) and of a CF human airway epithelial
cell line (SCFTE29o-). Cytometry experiments were conducted to evaluate the
transcytosis rate and the influence of cell polarization on the uptake and the trans-
fection efficiency of these polyplexes. These polyplexes were both well taken up
by HLMEC. But, His-pLK polyplexes were internalized through a clathrin-inde-
pendent pathway, while PEI polyplexes were endocytosed through clathrin-coated
vesicles. Unfortunately, transendothelial transport of plasmid complexed with these
cationic polymers was barely detected even after 4 h at 37 8C. However, it can be
increased by coating His-pLK polyplexes with serum albumin. Cell polarization has
an influence on polyplexes transfection efficiency. That of His-polyplexes was
dependent on the cell type: it decreased 10-fold in polarized HLMEC and did not
vary with SCFTE29o- polarization. In these latter, PEI- and His-polyplexes exhib-
ited a similar efficiency. By contrast, PEI was 1000-fold more efficient in polarized
HLMEC. Experiments are in progress to increase EC selectivity with chemokine-
targeted polyplexes. Time-lapse videomicroscopy under flow conditions is per-
formed to evaluate the targeting.
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Evidence for long-term epithelial chimerism in children following sex-
mismatched lung transplantation
H. Spencer , D. Rampling , P. Aurora , D. Bonnet , S.L. Hart , A. Jaffe1 2 1 4 3 1
Portex Respiratory Unit, Great Ormond Street Hospital for children NHS Trust,1
London, United Kingdom, Histopathology Department, Great Ormond Street Hos-2
pital for children NHS Trust, London, United Kingdom, Molecular Immunology3
Unit, Institute of Child Health, University College London, London, United King-
dom, Cancer Research UK, London, United Kingdom4
Recent reports have shown evidence of host-derived parenchymal engraftment in
several human allografts, including the adult lung, however long term engraftment
has never been shown. Aim: We examined archived transbronchial tissue at several
time points for evidence of long term chimerism from two male children, aged 11
and 13 years, with cystic fibrosis who had received a female heart-lung transplant.
Methods: Sections were dual stained for cytokeratin (epithelium) and a mixture of
leucocyte common antigen (CD45) and CD68 to exclude white cells. The same
section was then examined by fluorescent in-situ hybridisation to identify male cells.
Multi-section confocal microscopy was used to assess fusion. Results: We found
evidence of chimerism in (0–6.7%) epithelial cells: bronchial, median 1.4% (range
0–6.6%), alveolar, 3.6% (2.3–5.5%). No fusion was seen. This engraftment was
seen as early as 3 weeks and remained relatively constant up-to 37 months post
transplant. We found a large number of Y chromosome positive cells, which did
not co-stain for cytokeratin, CD45 or CD68, which may be endothelial cells or
fibroblasts. Conclusion: We have shown for the first time, longitudinal evidence of
host derived epithelial cells in two sex-mismatched transplanted lungs, without
apparent evidence of cell fusion. This raises the possibility of stem cell therapy for
the treatment of lung diseases such as CF. This work was made possible by a grant
from the Cystic Fibrosis Trust.
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Repeat administration of adenoassociated virus in murine airways
S.G. Sumner-Jones, A. Varathalingam, D.R. Gill, S.C. Hyde
UK Cystic Fibrosis Gene Therapy Consortium, NDCLS, University of Oxford,
Oxford, United Kingdom
In recent years, research into viral vectors for cystic fibrosis (CF) lung disease has
focussed on adenoassociated virus (AAV). Recombinant AAV demonstrates long
term expression in a variety of tissues, probably through a combination of the
absence of viral coding sequences that may otherwise induce an immune response
to transduced cells, and the persistence of recombinant genomes episomally or inte-
grated into chromosomal DNA. rAAV5 in particular has emerged as an interesting
candidate for lung gene therapy because it binds to sialic acid, found on the apical
surface of epithelial cells. We, and others, have shown that rAAV5 transduction in
mouse lungs persists for at least 32 weeks (9.69"3.17 RLUymg protein) close to
peak levels (week 4: 15.1"4.43 RLUymg protein, ANOVA on log-transformed
data: Ps0.023). However it is likely that the life-long expression of a therapeutic
gene needed for diseases such as CF will require repeat administration, since the
target cells in the airways are terminally differentiated. As yet, little research has
focussed on the repeat administration of rAAV5. Analysis of serum antibodies over
our 32-week time course study shows that anti-AAV antibody levels in the blood
reach peak levels by 4 weeks and remain high throughout the following 28 weeks.
We will present data demonstrating that repeat administration of rAAV5 carrying
different reporter genes to the lung, with an 8-week gap between instillations, leads
to some reporter gene expression on second administration (0.23"0.06 RLUymg
protein, ANOVA Ps0.016 compared with naıve mice), but none with a third dose.¨
We are currently investigating the effect of an increased gap between administra-
tions, and of a soluble CTLA4-expressing rAAV5 on the ability to repeat administer
this virus.
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Evaluating gene transfer products for gene expression in mouse nasal
epithelium
B.L. Jones, S.G. Sumner-Jones, D.R. Gill, S.C. Hyde
UK Cystic Fibrosis Gene Therapy Consortium, NDCLS, University of Oxford,
Oxford, United Kingdom
As part of the UK Cystic Fibrosis Gene Therapy Consortium, we are aiming to
identify gene transfer agents (GTA) that are candidates for delivery of CFTR to
human airways. Typically, products identified from the literature or developed by
members of the Consortium, including targeting peptides (e.g. HIV-TAT), lipidsy
liposomes (e.g. GL67) and polymers (e.g. JetPEI), are tested in a series of assays,
through which products can be evaluated systematically. The GTA are screened first
in the mouse nose using a luciferase reporter gene to identify promising formula-
tions; these are then taken through to our nPD (nasal potential difference) core
facility where changes in conductance of nasal airway are measured in CF mice
after treatment with a CFTR-encoding plasmid in the chosen formulation. The next
stage is aerosolisation of the GTA in sheep lungs, which models the physical deliv-
ery of our chosen GTA, in anticipation of human clinical trials. The initial testing
in the mouse nose involves the perfusion of 100 ml of GTA into the left nostril of
C57BL6 mice over 159. Our studies are powered at 0.8–0.95 with ns6–8 per
group. Luciferase and protein assays (with intra- and inter-assay variabilityF10%)
are combined to give activity in relative light unitsymg protein. The GTA are tested
in standardised conditions, including a dose response starting from the Maximum
Feasible Dose (MFD) to one tenth of MFD. Additionally, various ratios of com-
ponents can be tested. In the last 6 months, we have tested over 20 GTA. We
anticipate being able to test 1–2 novel products per week. We will show examples
of the iterative process required to optimise airway specific gene expression of a
particular GTA prior to its progression to the next stage of evaluation.
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Transgene expression in the mouse lung following administration of
gene transfer vectors expressing EGFP
L.A. Davies , A. Varathalingham , S.H. Cheng , S.C. Hyde , D.R. Gill1 1 2 1 1
UK Cystic Fibrosis Gene Therapy Consortium, Oxford, United Kingdom, Genzyme1 2
Corporation, Framingham, United States
The murine lung has served as a model for the evaluation of a variety of gene
therapy vectors for cystic fibrosis lung disease. Many studies have focussed on
enhancing overall gene expression in the lung but few have examined if expression
can be demonstrated in the ciliated epithelial cells believed to be the major target
for cystic fibrosis gene therapy. We evaluated transgene expression in the murine
lung using vectors incorporating the red-shifted variant of green fluorescent protein
(EGFP). BALByc mice were dosed intranasally with 300 mg of the plasmid p-
EGFP-N1 or 80 mg of pEGFP-N1 complexed to the cationic lipid GL67 (Genzyme,
Framingham, USA). 24 h after vector administration, 7 mm cryosections were pre-
pared from lung tissues and examined for GFP expression. GFP positive cells were
identified in all treated mice with a mean expression of 347"280 positive cells in
sections from animals dosed with pEGFP-N1. The majority (79%) of these cells
were located in the epithelium of conducting airways and the remainder (21%)
were located in the lung parenchyma. Subsequent immunohistochemical analysis
revealed that most of these GFP positive cells were ciliated epithelial cells. In mice
treated with DNAyGL67, 2020"435 GFP positive cells per mouse were observed.
In contrast to naked DNA the majority (99.4%) of GFP positive cells were located
in the lung parenchyma and only a very small number (0.6%) were observed in
the conducting airway epithelium. Antibody staining demonstrated that the majority
of GFP positive cells in mice treated with DNAyGL67 were Type I pneumocytes.
These data reflect that GFP expression is a robust first step in the detection and
identification of cell types targeted by gene transfer vectors in the mouse lung.
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Direct electroporation of the murine lung greatly enhances reporter
gene expression following intranasal delivery of plasmid DNA
I.A. Pringle , S.G. Sumner-Jones , A.E. Lawton , A. Varathalingam , A.E.1 1 1 1
Lawton , D.R. Gill , S.C. Hyde1 1 2
GeneMedicine Research Group, NDCLS, University of Oxford, Oxford, United1
Kingdom, The United Kingdom Cystic Fibrosis Gene Therapy Consortium, Oxford,2
United Kingdom
Current non-viral synthetic gene therapy vectors for the treatment of cystic fibrosis
are limited by inefficient uptake to cells of the respiratory tract, leading to very low
levels of gene transfer. Electroporation has been used to dramatically increase gene
transfer to a number of tissues. We are evaluating the use of electroporation to
enhance gene transfer to the airway epithelia in the mouse lung model. In ex vivo
studies it was found that following delivery of plasmid DNA, reporter gene expres-
sion could be increased by up to 500-fold depending on the combination of voltage
and pulse length used. In vivo studies were performed by combining intranasal
delivery of naked pCIKLux, (Lux reporter gene, CMVIE promoter and SV40
polyA) (100 mgy150 ml water) with a surgical procedure to expose the lung tissue
for electroporation. Electroporation was carried out using the BTX ECM830 Gen-
erator with 2-Needle electrodes with 5 mm gap and Lux activity was assayed 24 h
later. Following electroporation at 200 Vycm:20 ms, Lux activity was 70-fold higher
than naked pDNA alone (Ps0.012). When lungs were electroporated at 800 Vy
cm:2 ms, the Lux activity was 400-fold higher than plasmid DNA (Ps0.008). To
define the cell types and regions of the lungs affected, lungs were electroporated
following delivery of pEGFP-N1 expressing green fluorescent protein. Reporter
gene expression was observed mainly in the alveolar region of the lung, but elec-
troporation resulted in many orders of magnitude more GFP positive cells than non-
electroporated lungs. Studies are now underway to determine the duration of
reporter gene expression following electroporation of the mouse lung. The potential
and practicalities of electroporating the lung airways of a large animal model, are
also being investigated.
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DNA deposition and transgene expression following whole lung
aerosol delivery of gene therapy vectors in a large animal model
G. McLachlan , L. Renwick , S. Tate , H. Painter , A. Lawton , S.H. Cheng , A.C.1 1 1 2 2 4
Boyd , D. Gill , U. Griesenbach , S. Hyde , D.D.S. Collie5 2 3 2 1
Easter Bush Veterinary Centre, University of Edinburgh, Edinburgh, United King-1
dom, Gene Medicine Group, John Radcliffe Hospital, Oxford, United Kingdom,2
Department of Gene Therapy, Imperial College, London, United Kingdom, Gen-3 4
zyme Corporation, Framingham, Massachusetts, United States, Medical Genetics5
Section, University of Edinburgh, Edinburgh, United Kingdom
Non-invasive aerosol delivery to the airway epithelium is the preferred route for
administration of gene therapy vectors to patients with cystic fibrosis and this route
has been associated with less toxicity and inflammation. Size renders a number of
procedures such as aerosol delivery, repeat bronchoscopic lavage and biopsy sam-
pling impractical in small animals. We have developed a novel large animal model,
which facilitates inspiratory-gated aerosol delivery and bronchoscopic access with
the airway under atmospheric pressure. In an initial study, individual animals were
treated with either vehicle, plasmid DNA complexed to cationic liposome GL67 or
plasmid DNA complexed to polyethylenimine (25 kDa) using the PARI LC nebu-
liser. Bronchoalveolar lavage (BAL) cells and lung segments were obtained from
each animal at 24 h post-administration. Each segment was sub-divided and tissues
assayed for plasmid-derived mRNA, and reporter gene protein. Real-time quanti-
tative PCR revealed consistent DNA deposition throughout the lung and corre-
sponding mRNA expression across all segments in each of the treated animals.
Levels of reporter gene protein in samples treated with pDNA:PEI or pDNA:GL67
were higher than vehicle treated samples. We believe that the poor correlation
between mRNA levels and corresponding protein may be related to the issue of
which cells are being transfected. High levels of mRNA expression in the BAL
cells but very little protein may suggest that much of the mRNA is derived from
the mobile cell population and that these cells produce little or no protein. We
believe that the similarities to the human lung in terms of lung volume, architecture
and physiology make this ovine lung model a useful tool to guide the design of
clinical trial in humans.
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Effect of inhaled buffered reduced Glutathione (GSH) on the clinical
status of cystic fibrosis patients
C.T. Bishop , V. Hudson , S. Hilton1 2 2
Utah Valley Regional Medical Center, Provo, United States, Brigham Young Uni-1 2
versity, Provo, United States
Recent evidence demonstrates that mutation of the cystic fibrosis transmembrane
Conductance regulator (CFTR) protein results in significantly diminished efflux of
cellular glutathione (GSH) to epithelial lining fluid (ELF) of the lung. It has been
hypothesized that such ELF GSH deficit plays an important role in the pathophy-
siology of Cystic Fibrosis (CF), since GSH performs multiple functions, including
antioxidant protection, mucolysis, and regulation of inflammation and host defense.
Three patients with CF were treated with inhaled glutathione with improvement in
pulmonary function tests. Two infants with CF and failure to thrive treated with
oral and inhaled glutathione had improvement in growth, both height and weight.
A pilot study consisting of a randomized, double blind, placebo-controlled clinical
trial of nebulized glutathione in CF patients was conducted. Approximately 66 mgy
kg of body weightyday of a buffered glutathione solution, divided into four doses
given 3–4 h apart, was nebulized over 8 weeks. No adverse events in the treatment
group were noted. Thirteen lung function and quality of life indicators were exam-
ined. Mean change for peak flow, wasy6.5 for placebo group andq33.7 for GSH
group (Ps0.04), and improvement (1–5, with 1 much worse and 5 much better)
was self-reported as a mean of 2.8 for placebo and 4.7 for GSH group (Ps0.004).
Overall, eleven indicators favored the treatment group over the placebo group (Ps
0.002). These data corroborate the hypothesis that GSH replacement can ameliorate
CF disease manifestations.
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Albumin increases polyethylenimine-mediated gene transfer into
polarised respiratory epithelia in vitro and in vivo
S. Di Gioia , S. Carrabino, E. Copreni, M. Conese
Institute for Experimental Treatment of Cystic Fibrosis - HS Raffaele, Milano, Italy
Many of the nonviral delivery systems described thus far show that gene expression
in the lung is inhibited with repeated administration. Recently, it has been developed
a novel intravenous method to deliver small amounts of plasmid to lung tissue,
using nontoxic quantities of polyethylenimine (PEI) in combination with albumin
(Orson et al., Gene Ther. 9: 463-71, 2002). We have sought whether this formu-
lation is able to give transgene expression in the lung via tracheal injection of low
DNA amounts. Human serum albumin (HSA, 0.002–2 mg), added to preformed
PEIyDNA complexes, increased luciferase levels in a dose-dependent fashion as
compared to PEIyDNA in 9HTE and A549 airway epithelial cells at confluency.
PEIyHSAyDNA complexes were applied to the apical side of polarised CFT1 tra-
cheal epithelial cells and resulted in significant luciferase levels, whereas PEIyDNA
did not. Following an intratracheal administration of 10 mg DNA (ns8–16 C57Bly
6 mice per group), PEIyHSA (5 NyP; HSA range: 0.0002–2 mg) gave significantly
higher luciferase levels than PEI, only with 0.002 mg. In preliminary experiments,
GFP expression, as evaluated by immunohistochemistry, was found in the con-
ducting airways (bronchi and bronchioli) with either formulations. These data indi-
cate that PEIyalbumin can target a polarised respiratory epithelium with higher
efficiency than PEI using low DNA amounts. Future studies will include the pos-
sibility of repeat administration of albumin-containing polyplexes and will indicate
whether this nonviral system may have useful application in gene therapy of CF
lung disease. Supported by Lega Italiana Fibrosi Cistica, Italian Cystic Fibrosis
Research Foundation and Associazione Lombarda Fibrosi Cistica.
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Kaempferol stimulates chloride conductance in CF patients and healthy
subjects
D. Schueler , K. Weber , J. Pabst , C. Fegbeutel , G. Huels , P. Bittner-Dersch , H.1 1 2 1 1 1
Lindemann1
CF-Center, Medical Center of Pediatrics and Youth Medicine,University of Gies-1
sen, Giessen, Germany, PulmoTec GmbH, HochstadtyDonau, Germany2 ¨ ¨
A defective Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) in epi-
thelial cells of patients with cystic fibrosis (CF) leads to a decreased chloride ion
transport across the cell membrane. Flavonoids have been shown to increase the
CFTR-mediated chloride conductance in patients with DF508- and G551D-muta-
tions. In previous studies the effect of flavonoids could also been demonstrated in
vivo in healthy subjects (IllekyFischer; Am J Physiol 1998). Aim of this study was
to investigate the effect of kaempferol on the chloride conductance of respiratory
mucosa in CF patients. Goal of the study was the increase of Nasal Potential Dif-
ference (NPD). The phosphorylisation of chloride channels was done by the anti-
cholinergic tiotropium bromide (WeberySchuler; Atemw-Lungenkrkh in press). In¨
five healthy adults after determination of basal NPD under the concha nasalis infe-
rior, amiloride, kaempferol solution, and tiotropium bromide powder was sequen-
tially applicated at the nose. In 14 CF patients with DF508- and G551D-mutations
and in five CF patients with other mutations after measuring basal NPD amiloride
dry powder, tiotropium powder, and kaempferol solution were applied to the nose.
The increase of NPD after kaempferol in 5 healthy adults was 47.4"13.7%, after
tiotropium bromide 98.9"32.4%. In 14 CF patients with DF508- and G551D-muta-
tions an increase after tiotropium bromide and kaempferol was 28.4"8.7%. In 5
CF patients with other mutations the increase of NPD was significantly lower with
3.9"4.8% (P-0.05). Our results were in conformance with the results of Illek and
Fischer. The effect of kaempferol shows a high variability. Further investigation has
to be done to proof the enteral reabsorption.
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Etanercept – a tumour necrosis factor - a receptor agonist for the
treatment of arthritis in cystic fibrosis (CF)
D. Jyothish, M. Desai, C. Ryder, J.R. Clarke, P.H. Weller
Birmingham Children’s Hospital NHS Trust, Birmingham, United Kingdom
Etanercept – A Tumour necrosis factor -a receptor agonist for the treatment of
arthritis in cystic fibrosis (CF): Background: Joint involvement in CF may result
from classic ‘‘cystic fibrosis arthritis’’ characterised by recurrent episodes of dry
synovitis, hypertrophic pulmonary osteoarthropathy (HPOA) or coincidental juve-
nile idiopathic arthritis. Resultant reduction in function and mobility not only affects
the quality of life, but may also compromise pulmonary function by reducing activ-
ity and physiotherapy. Case description: A 7 year old girl with CF, significant
respiratory involvement, short bowel syndrome, liver disease and vitamin A defi-
ciency developed pain and swelling of both knees. There was no fever, skin rash
or family history of arthritis, psoriasis or uveitis. Examination revealed polyarticular
disease involving knees, ankles and wrists bilaterally and no uveitis. Synovial biop-
sy showed inflammation but rheumatoid factor and antinuclear antibodies were
negative with no radiological evidence of HPOA. Inflammation persisted in spite
of non-steroidal anti-inflammatory agents and intra-articular steroid injections and
she required second line therapy. Methotrexate was deemed inappropriate because
of her liver disease and Etanercept, a soluble TNF-a receptor agonist was com-
menced. She is probably the first cystic fibrosis patient to receive Etanercept but
after three months continues to have active arthritis. Discussion: Will Etanercept
effectively control the arthritis? What impact will Etanercept have on her lung
disease given its immunosuppressive mode of action? What role does the short
bowel syndrome and nutritional deficiencies play in the pathology of her chronic
arthritis? Clinicians looking after patients with CF should be aware of the various
treatment modalities available for concurrent arthritis and their possible impact on
the primary disease.
Microbiology and Antibiotics
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Mucosal and therapeutic vaccination against Pseudomonas aeruginosa
(PA)
A.W. Zuercher , M.P. Horn , C.J. Bundgaard , H. Wu , H.K. Johansen , N.1 1 2 2 2
Høiby , AB Lang2 1
Research Immunology, Berna Biotech Ltd., Bern, Switzerland, Dept. Clinical1 2
Microbiology, Rigshospitalet, Copenahgen, Denmark
A 10-year retrospective analysis of vaccination of CF patients with an octavalent
O-polysaccharide toxin A-conjugate vaccine revealed a significantly lower rate of
chronic lung infection with PA and increased time to initial infection in vaccinated
patients compared to a matched control group. As acquisition of PA occurs via the
upper respiratory tract, we have analyzed in mice mucosal immunity after intra-
muscular (i.m.) or intra-nasal (i.n.) immunization. Local immune responses were
assessed using the organ fragment culture technique and ELISA. We found induc-
tion of specific serum IgG antibodies by both routes of immunization. In contrast,
specific IgA antibodies in the upper respiratory tract were elicited via the i.n. route
only. However, induction of systemic and mucosal immune responses via the i.n.
route depended on the presence of mucosal adjuvant. In the mouse model used,
opsonophagocytic activity correlated with specific serum IgG levels. These results
indicate that i.n. administration of anti-PA conjugate vaccine might represent an
alternative route of immunization with induction of mucosal in addition to systemic
immunity. The protective capacity of i.n.-induced antibodies is currently evaluated
in a burn-wound sepsis model as well as in a lung challenge model using alginate-
embedded PA.
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Chronological timing of respiratory pathogen acquisition in infants with
CF in Northern Ireland
C.A. Kavanagh, A.J.M. Reid
Royal Belfast Hospital For Sick Children, Belfast, United Kingdom
Introduction: Children born with CF have apparently normal lungs that undergo
colonisation by bacteria and subsequent bacterial infection throughout infancy. This
results in well-documented CF lung disease. The nature and timing of pathogen
acquisition may provide treatment options which may reduce morbidity in affected
children. Methods: A 5-year retrospective review of patients born from 30 Juneth
1997 to 30th June 2002 was undertaken to identify pathogens acquired during the
first year of diagnosis. Organisms cultured from oropharyngeal swabs in the first
year of life were examined. Results: 44 patients comprised the study group (Fs
20; Ms24); The mean age of diagnosis was 37.5 days old, (R, 9–73 days); 5
(10.6%) significant positive swabs were obtained at diagnosis: 3 infants cultured
S. Aureus (60%); 2 infants cultured H. Influenza (40%). Other organisms cultured
at diagnosis included Coliforms and M Catarrhalis. 15 (34%) significant positive
swabs were obtained during the first year of life: 8 (18%) infants cultured H.
Influenza, 4 (9%) cultured S. aureus, 1 (2.2%) cultured Ps. Aeruginosa. Dual colon-
isation occurred in 3 infants: 2 (4.5%) infants cultured both Ps. Aeruginosa and H.
Influenza. 1 (2.2%) infant cultured both S. Aureus and H. Influenza. The prevalence
of H.Influenza was 25%. Conclusions: The rate of infection in our infants compares
favourably with those in other units.
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IgY for prophylaxis and treatment of infections – a way to reduce the
need of antibiotics
H. Kollberg , D. Carlander , B. Wretlind , P.-E. Wejaker , A. Larsson1 2 2 2 2˚
Dep. Medical Sciences, University Hospital, Uppsala, Sweden, Dep. Clin. Bac-1 2
teriol., Huddinge Univ. Hosp, Stockholm, Sweden
Introduction: Use of antibiotics has to decrease in order to stop the increasing rate
of antibiotic resistance. IgY (chicken immunoglobuline), purified from egg yolk,
is an alternative. Hens vaccinated with pathogens produce specific IgY against them.
One hen produces ;40 g IgYyyear. IgY decreases bacterial adhesion to epithelia.
In animal studies orally given IgY cures several kinds of GI infections. Humans do
not produce anti-IgY antibodies. It is very unlikely that pathogens will develop
resistance to IgY. IgY neither activates the human complement system nor reacts
with mediators of inflammation. IgY is generally recognised as safe (US Code of
Federal Regulations). Allergy to eggs is a contraindication. Methods and results:
Twelve patients have gargled daily with anti-pseudomonas IgY (anti-PA IgY) – the
longest for more than 9 years (together)75 patient years). The number of positive
PA cultures and the need of antibiotics have decreased greatly. The patients are
doing well with preserved pulmonary tests and good QOL (Reported in Pediatr
Pulmonol 2003;35:433). After that report the patient, who has been treated the
longest time, has got a chronic non-mucoid PA infection. A follow up of all patients
will be reported at the meeting. Specific IgY has also shown good results in small
feasibility studies on anti-candida IgY to immunosuppressed patients and anti-enter-
obacter IgY to prematurely borne infants. State of the art: Anti-PA IgY is now
commercially available. The Swedish Medical Agency has granted licence for anti-
PA IgY to specifically indicated CF patients. Conclusion: Studies in vitro, in animals
and humans, especially in CF patients, have shown that IgY offers great opportu-
nities to design strategies against infectious diseases in humans and animals.
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Does respiratory viral infections influence lung function and bacterial
colonisation in children with CF?
H.V. Olesen , L.P. Nielsen , P.O. Schiotz1 2 1
CF-centre West, Aarhus University Hospital, Skejby Sygehus, Aarhus, Denmark,1
Department of Clinical Microbiology, Odense University Hospital, Odense,2
Denmark
The incidence of viral infections has been investigated in CF. We wanted to evaluate
their impact on lung function and bacterial colonisation. Methods: Routine monthly
sputum samplesylaryngeal aspiration from 79 CF children (-16 years) attending
our clinic in a 12-month period were analysed by PCR for respiratory viruses (rhi-
no-, RS-, influenza A and B, parainfluenza-, metapneumo- and adenovirus). At
each visit lung function test was performed (from 2 years specific airway resistance
(SRAW) by whole body plethysmography, and from 6 years standard spirometry).
Signs of coryza were registered. Results: 13% of samples were positive with 87%
rhinovirus, 6% parainfluenza, 3% influenza A (vaccinated children without flu-like
symptoms), and 2% each of RS- and adenovirus. Positive bacterial culture was
equally frequent at virus-positive and -negative samples at the infection and the
following month. Nine virus-positive patients had 10 on-demand antibiotic courses
in spite of negative bacterial culture. Signs of coryza showed a sensitivity of 0.61
and a specificity of 0.87 for viral infection. Rhinovirus had no impact on lung
function, whereas the other viruses caused a transient worsening of both FEV-1 and
SRAW. Two 1-year-olds and an older girl with severe lung disease were hospitalised
due to viral infection. Conclusion: Respiratory viruses – other than rhinovirus show
significant short-term but no long-term impact on lung function in children )2
years. In infants and toddlers these pathogens may lead to hospitalisation due to
asthmatic symptoms. Viral infections may lead to over-treatment, but on a small
scale (3% of all antibiotic courses); coryzal signs were no help in identifying infect-
ed patients. Viral infections do not seem to alter the bacterial flora on a short-term
basis.
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Time of 1st airway infection in cystic fibrosis patients diagnosed with
neonatal screening or by symptoms
I. Baussano, E. Montanari, R. Bellezza, G. Cordola, A. Lezo, S. Fassio, L. Anfossi,
M. Castello, E. Bignamini
Paediatric CF Center, Torino, Italy
We analysed a cohort of 56 cystic fibrosis patients (28 Maley28 Female) born
between 1st January 1997 and 31st December 2002; 27 patients were diagnosed
with neonatal screening (group A) and 29 by symptoms. (group B). No statistical
differences were observed between age and sex; sex and diagnosis modalities
(screening or symptoms); sex and type of microrganism infection. First infection
was defined by positivity for pathogen microrganosms cultured from sputum or
faringeal swab. Mean time between diagnosis and first infection was for P. aeru-
ginosa of 13.25 moths in patients of group A (14y27) and 9.93 months in patients
of group B (15y29), no statistical significativity (Ps0.5). Mean time between
diagnosis and first infection was for Sphylococcus aureus metyicilline sensitive
(MSSA) of 6.47 moths in patients of group A (19y27) and 9.6 months in patients
of group B (21y29), no statistical significativity (Ps0.2). Mean time between
diagnosis and first infection was for Alcalygenes xylosoxidans of 9.1 months in
patients of group A (3y27) and 19.9 months in patients of group B (3y29), no
statistical significativity (Ps0.1). Our preliminary data do not confirm an increased
relative risk of early infection in patients diagnosed with neonatal screening.
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Initial colonization with Pseudomonas aeruginosa in cystic fibrosis: an
eradication protocol
F.V. Adde, L.V.F. Silva Filho, F.J. Pegoretti, F.P. Muchao, J.C. Rodrigues˜
Pulmonology Unit, Instituto da Crianca-University of Sao Paulo, Sao Paulo, Brazil¸ ˜ ˜
Antipseudomonal therapy at the time of early Pseudomonas aeruginosa infection
has been used in cystic fibrosis (CF) patients in order to try to eradicate this path-
ogen but the optimal drug regimen is not established. Objectives: Evaluate the rate
of eradication of initial P. aeruginosa isolation in CF patients that received systemic
and inhaled antibiotics following a standard protocol. Material and Methods:
Between Decy00 and Mayy03 seven patients, 3My4F, were evaluated in their first
P. aeruginosa isolation. The eradication protocol consisted of: step 1 (1st isola-
tion)s3 weeks of ciprofloxacin or intravenous antibioticsqinhaled gentamicin or
colistin; step 2 (2nd isolation)sthe same as step 1; step 3 (3rd isolation)s6 weeks
of ciprofloxacinq6 months of inhaled gentamicin or colistin. Oropharyngeal swabs
cultures were performed approximately every 2 months. Results: Median age at first
P. aeruginosa isolation was 10 months (age range 8 to 17 m). Two patients received
only step 1, one received step 2 (will start step 3) and four received step 3 treatment.
Eradication of P. aeruginosa occured in 4 patients, for a period between 7 and 36
months. Conclusions: The first P. aeruginosa isolation occured in very young
patients. The majority of patients needed more than one treatment and this resulted
in P. aeruginosa eradication in 4y7 patients till the present moment. Although a
small number of patients were evaluated, most of them needed step 3 treatment for
proper eradication. In view of the early age of P. aeruginosa acquisition among our
patients, one should consider longer periods of treatments as the first step, in order
to have more success in the eradication and try to postpone chronic P. aeruginosa
infection, mainly in this very young patients.
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Eradication of first growth of Pseudomonas aeruginosa in 95 cystic
fibrosis patients: Factors associated with success
T.W.R. Lee, S.A. Ho, J.M. Littlewood, K.G. Brownlee, S.P. Conway
Leeds Regional Paediatric Cystic Fibrosis Centre, St James’s University Hospital,
Leeds, United Kingdom
Introduction: There is increasing evidence that intensive early eradication regimens
using anti-Pseudomonal antibiotics can delay the onset of chronic P. aeruginosa
(PA) infection. This study describes the natural history of first growth of PA, and
determines factors associated with successful eradication. Methods: Retrospective
analysis of patients receiving full care at Leeds Paediatric CF Centre from Jan 1990
- Mar 2003 identified 97 patients with first ever growth of PA. 95 patients with full
documentation were included in the study. Eradication was considered successful
if the patients had at least 3 negative airway cultures over a period of 3 months
after cessation of treatment. Results: Eradication was successful in 74.7% (71y95)
patients. 4.2% (4y95) of first isolations were mucoid PA, of these 50.0% (2y4)
had successful eradication. 16.8% (16y95) were resistant to at least one antibiotic,
of these 68.8% (11y16) had successful eradication. In patients who had antibody
levels to PA checked in the 12 months prior to first growth 22.2% (14y63) were
positive prior to first positive airway culture. Patients who had a positive PA anti-
body level 0–4 months after first growth of PA had a significantly greater chance
of successful eradication w92.9% (13y14)x than those with a negative antibody level
w69.1% (38y55), P-0.05x. Conclusions: In CF most first isolations of PA are fully
sensitive and non-mucoid. Measurement of PA antibody levels at least annually
may often allow early detection prior to positive airway culture. For 4 months
following first positive airway culture, positive antibodies to PA identify patients
that are significantly more likely to undergo successful eradication, suggesting that
at early stages in infection antibodies against PA may be protective.
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Successful antibiotic eradication of Pseudomonas aeruginosa infection
does not promote drug resistance in subsequent re-growths of this
bacterium in children
S.A. Ho , T.W.R. Lee , M. Denton , S.P. Conway , K.G. Brownlee1 2 3 2 2
University of Leeds, Leeds, United Kingdom, St. James’s University Hospital,1 2
Leeds, United Kingdom, Leeds General Infirmary, Leeds, United Kingdom3
Aims: There is concern that repeated, intensive and prolonged antibiotic regimens
aimed at eradication of Pseudomonas aeruginosa (PA) from the airway may pro-
mote antibiotic resistance. No data has been published to support or refute this
possibility. This study was performed to address this issue. Methods: A retrospective
study was completed on all patients attending the Leeds Regional Cystic Fibrosis
Unit from January 1990 to December 2000. All patients with first ever isolation of
PA who successfully completed an eradication regimen were included. Re-growth
was defined as a patient positive for PA who had had repeated negative samples
for at least the preceding 12 months. Antibiotic sensitivities of PA isolates were
compared between initial acquisitions and subsequent re-growths to piperacillin,
ceftazidime, ciprofloxacin, amikacin, colomycin and tobramycin. Results: Forty one
patients (23 males) median age 2.80 (0.25 to 12.6) years with first acquisitions for
PA were identified who subsequently became free of PA infection for at least 12
months. Eradication treatments consisted of oral, intravenous, nebulised antibiotics
or a combination of these. The percentage of fully sensitive samples of PA, for each
subsequent re-growth, were as follows; 1st ever growth 78.7%, 1st re-growth 64.0%,
2nd re-growth 84.6%, 3rd re-growth 80.0%, 4th re-growth 100% (Chi squared, P)
0.05). Conclusions: These data show that repeated intensive antibiotic regimens
used to successfully eradicate PA do not result in a significant increase in drug
resistance over the period of this study.
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Pseudomonas aeruginosa in cystic fibrosis patients: early eradication
vs. historical therapy
G.H. Thalhammer, B. Pratl, E. Eber, M.S. Zach
Respiratory & Allergic Disease Division,Paediatric Department,University of Graz,
Graz, Austria
Background: Chronic airway infection with Pseudomonas aeruginosa (PA) is a
major factor contributing to lung disease in cystic fibrosis (CF). Early aggressive
antibiotic treatment may delay chronic infection, and improve lung function and
survival. In 1999, we introduced an eradication regimen into the clinical routine of
our centre. We performed a retrospective analysis comparing the treatment strategies
before 1999 and since then. Patients and methods: Sputum or throat swab samples
were obtained from all CF patients at least every 3 months. Before 1999, no specific
therapy was initiated at first PA positivity. Since 1999, in this situation an eradi-
cation regimen consisting of an iv. anti-PA therapy for 3 weeks, followed by oral
ciprofloxacin for 6 weeks and twice daily inhaled anti-PA therapy (colistin or gen-
tamicin) for at least 2 years, was started immediately. Evaluation of this eradication
regimen was done by microbiological studies from bronchial lavage (BL) fluid 2
weeks after stopping oral ciprofloxacin. There was a time interval of at least 18 hrs
between flexible bronchoscopy with BL and the last inhalation of antibiotics.
Results: We performed 32 PA eradications in 24 CF patients; 28 out of these (88%)
were initially successful, as demonstrated by negative microbiological cultures in
BL fluid. In 2 patients, 3 attempts were made to eradicate PA. At present, 23 out
of the 24 patients treated with our eradication regimen are still PA free. In contrast,
only 3 out of 33 patients, who showed PA positivity before 1999 are free of PA
now. This difference is significant (P-0.001). Conclusion: With the caveat that
this comparison uses historical controls, these preliminary results of our ongoing
study are encouraging.
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Effects of intratracheal administration of Novispirin G10 on a rat model
of mucoid Pseudomonas aeruginosa lung infection
Z.J. Song , H. Wu , K. Schnorr , P. Mygind , D. Raventos , C. Sonksen , M.1 1 2 2 2 2
Hansen , H.H. Kristensen , N. Høiby2 2 1
Department of Clinical Microbiology, University Hospital of Copenhagen, Copen-1
hagen, Denmark, Novozymes AyS, Building 1U, Bagsværd, Denmark2
Chronic Pseudomonas aeruginosa lung infection is commonly found in cystic fibro-
sis (CF) patients, which correlates with high morbidity and mortality in CF patients.
The bacterial infection is difficult to eradicate due to the biofilm mode of growth
of the bacteria in spite of intensive antibiotic treatment, which encourages the efforts
in development of alternative treatments. Novispirin G10 is an antimicrobial peptide
related to ovispirins. It has been demonstrated that Novispirin G10 can rapidly kill
different kinds of bacteria in vitro. In the present study, Novispirin G10 (0.1 mgy
ml, 0.2 mlyrat) was administered intratracheally in a rat model twice in 3 hours
after intratracheal challenge with mucoid P. aeruginosa suspension (1=10 CFUy9
rat) and the control group received only the vehicle after bacterial infection. Param-
eter evaluation was done on days 3, 5, 7 and 10 post-infection. On days 3 and 5,
the remained bacteria in the Novispirin G10 treated lungs were 175- and 335-fold
lower than those in the control lungs respectively (P-0.0005 & P-0.0003). On
day 5, 50% of the Novispirin G10 treated rats cleared the bacteria completely from
the lungs, whereas none of the control animals did so (P-0.03). Furthermore, the
Novispirin G10 treated rats showed significantly milder lung pathology in all the
4 time-points (P-0.0002 or P-0.0001). These results suggest that Novispirin G10
treatment showed a significantly protective effect on the animals infected with
mucoid P. aeruginosa. Novispirin G10 may, therefore, be a potential alternative
drug for the control of mucoid P. aeruginosa lung infection in CF patients.
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A novel synthetic defensin-like peptide with antimicrobial activity
against a range of multiresistant cystic fibrosis pathogens
R.J. Langley , D.J. Clarke , J. Dorin , D.J. Campopiano , J.R.W. Govan1 2 3 2 1
Cystic Fibrosis Laboratory, Medical Microbiology, University of Edinburgh, Edin-1
burgh, United Kingdom, School of Chemistry, University of Edinburgh, Edinburgh,2
United Kingdom, MRC Human Genetics Unit, Western General Hospital, Edin-3
burgh, United States
The emergence of multi-resistant bacterial pathogens in cystic fibrosis (CF) lung
infections continues to reduce the choice of effective therapies available for the
clinician. This issue particularly concerns infections caused by Burkholderia cepa-
cia complex species (Bcc), multiresistant Pseudomonas aeruginosa, Methicillin
Resistant Staphylococcus aureus (MRSA), Stenotrophomonas maltophilia and Ral-
stonia spp. Although clinical outcome is dependant on both host and bacterial fac-
tors, these pathogens share the potential to infect immunocompromised patients and
exhibit multiresistance. MRSA and multiresistant P. aeruginosa are considered to
pose two important problems. Both are highly resistant to conventional antibiotics
and are capable of epidemic spread between CF patients. Recent evidence from
Liverpool, Manchester and Australia highlights the problems of epidemic strains of
P. aeruginosa, including increased morbidity and mortality. To address these issues,
we examined the antibacterial activity of synthetic forms of the murine b-defensin-
like peptide, Defr1, against a panel of highly resistant clinical CF isolates, including:
Bcc, epidemic P. aeruginosa, MRSA, S. maltophilia, and Ralstonia spp. b-defensins
are typically characterised by the presence of six conserved cysteine residues; Defr1
is unusual in containing only five cysteine residues (Morrison et al., 2002). We
report that Defr1 has a broad spectrum of bactericidal activity against four epidemic
P. aeruginosa strains, MRSA and S. aureus, S. maltophilia, and Ralstonia spp. Our
data indicates that Defr1 has an unusually broad spectrum of activity, including
some activity against Bcc, and may be worth further investigation as an antimicro-
bial agent in the treatment of CF respiratory infections. Morrison G.M., Rolfe M.,
Kilanowski F.M., Cross S.H., Dorin J.R. (2002). Identification and characterization
of a novel murine beta-defensin-related gene. Mammalian Genome 13, 445–51
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Clinical follow-up of 122 Italian cystic fibrosis patients with B. cepacia
complex infection
G. Taccetti , M. Ambroni , B. Assael , A. Cosimi , D. Costantini , M.L. Furnari ,1 1 1 1 1 1
R. Gagliardini , G.L. Grzinchich , A. Manca , A. Negri , G. Pizzamiglio , F. Poli ,1 1 1 1 1 1
V. Raia , G. Tuccio , P. Vandamme1 1 2
Italian Cystic Fibrosis Study Group, Palermo, Italy, Laboratorium voor Micro-1 2
biologie, Universiteit Gent, Gent, Belgium
The goal of this study was to investigate the clinical evolution of a cohort of Italian
CF patients colonised by B. cepacia complex (BCC) through questionnaires sent
to all Italian CF Centres. Fourteen out of 22 CF centres participated to the study.
Data on 122 patients (52 M, 70 F) were collected. Of them, 26 patients (21.3%)
were DF508 homozygous, 59 (48.4%) were DF508yother. Forty (32.7%) patients
were colonised only by BCC. Ninety patients (77.5%) were chronically colonised,
26 (22.5%) were colonised transiently (4 missing). Mean age at colonisation was
16.1 years (median 15, range 2–41, 8.3 S.D.). The mean change in FEV1 (percent
change compared to baseline) 2 years after BCC colonisation was y9.8% (22.2
S.D.) in chronically colonised and y4.93 (9.6 S.D.) in intermittently colonised.
Three years after BCC colonisation mortality was 14.4% among chronically colon-
ised patients (missing data: 2) whereas no deaths occurred in patients colonised
transiently (Fisher test Ps0.03). The genomovar (gv) status was defined for 56y
122 (45.9%) isolates. Thirty patients (53.6%) had gv III, 6 (10.7%) had gv I, 6
(10.7%) had gv IX, 5 (8.9%) gv II, and 9 (16.1%) had other gv. Mortality at year
5 after infection was 20.5% among patients with gv II or gv III, vs. 5.5% among
patients colonised by other gv. The mean change in FEV1 (percent change com-
pared to baseline) 2 years after colonisation was y17.6% (21.8 S.D.) in patients
colonised with gv II or III, and y3.02% (19.2 S.D.) in those colonised by other
gv (t-test Ps0.03). Conclusions: three-year survival is worse in patients with
chronic BCC colonisation, compared to those colonised transiently. The mean
decrease in FEV1 is significantly higher in patients with gv II or III than in those
colonised by other gv.
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Novel strategy for the isolation of Burkholderia cepacia complex from
the environment
E. Vanlaere, T. Coenye, E. Samyn, J. Govan, F. De Baets, K. De Boeck, C. Knoop,
P. Vandamme
University of Ghent, Ghent, Belgium
The purpose of this study was to develop a new strategy for the isolation of B.
cepacia complex (Bcc) bacteria from the environment and to use this approach to
investigate the presence of these bacteria from the homes of Bcc positive CF
patients in Belgium. Water and soil samples were collected from the house and
gardens from 6 patients. For the water samples, 100 ml was filtered and the filter
was placed in 20 ml of a selective enrichment broth (containing 0.1% L-arabinose,
0.1% L-threonine and a selective mixture with 1 mgyml C-390, 600 Uyml poly-
myxin B sulfate, 10 mgyml gentamycin, 2 mgyml vancomycin and 10 mgyml cyclo-
heximide). For the soil samples, 5 g of soil were placed directly in 90 ml of the
enrichment broth. Following incubation at 28 8C for 5 days, serial dilutions were
made on selective agar plates (formula as above plus 1.8% agar). Following incu-
bation, colonies were subcultured on standard media. As a first screening, all isolates
were inoculated on Stewart’s medium to investigate the utilization of glucose and
arginine. Isolates showing glucose oxidation but no arginine dehydrolase activity
were further identified using recA RFLP. For all recA PCR positive isolates, a RAPD
pattern was obtained and compared with a database containing patterns of all Bcc
isolates recovered from Belgian CF patients. So far, we have identified multiple
Bcc strains from different genomovars from the environmental samples. Our data
indicate that this approach allows an efficient recovery of Bcc from the environment
and that Bcc organisms may be more widespread in this type of environment than
previously assumed.
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Burkholderia cepacia-an infrequent cause of a sepsis in a non-CF
patient
A. Holcikova , P. Drevinek , D. Burgetova1 2 3
Pediatric Infectious Clinic, Masaryk University, Brno, Czech Republic, Pediatric1 2
Clinic, Charles University, Prague, Czech Republic, Microbiology Department,3
University Hospital, Brno, Czech Republic
Introduction: Burkholderia (formerly Pseudomonas) cepacia, a widespread Gram-
negative environmental bacillus, has frequently been associated with chronic pul-
monary infections in patients with cystic fibrosis (CF). Bacteriemia in those patients
is not frequent, but if it occurs, it is usually fatal. In non-CF patients systemic
infections occur mostly as nosocomial in immunocompromised and other high risk
patients, resulting from use of contaminated medications, instruments and even anti-
septics. A conclusive evidence of this Gram-negative bacteria in previously healthy
people as a septic pathogen is very rare. Case report: A 16-year old country boy,
a future professional cook, completely healthy hitherto, felt suddenly ill. Typical
clinical and laboratory septic symptoms including DIC were present. The blood
cultivation was repeatedly (3=) positive for Burkholderia cepacia-genomovar IV,
so we were confident that the positive result of the culture was not due to laboratory
contamination. After that the previously unsuccessful antibiotic treatment with non
sensitive Cefotaxim was replaced by sensitive Cotrimoxazol and Ceftazidim and
the patient’s condition gradually improved and he was released home healthy. No
following aggravation, an immunodefect or any other illness was present in next
12 months. Conclusion: Burkholderia cepacia as a septic cause is unusual and unex-
pected pathogen in healthy people. Our patient had no known exposure to any
source of Burkholderia cepacia. A bacterium was first identified in agricultural
produce, so inasmuch as one of the patient’s job responsibilities is food preparation,
he may have acquired it at work or as a village boy from environment in the country.
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Combination aerosol therapy can eradicate Burkholderia Cepacia
complex from CF adults
P.G. Middleton, B. Williams
Department of Respiratory Medicine, Westmead Hospital, Sydney, Australia, Dept1 2
of Pharmacy, University of Sydney, Sydney, Australia
Burkholderia (previously Pseudomonas) Cepacia is an important pathogen in Cys-
tic Fibrosis (CF) lung disease, associated with an accelerated decline in lung func-
tion, and in some patients, a ‘‘Cepacia syndrome’’ of necrotising pneumonia
inducing septicaemia and death. The B. Cepacia complex is often resistant to most
antibiotics, and no treatments have so far been published which can eradicate B.
Cepacia from the lungs, once a patient has been colonised. We now report the use
of nebulised amiloride and tobramycin in combination to eradicate newly acquired
B. Cepacia. Three of 4 patients given this combination eradicated the B. Cepacia
complex from their sputum cultures over a period of 1-2 months. Followup cultures
over the next 9–18 months following treatment have all remained negative for B.
Cepacia., suggesting that the combination of amiloride & tobramycin may eradicate
B. Cepacia complex in some CF patients. Further studies are necessary to confirm
this finding, the optimal treatment regimen, and the likely reason(s) why the 4th
patient continued to be colonised with the B. Cepacia complex.
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Metallo -b-Lactamase-Producing Pseudomonas aeruginosa and
Burkholderia cepacia complex in Sputum from Patients with Cystic
Fibrosis in Denmark
M.D. Overballe , K. Fuursted , H. Schumacher , H. Olesen1 1 1 2
The University Hospital of Aarhus, Clinical Microbiology, Aarhus, Denmark, The1 2
University Hospital of Arhus, Cystic Fibrosis Center Vest, Aarhus, Denmark
Introduction: Pseudomonas aeroginosa (PA) and Burkholderia cepacia complex
(BC) are opportunistic human pathogen posing both a clinical and microbiological
challenge especially among patients suffering from cystic fibrosis (CF). The inci-
dence of multidrug-resistant PA or BC isolated from the sputum of CF patients
suffering from CF is increasing. Resistance to carbapenem due to the presence of
a metallo-beta-lactamases (MBL) in PA has recently been described. We here
describe the occurrence of MBL in Danish strains of PA and BC isolated from CF
patients. Methods: The clinical isolates of PA and BC in sputum were collected
among the 135 cystic fibrosis patients attending our Cystic Fibrosis Centre at Aarhus
University Hospital once a month in 2003. PA and BC that were resistant to mer-
openem by our routine disk diffusion method were selected and examined for the
presence of an MBL with the Etest MBL strip. The presence of an MBL was
defined when the MIC ratio of (Imipenem)y(ImipenemqEDTA) was ) 8 or with
the appearance of a phantom zone. Furthermore all isolates with an MBL were
typed by pulse-field gel electrophoresis (PFGE) (speI). Results: 243 PA (63 mucoid
and 180 nonmucoid) from 67 different patients were isolated. 89 PA isolates were
resistant to meropenem (23 mucoid and 66 nonmucoid) and 17 isolates were tested
for MBL. We found two patients with MBL-positive PA isolates (both were non-
mucoid. 91 isolates of BC from 11 different patients were isolated of which 33
were resistant to meropenem. Seven BC isolates were tested for a MBL and two
patients carried MBL-positive BC (one patient carried both an MBL-positive PA
and -BC). None of the MBL-positive isolates were related in terms of antibiogram
or PFGE typing. Conclusion: We report here the occurrence of MBL-positive PA
and -BC isolated from the sputum of Danish CF patients. We could not demonstrate
any patient-to-patient transmission of these MBL-positive PA or –BC but one
patient carried both an MBL-positive PA and BC, which suggests that the MBL,
in this patient, is carried on a plasmid.
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Factors affecting the survival rate in Burkholderia cenocepacia infected
Czech CF patients
D. Zemkova , P. Drevınek , J. Bartosova , L. Fila , V. Vavrova1 1 1 2 1´ ˇ ´ ˇ ´ ´ ´
Clinic of Pulmonology, Prague, Czech Republic
Up to 25% of patients from the Prague CF Centre are infected with the strains
belonging to the same genomovar of Burkholderia cepacia complex (i.e. to geno-
movar III or Burkholderia cenocepacia). However, the infection manifests itself in
patients differently from a slight progression to fatal cepacia syndrome. The aim of
our study was to specify the clinical factors predisposing to more severe clinical
course of the B. cenocepacia infection. Methods: Survival analysis showed that
mean survival of patients infected 1994–1997 was 6.4 years, in patients infected
since 1998 significant improvement is observed. 56 culture and PCR positive
patients were divided into groups according to survival () or- 6 yrs) and clinical
status. Nutritional status, pulmonary function tests (PFTs) were compared by Stu-
dent t-test. Results: We proved that shorter survival was associated with worse
nutritional status and worse PFTs at the time of infection (weighty1.8"0.8. S.D.
vs. y1.09"0.7 S.D., P-0.001, mid-arm circumference y2.3"1 S.D. vs. y
1.1"0.8 S.D., P-0.0001, FEV . 46.7q16.3% pv vs. 64.1q14.6% pv, Ps0.0002).1
In the group surviving 6 years clinical status and survival depend on the rate of
lung function worsening during the first 3 years after infection. Conclusion: Modern
management of nutritional status, early diagnosis and intensive treatment of infec-
tion and inflammation together with modern physiotherapy can improve the out-
come even of patients infected by Burkholderia cenocepacia. Supported by MSMT.
111300003 and MZCR 00000064203
Group Definition No. patients/
1 Patients who died by 6 years from the 29
B. cenocepacia acquisition
1A Died by 3 years 15
1B Died between 3 and 6 years 14
2 Patients who wereyare alive more than 6 27
years from the B. cenocepacia acquisition
2A With last FEV1 -39% 11
2B With last FEV1 )40% 16
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Burkholderia cepacia infection and clinical course in cystic fibrosis
patients
L. Pereira, S. Correia, C. Nascimento, T. Bandeira, C. Barreto
Santa Maria Hospital, Lisbon, Portugal, Instituto Superior Tecnico, Lisbon,1 2 ´
Portugal
Burkholderia cepacia (BC) complex is a problematic pathogen in cystic fibrosis.
There is heterogeneity in pulmonary deterioration of BC infected patients, some-
times leading to a fulminant evolution – cepacia syndrome. To verify the relation
between infection with different BC phenotypesygenomovars and clinical course
the authors conducted a retrospective analyses of 22 patients (13% of total fol-
lowed) infected with BC. Patients were divided in two groups: Group 1 – inter-
mittent isolation (1 or 2 isolations); Group 2 – chronic isolation (G3 isolations).
For each patient the authors determined sex, age at diagnosis, age at first isolation,
genotype, co-infection with other bacteria, pulmonary function (FEV1), admissions
and body mass index (BMI). The progression of the three last parameters has been
assessed periodically since first isolation. Phenotypesygenomovars were identified
by molecular analysis in Instituto Superior Tecnico. The phenotypeygenomovar´
prevalence was found to be: Gv I 24%; B. multivoransyGv II 11%; B. cenocepaciay
Gv III 52%; B. stabilisyGv IV 13%. Isolations were intermittent in 12 patients and
chronic in 10. A wide variety of clinical evolutions have been observed in the
categories of phenotypesygenomovars. There was more mortality in Group 2 than
in Group 1 (3 in Group 1 and 5 in Group 2). Three Group 2 patients died with
cepacia syndrome: one with B. multivoransyGv II and B. cenocepaciayGv III, one
with B. cenocepaciayGvIII and Gv I and the third with B. stabilisyGv IV. No
significant differences were found in FEV1 and BMI before and after BC isolation.
The results did not verify any correlation between BC phenotypeygenomovar and
more rapid progression of pulmonary disease, although the chronic group had more
mortality.
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Use of multilocus restriction typing method to detect hyper-
transmissible P. aeruginosa strains from patients attending cardiff CF
clinics
H.C. Ryley , J.L. Weeks , D.J. Shale , I.J.M. Doull1 1 2 3
Dept of Medical Microbiology, UWCM, Cardif, United Kingdom, Section of Res-1 2
piratory Disease,UWCM, Penarth, United Kingdom, Dept of Child Health, Cardiff,3
United Kingdom
Hyper-transmissibility of Pseudomonas aeruginosa is emerging as a potential
important clinical problem in CF clinics but continual monitoring for such emer-
gence by the current most popular methods for detecting genotype is not practicable
in all but the largest routine clinical laboratory. We wish to report here the devel-
opment of a multilocus restriction typing (MLRT) method for P. aeruginosa and
its application to isolates from patients attending both the adult and paediatric CF
clinics in Cardiff. Methods: P. aeruginosa isolates from the paediatric CF clinic (35
patients) and the adult clinic (65 patients) were collected over a 6 month period
and stored prior to analysis. PCR was used to amplify three gene products; a hypo-
thetical pilin protein gene (PA4086), pilinA gene and flagellin gene. From the PCR
products, five restriction endonuclease fragment patterns were generated usingMsp1
in all cases and MboI with the first two and combined for a final MLRT genotype.
Isolates with a similar MLRT genotype were further analysed by Random Amplified
Polymorphism DNA (RAPD) PCR. Results: Several genotype clusters (same
MLRT and RAPD) were found. One cluster contained 10 isolates all from the adult
clinic and was identical to the Liverpool epidemic strain and carried the P21 marker.
However three other isolates with distinctly different genotypes were also found to
carry the P21 marker. One cluster of 7 and two clusters of four isolates were also
detected with patients all attending the adult clinic except for two younger siblings.
Conclusion: Hyper-transmissible P. aeruginosa has been detected with genotype
clusters mostly associated with older patients. Emergence of such strains may be
linked with long term carriage.
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Longitudinal surveillance for Pseudomonas aeruginosa cross-infection
at an adult cystic fibrosis centre
A.M. Jones , C.M. Smith , M.E. Dodd , C.J. Doherty , J.R.W. Govan , A.K.1 1 1 2 2
Webb1
Manchester Adult Cystic Fibrosis Centre, Manchester, United Kingdom, Medical1 2
Microbiology, Edinburgh, United Kingdom
Introduction: The epidemiology and correct management of Pseudomonas aerugi-
nosa cross-infection in cystic fibrosis is controversial. An initial study at our centre
established evidence for P. aeruginosa cross-infection wLancet 2001;557–8x. Two
patients free of P. aeruginosa infection developed infection with a transmissible P.
aeruginosa strain; subsequently, we introduced segregated outpatient clinics and an
inpatient isolation policy for P. aeruginosa-free patients. We now report the results
of longitudinal microbiological surveillance for P. aeruginosa cross-infection at our
centre for the last 4 years. Methods: P. aeruginosa isolates cultured from sputa of
patients attending our CF Centre were investigated by pyocin typing, then further
evaluated by pulsed-field gel electrophoresis. Results: The incidence of infection
with transmissible P.aeruginosa among patients with chronic P. aeruginosa infection
was between 3.0 and 6.6% per year. The prevalence of transmissible P. aeruginosa
in this group of patients increased from 17.9% to 25.0% between 1999 and 2003.
No patients segregated because of Burkholderia cepacia complex infection have
ever been infected with transmissible P. aeruginosa. No patients free of P. aerugi-
nosa infection have become infected with a transmissible strain since the new meas-
ures were introduced. Conclusions: Despite a modern building and modern infection
control techniques, there has been cross-infection with transmissible P. aeruginosa.
Individuals segregated from patients with P. aeruginosa infection have not acquired
infection with a transmissible strain. Simple infection control measures alone do
not prevent the spread of transmissible P. aeruginosa between individuals with CF.
Patient segregation may effectively control spread of transmissible P. aeruginosa.
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Characterisation of a diagnostic probe for the Pseudomonas
aeruginosa Liverpool CF epidemic strain
C.H. Smart, C.A. Hart, C. Winstanley
University of Liverpool, Liverpool, United Kingdom
In 2002 we reported a PCR-based diagnostic test for a Cystic Fibrosis (CF) epi-
demic strain of Pseudomonas aeruginosa first reported in a CF centre in Liverpool
(LES for Liverpool Epidemic Strain; Parsons et al. 2002). This test has been further
validated using a large number of CF isolates (Panagea et al. 2004). The purpose
of this study was to characterise the DNA identified as diagnostic for the LES. The
original PCR test targeted a short genomic DNA sequence (400 bp; known as PS21)
with no similarity to database sequences (Parsons et al. 2002). Using the CLON-
TECH GenomeWalker system, we extended this sequence upstream and down-
stream. The extended sequence was used to interrogate database nucleotide and
amino acid databases using the programs BLASTN and BLASTX. The database
searches indicated that sequence PS21 lies within a putative mercury-resistance
operon. PS21 includes a 48 bp overlap with the C-terminal region of a putative
gene with similarity to a number of merA genes (encoding mercuric reductase).
The best BLASTX matches for the extended sequence were with merA genes from
Streptomyces spp. The diagnostic test for the LES targets a mercury-resistance oper-
on that may form part of a larger low-GC content genomic island. References:
Parsons, Y.N., Panagea S., Smart, C.H.M., Walshaw, M.J., Hart, C.A. and Win-
stanley, C. (2002) Use of subtractive hybridization to identify a diagnostic probe
for a cystic fibrosis epidemic strain of Pseudomonas aeruginosa. Journal of Clinical
Microbiology 40: 4607–4611; Panagea, S., Winstanley, C., Parsons, Y.N., Walshaw,
M.J., Ledson, M. J., and Hart, C.A. (2004). PCR-based detection of a cystic fibrosis
epidemic strain of Pseudomonas aeruginosa. Molecular Diagnosis (in press). This
work was supported by the UK Cystic Fibrosis Trust.
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Identification and prevalence of DNA markers specific to a
multiresistant and transmissible clone of Pseudomonas aeruginosa
D.A. Miller , A.M. Jones , A.K. Webb , J.R.W. Govan , D.P. Speert , C. Smith ,1 2 2 3 4 2
E. Mahenthiralingam1
Cardiff School of Biosciences, Cardiff University, Cardiff, United Kingdom, Brad-1 2
bury CF Unit, Wythenshawe Hospital, Manchester, United Kingdom, Medical3
Microbiology, University of Edinburgh, Edinburgh, United Kingdom, Dept. of Pae-4
diatrics, University of British Columbia, Vancouver, Canada
Pseudomonas aeruginosa infection is associated with an increased morbidity and
mortality for individuals with cystic fibrosis (CF). The emergence and spread of
transmissible strains of P. aeruginosa in CF centres has recently become a major
concern to the CF community. The molecular epidemiology of two problematic
transmissible P. aeruginosa strains has been well characterised: the Liverpool clone
(LI) and the Manchester clone (MA). Using a subtractive DNA hybridisation
approach we identified 33 putatively MA-strain specific DNA markers. The prev-
alence and specificity of each marker was examined by Southern hybridisation to
a collection of genomic DNAs from 141 genetically distinct P. aeruginosa strains.
Five markers, MA15, 18, 21, 22 and 30, were absolutely specific to strain MA. In
addition, each of the latter markers mapped to the same genomic segment of the
Manchester strain. DNA sequence analysis of the MA-specific marker fragments
showed that they were unique, with no homology to known genes in the genetic
databases. Diagnostic PCRs specific to strain MA were also developed from these
markers and shown to be capable of detecting infection directly from CF sputum.
The specificity of a previously published Liverpool strain DNA marker was also
assessed using the same strain collection. Distinct P. aeruginosa strains cross-react-
ing with this marker were found in one Scottish and one Canadian CF patient. The
significance of these data to our epidemiological understanding of P. aeruginosa
infection in CF will be discussed. This work was funded by grant PJ503 from the
UK CF Trust.
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Clinical consequences of transmissible Pseudomonas aeruginosa
infection in patients with cystic fibrosis—a 4 year prospective study
C.M. Smith, M.E. Dodd, A.K. Webb, A.M. Jones
Wythenshawe Hospital, Manchester, United Kingdom
Patients with cystic fibrosis infected with P. aeruginosa have increased morbidity
and mortality. Most patients are infected with sporadic, unique strains of P. aeru-
ginosa(sPa) but more recently we have become aware of transmissible strains. We
have reported that patients harbouring the Manchester transmissible P. aerugino-
sa(MA) have increased treatment requirements. The long term outcome of chronic1
infection with a transmissible P. aeruginosa on lung function is unknown. We per-
formed a 4 year prospective study comparing patients infected with sPa with those
infected with MA. We measured change in %pred FEV , %pred FVC, BMI, number1
of lung transplantations and number of deaths. We studied 78 patients, sPa ns56,
MA ns22. We report no significant difference in change in %pred FEV , %pred1
FVC and BMI over this period. Mean (S.D.) change in %pred FEV yyear, 0.35%1
(3.15) decline sPA, 0.65% (2.1) decline MA. Mean (S.D.) change in %pred FVCy
year, 0.45% (2.59) increase sPA, 0.57% (2.75) decline MA. Mean (S.D.) change
in BMIyyear, 0.12 (0.44) decrease sPa, 0.12 (0.44) decrease MA. There were equal
numbers of lung transplant recipients (sPA ns3y56, MA ns1y22) and deaths (sPA
ns10y56, MA ns4y22) in each group. 5 patients in sPa acquired a transmissible
P. aeruginosa during the 4-year period and were excluded. We conclude that
although patients who harbour MA have an increased burden of treatment, over a
4-year period, they do not have a greater rate of decline in lung function. Further
long term study is required of these groups of patients. Reference: Jones AM et1
al. Increased treatment requirements of patients with cystic fibrosis who harbour a
highly transmissible strain of Pseudomonas aeruginosa. Thorax 2002:924–925.
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Outcome of intravenous antibiotic treatment in adult patients colonised
with transmissible and non-transmissible strains of Pseudomonas
aeruginosa
I. Clifton , D. Peckham , M. Denton , S. Conway1 1 2 1
Regional Cystic Fibrosis Unit, Seacroft Hospital, Leeds, United Kingdom, Depart-1 2
ment of Microbiology, Leeds General Infirmary, Leeds, United Kingdom
The aim of this study was to investigate the clinical response to intravenous anti-
biotics in patients with and without transmissible strains of Pseudomonas aerugi-
nosa (PA). All patients chronically infected with PA who presented with acute
infective exacerbations between September 2003 and December 2003 were entered
into the study. The choice of antibiotic treatment was decided according to the
Unit’s guidelines and included two intravenous antibiotics. Spirometry, C reactive
protein (CRP), plasma viscosity (PV) and full blood count were recorded at the
start and end of two weeks of treatment. Transmissible strains of PA were identified
using RFLP to identify strains with more than 80% similarity. Data were analysed
using the Mann-Whitney and Chi-Square tests (SPSS). A p value of -0.05 was
regarded as significant. 43 patients were identified with infective exacerbations. 22
of these patients had non-transmissible strains and 21 transmissible strains. There
was no significant difference between the two groups at baseline in terms of gender,
age or Schwachman score. There was no difference in maintenance treatment apart
from the use of macrolide antibiotics (Transmissible 9y21, Non-transmissible 3y22
P-0.05). There was no significant difference in change in FEV1, FVC or FEF25-
75. There was a significant difference in percentage change in WCC (Transmissible
y11%, Non-transmissible y35% P-0.05), but no significant difference in per-
centage change of the other markers of inflammation. These preliminary results
suggest that there is no significant difference in the clinical response to intravenous
antibiotic therapy in patients chronically infected with either transmissible or non-
transmissible strains of PA. The study is ongoing.
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Fingerprinting of cystic fibrosis sputum metagenome reveals unique
amplicon length heterogeneity (ALH) profiles for each patient
S. Miller , D. Mills , T. Pressler , C. Koch , K. Mathee1 1 2 2 1
Florida International university, Department of Biological Sciences, Miami, United1
States, The National University Hospital (Rigshospitalet), Department of Pediat-2
rics, Copenhagen, Denmark
Cystic fibrosis (CF) is a recessive genetic disorder that results in the accumulation
of abnormal and tenacious mucus in the bronchial tree providing a unique environ-
ment to potential microbial pathogens. Chronic microbial colonization leading to
debilitating exacerbations of pulmonary infection is the major cause of morbidity
and mortality in CF patients. Since only 5% of the microbes in nature are culturable,
it is likely that the routine methods currently used yield limited microbiological
information, and fail to identify numerous pathogenic bacterial species that are
potentially present in the CF airways. Natural variations in the length and compo-
sition of the 16S rRNA genes can be used in discrimination and identification of
novel microbes, and generation of microbial community DNA profile. It was
hypothesized that sputum DNA analysis for 16S rRNA genes could provide a profile
that is unique to each sample, and will lead to the discovery of novel organisms.
The length heterogeneity-polymerase chain reaction (LH-PCR) technique, a com-
mon tool used to identfy soil microbial community was used in our analysis. The
result showed that Amplicon Length Heterogeneity (ALH) profiles can be obtained
from metagenomic DNA extracted from CF sputum, and that the profiles are unique
to each patient. Cloning and sequencing of amplicons revealed the presence of both
known and novel organisms in the CF sputum samples. The ALH profiling method
is robust, fast, and highly reproducible for assessing differences in complex micro-
bial communities. This profiling technique has the potential to become a routinely
used screening method in clinical laboratories.
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Pharmacokinetics of azithromycin in plasma, blood,
polymorphonuclear neutrophils and sputum during chronic use in
patients with cystic fibrosis
E. Wilms , H. Heijerman , D. Touw1 2 1
Central Hospital Pharmacy, The Hague, Netherlands, Leyenburg Hospital, The1 2
Hague, Netherlands
Introduction: The macrolide antibiotic azithromycin (AZM) is used in Cystic Fibro-
sis (CF) patients with chronic lung infection with P. aeruginosa (Jaffe 1998, Equi
2002). For this indication AZM is prescribed in different dosages. Pharmacokinetic
data of AZM during chronic use are lacking. The purpose of this study was to
describe the pharmacokinetics of AZM at a dose of 500 mgyday at daily use.
Methods: Adult CF patients (ns8) with chronic lung infection with P. aeruginosa
were included. AZM therapy was stopped during a 10 day blood sampling period.
Polymorphonuclear neutrophils (PMNNs) were isolated with mass density separa-
tion. AZM was quantified in plasma, blood, isolated PMNNs and sputum by HPLC.
Results: A distribution t in plasma of 0.1"0.02 h (mean"standard deviation)1y2
was found and an extended elimination t in plasma (102"20 h), blood (180"681y2
h) and in PMNNs (289"166 h). A C of 0.67"0.31 mgyl in plasma andmax
2.01"0.74 mgyl in blood of which 1.44"0.69 mgyl was found in PMNNs. Sputum
concentrations varied between 12 and 53 mgyl at day 1 and dropped to 4 and 27
mgyl 10 days after the last dose. The concentration in PMNNs was 2100 times the
C 24 h after the last dose. Conclusion: These results confirm the accumulationplasma
of AZM in PMNNs. We conclude that sputum levels are elevated far above plasma
and blood concentrations. These results may lead to alternative dosing schedules
and the results will be taken into account in studies towards the mode of action of
AZM in this pathology.
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Azithromycin use in children with CF colonised with Pseudomonas
aeruginosa in Northern Ireland
C.A. Kavanagh, A.J.M. Reid
Royal Belfast Hospital for Sick Children, Belfast, United Kingdom
Recent published trials have established a role for Azithromycin in CF patients
chronically infected with Pseudomonas aeruginosa. We retrospectively reviewed all
of the patients with Pseudomonal infection in our clinic that we have commenced
on Azithromycin. Methods: In the last year patients colonised with pseudomonal
infection have been commenced on 250 mg or 500 mg of Azithromycin thrice
weekly. We retrospectively reviewed all these patients. We compared their FEV1%
predicted, FVC% predicted, BMI, no. of days on antibiotics, and any adverse effects
in the 6 months before starting the Azithromycin to the 6 months after starting the
drug. Results: 16 patients were commenced on Azithromycin. One patient developed
raised liver function tests after 2 weeks and it was therefore discontinued. 15
patients were therefore analysed. Pre-Azithromycin: Age Range: 145–202 months
(Av. 177 monthss14 years 7 months); BMI Range: 16.1–21.0 Kgym (Av. 18.362
Kgym ). Post Azithromycin therapy for 6 months: Av. Gain in BMIs0.94 Kgy2
m ; Av. Increase in FEV1% predicteds3.5%; Av. Increase in FVC% predicteds2
4.1%; Av. Decrease in antibiotics intravenouslys9.4 days; None of the 15 patients
suffered any adverse effects from taking the drug. Conclusions: Azithromycin
appears to be a safe and effective therapy in patients with CF who are colonised
with Pseudomonas aeruginosa. Our results concur with other authors.
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Analysis of GCC repeat in 59 untranslated region of the multidrug
resistance-associated protein 1 gene: potential relevance for response
to azithromycin in CF patients
E. Nicolis , M. Pasetto , C. Cigana , B.M. Assael , U. Pradal , P. Melotti1 2 1 1 1 2
Cystic Fibrosis Center-Azienda Ospedaliera di Verona, Verona, Italy, Italian Cys-1 2
tic Fibrosis Research Foundation, Verona, Italy
In this work we aimed to identify possible genetic mechanisms of variable response
to azithromycin (AZM) in CF patients. It has been considered that AZM might
promote a functional complementation of CFTR defect by induction of expression
of the multidrug resistance-associated protein 1 (MRP1) gene which is the most
homologous to CFTR among the members of the ATP binding cassette transporter
superfamily. Improved nasal potential differences was observed in some of our CF
patients treated with AZM (Pradal et al., Pediatric Pulmonology, 2000) as well as
increased MRP1 mRNA levels (Pradal et al., Journal of Cystic Fibrosis, 2002). We
hypothesized a polymorphic length of the MRP1 GCC repeat in the 59 untranslated
region. The MRP1 59 flanking region from 28 CF patients and 100 non CF subjects
was amplified by PCR and the number of triplets of each allele determined by
sequencing and electrophoresis analysis. We found that the repeat is polymorphic
ranging from 7 to 14: 7 (32%), 10 (3%), 11 (16%), 12 (13%), 13 (31%), 14 (5%)
in non CF subjects. No statistically significant difference in frequences were
observed between CF and non CF. This polymorphism might have a potential influ-
ence on gene expression at both transcriptional and translational levels: it will be
analyzed in other CF patients treated with AZM in order to identify an eventual
association of specific allele(s) with responses to AZM. As this channel shares with
CFTR several functions potentially relevant for the pathogenesis of CF, it can be
considered as a potential modifier gene in CF patients. The novel polymorphism
described in this study can be exploited to address this issue. Supported by Italian
Cystic Fibrosis Research Foundation and Azienda Ospedaliera di Verona–Italy.
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Azithromycin (AZM) inhibits quorum sensing (QS) and biofilm
formation of P. aeruginosa (PA) in vitro and decreases chronic PA lung
infection in cystic fibrosis-mice
Nadine Hoffmann , Helle Krogh Johansen , Michae Givskov , Niels Høiby1 1 2 1
Rigshospitalet, Copenhagen, Denmark, Biocentrum-DTU, Lyngby, Denmark1 2
PA causes chronic lung infection in cystic fibrosis (CF) patients by establishing an
alginate containing biofilm. Several studies have highlighted the significantly effect
of macrolide therapy in Japanese patients suffering from diffuse panbronchiolitis, a
disease with many similarities to CF. In vitro inhibitory effect of AZM on the
synthesis of alginate and the production of QS regulated virulence factors as elastase
and chitinase was investigated in a stable, CF mucoid PA isolate NH57388 hyper-
producing alginate and expressing QS. At concentration between 1 and 8 mgyml,
AZM suppressed exoproducts secretion without affecting the growth of the bacteria.
To study the in vivo therapeutic effects of AZM, we established a novel CF-mouse
model (Cftr ) of PA lung infection using isolate NH57388 which is capabletmlUncyyy
to cause chronic lung infection, both in the respiratory and conducting zones of the
airways, without using artificial embedding. Mice were orally treated with AZM
(500 mgykg, once daily) or saline for 6 days. Bacterial lung CFU was significantly
lower (P-0.01) in the AZM treated mice (50 CFUylung, median) compared to
the saline group (7.5=10 CFUylung, median). Alginate could be precipitated5
chemically from lung homogenates and was quantitated by carbazole-borate assay.
AZM treated mice had a range of 0–182 mg alginateyml, median 10 mgyml and
saline group had a range of 194–946 mg alginateyml, median 366 mgyml (P-
0.0001). In conclusion, azithromycin appears to have a promising effect in pre-
venting PA biofilms in the lungs of CF patients.
144
Inhibition of lysosomal V–type H ATPase impairs azithromycinH
accumulation in human polymorphonuclear neutrophils
N. Boone , E. Wilms , H. Heijerman , D. Touw1 1 2 1
Central Hospital Pharmacy, The Hague, Netherlands, Leyenburg Hospital, The1 2
Hague, Netherlands
Introduction: Azithromycin (AZM) a di-basic macrolide antibiotic accumulates in
polymorphonuclear neutrophils (PMNNs) (Wildfeuer 1994). We performed inhi-
bition experiments to elucidate the uptake mechanisms of AZM in PMNNs. We
hypothesise that de-protonation and protonation of AZM is important for entering
the cell and entrapment in acidic lysosomes. To investigate our hypothesis we stud-
ied the effect of inhibition of the lysosomal proton pump V–type H ATPase onq
AZM uptake in human PMNNs. Methods: PMNNs were isolated by mass density
separation from venous blood from a healthy volunteer. The cells were incubated
in the presence of a specific V–type H ATPase inhibitor bafilomycin A1 (BAF)q
(0.1 and 1 mM). AZM incubation followed for 3 h. Furthermore, influence of a P
glycoprotein (P-gp) mediated efflux mechanism was examined with combined
AZM uptake inhibition experiment with the P-gp inhibitor verapamil (VER) (21
mM) and BAF (0.1 mM). PMNNs were counted, isolated and washed twice after
the incubation period. After lysis AZM was determined by HPLC. Results: AZM
uptake in the blank series achieved 0.103"0.008 mgy10 PMNNs. This was sig-6
nificantly reduced to 0.053"0.005 mgy10 PMNNs in presence of 0.1 mM BAF6
(Ps0.006). There was no significant difference between AZM uptake by blank
cells and cells incubated with VER (Ps0.142). AZM uptake in the presence of
BAF alone did not differ from uptake in presence of both BAF and VER (Ps
0.383). Conclusion: These results support our hypothesis that acidic lysosomal pH,
as maintained by V–type H ATPase, is the driving force for AZM accumulation.q
We could not find an effect of P-gp inhibition on AZM accumulation in PMNNs.
With this knowledge influence of co-medication or endogenous inhibitors on this
mechanism can be studied.
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Chronic use of azithromycin in CF is associated with a substantial
increase in macrolide resistance of S. aureus and Haemophilus species
S.J. Phaff , H.A.W. Tiddens, A. Ott
ErasmusMCySophia’s Childrens Hospital, Rotterdam, Netherlands
Two years ago we started to use azithromycin as maintenance therapy in a propor-
tion of CF patients. This therapy may lead to emergence of resistant strains of
bacterial pathogens. Aim: To evaluate changes over time in rate of macrolide resis-
tance of S. aureus and Haemophilus species in CF patients. Methods: Routine spu-
tum cultures were obtained at periodical visits and at time of pulmonary
exacerbations. Antibiotic susceptibility of S. aureus and Haemophilus for macroli-
des was tested routinely. All S. aureus and Haemophilus positive cultures from CF
patients (year of birth 1978-2003) during 1999-2004 were included. Results: Pres-
ently one-third of our patients is on azithromycin maintenance treatment. S. aureus
(713 isolates) andyor Haemophilus (537 isolates) were cultured in 141 patients at
one or more occasions. Of 125 patients with S. aureus, 5 (4%) were identified as
MRSA. During eight octiles of follow-up erythromycin resistance in S. aureus
increased from 8.2% to 57.7%, and clarithromycin resistance in Haemophilus from
5.4% to 39.1%, with highest level of 56% in the 7th quartile (p-value for linear
trend in both: -0.001). We will further analyse effects of azithromycin usage on
cultured pathogens and susceptibility patterns on an individual level. Conclusion:
Over a four-year period we noticed a 6 fold increase in macrolide resistance in CF
pulmonary pathogens. This is likely to be related to chronic use of azithromycin in
our CF population. The clinical consequence of this observation remains unknown.
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Long term therapy with azitromycine (Sumamed) and rhDNAse
(Pulmozyme) in CF patients
H. Kayserova , M. Brezina , B. Remis , D. Zlochova , M. Hajkova , S. Katina1 1 1 1 1 2
National Institute for TB and Respiratory Diseases,CF Centre, Bratislava, Slovak-1
ia, Comenius University, Fac. of Biology, Bratislava, Slovakia2
The prognosis, life expectancy and quality of life in CF patients significantly
improved with the recognition of the underlying pathogenic mechanisms of CF
(CFTR, immunological abnormalities) and subsequent new therapeutical modalities
(rhDNAase, physiotherapy, diet, macrolides). We use Pulmozyme in standard
treatment of CF patients since 1997; from 82 CF patients are 49 treated for 48
months and 42 pts more than 60 months. LFT, number of exacerbation’s, need for
i.v. antibiotics and changes on HRCT (mucus plugs) shows efficacy of this muco-
lytic agent. Especially FEV1 and MEF50 are stabile during all this period, in
patients with FEV1-60% in run-in with nearly 20% improvement after 5 years. 3
pts died in this period with previous short-time benefit of treatment. Sumamed is
another new therapeutical modality with anti-inflammatory properties. Efficacy of
long-term treatment (3–12 months) was approved in 104 CF pts by: improvement
of LFT after 3y6 months was shown (FEV1: 2y10% of p.v.; MEF50: 2y7% of
p.v.), score in dyspnoe, caught, sputum production, fatigue; number of exacerbation,
i.v. antibiotics and changes on HRCT (peribronchial thickening). About 10% CF
pts did not respond to this therapy. We concluded, that azithromycine have to be a
part of standard long-term CF therapy.
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Inhaled tobramycin in cystic fibrosis: preliminary results in 21 patients
S. Hashimoto, F.O.P. Abreu, S.La.R.R. Perin, F.V. Adde, L.V.F. Silva Filho, J.C.
Rodrigues
Pulmonology Unit, Instituto da Crianca - University of Sao Paulo, Sao Paulo,¸ ˜ ˜
Brazil
Antibiotic nebulization plays an important role in the control of Pseudomonas aeru-
ginosa chronic infection and in maintaining pulmonary function in CF. Objectives:
Evaluate the clinical status of a group of CF patients followed at the Pediatric
Pulmomology Clinic of Instituto da Crianca treated with TOBI and monitor their¸
pulmonary function and colonization during this treatment. Material and Methods:
Twenty two patients with chronic colonization with P.aeruginosa, 8My14F, mean
age 13.1"3 years, FEV1F75% were included in the study. Pulmonary function
and sputum cultures were evaluated prior to TOBItreatment (cycles of 28 days
on and 28 days off tobramycin), 1 to 2 months after the first cycle of TOBI and
in the 6th and 12th month of treatment. Renal function was evaluated before and
after every 3 cycles of TOBI. Results: Twenty one patients with a median Shwach-
man score of 60 were evaluated (one was excluded due to intolerance to the med-
ication). The first cycle of TOBI has been concluded by 15 patients, the third by
7 and the sixth by only one. Mean FEV pre TOBI and after the first and third1
cycles were respectively 42.3"14, 43"14 and 38"5%. Aminoglycoside resistance
was observed in P.aeruginosa isolates of 5 patients. MRSA was newly isolated
(sputum culture) in one patient, S. malthophilia in three and B.cepacea in another.
In two patients multiresistant P.aeruginosa grew in the sputum. Renal function
remained normal. Conclusion: Close surveillance of the sputum bacteriology, con-
cerning the emergence of new pathogens and P.aeruginosa resistance, must be per-
formed in these patients. No pulmonary function improvement was observed
probably due to the small sample studied and the presence of severe lung disease
in the majority of patients.
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Risk factors for MRSA colonization in patients with cystic fibrosis
K. Nadesalingam , S.P. Conway , M. Denton1 2 1
Department of Microbiology, Leeds Teaching Hospitals, Leeds, United Kingdom,1
Regional Cystic Fibrosis Unit, Leeds Teaching Hospitals, Leeds, United Kingdom2
Methicillin-resistant Staphylococcus aureus (MRSA) is an increasing problem for
patients with cystic fibrosis (CF). Recent attempts to eradicate the organism have
met with only moderate success. Understanding risk factors for acquisition of
MRSA by CF patients will aid the development of effective preventative strategies.
We conducted a retrospective case-control study comparing a variety of risk factors
for 15 MRSA-positive patients and 30 age-sex-matched MRSA-negative controls
who attended either the Regional Paediatric or Regional Adult Cystic Fibrosis Units
in Leeds. During the year prior to initial isolation, MRSA-positive CF patients spent
significantly more days in hospital (mean 19.8 days versus 5.5 days, P-0.01),
more treatment days of oral ciprofloxacin (43.5 days vs. 13.9 days, P-0.05), and
were more likely to be chronically colonized with Aspergillus fumigatus (40% vs.
10%, P-0.05) than controls. There were no significant differences in observed
clinical parameters (clinical and X-ray scores) or in the number of patients chron-
ically colonised with Pseudomonas aeruginosa (23% vs. 20%) or Burkholderia
cepacia complex (7% vs. 3%). Minimising the number and length of hospital
admissions and judicious use of antibiotics, particularly ciprofloxacin, should be
the key components of any strategies designed to reduce the risk of MRSA acqui-
sition by patients with CF.
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Methicillin-resistant Staphylococcus aureus (MRSA) in French CF
patients : an epidemiologic approach
C. Segonds , P. Clavel-Batut , K. Eydieux-Laporte , I. Le Thomas-Bories , E.1 1 1 1
Bingen , P. Mariani , N. Brahimi , S. Ravilly , G. Chabanon2 2 2 3 1
Hopital Rangueil, Toulouse, France, Hopital Robert-Debre, Paris, France, Vain-1 2 3ˆ ˆ ´
cre la Mucoviscidose, Paris, France
The aim of the present study is to assess the characteristics of methicillin-resistant
S. aureus (MRSA) colonisations in French patients with CF, whereas the prevalence
of MRSA has reached 10,9% in 2001. One-hundred and eleven MRSA-colonised
patients from 14 CF centres were included. Bacterial isolates were collected for
antimicrobial susceptibility testing and genotyping, using pulsed-field gel electro-
phoresis (PFGE). The mean age of acquisition is 13,7 years (range -1–37), and
colonisation is chronic in 65% of cases. Of 82 documented cases, 54 (66%) had
been hospitalized during the prior year, whereas 28 (34%) had not; 40 (49%)
received an antistaphylococcal antibiotic shortly (-30 days) after MRSA diagnosis,
mainly cotrimoxazole (19 patients) or pristinamycin (11 patients); a glycopeptide
has been used in 5 patients. Most isolates (75%) are susceptible to gentamicin, and
resistant to tobramycin and amikacin. Pristinamycin, cotrimoxazole, fusidic acid
and rifampicin are respectively effective on 100, 97, 79 and 78% of isolates. Seven
gentamicin resistant isolates exhibit a reduced susceptibility to glycopeptides.
Twelve PFGE groups include 2 to 24 isolates, whereas other profiles are unique.
Ten of the 12 PFGE groups are present in 2 to 10 different CF centres. This analysis
shows that within the CF population, the gentamicin-susceptibleytobramycin resis-
tant phenotype is predominant and that reduced susceptibility to glycopeptides is
encountered; it suggests that MRSA in CF patients might be community-acquired
andyor patient-to-patient transmitted.
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Nebulized vancomycin in a cystic fibrosis patient chronically colonized
by MRSA: case report
G.F. Fongaro, L.C. Menezes, F.V. Adde, L.V.F. Silva Filho, J.C. Rodrigues
Pulmonology Unit, Instituto da Crianca, University of Sao Paulo, Sao Paulo, Brazil¸ ˜ ˜
Introduction: Methicillin-resistant Staphylococcus aureus (MRSA) is an emergent
pathogen with significant clinical impact for cystic fibrosis (CF) patients, but its
clinical management remains controversial. Objective: We report a case of a CF
patient chronically colonized by MRSA with progressive clinical deterioration who
was treated with inhaled vancomycin. Case report: A 7 year-old white female with
CF diagnosed at 21 months of age was intermittently colonized by P. aeruginosa
and methicillin-sensitive S. aureus (MSSA) since 2 years-old. She started frequent
respiratory exacerbations by age 4, becoming chronically colonized with MSSA.
At age 6, MRSA was firstly and then frequently isolated and clinical deterioration
ensued. Inhaled vancomycin was started with good clinical response. During the
treatment period she presented only one mild exacerbation, treated with oral line-
zolid at home. However, we did not observe any improvement in lung function
tests and sputum cultures remained positive for MRSA. Besides that, reappearance
of P. aeruginosa and emergence of B. cepacia (4 sputum samples) occurred. Van-
comycin-resistant Enterococcus faecium was isolated in a rectal swab in the 7th
month of treatment, and therefore it was discontinued. She remained clinically stable
albeit she was admitted once because of moderate respiratory exacerbation with
isolation of MRSA. Vancomycin-resistant Enterococcus disappeared without any
specific intervention. Conclusions: Clinical response to inhaled vancomycin may
occur in patients with CF colonized by MRSA but the risks for acquisition of new
pathogens must be outweighed and strict surveillance for the emergence of van-
comycin-resistant Enterococcus is recommended.
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Pseudomonas aeruginosa in water of public outdoor and indoor
swimming pools and bathroom water taps of patients with cystic
fibrosis during the hot summer 2003
J. Barben , G. Hafen , J. Schmid1 1 2
Paediatric Pulmonology, Children’s Hospital, St. Gallen, Switzerland, Official1 2
Food Control Laboratory, St. Gallen, Switzerland
Background: In patients with cystic fibrosis (CF), acquisition of Pseudomonas aeru-
ginosa (PA) in the lungs is a marker of poor survival as it reduces life expectancy.
PA is an ubiquitous facultative pathogen prevalent in humid environments. In a
previous study we have investigated the prevalence of PA in public outdoor and
indoor pools as well as bathroom water taps of patients with CF in autumn and
winter 2002. In this study we wanted to determine the prevalence of PA during the
hot summer months in 2003. Methods: Water, sampled by Environmental Health
Officers, was collected in 100 ml sterile plastic disposal bottles (g-sterilized with
sodium-thiosulfate) from public swimming pools in the greater area of St. Gallen
in summer 2003. In addition, water was sampled from bathroom water taps of 50
CF patients in August 2003: 1st sample was standing water from the tap early in
the morning, 2nd sample was running water (for at least one minute) from the same
tap. All specimens were examined within 24 hours following collection. Results:
From 35 public outdoor pools, 117 specimens were investigated and 3 revealed PA;
all these 3 specimens were from paddling pools. From the 56 public indoor pools,
2 out of 128 specimens revealed PA, both were from hydrotherapy pools. Two out
of 50 specimens of the standing water from the bathroom water taps revealed PA
but none of the 50 specimens of the running water. Conclusion: Water of public
indoor and outdoor swimming pools in the greater area of St. Gallen–if maintained
according to local hygiene guidelines–appears not to place people with CF at risk
of acquiring PA. However, water of outdoor paddling pools can contain PA during
hot summer days. Running water from water taps in bathrooms of homes in the
area of St. Gallen appears safe.
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Microbiological efficiency control of a domestic steam disinfector
against nebulizers of cystic fibrosis (CF) patient
C. Doit , C. Gouot , B. Delaisi , E. Bingen1 1 2 1
Service de Microbiologie-Hopital Robert Debre, Paris, France, Service de Gastro-1 2ˆ ´
enterologie-Hopital Robert Debre, Paris, France´ ˆ ´
Nebulizers are a potential source of respiratory tract contamination in CF patients.
At home, nebulizer’s disinfection method recommended in France, use immersion
in sodium hypochlorite. The objective of this study was to compare the microbio-
logical efficiency of a domestic steam disinfector (NUK), with the recommended
method. Nebulizer (PARI LC plus) were artificially contaminated with 3 bacterial
strains isolated from CF patients (Pseudomonas aeruginosa, Staphylococcus aureus
and Bulkhorderia cepacia) with an initial inoculum of at least 10 colony forming5
unit (cfu)ypiece. Nebulizers were disinfected by the NUK system or by immer-
sion in sodium hypochlorite. After complete drying in ambiant air, viable test bac-
teria were numerated on each piece by sonication in sterile water, filtration of the
water on membrane filters which were transferred onto agar plates and incubated
48 h at 37 8C. Based on the bacterial count of the controls (initial count) and the
bacterial count of disinfected pieces, log reduction was calculated. The acceptance
criteria was a reduction of at least 5 log cfuypiece. Each experiment was repeated
5 time. With the NUK system, reduction of G5 log CFUypiece was obtained in
100% with P. aeruginosa, in 96% with S. aureus, and in 83% with B. cepacia.
With sodium hypochlorite, reduction of G5 log CFUypiece was obtained in 100%
with S. aureus and B. cepacia and in 90% with P. aeruginosa. Statistical differences
between the two methods were not significant except for B. cepacia (Khi2, Fischer’s
test, Ps0.03). Steam disinfector NUK could be use to disinfect home nebulizers
with two restrictions: patient infected or colonized by B. cepacia; prior cleaning is
indispensable; Further experiment with prior cleaning is needed to confirm these
results.
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Domestic washing machines: a reservoir for Pseudomonas
aeruginosa?
T.L. Pitt, H. Englender, H.M. Aucken
Laboratory of HealthCare Associated Infection, SRMD,HPA Colindale, London,
United Kingdom
A survey of water reservoirs in domestic washing machines showed that 14 of 20
machines sampled contained Pseudomonas aeruginosa in varying numbers. We
questioned whether contamination of clothing could occur during washing and thus
represent a potential hazard to susceptible patients such as those with cystic fibrosis.
Water samples were taken from the sump of a domestic washing machine normally
used at a 40 8C cycle. P. aeruginosa serotype O6 with indistinguishable phage
typing patterns and DNA fingerprint profiles were repeatedly isolated from the test
machine over a 6 week period. Other strains of P. aeruginosa were occasionally
isolated. Three sterile tea towels were put through a 40 8C washing cycle and then
placed in containers of selective recovery broth for 3, 6 and 18 h. These were
subcultured to Pseudomonas selective agar. P. aeruginosa serotype O6 with the
same genotype as the dominant resident strain were recovered from each tea towel.
After drying and ironing, P. aeruginosa was not recovered from the cloths. The
potential of washing machines as a domestic environmental source for P. aeruginosa
should be recognised. These results suggest that although P. aeruginosa from the
machine can contaminate clothing during normal washes, drying and ironing is
sufficient to eradicate the organism from clothing.
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In children with cystic fibrosis can bacteria isolated from spirometry
filters guide clinical management?
J.L. Hartley , J.H.M. Rees , M.C.J. Rudolf2 1 3
Royal Shrewsbury Hospital, Shrewsbury, United Kingdom, Birmingham Chil-1 2
dren’s Hospital, Birmingham, United Kingdom, Leeds General Infirmary, Leeds,3
United Kingdom
Background: Concerns regarding cross contamination of organisms during cystic
fibrosis clinics, has lead to the widespread use of disposable filters on spirometry
equipment. Cross-infection risk from forced exhalation during spirometry would
suggest that cultures taken from such filters might be used for lower respiratory
tract pathogen isolation. The technique removes the potential for contamination
from pharyngeal flora, and may also be a preferred technique than cough swab
sampling. Aims: To compare pathogens isolated from cough swabs andyor sputum
with spirometry filters following lung function testing. To ascertain whether cough
swabs are truly disliked by children. Methods: Preliminary studies on spirometry
filters (Vitalograph) demonstrated their suitability for yielding pathogens. Chil-
dren able to perform spirometry were recruited from cystic fibrosis clinics at the
Royal Shrewsbury Hospital, Shrewsbury, and Princess Royal Hospital, Telford.
Children’s opinion of cough swabs was obtained. Results: The spirometry filter
yielded pathogen growth in 3% of cases (1y30). One case had a growth of Candida
spp., which corresponded with the cough swab. This compared with positive bac-
teriology in 69% of cough swabs and 86% of sputum specimens collected at the
same clinics. Seventy-seven percent of children expressed a dislike of cough swabs
(20y26). Conclusions: The spirometry filter culture technique for isolating bacteria
cannot aid clinical management. Results raise doubts over spirometry equipment
being a significant cause of cross contamination. The high level of dislike for cough
swabs should prompt further investigation into patient acceptability of other avail-
able techniques such as cough plates or upper airway aspirate cultures.
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Characterization of poxB, a chromosomal-encoded Pseudomonas
aeruginosa oxacillinase
K.F. Kong , S. Jayawardena , A. del Puerto , L. Wiehlmann , U. Laabs , B.1 1 1 2 2
Tuemmler , K. Mathee2 1
Florida International University, Miami, United States, Klinische Forschergruppe,1 2
Medizinische Hochschule Hannover, Hannover, Germany
Pseudomonas aeruginosa is the major pathogen associated with the morbidity and
mortality of patients with cystic fibrosis. One of the reasons for the failure of b-
lactam antibiotic regimens appears to be mediated by de-regulation of the ampC
gene, encoding the chromosomal Ambler’s Class C b-lactamase. Currently, the
AmpC is the only known chromosomal b-lactamase whose expression is regulated
by a transcriptional regulator, AmpR. We generated an ampC mutation in the pro-
totypic P. aeruginosa PAO1. The mutation in ampC did not abolish the b-lactamase
activity entirely suggesting the expression of yet another unreported b-lactamase.
Our genomic analysis revealed the presence of an open reading frame encoding a
protein with high homology to the Class D b-lactamases, commonly known as
oxacillinases. The gene was named poxB for Pseudomonas oxacillinase. Cloning
and expression of poxB in Escherichia coli conferred b-lactam resistance to the
host. We detected the presence of poxB both in clinical and environmental isolates.
Our studies show that P. aeruginosa possesses two b-lactamases, AmpC and PoxB,
which contribute to its resistance against wide spectrum of b-lactam antibiotics.
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Effect of pH on inorganic polyphosphate accumulation in
Pseudomonas aeruginosa and Burkholderia cepacia isolates from
patients with cystic fibrosis
T.F. Moriarty , C. Laverty , A. Mullan , J. McGrath , J.S. Elborn , M.M. Tunney1 1 2 2 3 1
School of Biology and Biochemistry, Queen’s University, Belfast, United Kingdom,1
Respiratory Medicine Research Group, Queen’s University, Belfast, United King-2
dom, Belfast City Hospital, Belfast, United Kingdom3
Polyphosphate kinase (PPK) is the principal enzyme in many bacteria for the syn-
thesis of inorganic polyphosphate (poly P) from ATP. PolyP and PPK have been
shown to be required for both motility (Rashid MH, Kornberg A. 2000, PNAS
97(9): 4885–90) and quorum sensing (Rashid et al. 2000, PNAS. 97(17): 9636–
41) in Pseudomonas aeruginosa. Furthermore, it has been suggested that PolyP has
a regulatory role in the adaptation of some microbial cells during alterations in their
environment (Kornberg et al. 1999, Annu Rev Biochem. 68: 89–125). As previous
studies have shown that there is chronic acidification of the airways in cystic fibrosis
patients with acute pulmonary infection (Tate et al. 2002, Thorax 57: 926–929),
the effect of pH on intracellular phosphate accumulation was investigated in this
study. Clinical Pseudomonas aeruginosa and Burkholderia cepacia isolates were
initially tested using Neisser staining for phosphate accumulation at both neutral
and acidic pH’s. Sixty percent of isolates tested contained detectable intracellular
polyphosphate when grown at pH 6.4 in comparison with only 24% of isolates
when grown at pH 7.0. A number of isolates were selected for quantification of
total intracellular phosphate using Biomol Green (Biomol, PA, USA). Growth of
the isolates at pH 6.4 resulted in increases in phosphate accumulation of up to
150% in comparison with growth at pH 7.0. The results show phosphate metabolism
is altered when external pH is lowered suggesting a microbial response to an acidic
environment which may be important for quorum sensing and virulence in these
clinically important pathogens.
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Direct sputum sensitivity testing in cystic fibrosis patients. To detect
resistant Pseudomonas aeruginosa isolates and the potential of the
method to demonstrate synergy
D. Matley, M. Carroll, G. Jones, D. Serisier, A. Tuck
HPA Southampton, Southampton, United Kingdom
The Cystic Fibrosis (CF) lung can become chronically colonised with Pseudomonas
aeruginosa (PsA), where the administration of antibiotics is required to reduce the
bacterial load. In vitro susceptibility testing is crucial for the guidance and selection
of the most appropriate antibiotic. For most bacterial infections standard disc dif-
fusion techniques are more than adequate for deciding on the best antibiotic of
choice. In the treatment of chronic pulmonary PsA the selection of antibiotic guided
by the disc diffusion method is known to have limitations. Within a CF sputum
culture there maybe many PsA isolates of different morphology and sensitivity
present; as only a single colony is selected for disc sensitivity, this may not truly
reflect the population susceptibility to antibiotics. To investigate, PsA isolates were
obtained from the culture of CF and non-CF sputum and subjected to 2 disc dif-
fusion methods; Stokes and British Society of Antimicrobial Chemotherapy
(BSAC). Data obtained from these two methodologies were compared to those
results obtained from a novel Direct Sputum Sensitivity Testing (DSST) technique.
DSST is the use of E-tests (AB Biodisks, Sweden) on whole sputum. This method
provides an overall MIC on the different morphological types of PsA that maybe
present in CF sputum. The direct comparison of CF sputum to that of non-CF
sputum revealed that this type of hetereogeneity between isolates is a characteristic
specific to CF lung and not found in non-CF patients. This investigation also reveals
that DSST is a viable method for the detection of resistant strains of PsA and in a
small percentage of cases antibiotics when used in combination can demonstrate
synergy, something that disc sensitivity testing cannot do.
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Evaluation of the automated Merlin, Micronaut System for susceptibility
testing of mucoid and non-mucoid Pseudomonas aeruginosa isolates
from cystic fibrosis patients
B. Balke , L. Hoy , H. Weissbrodt , S. Haeussler1 2 1 3
MHH-Inst.fur Med.Mikrobiologie u. Krankenhaushygiene, Hannover, Germany,1 ¨
MHH-Institut fur Biometrie, Hannover, Germany, Gesellschaft fur Biotechnolo-2 3¨ ¨
gische Forschung-Abt. Zellbiologie, Hannover, Germany
Accurate susceptibility testing of bacterial isolates from cystic fibrosis (CF) patients
is known to pose problems. Although commercially available automated test sys-
tems could facilitate susceptibility testing of CF isolates in routine diagnostics, these
systems have not been recommended so far. However, recently a pilot study impli-
cated that the automated Merlin (Micronaut, Germany) broth microdilution system,
based on an end-point measurement rather than on growth curves, might be appli-
cable in the susceptibility testing of CF isolates. In this study the Merlin system
was further evaluated using an extended panel of non-mucoid and mucoid Pseu-
domonas aeruginosa strains. It was demonstrated that the Merlin system tends
towards more susceptible MIC results compared to MIC results generated by agar
dilution and that this becomes increasingly apparent when testing mucoid Pseu-
domonas aeruginosa. The correlation coefficients (r values) for all strains of only
2 out of 7 antimicrobial agents (meropenem and ciprofloxacin) were )0.8. How-
ever, since the overall rate of serious discrepancies in interpretive category results
was in an acceptable range, the Merlin system appears to be applicable for routine
clinical use in susceptibility testing of Pseudomonas aeruginosa CF isolates.
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Antimicrobial susceptibility and synergistic activity against
multiresistant Gram-Negative non-fermentative bacteria isolated from
cystic fibrosis patients
N. Ravenni, S. Campana, S. Farina, A. Di Como, F. Festini, G.F. Mergni, G. Taccetti
Cystic Fibrosis Center, Department of Pediatrics, University of Florence, Florence,
Italy
The predilection of Pseudomonas aeruginosa and Burkholderia cepacia complex
for the CF lung has been well described. However, during the past decade, several
additional pathogens, including Stenotrophomonas maltophilia and Alcaligenes
xylosoxidans, have been recovered from CF patients with increasing frequency. Due
to intrinsic and acquired resistance to antimicrobial agents, there are limited ther-
apeutic options available. The objective of the present study was to evaluate the
activity of meropenem of ticarcillin, ceftazidime ciprofloxacin, tobramycin, and
cefepime. Determinations of the MICs and synergy testing were performed by E
test. The bactericidal effect was tested on 18 multiresistant strains. Furthermore, the
in vitro synergistic effect of meropenem in association with the other antibiotics
was evaluated. Meropenem, ceftazidime and ciprofloxacin had the most activity and
inhibited 72%, 50% and 61% of strains, respectively. The addition of a second
antibiotic to meropenem resulted in a synergistic effect on two (11%) isolates. Our
study indicates that a choice of effective double antibiotic therapy cannot be made
empirically for CF patients infected with gram-negative multiresistant bacilli. In
fact the most effective double-antibiotic combination is bactericidal only in a small
percentuage of isolates (11%). The synergistic effect is detected with meropenemq
ticarcillinyceftazidimeytobramycinycefepime. Furthermore, the addition of a second
antibiotic was found to be potentially counterproductive. In fact in 16% of the
isolates, most of them sensitive to a single antibiotic, adding a second antibiotic
resulted in antagonisms with loss of bactericidal effects. Our results underline the
importance of association antibiotic susceptibility testing to improve the bactericidal
effect.
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Comparative in vitro activities of beta-lactams against multiresistant
Gram-negative bacilli isolates from patients with cystic fibrosis
S. Campana , F. Favari , N. Ravenni , G. Braccini , M.P. Ottolini , R. Fontana , G.1 2 1 1 2 2
Taccetti1
Cystic Fibrosis Center, Department of Pediatrics, University of Florence, Florence,1
Italy, Servizio di Microbiologia, Ospedale Civile Maggiore, Verona, Italy2
The predilection of Pseudomonas aeruginos and Burkholderia cepacia complex for
the CF lung has been well described, but other Gram-negative bacilli such as Alca-
ligenes xylosoxidans and Stenotrophomonas maltophilia are being isolated from CF
patients with increasing frequency. Due to intrinsic and acquired resistance to anti-
microbial agents of these pathogens, there are limited therapeutic options available.
During the past decade, no new antibiotics have been developed for treatment of
pathogens in CF patients. Thus the CF community has been exploring the novel
use of currently available agents. From many years some authors have shown good
results in treating CF patients that are infected by Burkholderia cepacia with tem-
ocillin. We evaluated the efficacy of meropenem, imipenem, ceftazidime and tem-
ocillin for 68 multiresistant Gram-negative bacilli (45 Burkholderia cepacia
complex, 9 Alcaligenes xylosoxidans, 13 Pseudomonas aeruginosa, 1 Stenotropho-
monas maltophilia) obtained from the sputum of 65 cystic fibrosis patients. Anti-
biotic susceptibility patterns for these b-lactams drugs were determined using the
disk diffusion method. Among the tested antibiotics temocillin showed the higher
activity (54%), followed by ceftazidime (43%), imipenem (25%) and meropenem
(19%). Furthermore 9 (13%) isolates showed resistance to all b-lactams drugs
tested except temocillin. In conclusion temocillin is the most active b-lactam (54%)
against multiresistant bacteria, compared with the traditional b-lactam antibiotics
such as meropenem, imipenem and ceftazidime (ranging from 43% to 13%). Over-
all temocillin is the only active b-lactam for 13% of the isolates. These data show
that temocillin could represent a good therapeutical option for treating infection of
multiresistant Gram-negative bacilli in CF patients.
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Effect of growth under anaerobic conditions on the antimicrobial
susceptibility of Pseudomonas aeruginosa isolates from cystic fibrosis
patients
M.M. Tunney , A. White , J.S. Elborn1 1 2
Respiratory Medicine Research Group, Queen’s University, Belfast, United King-1
dom, Belfast City Hospital, Belfast, United Kingdom2
Recent evidence indicating that airway mucus in cystic fibrosis patients is anaerobic
has led to the suggestion that bacteria, such as Pseudomonas aeruginosa, are grow-
ing under anaerobic conditions within the lungs of CF patients with persistent repir-
atory infection. As the efficacy of antibiotics used to treat CF lung infection, such
as the aminoglycosides, is likely to be reduced under anaerobic conditions, it may
be more appropriate if antimicrobial susceptibility tests were performed under anaer-
obic rather than aerobic conditions. The aim of this study was, therefore, to deter-
mine the susceptibility of clinical P. aeruginosa isolates growing under both aerobic
and anaerobic conditions, to antibiotics currently used to treat cystic fibrosis lung
infection. The minimum inhibitory concentrations (MICs) of ceftazidime, tobra-
mycin, meropenem, aztreonam, piperacillin and piperacillinytazobactam, for clinical
P. aeruginosa isolates were determined using the British Society for Antimicrobial
Chemotherapy broth microdilution method. Although there were differences
between the MICs for some of the isolates under aerobic and anaerobic conditions,
the overall results showed that of the antibiotics tested, only tobramycin was less
effective at inhibiting growth when the isolates were grown anaerobically. The
results suggest, therefore, that even if P. aeruginosa isolates are growing under
anaerobic conditions in the lungs of cystic fibrosis patients, informed decisions
regarding treatment can still be made on the basis of MICs determined for the
isolates growing under aerobic conditions.
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Investigation of the interaction of B. cepacia complex with lung
epithelial cells in vitro
CE Duff , T Mullen , PG Murphy , M Callaghan , S McClean1 1 2 1 1
Institute of Technology, Tallaght, Dubline, Ireland Adelaide, Meath and Incor-1 2
porating National Children’s Hospital, Tallaght, Dublin, Ireland
B. cepacia complex are a major cause for concern in cystic fibrosis patients. They
are antibiotic resistant opportunistic pathogens, which can cause a very rapid
decline, fatal pneumonia and septicaemia in a subgroup of patients, a condition
known as Cepacia syndrome. There are at least nine species of this pathogen, with
varying clinical outcomes. Two species in particular, B. multivorans and B. ceno-
cepacia have been associated with the majority of clinical cases. The mechanisms
of adhesion, invasion and translocation of this pathogen are not yet fully understood.
The objective of this research is to examine polarised epithelial cell models for the
investigation of mechanisms of invasion by B. cepacia complex. We have evaluated
different lung epithelial cell lines, as models for studying invasion by a series of
B. cepacia complex strains. We have found significant differences between the B.
cepacia complex invading 16HBE14o- and Calu-3 cells compared with A549 cells
when grown on plastic, indicating there are epithelial factors involved in the mech-
anism. These cell lines form tight junctions and grow on an airyliquid interface,
making them more a physiological relevant model. Using this model, we have been
able to investigate the potential for different species of B. cepacia to invade, into
and through the epithelial monolayer. We have also found that the two most virulent
species show different levels of transmigration, indicating that they may utilise
different mechanisms of invasion. We are currently examining the effects of bacteria
on tight junction proteins and their interactions with cell surface receptors. Under-
standing the mechanisms of attachment and invasion, should allow better therapies
to be developed for the control and treatment of B. cepacia.
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Fas-induced apoptosis of Staphylococcus aureus-infected airway
epithelial cells
M.C.A. Da Silva , M.C. De Assis , J.-M. Zahm , E. Puchelle , M.C. Plotkowski1 2 3 3 2
Institut of Microbiology, Federal University of Rio de Janeiro, Rio de Janeiro,1
Brazil, Department of Microbiology and Immunology, State University of Rio de2
Janeiro, Rio de Janeiro, Brazil, INSERM U314, Reims, France3
We have shown that bacteria can enter into airway cells, persist intracellularly and
induce cell apoptosis. In this report, to investigated the role of the Fas–Fas ligand
(FasL) system in airway cell death, 16HBE cells exposed to a S. aureus strain
isolated from airway secretions of a CF patient were examined for the surface
expression of Fas receptor and FasL by FACS. S. aureus intracellular (IC) infection
led to a significant increase in cell surface expression of both Fas (from 3.4%"1.2
in non-infected cells to 18.0%"7.7 in infected cells; P-0.05) and FasL (from
2.8%"1.0 to 26.1%"10.9; P-0.05). To ascertain whether the upregulation of Fas
and FasL would predispose infected cells to death, cells harboring IC bacteria for
24 h were treated with an anti-Fas IgM and cell apoptosis was assessed by FACS
analysis of phosphatidylserine surface expression by the annexin V binding assay.
In parallel, human polymorphonuclear leukocytes (PMN) were seeded onto the
upper chamber of Transwell inserts above S. aureus-infected cell cultures, allowing
for potential diffusion of soluble FasL (sFasL) mediators but preventing cell–cell
contact. The percentage of apoptotic cells in infected cultures treated with the ago-
nistic antibody (19.5%"4.1) or with the PMN soluble mediators (15.9%"2.5)
were significantly higher (P-0.01) than in non-infected cultures (6.9%"2.4) or
in untreated infected cultures (11.4"3.3). Based on these results we speculate that
in vivo, the increased expression of Fas receptors induced by S. aureus infection
may favor the apoptosis of airway cells by sFasL or by FasL-expressing inflam-
matory cells detected in CF patient airways, further contributing to epithelial dam-
age and secondary colonization by opportunistic pathogens. Supported by AVLM
(France) and CAPES (Brazil).
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Identification of interacting groups of bacterial species colonising the
CF lung, through statistical analysis of T-RFLP profiles
G.B. Rogers , M.P. Carroll , P.M. Hockey , K.D. Bruce1 1 1 2
Southampton General Hospital, Southampton, United Kingdom, King’s College1 2
London, London, United Kingdom
Previously, Terminal Restriction Fragment Length Polymorphism (T-RFLP) anal-
ysis has been used to demonstrate the large and phylogentically diverse range of
bacterial species colonising the lungs of adult cystic fibrosis patients. In other eco-
logical niches, those found in the human oral cavity for example, inter-specific
interactions are widespread and necessary for the formation of stable communities.
Further, traditional, culture-based techniques have been used to show that the growth
of key CF pathogens such as P. aeruginosa and S. aureus is affected by inter-specific
interactions. The identification of relationships between novel lung colonising spe-
cies would provide clues as to the role they play in infections and may identify
new approaches to treatment. T-RFLP profiles generated from 72 adult CF sputum
samples were analysed. 252 different T-RF band sizes were detected, representing
31626 possible separate relationships. Fisher’s exact test was used to examine the
frequencies at which different pairs of T-RF bands were co-resolved, and these were
compared to the frequencies at which they were resolved separately. 270 of the
31626 pairwise relationships examined were found to be significant, with a prob-
ability of a chance association being 0.01 or less. Further, the identification of
statistically significant pairwise associations allowed the construction of clusters
formed of inter-relating species. The majority of T-RF bands shown to be in sig-
nificant associations have not, as yet, been assigned to bacterial species, an ongoing
process involving 16S clonal analysis. Further, the manner in which these species
interact must be determined. However, these findings represent an important insight
into the complexity of the processes within the CF bacterial community.
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Staphylococcus aureus and airway epithelial cell interaction
D. Gras , M. Da Silva , M. Milliot , J.M. Zahm , O. Bajolet , M.C. Plotkowski ,1 3 1 1 2 3
E. Puchelle1
INSERM UMRS 514, Reims, France, Laboratoire de Bacteriologie-Virologie-1 2 ´
Hygiene, CHU, Reims, France, Department of Microbiology, University of Rio3`
Janeiro, Rio Janeiro, Brazil
The host-defense response of airway epithelial cells to the exposure of microorgan-
isms relevant to CF depends on the balance between the capacity of bacteria to
adhere to airway epithelial cells and release soluble virulence factors and the capac-
ity of host cells to maintain their integrity and exert antibacterial activity. We used
videomicroscopy to analyze the interaction of Staphylococcus aureus with airway
cells. In parallel we analyzed the release of an antimicrobial protein, secretory leu-
cocyte protease inhibitor (SLPI) by airway epithelial cells and of alpha-toxin by
bacteria. A reference S. aureus strain 8325-4 was incubated at increasing concen-
trations with a glandular airway epithelial cell line (MM-39). The percentage of
airway epithelial cells showing adherent bacteria was 0.8"0.6%, 2.7"2.6%,
7.9"5.1% after 1 h and 2.8"0.5%, 7.5"5.5%, 27.5"19.8% after 24 h of inter-
action with 10 , 10 or 10 CFUyml of S. aureus, respectively. After 1 h, 50% of6 7 8
the bacteria showed an altered membrane integrity, whereas the airway cell
membrane permeability and release level of SLPI were not altered whatever bac-
terial concentration. In contrast, after 24 h, the airway epithelial cells exhibited an
altered membrane permeability and a significant bacterial concentration-dependent
decrease in SLPI release. In parallel, an increase in alpha-toxin secretion by bacteria
was observed. These results suggest that the host defense activity of epithelial cells
is efficient at the onset of the infectious process. After a prolonged interaction of
S. aureus with airway epithelial cells, the membrane integrity of airway epithelial
cells is damaged, likely due to the release of soluble bacterial virulence factors.
Supported by INSERM, ARDySolliance and Association Vaincre la Mucoviscidose.
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Comparison of two methodologies of Pseudomonas aeruginosa
antibody assessment in cystic fibrosis patients
C.W.M. Ang , T.W.R. Lee , K.G. Brownlee , H.C. Gooi , A. Latiff , S.P.1 1 1 2 2
Conway1
Leeds Regional Paediatric Cystic Fibrosis Unit, St James’s University Hospital,1
Leeds, United Kingdom, Department of Clinical Immunology, St James’s Univer-2
sity Hospital, Leeds, United Kingdom
Introduction: Pseudomonas aeruginosa antibody assessment may facilitate the early
diagnosis and treatment of P. aeruginosa pulmonary infections in patients with
cystic fibrosis. Different antibody assays make comparative studies and standardi-
sation between different centres difficult. Aim: To compare the validated ELISA
antibody assay used at the Leeds Regional Cystic Fibrosis Unit with a commercial
kit (Genesis). Methodology: Paired serum samples were obtained from 79 patients
with cystic fibrosis and assayed for Pseudomonas aeruginosa antibody by the Leeds
ELISA method and the commercial kit. Based on regular sputum andyor cough
swab culture results, the infection status of each patient was determined and com-
pared to the antibody test results. Results: The commercial kit was significantly
more specific (0.92 w24y26x) than the Leeds ELISA (0.77 w20y26x, P-0.05), but
there was no significant difference between the 2 measurements in sensitivity, 0.64
w29y45x vs. 0.73 w33y45x. Conclusions: The data suggest that the commercial kit
is adequate for testing for pseudomonal antibodies and would also be useful to
compare results between centres.
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Maintenance of high adherence capacity of Pseudomonas aeruginosa
cystic fibrosis isolates during chronic infection is associated with more
severe lung disease
U. Laabs , P. Gudowius , L. Wiehlmann , A.S. Limpert , A. Filloux , B.2 3 2 2 1
Tummler , S. de Bentzmann2 1¨
CNRS IBSM UPR9027, Marseille, France, Medizinische Hochschule Hannover,1 2
Hannover, Germany, Universitats kinderklinik, Dusseldorf, Germany3 ¨ ¨
In vivo and in vitro evidences strongly suggest that P. aeruginosa forms a biofilm
within the CF airways of adult patients suffering from chronic pulmonary infections.
Adherence is undoubtedly a major virulence trait, but its evolution during the course
of the chronic P. aeruginosa infections in CF is unknown. We addressed the question
whether P. aeruginosa binding to respiratory epithelial cells is a clone-specific prop-
erty andyor is subject to adaptation during colonization of CF lungs. Pseudomonas
aeruginosa binding capacity to respiratory epithelial cells was studied in a repre-
sentative panel of 634 sequential P. aeruginosa strains isolated from 26 cystic fibro-
sis (CF) patients, from the onset of colonization for up to 15 years of infection.
The temporal evolution of the binding capacities of the P. aeruginosa isolates
showed three different patterns in the CF hosts. Fourteen CF patients were predom-
inantly harbouring high binders at all times. In 7 CF patients, strong binders were
identified during early colonisation but these clones shifted to weak binders later
on. Two patients had a majority of weak binders identified all along the course of
the disease. Binding capacity of CF P. aeruginosa isolates to bronchial epithelial
cells was found to be associated with the outcome of chronic P. aeruginosa infec-
tions in CF. Patients chronically harbouring high binders had a worse prognosis
than the others. We concluded that high binding activity is not only required for
the bacteria to initiate airway infection in the CF host but is also associated with
more severe lung disease at later stages of the chronic infection. Financial support
by the French and German cystic fibrosis foundations VLM and Mukoviszidose
e.V. is gratefully acknowledged.
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Inquilinus limosus: an unusual bacterium recovered in two French
patients sputum with cystic fibrosis
R. Chiron , F. Counil , F. Bremont , C. Segonds , E. Jumas-Bilak , H. Jean-1 1 2 2 3´
Pierre , H. Marchandin1 1
CHU Arnaud de Villeneuve, Montpellier, France, CHU Rangueil, Toulouse,1 2
France, Faculte de Pharmacie, Montpellier, France3 ´
Inquilinus limosus is a new emerging pathogen being detected recently in patients
with cystic fibrosis (CF). The impact of this organism on lung function is unknown.
We report on two CF children who presented different clinical situations at the time
of their first colonization with Inquilinus limosus. In first case a 12 year old boy
had intermittent Pseudomonas aeruginosa colonization treated as needed and a mild
respiratory disease. Inquilinus limosus was demonstrated in a routine follow-up
analysis without pulmonary function tests or CT-scan’s changes. The other case,
was a 13 year old girl with advance respiratory disease and allergic bronchopul-
monary aspergillosis criteria. Inquilinus limosus was demonstrated with mucoid
Pseudomonas aeruginosa, Staphylococcus aureus and Aspergillus fumigatus in the
same sample when she had clinical, functional and radiolocal respiratory signs of
exacerbation. Identification of Inquilinus limosus was only reached after 16S rDNA
sequencing in both cases and the strains displayed a multiresistant pattern to anti-
biotics except for imipenem and fluoroquinolones. Despite the clinical and func-
tional improvement and intraveinous antibiotics against Pseudomonas aeruginosa,
Inquilinus limosus was demonstrated again in both cases after 3 months. These
cases highlight the usefulness of specialized laboratories capable of identifying unu-
sual species recovered from CF sputum in addition to support the need to collect
other cases to determine wether Inquilinus limosus is a significant pathogen.
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Scedosporium apiospermum sputum isolation in cystic fibrosis
M. Wickremasinghe, K. Gyi, A. Hall, M. Hodson
Royal Brompton Hospital, London, United Kingdom
Scedosporium apiospermum is an opportunistic fungus of unclear clinical signifi-
cance that infrequently colonises airways in cystic fibrosis (Mycoses 2001;44(7–
8):321–5) (Eur. J. Clin. Microbiol. Infect. Dis.2000;19(1):53–6). Colonisation is
hard to distinguish from infection. Multi-resistance can make drug therapy difficult
(Eur. J. Cardiothorac. Surg. 2002;21(5):938–9, Mycoses 2003;46:418–21). Case
notes of patients with Scedosporium apiospermum sputum isolates were retrospec-
tively analysed. Clinical, radiological, lung function and microbiological data were
obtained. Scedosporium apiospermum was isolated from eight patients (3 male, 5
female, mean age 28.7 years) in 1 year, a 1.3% prevalence. 5 patients had single
isolates. 3 who had multiple (35, 5, and 9) isolates were considered colonised not
infected and required no treatment. Colonised patients had Staphylococcus aureus,
Candida and Pseudomonas aeruginosa as sputum co-pathogens during follow up
and one was colonised with Mycobacterium chelonae and Aspergillus fumigatus.
No patients with single isolates grew Staphylococcus aureus; Candida, Pseudo-
monas aeruginosa and Aspergillus fumigatus (in 4 patients) were found. Patients
with single isolates had better lung function than those colonised (FEV 63.1% vs.1
43.4%, FVC 79.2% vs. 61.3%, mean% predicted values). In colonised patients,
lung function deterioration was 0%, 2% and 3% over 1 year. No new radiological
changes occurred, except one colonised patient developed focal parenchymal opa-
cification on HRCT thought related to Mycobacterium chelonae. Scedosporium
apiospermum prevalence is low but colonisation may occur. Colonised patients had
worse initial lung function than those with single isolates but had no significant
deterioration while colonised
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Achromobacter xyloxocidans a new emerging microorganism in cystic
fibrosis
C.R. Hansen, T. Pressler, C. Koch, H.K. Johansen, N. Hoiby
Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Pseudomonas aeruginosa is the most common bacterial isolate obtained from
patients with cystic fibrosis. Recently, however, new multiresistant organisms have
emerged, whose identification may be difficult and whose pathogenic role is not
define. The aim of this study was to describe the occurrence of A. xyloxocidans in
our patient population. In 2002 A. xyloxocidans was detected in lower respiratory
tract secretions from 19 patients with CF followed at our CF clinic. In average each
patient have 5 positive culture (range 1–13). The 16 patients fulfilled the criteria
for chronic broncho-pulmonal A. xyloxocidans infection; defined by either 6 con-
secutive positive cultures or a rise in precipitating antibodies to at least 2. The
median antibody levels in chronic infected patients were 15.5 (range 2–46). The
possibility for epidemic patient-to-patient spread of A. xyloxocidans gave rise to
concern. The clonality of 16 different strains of A. xyloxocidans was investigated
by pulsed-field gel electrophoresis. We did not find any sign of cross infection. The
clinical significance of this microorganism has to be further investigated.
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Risk factors for allergic bronchopulmonary aspergillosis and
sensitisation to Aspergillus fumigatus in patients with cystic fibrosis
N. Ritz, R.A. Ammann, C. Casaulta, F. Schoni-Affolter, M.H. Schoni¨ ¨
Department of Paediatrics, Universitiy of Berne, Berne, Switzerland
Background: Increasing incidence of allergic bronchopulmonary aspergillosis
(ABPA) as a complication in patients with cystic fibrosis (CF) is reported. Potential
risk factors were investigated by a case-control study. Cases: 11 patients with clin-
ical signs and serologic data for ABPA and 20 patients with serologic evidence of
Aspergillus fumigatus sensitisation (ASF). Controls (with extended matching): 62
CF patients using extended matching for sex, age and weight with no evidence for
ABPA or ASF. Results: 160 patients of the CF Clinic were screened; 7% (95%
confidence interval wCIx, 4–12%) qualified for ABPA and 13% (95% CI, 8–19%)
for AFS. Before diagnosis of ABPA or AFS both groups had received higher cumu-
lative doses of inhaled corticosteroids than their respective controls (ABPA: odds
ratio wORx, 4.8; 95% CI, 0.97–38. AFS: OR, 8.0; 95% CI, 1.74–63). Colonisation
with Stenotrophomonas maltophilia was strongly and independently associated with
ABPA (OR, 20; 95% CI, 2.8 – infinity). A longer duration of Pseudomonas aeru-
ginosa colonisation was independently associated with AFS (OR per year, 1.50;
95% CI, 1.12-infinity). Z-scores for body mass index (BMI) of patients with ABPA
were significantly lower compared to controls (OR, 0.13; 95% CI, 0.01 – 0.65).
Conclusion: ABPA patients have lower BMI and more frequent isolation of S.
maltophilia in their sputum than their controls. Duration of colonisation with P.
aeruginosa is a risk factor for AFS. Higher cumulated doses of inhaled corticoste-
roids are associated both with ABPA and AFS and their role as a risk factor needs
to be taken into account.
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Increasing prevalence of Stenotrophomonas maltophilia in patients
with cystic fibrosis
J. Larsson Friden, M. Gilljam, B. Jonsson´ ¨
Sahlgrenska University Hospital, Goteborg, Sweden¨
Objective: To assess if there was an increase in growth of Stenotrophomonas mal-
tophilia in sputum cultures from CF patients between Period 1 (May 1989-May
1996) and Period 2 (May1996-May 2003), and also if there was a relation to change
of antibiotic regimen. Method: Retrospective study including all CF patients at the
West Swedish CF Centre. Patient charts were reviewed and results of sputum cul-
tures were analyzed. Groups were compared by the chi-square test. Results: At the
end of Period 1, there were 99 CF patients (55% males, median age 15 years, range
0.2-49); 23 patients (23%) hadG1 culture positive for S. maltophilia and 11 (11%)
had G3 positive cultures. At the end of Period 2 there were 129 patients (55%
males, median age 19 years, range 0.9-78); 41 patients (33%) had G1 and 16
(12%) had G3 positive cultures. The proportion of patients with G1 as well as
G3 positive cultures was higher for Period 2 (P-0.05). 13y23 (56%) patients,
positive during Period 1, continued to be positive during Period 2. There were 7
(17%) patients with positive cultures during Period 2 who had been on long-term
treatment with Azitromycin. Discussion: We found an increase in the proportion of
CF patients with growth of S maltophilia in sputum throughout the study period.
Whether this increase is related to overall change in antibiotic regimen, or a reflec-
tion of the increased use of Azitromycin in this patient group has to be further
studied.
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Cytokine induction by Pseudomonas aeruginosa cystic fibrosis
isolates
C.H. Smart, B.F. Flanagan, M.J. Walshaw, C.A. Hart, C. Winstanley
University of Liverpool, Liverpool, United Kingdom
In recent years there have been a number of reports of transmissible strains of P.
aeruginosa among Cystic Fibrosis (CF) patients. The effect of harbouring such
strains remains unclear. Recent studies (Jones et al. 2003) investigating the levels
of inflammatory markers in patients infected with transmissible strains of P. aeru-
ginosa, compared with patients colonized by sporadic P. aeruginosa strains, found
no differences in inflammatory markers between these two groups. The purpose of
this study was to investigate the effects of different P. aeruginosa CF isolates on
cytokine induction in the human alveolar type II cell line A549 and the human
histiocytic lymphoma cell line U937. In particular, we wanted to examine whether
the Liverpool epidemic strain (LES) of P. aeruginosa induced a different cytokine
response to other, non-epidemic strains. Following infection of A549 or U937 cells
with bacteria, the total RNA was isolated after several time points. Cytokine mes-
sage was detected using the RiboQuant multi-probe RNase Protection Assay sys-
tem (Pharmingen). In A549 cells elevated levels of IL-8 and MCP-1 transcripts
were detected in response to some isolates. Strain differences were also observed
with respect to RANTES in A549 cells and IP-10 and TNF-a in U937 cells. Dif-
ferent cytokine responses were observed in the two cell lines used. There was no
evidence to suggest that the LES induces a different cytokine response to other P.
aeruginosa isolates. This work was supported by the UK Cystic Fibrosis Trust.
References: Jones, A.M, Martin, L., Bright-Thomas, R.J., Dodd, ME., McDowell,
A., Moffitt, K.L., Elborn, J.S., Webb, A.K. (2003) Inflammatory markers in cystic
fibrosis patients with transmissible Pseudomonas aeruginosa. European Respiratory
Journal 22: 503–506.
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Comparative proteomic analysis of planktonic and biofilm
Pseudomonas aeruginosa cells: identification of differentially
expressed proteins
S. Vilain, P. Cosette, D. Seyer, G.A. Junter, T. Jouenne
UMR 6522 CNRS, IFRMP 23, Mont-Saint-Aignan, France
To identify physiological alterations following bacterial adhesion, protein extracts
from planktonic and sessile P. aeruginosa cells were subjected to two-dimensional
gel electrophoresis. Principal Component Analysis (PCA) was used to interpret spot
quantity variations. As the ability of bacteria to attach to surfaces depend in part
on the nature of the surface material and process conditions, we used two biofilm
formation processes. Moreover, as the proteomes of biofilm bacteria are strongly
dependent on biofilm age, we used two biofilm incubation times, i.e., 18 and 48 h.
Thus, eight different incubation conditions were tested: bacteria attached to glass
wool or clay beads after incubation for 18 h or 48 h, and the corresponding free
cell counterparts. A total of 914 protein spots were detected on 2-DE electropher-
ograms and quantified by computing scanning densitometry. PCA extracted three
components from standardized values, accounting together for 78.4% of the vari-
ability in the data. Component 1 opposed free-cell cultures to biofilm ones. Com-
ponent 2 was related essentially to free-cell cultures, discriminating between the
two incubation times. Component 3 opposed the two modes of biofilm growth. The
dependence of the protein patterns on the biofilm formation process was further
illustrated by the identification of more than 80 polypeptides whose amount
remained unchanged or was altered in adherent bacteria. The results reinforce the
topical assertion that biofilm display a specific physiological behaviour but also
question the existence of a unique biofilm phenotype.
s48 Journal of Cystic Fibrosis 3 (2004) S33–S50
175
Detection of volatile compounds released by Pseudomonas aeruginosa
in vitro by selected ion flow tube mass spectrometry (SIFT-MS)
W.D. Carroll , D. Smith , T.S. Wang , P. Spanel , P.A. Alcock , W. Lenney1 2 2 3 4 1
Academic Department of Paediatrics, University Hospital of North Staffordshire,1
Stoke-on-Trent, United Kingdom, Centre for Science & Technology in Medicine,2
Keele University, Keele, United Kingdom, J. Heyrovsky Institute of Physcial Chem-3
istry, Academy of Sciences, Prague, Czech Republic, Department of Medical4
Microbiology, University Hospital of North Staffordshire, Stoke-on-Trent, United
Kingdom
Introduction: SIFT-MS is a novel technique allowing rapid identification and quan-
tification of volatile organic compounds (VOCs) to extremely low levels (ppb) (1).
Pseudomonas aeruginosa (PA) growth has a distinctive odour. Gas chromatography
mass spectrometry has identified several VOCs that may be released by PA (2).
Our primary objective was to identify whether gases released by PA species in vitro
can be detected by SIFT-MS (3) as a prelude to further work in vivo. Methods:
Patients with cystic fibrosis colonised with PA were eligible for study. 7 patients
provided a cough swab or sputum sample for culture on blood agar (BA) and
Pseudomonas-selective media (PSM). Samples and uninfected control plates were
incubated at 378C inside sealed plastic bags. Following culture the gas around these
samples was directly aspirated via a single puncture to the bag into the SIFT-MS
device for analysis. Results: PA growth is associated with release of large quantities
of ethanol and ammonia. Compared to controls there were also significant amounts
of acetonitrile, hydrogen cyanide (HCN) and dimethyl disulphide (DMDS). Dis-
cussion: Acetonitrile, HCN and DMDS are virtually undetectable in the breath of
healthy, non-smoking human volunteers. These VOCs are produced by PA in vitro
and are attractive candidates for breath analysis studies in vivo using SIFT-MS.
As ppb"SE Ethanol Ammonia Acetonitril HCN DMDS
PSM only 378C 2100 210 0 0 0
PSM only 208C 1900 150 0 0 0
PSMqPA 378C 7200"2600 9500"4400 60"20 130"70 160"80
BAqPA 378C 1200"500 37 000"10 000 80"50 40"20 520"180
Lab air 300"100 150"120 0 0 0
References: 1. Spanel P, Smith D. Int Rev Phys Chem 1996;15:231. 2. Labows JN
et al 1980;12:521. 3. Wang TS, Smith D, Spanel P. Int J Mass Spec 2004 (In press).
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DNA chip for geno- and pathotyping of Pseudomonas aeruginosa
L. Wiehlmann , G. Morales , B. Siebert , G. Wagner , P. Slickers , B. Tummler1 2 1 3 3 1¨
Klinische Forschergruppe, OE 6710, Medizinische Hochschule Hannover, Han-1
nover, Germany, Centro Nacional de Biotecnologia, Madrid, Spain, Clondiag2 3
Chip Technologies, Jena, Germany
Pseudomonas aeruginosa is the most common and clinically important pathogen in
patients with CF. Prevention of nosocomial spread and transmission is one major
task of infection control at centers who provide care for CF patients. PCR-based
techniques such as RAPD or macrorestriction fragment pattern analysis by PFGE
are discriminatory in-house typing techniques for the comparison of a small number
of strains that can be separated on one gel. However, unequivocal assignment and
identification of genotypes in databases, exchange of data between laboratories for
surveillance at the regional, national or international levels, and longitudinal (mul-
ticenter) studies on the evolution of the P. aeruginosa population are hampered by
the gel-to-gel variations of fragment patterns. These obstacles of the established
techniques are overcome by a specific low resolution DNA chip that we developed
for the quick genotyping of P. aeruginosa. The procedure is based on oligonucleo-
tides generated from 30 genes that are known to be present in genome islands or
genome islets, particularly from pathogenicity and fitness islands, and on 13 single
nucleotide polymorphisms (SNPs) in highly conserved P. aeruginosa genes. Each
island-specific gene and each sequence variant of a SNP occur at a frequency
between 15% and 85% in the today P. aeruginosa population. Strains can be dis-
criminated with a sensitivity of more than 99.99% thus excluding any accidential
false–positive matching of unrelated strains. From colony picking from the culture
plate to the readout of the chip this procedure takes just 6 h.
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SAP virulence gene expression of C. albicans sputum isolates from CF-
patients
F.-M. Muller , S. Salvenmoser , R. Hess , M. Wiebel , C. Gil-Lamaignere1 1 1 2 1¨
Pad. Pneumolgie, Mukoviszidose u. Infektiologie, Heidelberg, Germany, CF-1 2¨
Ambulanz, Thoraxklinik, Heidelberg, Germany
Introduction: Isogenic Candida strains can persist for months in the respiratory tract
of CF-patients. To evaluate whether Candida spp. are involved in the chronic
inflammation and destruction of CF lungs, we conducted virulence studies with
Candida albicans from sputum isolates for stage-specific gene expression of secret-
ed aspartyl proteinases (SAPs). Methods: Sputum was solubilized by SDS 20%.
After cell-wall lysis by standard lyticase method followed by phenol chloroform
extraction, the relative gene expression of 18S rRNA, SAP 4 and SAP 5 was deter-
mined by real-time RT-PCR. Results: Of 26 CF-patients that were colonized in the
sputum with C. albicans, 9 (35%) were co-colonized with a non albicans Candida
spp. In 15 patients, that were only colonized with C. albicans, SAP 4 and 5 were
expressed in 4 patients, and SAP 4 or SAP 5 in 2 patients. In one patient, that was
colonized with C. albicans and C. famata, only SAP 4 was expressed. In 4 patients
that were colonized with C. albicans and C. dubliniensis, SAP 4 and 5 was
expressed in 2 patients, and SAP 4 alone in one patient. In 4 patients that were
colonized with C. albicans and C. glabrata, SAP 4 and 5 was expressed in 3
patients, and SAP 4 alone in the fourth patient. Conclusion: Expression of SAP 4
and 5 in C. albicans may be an indication of a more advanced stage than just
colonization more towards parenchymal affection. Potential implications for
involvement of C. albicans in chronic destruction of the lungs is a future research
task.
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Peri-operative antibiotic therapy for children with cystic fibrosis: a
multi-centre survey
J.M. Bhatt, M.L. Everard, P. Fenton, C.J. Taylor
Sheffield Childrens Hospital, Sheffield, United Kingdom
Background: There are no guidelines in the literature for prescribing antibiotics in
the peri-operative period for children with CF. The CF Trust gives no guidance on
this in (‘Antibiotic treatment for CF’) nor is there any guidance within a recent
review of management. (Gibson et al AJRCCM 03). We undertook a questionnaire
survey to determine current practice in UK CF centres. Methods: Postal question-
naires with return pre-paid envelopes were sent to 20 paediatric CF specialist centres
caring for 50 or more patients. Results: There was a 95% response rate. 47% of
units have a formal policy of antibiotic prescription. There was little uniformity of
approach.
Pseudomonas status Negative Positive
Antibiotic
No answer 16% 32%
Specific antibiotic regime 42% 36%
Depends on patient, procedure, lung 42% 32%
function, sensitivities
Pseudomonas cover (% of total specifying 38% 100%
antibiotics)
Duration (days)
Pre surgery 0 to 14 0 to 14
Post surgery 2 to 14 2 to 14
Route (if replied) 62% IV 100% IV
Conclusions: There is no consensus regarding the use of antibiotics around the time
of a general anaesthetic. A minority of centres routinely use antibiotics that will
cover pseudomonas irrespective of pseudomonas status. There is a need for
guidelines on the use of antibiotics for patients with CF in the peri-operative period.
These would be a useful supplement to the antibiotic guidelines already in existence.
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Refractory, symptomatic hypomagnesaemia secondary to
aminoglycosides successfully treated with amiloride
M.J. Steward, M.K. Benson, L.S. Bennett
Oxford Centre for Respiratory Medicine, Oxford, United Kingdom
Hypomagnesaemia is often only recognised in cystic fibrosis (CF) when patients
are symptomatic. There have been several reports of aminoglycoside-associated
hypomagnesaemia and documented potential life-threatening complications includ-
ing paraesthesiae, tetany and seizure. Treatment with intravenous (IV) and oral
electrolyte replacement is often inadequate with levels remaining at the lower limit
of normal and dropping with repeated antibiotic courses. We report an adult patient
awaiting lung transplantation with severe CF who developed symptomatic hypom-
agnesaemia (Mg 0.29 mmolyl) but with normocalcaemia (Ca 2.19 mmolyl,2q 2q
corrected) following IV gentamicin for exacerbations of Pseudomonas aeruginosa
infection. Initial electrolyte replacement with IV and oral Mg & K failed to2q q
achieve Mg even at the lower limit of normal after 12 days of treatment2q
(Mg 0.34, K 4.1, Ca 2.29). She was successfully treated with amiloride (52q q 2q
mg od) to maintain normal magnesium and potassium levels (Mg 0.72, K 4.2).2q q
Previous reports have linked symptoms of Mg deficiency to its severity and2q
Ca & K deficiency. Failure to sufficiently increase and sustain levels of2q q
Mg with both IV and oral replacement is postulated as secondary to renal tubular2q
damage and a continued renal leak of magnesium. Serum creatinine is a poor indi-
cator of renal function in these cases. This case demonstrates Mg deficiency with2q
normocalcaemia that shows resistance to standard replacement regimens and the
adoption of a novel approach with the use of amiloride. It also highlights the impor-
tance of the routine measurement of Mg , as the prevalence is probably under-2q
estimated especially during aminoglycoside treatment.
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Urinary N-acetyl -b-D-glucosaminidase wNAGx in adults with CF – a
marker of nephrotoxicity?
C. Etherington , S.P. Conway , D.G. Peckham , M. Bosomworth1 1 1 2
Seacroft Hospital, Leeds, United Kingdom, St James’, Leeds, United Kingdom1 2
Patients with CF are at high risk of antibiotic induced nephrotoxicity. Routine meth-
ods of monitoring renal injury are insensitive. NAG is a lysosomal enzyme present
in high concentrations in renal proximal tubular cells. Increased urinary NAG activ-
ity is an early sign of nephrotoxicity. Urinary NAG levels were measured on days
1, 14 wend treatmentx, and at follow up. Patients received treatment with Tobramycin
w10 mgykgydayx or Colomycin w2 MU tdsx and a second antibiotic. To compensate
for daily variation in urine flow NAG activity was related to urine creatinine con-
centration wnormal range 0.12–0.47 umolyminymmol creatininex. Renal function
tests were performed on day 1 and 14. 98 courses of treatment in 72 patients w35
male, 27 diabeticx were analysed. Mean age 27.4 years. Median time to follow up
was 45 days. There were no significant changes in renal function tests. 40 (41%)
of 98 courses had raised NAG levels at baseline. 84 w86%x showed increased NAG
activity by day 14 wMedian NAG increased from 0.38 day 1 to 1.5 at day 14x. 55
w56%x follow up values did not return to baseline. NAG values were higher in each
successive course in 15y20 patients who had )1 course of treatment. 21 (52%) of
40 courses with high initial NAG levels, but only 7 (12%) of 58 courses with
normal initial NAG levels were in patients with CFRD. Median day 14 NAG levels
after treatment with Colomycin wns56x and Tobramycin wns42x were 0.99 and
2.47, respectively wP-0.0005x. NAG levels indicate subclinical renal damage from
both Tobramycin and Colomycin. Diabetic patients are at greatest risk. Cumulative
toxicity is evident. Serial NAG measurements should be considered for routine
monitoring of intravenous antibiotic treatments.
181
Continuous home IV therapy: the introduction of the CADD – legacy
pump for treatment with young adult cystic fibrosis patients
K. Colpaert, T. Havermans, M. Proesmans, K. De Boeck, L. Dupont
University Hospital Gasthuisberg, Leuven, Belgium
Over the past decade intravenous home therapy has become a well-establishedmeth-
od for the administration of antibiotics to CF patients. Two strategies can be used:
Intermittent bolus administration of the antibiotic or continuous therapy over a
period of 23h using a pump. The CADD – legacy pump was initially designed for
patient controlled analgesia therapy, but is suitable for continuous antibiotic therapy.
In the summer of 2003 the CADD – legacy pump for continuous therapy was
introduced in the Cystic Fibrosis Center of the university hospital Gasthuisberg,
Leuven, Belgium. A questionnaire was developed to evaluate home intravenous
therapy with antibiotics by means of the CADD – legacy pump in CF patients. 21
patients were asked to fill out the questionnaire after they had used the CADD –
legacy pump. 17 patients returned the questionnaire, mean age 20 years (S.D.s
5.073). As the main advantages of home therapy patients mentioned being ‘with
their family’ (ns12) and ‘out of the hospital’ (ns13). the main disadvantages
were ‘less sleep’ (ns4) and ‘burden for parentsypartners’ (ns4). Sleep quality
was better with continuous therapy using the CADD – legacy pump (ns4). Patients
considered continuous therapy less bothersome than intermittent therapy (ns9).
The mean runtime of the pump per patient was 23.01 h a day (S.D.s0.2531, min
22.70 h and max 23.77 h). In accordance with the data registered by the device all
patients claimed to be compliant during home intravenous therapy using the CADD
– legacy pump (ns17). Nearly all patients preferred the IV – pump for home
therapy in the future (ns14). The introduction of the CADD – legacy pump for
home IV therapy with antibiotics in CF patients was associated with improved
patient satisfaction.
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Efficacy of Meropenem in the treatment of pulmonary exacerbations in
CF patients
G. Braccini, G. Taccetti, F. Festini, S. Campana, N. Ravenni, T. Repetto, M. de
Martino
CF Centre of Tuscany, Florence, Italy
Antimicrobial treatment of pulmonary exacerbations in CF patients is associated
with a clinical improvement and with an increase of lung function parameters. An
association of two IV antibiotics is usually indicated to treat a pulmonary exacer-
bation in CF. The aim of this retrospective study was to evaluate the efficacy of
Meropenem -used to treat pulmonary exacerbations in a cohort of CF patients-in
improving FEV1. To this purpose, we examined all the IV courses with Meropenem
administered to the patients followed at the CF Center of Tuscany, Italy from 1996
to 2003. FEV1 (measured as% of predicted) before and after each treatment was
used as the outcome variable. FEV1 values measured more than 60 days after each
treatment were not considered. Results: In the period considered, 34 CF patients
(17 M, 17 F, mean age 25.1 years"8.9 S.D.) underwent 129 two-week IV antibiotic
courses with Meropenem in association with an aminoglicoside (mean: 3.6 courses),
due to a pulmonary exacerbation. At the beginning of the courses, 88.2% patients
were colonized by P. aeruginosa and 11.7% by B. cepacia. Complete data were
available from 88 IV courses. Mean FEV1 resulted 37.98% ("8.5 S.D., range 15–
64) before the treatment and 40.06% ("8.7 S.D., range 15–69) after the treatment
(95%CI about mean difference: 0.81–3.34, paired t-test Ps0.0016). Discussion:
In our experience, IV antibiotic treatment of pulmonary exacerbations with Mero-
penem has proved effective in improving FEV1 in CF patients.
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CmaxSS-MIC ratio, as a predictor of CF patients infected with
Burkholderia cenocepacia
D. Zemkova , P. Drevinek , J. Bartosova , L. Fila , V. Vavrova1 1 1 2 1
Paediatric Dept, 2nd Medical School, Prague, Czech Republic, Adult Pulmon-1 2
ology Dept, University Hospital Motol, Prague, Czech Republic
Up to 25 % of patients attending the Prague CF Centre are infected with strains
belonging to the genomovar III of Burkholderia cepacia complex (designated as
B. cenocepacia). Despite this genomovar homogeneity the infection is manifested
in its whole spectrum from its slow progression to the fulminant cepacia syndrome.
The aim of our study was to define the clinical factors predisposing to more severe
clinical course of the B. cenocepacia infection. The mean value of survival period
in patients infected in 1994–997 was 6.4 years. Therefore, we compared 29 culture
positive patients who had died within six years after their B. cenocepacia acquisition
(group 1) with 27 culture positive patients surviving more than six years (group
2). The group 1 was further subdivided according to duration of the infection period
(group 1A: less than 3 years, group 1B: from 3 to 6 years). Subclassification of
the group 2 took into account the last measured FEV1 value (group 2A: less than
40%, group 2B: 40% or more). Nutritional status and FEV1 were compared by
Student t-test. At the time of B. cenocepacia diagnosis, groups 1 and 2 differed in
their FEV1 values (46.7"16.3% vs. 64.1"14.6%, mean"S.D., P-10 ) andy3
nutritional status (mid-arm circumference y2.3"1S.D. vs. y1.1"0.8S.D., P-
10 ). No difference was seen in pancreatic or hepatic alterations, sweat tests, agey4
of CF diagnosis or type of CFTR mutations. Subgroups 1A and 1B did not differ
either in FEV1 or in nutrition status. Patients from 2B represented those with sig-
nificantly higher and stable-in-time FEV1 values comparing to all remaining sub-
groups. The data indicate that bad lung functions, their further decline and impaired
nutritional status are the risk factors of worse infection prognosis. Supported by
MSMT 111300003 and MZCR 64203
184
The analysis of the isolated microorganisms from the respiratory tract
of CF children treated in Children’s Memorial Health Institute 1999–2003
K.S. Semczuk, H.D. Dmenska, D.D. Dzierzanowska, P.G. Gutkowski, M.M.
Modrzewska, E.G. Gabinska, H.Z. Zareba
Warsaw, Poland
Aim: The aims of the study were: (1) to characterize microorganisms isolated from
the respiratory tract of children with cystic fibrosis (CF) and (2) to analyze phe-
notypes and genotypes of Staphylococcus aureus isolated from chronically colo-
nized CF patients. Materials and methods: Between January 1999 of December
2003, 810 respiratory tract specimens were collected from 58 children with con-
firmed cystic fibrosis, treated in the Children’s Memorial Health Institute, Warsaw,
Poland. Specimens for bacteriological evaluation were taken during routine visits
in the Outpatient Pulmonology Clinic scheduled 3–4 times a year. Identification
and susceptibility testing of isolated strains were performed by use of standard
methods. Molecular typing of S. aureus was performed in patients with the lonest
colonization by pulse field gel electrophoresis (PFGE). Results: The most frequently
isolated microorganism was S. aureus (50%), followed by Haemophilus influenzae
(17%) and Pseudomonas aeruginosa (14%). Other microorganisms such as Mor-
axella catarrhalis, Streptococcus pneumoniae, S. pyogenes and group B, C and G
streptococci, rod Enterobacteriaceae were isolated much less frequently. Most S.
aureus, P. aeruginosa and H. influenzae isolates showed high susceptibility to tested
antimicrobial agents. Fungi such as Candida sp. and Aspergillus sp. were found
only sporadically. More than 80% of patients were colonized with S. aureus. About
5% of all S. aureus isolates were resistant to methicillin (MRSA). Majority of S.
aureus isolates obtained sequentially showed nearly identical PFGE patterns sug-
gesting chronic colonization with the same strain. Conclusions: S. aureus was the
most prevalent microorganism in CF patients.
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The Liverpool epidemic strain of Pseudomonas aeruginosa; 8 years
after initial identification
E.A. Gaillard , H.L. Wallace , L.J. Heaf , S. Panagea , P. Shears , E.F. Burrows ,1 2 1 3 3 1
P. Garnett , J.J. Cottrell , M.J. Walshaw , M.J. Ledson , J.M. Couriel , R.L.1 1 4 4 1
Smyth , C.A. Hart , K.W. Southern , D.P. Heaf2 3 2 1
Royal Liverpool Children’s Hospital, Liverpool, United Kingdom, Institute of1 2
Child Health, University of Liverpool, Liverpool, United Kingdom, Medical Micro-3
biology, University of Liverpool, Liverpool, United Kingdom, Cardiothoracic Cen-4
tre Adult CF Unit, Liverpool, United Kingdom
Background: In 1995, 55 of 120 patients attending the Royal Liverpool Children’s
Hospital were recognised to have chronic respiratory infection with a genetically
identical strain of Pseudomonas aeruginosa (Lancet 1996;348:639–42). Assuming
this to be a transmissible strain, segregation policies based on antibiotic resistance
were implemented. Aims of this study: Development of a rapid PCR assay to identify
the Liverpool epidemic strain (LES) has enabled us to reassess prevalence in our
clinic population 8 years after first identifying LES. Methods: PCR assay was under-
taken on all available isolates from children attending the clinic (J Clin Microbiol.
2002;40:4607–11). Results: Of the 55 patients recognised in 1995, seven have died
and 11 are not traceable. The remaining 37 patients are still infected with the LES
(24 have moved on to the regional adult CF). The Paediatric Clinic currently has
100 full-time patients. 41 of these are chronically infected with LES (13 from
1995). Two patients who were infected with a non-LES P. aeruginosa in 1995 now
have the LES. 22 children are infected with a non-LES of P. aeruginosa, two with
Burkholderia species and 35 have no P. aeruginosa infection. Conclusions: (1)
Once a patient is infected with the LES, there is no evidence to date that this strain
can be eradicated or another strain displace it from the respiratory tract. (2) LES
identification based on antibiotic resistance is not reliable. (3) Prevalence of LES
in this clinic has not increased following introduction of a segregation policy.
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Real-time PCR detects non cultivable Pseudomonas aeruginosa in the
early phase of CF lung colonisation
G. Couetdic, F. El’Garch, J. Schneider, C. Millardet, M.L. Dalphin, J.C. Dalphin,
P. Plesiat´
Hopital Jean Minjoz, Besancon, France
Culture is considered as the method of choice for the detection of P. aeruginosa
(PA) in the sputums of CF patients. However, analysis of consecutive samples in
a same patient, especially during the phase of primo-colonisation, may show inter-
mittent positive results because of low bacterial counts. In order to evaluate the
interest of genetic approaches in the diagnosis and follow up of CF lung infection,
two real-time PCR (RT-PCR) techniques - a commercial kit (Roche LightCycler
Pseudomonas) and an in house protocole using fluorescent probes specific of
gene oprL - were compared to quantitative cultures for the detection and numeration
of PA in respiratory specimens. Both RT-PCR showed excellent sensitivity as they
detect PA in all the culture positive samples examined (ns13), with good esti-
mation of bacterial loads (within one Log range compared with colony counts).10
8y50 (16%) and 3y25 (12%) of the culture negative sputums analysed appeared
weakly positive (from 10 to 100 bacteria per ml) with the in house protocole and
the Roche kit, respectively. These samples belonged to 9 patients with inconstant
positive cultures. In conclusion, these results tend to demonstrate the persistence of
few PA in the early phase of colonisation between aggressive cures of chemother-
apy. They also show that culture may overestimate the ability of antibiotics to
eradicate PA.
Pulmonology
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New cases of cystic fibrosis: clinical and laboratorial presentation
T.W. Folescu, I.R. Sad, R.F. D’Amoed, A. Brasil, V. Costa, L.Y.S. Higa
Instituto Fernandes Figueira-Fiocruz, Rio de Janeiro, Brazil
The diagnosis of Cystic Fibrosis (CF) should be based on characteristic phenotypic
features or familiar history of CF or positive newborn screening test plus elevated
sweat chloride concentrations, or identification of 2 mutations known to cause CF,
or demonstration of abnormalities in ion transport across nasal epithelium. Early
diagnosis and treatment of CF are fundamental for improvement in prognosis and
quality of life. The aim of this study is to describe clinical and laboratorial pres-
entation of CF patients at the time of diagnosis. The authors reviewed data from
29 CF patients (median age 11 m.o.) who had their diagnosis from January 2001
to December 2003 in a Pediatric CF Center of Rio de Janeiro-Brazil. Most patients
had history of recurrent pneumonia (20y29), and 25 had already been hospitalized
for pulmonary disease (2.3 admissionsypatient):11 in pediatric intensive care units,
and 12 needed oxygen during hospitalization. At the first visit clinical exam, the
most prominents features were: cough (23), tachypnea (22) and failure to thrive
(18). Sputum cultures for bacterial patogens were negative in nine patients and
positive in 20 (6y20 mixed cultures): P. aeruginosa (17), S. aureus (5) and B.
cepacia (1). At the end of this visit, eight patients were hospitalized, two of them,
in pediatric intensive care unit. These recently diagnosed CF patients presented
important organic dysfunction, that made us think over the whereabouts of patients
with less systemic impairment. Since CF diagnosis is supported by non-invasive
and not expensive tests, the possibility of this disease should never be discharged
just because the patient appears well. Ref: Cystic Fibrosis medical care, Orenstein
2000 Lippincott, Williams and Wilkins.
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Nasal potential difference discriminates between cystic fibrosis (CF)
and non-CF individuals but does not correspond to disease severity
S. Higgs, J. Stone, N.A. Jarad
Adult CF Centre, Bristol Royal Infirmary, Bristol BS2 8HW, United Kingdom
Background: Disease severity varies between adult CF patients. Genetic profile does
not appear to account for this difference. A previous analysis demonstrated some
prognostic value to the degree of nasal potential difference (NPD) in mainly ado-
lescent and paediatric patients. This study aims at investigating the prognostic value
of NPD in a cohort of adult CF population. Patients and methods: We investigated
22 CF patients, 11 (50%) female, mean age 23.5 years (range 14 to 38 years).
Nasal potential difference was measured on both nostrils and the average was taken.
Factors investigated were FEV1, number of IV antibiotics taken in the previous 12
months, genetic profile and body mass index BMI. 20 age-matched and sex matched
healthy individuals were recruited as a control group. Results: NPD was signifi-
cantly higher in CF patients (meany33.2 mv) compared to that in healthy subjects
(mean y15 mv), P-0.0001. There was no correlation between NPD and FEV1
or BMI. Genetic profile did not account for NPD and there was no difference in
the NPD according to number of antibiotics given in the previous year. Conclusion:
In adult CF patients, NPD is a useful diagnostic method, but NPD values measured
in adult CF patients do not have any prognostic value.
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Lessons to be learnt from a late diagnosis
C. Etherington, M. Moffatt, D.G. Peckham, S.P. Conway
Seacroft Hospital, Leeds, United Kingdom
A 61-year-old man presented with a 7 month history of weight loss w22 kgx and
recurrent lower respiratory tract infections. Past history included oesophageal car-
cinoma wOesophago-gastrectomy 19996qchemotherapyx. He had been investigated
for infertility at age of 27 years. Semen analysis revealed azoospermia. On pres-
entation he had a BMI of 17.2 and left basal crackles on auscultation. CXR and
HRCT scan demonstrated bronchiectasis with left sided collapseyconsolidation.
Respiratory function tests showed an FEV1 and FVC of 60 and 65% predicted
respectively. Sputum cultured Mycobacterium avium complex and Stenotrophomon-
as maltophilia. CRP, WCC and PV elevated at 182, 16 and 2.5 respectively with
iron deficiency anaemia. Investigations excluded a recurrence of malignancy.
Abdominal CT revealed fatty pancreas and faecal pancreatic elastase of -15 mgy
g confirmed pancreatic insufficiency. DEXA scan demonstrated osteopenia with a
T score spine of y2.2. Formal sweat testingw=2x revealed a sodium and chloride
of 62y55 mmol and 56y48 mmol respectively. Genetic analysis demonstrated
N1303KyR117H with poly T genotype 9Ty7T. He was commenced on 18 months
of therapy with Rifampicin, Ethambutol and Clarithromycin for NTM. Overnight
nasogastric feeding was followed with insertion of a PEJ when clinically stable.
LLL changes persisted and high dose prednisolone was commenced in view of
possible underlying cryptogenic organising pneumonitis. Six months following
diagnosis, weight has increased by 15 kg wBMI 21.6x with normal exercise toler-
ance. Blood tests have normalised. Latest percent predicted FEV1 70% and FVC
78%. This case of a late presentation highlights that all patients presenting with a
mono-symptomatic diagnosis of CF need at least annual follow up with a full
assessment allowing appropriate early intervention.
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Is cough indicative of an infective exacerbation in adults with CF?
E.C. Hambleton, J.A. Smith, C.J. Brammar, M. Dodd, A.K. Webb, A.A. Woodcock,
A. Jones
Wythenshawe Hospital, Manchester, United Kingdom
We investigated the response of cough to treatment in acute exacerbations of CF
and the relationship between objective and subjective measurements. We studied
13 adult patients wseven female, mean age 25.6 years ("6.6), median FEV 48.4%1
predicted (24.8–100.7), non-smokersx with pulmonary exacerbation of CF admitted
to hospital for IV antibiotic treatment. Sound recordings were made using a lapel
microphone on admission and after treatment (mean 8 days apart; 10 h ambulatory
daytime and 9.5 h overnight). Coughs were manually quantified as cough seconds
by custom written software. Patients subjectively scored cough severity by visual
analogue scale (VAS) and numerical scoring chart (NSC) (scale 0–5). After treat-
ment objective cough rate significantly improved; 13.7 csyh (6.0–37.5)™4.9 csy
h (3.4–18.1) PF0.01, wdaytime 23.5 csyh (7.6–58.0)™8.7 csyh (2.0–33.0),
PF0.01 and overnight 5.3 csyh (0.0–29.2)™1.4 csyh (0.0–5.4), Ps0.055x. On
admission objective night cough rate correlated with night VAS (rs0.68, PF0.01)
and night NSC (rs0.50, PF0.01) but objective day rate had no correlation with
either VAS or NSC. On discharge day VAS correlated with day NSC (rs0.59, Ps
0.04) and night VAS with night NSC (rs0.70, Ps0.01) but there was no corre-
lation between subjective and objective measures. Change in objective night cough
rate correlated with change in night VAS (rs0.76, PF0.01) but there was no
correlation between objective change in day cough rates and subjective scoring.
Conclusions: Subjective reporting of a nocturnal cough in CF may be indicative of
an infective exacerbation. Cough improves with treatment for an exacerbation of
CF. CF patients seem unaware of their daytime cough rate.
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The relationship between respiratory symptom scores and overnight
oxygen saturations in children with cystic fibrosis
P.S. McNamara , C. Darracott , P. Holmes , J.M. Couriel , N.J. Shaw , K.W.1 1 1 1 2
Southern3
Royal Liverpool Children’s Hospital, Liverpool, United Kingdom, Liverpool Wom-1 2
en’s Hospital, Liverpool, United Kingdom, Institute of Child Health, University of3
Liverpool, Liverpool, United Kingdom
Introduction: A parent-completed symptom questionnaire has been employed pre-
viously to differentiate respiratory disease states in young children (Powell et al.
Arch Dis Childh, 2002). The aim of this study was to determine the relationship
between questionnaire responses and overnight oxygen saturation (SaO ) in chil-2
dren with cystic fibrosis (CF) and a control group. Methods: A Nellcor oximeter
(NPB595) was used to measure overnight SaO in the home environment. Parents2
completed the respiratory questionnaire from which an overall symptom score and
8 domain scores (daytime, night-time etc) were calculated. Results: Questionnaires
were completed by parents of 45 CF children (mean (S.D.) age, 10 (5.1) years and
parents of 42 non-CF children without respiratory disease (9 (4.4) years). All the
children were considered to be stable at the time of the questionnaire. Mean
("S.E.M.) overall respiratory symptom scores for CF children were significantly
greater than non-CF controls (20.5"2.5 versus 3.1"0.9, P-0.001). In children
with CF, the overall respiratory symptom score did not correlate with overnight
SaO . Analysis of the individual domain scores revealed a correlation between inter-2
val symptoms and mean overnight SaO (rsy0.407; Ps0.007). Conclusions:2
Although this questionnaire is designed for young children and is not validated for
children with CF, this study demonstrates the potential of this tool in this population.
Children with CF scored higher on a respiratory symptom questionnaire and their
interval symptoms correlated with mean overnight SaO s. These preliminary find-2
ings highlight the potential for this tool to be used in assessing and monitoring
clinical status in children with CF.
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Towards the development of cumulative overnight oximetry curves for
children with cystic fibrosis
C. Darracott , P.S. McNamara , M. Pipon , A.F.G. Taktak , J.M. Couriel , N.J.1 1 1 2 1
Shaw , K.W. Southern3 4
Royal Liverpool Children’s Hospital, Liverpool, United Kingdom, Department of1 2
Clinical Engineering, Royal Liverpool University Hospital, Liverpool, United King-
dom, Liverpool Women’s Hospital, Liverpool, United Kingdom, Institute of Child3 4
Health, University of Liverpool, Liverpool, United Kingdom
Introduction: There is a lack of data concerning oxygenation during sleep in chil-
dren with CF who are clinically stable. The aim of this study was to develop
overnight oximetry curves (demonstrating cumulative peripheral oxygen saturation)
that can be used in the clinical setting to guide oxygen therapy. Methods: A Nellcor
(NPB595) oximeter was used to measure overnight saturations in the home. Data
were downloaded to a software programme (POBAB), which enables the generation
of cumulative curves. The following day the patients were assessed clinically and
performed respiratory function testing. A spot oximetry measurement was taken.
The chest X-ray score from the last annual assessment was noted. Results: 72 chil-
dren with CF were studied (mean age 10.8 years, range 1.3–17.9). Mean overnight
oxygen saturation (SaO ) was 96.1% (range, 92.7–98.9) and heart rate, 75 bpm2
(51–102). All the children were clinically stable and following day spot measure-
ments were consistently higher (mean, 97.8% ("1.1), P-0.0001 paired ttest).
There was a negative correlation with chest X-ray score (rsy0.57, P-0.0001)
and weaker correlations with the spot SaO and lung function tests. 63 children2
without CF (mean age, 9.0, range 1.7–17.6) had higher mean overnight SaO s2
(mean 97.3"0.8, P-0.0001). Conclusion: These data demonstrate abnormal over-
night oximetry in children with CF who are clinically stable. There is a negative
correlation with the chest X-ray score (a marker of lung involvement). These data
will enable the development of overnight cumulative curves to guide oxygen
therapy.
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Chest radiograph is as sensitive as high resolution computed
tomography in detecting CF related pulmonary changes when analyzed
with Wisconsin and Bhalla scoring
A. Geborek , I. Wikstad , L. Hjelte1 2 1
Stockholm CF Center, Karolinska University Hospital Huddinge, Karolinska Insti-1
tutet, Stockholm, Sweden, Department of Radiology, Karolinska University Hos-2
pital Huddinge, Karolinska Institutet, Stockholm, Sweden
HRCT scan of the chest gives a clear view of structural damage, bronchial thick-
ening and mucus plugs in patients with CF. The radiation dose is higher for HRCT
(approximately 4 mSv) than for chest X-ray (0.1 mSv), to be compared with the
naturally occurring environmental radiation in Sweden of 2 mSvyyearly. We per-
formed a retrospective study of 122 patients that attended Stockholm CF-center
from 1992–1998. Data from every second year, when the annual check up also
included a HRCT scan, as well as the yearly chest X-ray and lung function test,
were analyzed. In total 170 chest X-rays and HRCT respectively were scored by
an independent radiologist. HRCT scans were evaluated with Bhalla score, and chest
X-rays with Wisconsin score. Median age was 17 (5–60) years. Median FEV1.0
was 78 (15–136)%. Results: A strong correlation between Bhalla score, Wisconsin
score and FEV was seen. The patients with FEV )70% had a slightly stronger1.0 1.0
correlation between age and Wisconsin score. The correlation between Wisconsin
and Bhalla score was somewhat weaker for patients F15 years (P-0.025) than
for )15 years (P-0.001). The patients )15 years had a weaker correlation
between FEV and Wisconsin (P-0.022) than Bhalla (P-0.001). Conclusion:1.0
Wisconsin score was as sensitive as Bhalla score in detecting CF-related pulmonary
disease. For the younger patients and for those with a mild disease Wisconsin score
seemed more sensitive. Chest radiograph, resulting in a lower radiation dose than
HRCT, can thus be an acceptable method to follow the progression of pulmonary
disease during the patient’s lifespan. When choosing method one has however to
take into account that the visual information from the HRCT scan is more precise,
and that Wisconsin scoring requires a trained pulmonary radiologist.
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Spirometry is poorly sensitive for the detection of early CF related lung
disease
K.A. Padoa, J. Fairhurst, G.J. Connett
Southampton University Hospital, Southampto, United Kingdom
Throughout the life of a CF individual, declining forced expiratory volume in 1 s
(FEV1) measurements are usefully indicative of progressive lung damage. Although
some individuals maintain high FEV1values throughout childhood, when free of
acute infection, worsening lung disease might be still be occurring. This study aimed
to discover whether other lung function indices might more sensitively detect such
pulmonary complications as demonstrated by high resolution computed tomography
(HRCT) using the Mafessanti (M) and Bhalla (B) scoring systems and Chest X-
rays (CXR) using Crispin-Norman (CN) scores. Thirty children (aged 5.02–17.35
years; 13 male), and free of acute exacerbation, underwent PA and lateral CXR,
HRCT and Spirometry. All X-rays were scored independently by two paediatric
radiologists. There was good correlation between FEV1 and HRCT scores (M rs
y0.6, B rsy0.5) but the relationship was not improved when other lung function
indices including FEV%, FEF75 and MMEF25-75 were substituted. When the data
were re-analysed excluding those with an FEV1 -y1.96 S.D. of their predicted
mean (ns26), there was no relationship between HRCT scores and any index of
lung function. CN CXR scores were highly correlated to HRCT scores (rs0.9,
P-0.001) irrespective of whether those with reduced FEV1 measurements were
included. We conclude that spirometry is poorly indicative of early CF related lung
disease as revealed by HRCT irrespective of the parameters used. In this age group,
HRCT scores were no more informative about disease progression compared with
CXR scores and cannot be justified routinely. Accurately scored chest X-rays are
the most practical, sensitive test for staging baseline respiratory status and assessing
the effects of long-term treatment strategies.
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Relationship between clinical status and HRCT scoring in cystic
fibrosis patients
G.L. Grzincich , G. Pisi , C. Spaggiari , A.A. Lombardi , G. Attanasi , M.1 1 1 2 1
Zompatori1
Cystic Fibrosis Center of University of Parma, Parma, Italy, Department of Radi-1 2
ology-H. of Parma, Parma, Italy
Aim: To evaluate if Oikonomou HRCT scoring correlates with lung function, gen-
otype and chronic infection by Pseudomonas aeruginosa (PA) in CF patients. Meth-
ods: 31 CF patients, 19 males, mean age 20.4 years, 9 homozygous for DF508 and
23 chronically infected by PA. Each patient performed pulmonary function tests
(PFT) with body plethysmography, sputum culture and HRCT. Radiographs were
independently evaluated by 3 radiologists to calculate Oikonomou score. The score
was later compared and discrepancies were resolved by consensus. The HRCT score
was correlated with FVC, FEV , FEF , RV and TLC. Pearson correlation and1 25–75
multiple regression (step-wise) were used for the statistical analysis. Results: The
table shows the significant correlation between HRCT component scores and PFT
parameters (Ps0.01).
FVC FEV1 FEF25-75 VR
Extent mucus plugging rs0.5 rs0.7 rs0.7 rs0.6
Severity of bronchiectasis rs0.6 rs0.6 rs0.7
Extent of bronchiectasis rs0.6 rs0.6 rs0.6
Air trapping rs0.7
Moreover multiple regression analysis shows that FEV and FEF are the most1 25-75
predictive variables of the HRCT lung damage. Conclusions: Our results show that
mucus plugging, extent and severity of bronchiectasis and air trapping for HRCT
score and FEV and FEF for PFT are the most predictive parameters to evaluate1 25–75
the decline of respiratory function in CF patients.
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Visualisation of parenchymal lung changes in patients with cystic
fibrosis (CF)-MRI versus HRCT
M. Puderbach , M. Eichinger , S. Ley , C. Fink , C. Plathow , J. Gahr , M.1 1 1 1 1 2
Wiebel , S. Tuengerthal , A. Schmaehl , F.-M. Mueller , H.-U. Kauczor3 3 3 2 1
Deutsches Krebsforschungszentrum, Heidelberg, Germany, Universitatakinderk-1 2 ¨
linik, Heidelberg, Germany, Thoraxklinik, Heidelberg, Germany3
Purpose: CF is the most frequent inherited disorder leading to premature death in
the Caucasian population. As life expectancy is limited by pulmonary complica-
tions, repeated imaging (chest X-ray, HRCT) is required in the follow up. MR
imaging of the lung parenchyma is a promising new diagnostic tool. Its value for
imaging of lung changes due to CF compared to HRCT (gold standard) is evaluated.
Methods and Materials: Eleven patients (nine female, two male; 12–18 years) were
examined by HRCT and MRI. HRCT: Body weight adapted protocol (120 kV, 30–
65 mAs), thin section helical CT (1.25 mm). MRI: 1.5T, T1-Flash-2D (TRyTEy
FA: 226 msy4.3 msy708, slice thickness 6 mm, patient adapted FoV), breathhold
2=24 s, coronal and transversal orientation. T2-HASTE (TRyTEyFA: 600 msy28
msy1808, slice thickness 6 mm, patient adapted FoV), breathhold 18 s, coronal and
transversal orientation. Total table time 5 min. One hundred and ninety eight lung
segments were assessed at MRI and HRCT for presence of: bronchiectasis, bron-
chial wall thickening, mucus plugging, air fluid level, consolidation and infiltration.
Results: Sensitivity and specificity of MRI-changes compared to HRCT-findings
based on the analysis of 198 lung segments were: bronchiectasis (96y100); bron-
chial wall thickening (96y100); mucus plugging (67y89); air fluid level (100y99);
consolidation (57y97); infiltration (32y90). Consolidation was optimal visualized
by T1-Flash-2D, all other findings were best analyzed by T2-HASTE. Conclusion:
In comparison to HRCT morphological changes in lungs of CF-patients can be
visualized by MRI. It is a promising radiation free method for pulmonary follow
up and therapy control in patients with CF.
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Severity of air trapping (RVyTLC) correlates with airflow obstruction
(FEV % predicted) in a pediatric cystic fibrosis population1
M. Ni Chroinin, L.C. Lands
Montreal Childrens Hospital- McGill University Health Center, Montreal, Canada
FEV % predicted (FEV %) for age is the most widely used index in CF. RVyTLC1 1
represents the degree of air trapping in these patients. As air trapping may progress
without a significant decrease in expiratory flows, we sought to study the relation-
ship between changes in flow rates and air trapping. Methods: Out-patient pulmo-
nary function data from all patients with CF from 1998–2003 was analysed. Only
patients with at least 2 years (range 2.1–5.8) of data and at least three measurements
per year were included. Linear regression analysis was performed for FEV %,1
FEV yFVC and RVyTLC. Results: 65 patients (32 male) with age range 5–181
years were eligible for inclusion. The mean FEV % was 74.5%, 95% CI"S.D.1
(73.5, 75.5"18.7), mean RVyTLC was 33.0 with 95% CI"S.D. (32.5,
33.4"9.94) and FEV yFVC 74.8 95% CI"S.D. (74, 75"9.9).There was a mean1
annualised rate of change of FEV % of 0.7% with 95% CI"S.D. (y2.6, 4.0"13),1
of RVyTLC of 1.26% 95% CI"S.D. (y1.9, 4.4"12.7) and FEV yFVC 0.47%,1
95% CI"S.D. (y2, 3.6"18). There was a marked correlation between FEV %1
and RVTLC with rsy0.8 and P-0.001.and between FEV yFVC and RVyTLC1
with rsy0.66, P-0.001. There was also a marked correlation between the mean
annualised rate of change in FEV % and the rate of change of RVyTLC with rs1
0.9, P-0.001 and the rate of change of FEV yFVC and the rate of change in1
RVTLC with rs0.9, 0-001. Conclusion: Airflow limitation in CF is well-tracked
by changes in air trapping.
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Contrast-enhanced 3D MRI of lung perfusion in children with cystic
fibrosis
M. Eichinger , C. Fink , M. Puderbach , S. Ley , C. Plathow , J. Gahr , M.1 1 1 1 1 2
Wiebel , S. Tuengerthal , A. Schmaehl , F.-M. Mueller , H.-U. Kauczor3 3 3 2 1
Deutsches Krebsforschungszentrum, Heidelberg, Germany, Universitatskinderkli-1 2 ¨
nik, Heidelberg, Germany, Thoraxklinik, Heidelberg, Germany3
Purpose: Feasibility study of lung perfusion imaging using contrast-enhanced 3D
MRI. To assess the correlation of lung perfusion changes with structural abnor-
malities of the lung in children with cystic fibrosis. Methods and Materials: Eleven
patients (nine female, two male; 12–18 years) with cystic fibrosis were examined
at 1.5 T (Magnetom Symphony). Perfusion imaging was performed with a time-
resolved 3D GRE pulse sequence (FLASH, TEyTRya: 0.8y1.9 msy408) using par-
allel imaging (GRAPPA, PAT factor 2). A total of 25 data sets were acquired after
intravenous injection of 0.1 mmolykg body weight of Gadodiamide at a rate of 3–
5 mlys. Additional morphologic MRI of the lung (HASTE) and HRCT were avail-
able for correlation. The image analysis was performed by two radiologists in
consensus. Results: All examinations were of diagnostic quality and were well tol-
erated. Segmental perfusion defects were observed in all patients and were prefer-
entially located in the upper lobes. Perfusion abnormalities correlated well with
structural abnormalities of the lung (bronchiectasis, consolidation, etc.). Higher sig-
nal intensities of the lung were observed in gravity dependent lung, most likely
indicating preferential perfusion. Conclusion: Contrast-enhanced 3D MRI of lung
perfusion is feasible and may be used for the functional assessment of cystic
fibrosis.
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The use of recombinant allergens in the diagnosis of ABPA in cystic
fibrosis
I. Adams , F. Buhling , R. Schuster-Wonka , V. Sollich1 2 1 1¨
Department of general paediatrics and neonatology, Otto-von-Guericke-University,1
Magdeburg, Germany, Institute of Immunology, Otto-von-Guericke-University,2
Magdeburg, Algeria
Allergic bronchopulmonary aspergillosis (ABPA) is the most frequent allergic bron-
chopulmonary mycosis in humans and may lead to severe pulmonary insufficiency.
CF-patients beside asthmatics are a predisposed group. In cystic fibrosis, the prev-
alence of ABPA ranges from 2 to 15%. Up to 23% of the Aspergillus fumigatus-
sensitized CF-patients develop ABPA. The diagnosis of ABPA in CF is difficult,
especially in the early stages of the disease. The development of recombinant mon-
ovalent allergens of Aspergillus fumigatus facilitates the diagnosis. The disease-
specific allergens rAspf4 and rAspf6 allow to diagnose ABPA with a specificity of
100% and a sensitivity of more than 90%. We investigated all our CF-patients )
6 years (ns35) with regard to Aspergillus fumigatus-sensitization (prick test, spe-
zific IgE) and possible ABPA (Nelson’s criteria and additionally rAspf1-4, 6). 19
(54%) of these patients had an allergic sensitization to Aspergillus fumigatus. Six
of these sensitized patients (32%) developed ABPA. Altogether we found a prev-
alence of 17% ABPA in the investigated patients. Only in patients with ABPA we
found rAspf4 andyor rAspf6 to be positive. All ABPA-patients were Pseudomonas-
positive. In conclusion we could confirm the high specificity and sensitivity of the
recombinat allergens rAsp4 and 6 in ABPA and recommend them to use for further
diagnosis.
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Impulse oscillometry in cystic fibrosis
A.V. Cherniak, E.L. Amelina
Research Institute of Pulmonology, Moscow, Russia
Impulse oscillometry (IOS) measures total respiratory system impedance (Z), at
incremental frequencies during normal tidal breathing. For every frequency Z
describes the resistance (R) and the reactance (X) of the respiratory system. Our
aim was to establish how IOS measurements, in the frequency spectrum 5–35 Hz,
in patients with cystic fibrosis (CF). Results from spirometry, static lung volumes
and IOS (R, X, Z, resonant frequency (Fres) and reactance area 5 Hz-Fres (AX))
were compared in 12 adult CF patients recruited from CF Care Centre of Moscow.
Patients had airflow obstruction (FEV 50q31%pred., meanqS.D.), hyperinflation1
(RV: 271q81%pred., FRC: 159q32%pred., RVyTLC: 56q18%). IOS demon-
strated a frequency dependent increase in R (R : 211q71%pred., R : 161q5 20
49%pred.) and a marked decrease in X (X : y0.35q0.24 kPayLys) with a shift5
in Fres to higher frequencies (Fres: 24q7 Hz, AX: 0.28q0.24 kPayL). There were
significant correlations between Fres, X , AX and conventional lung function indi-20
ces (FEV – 0.74; 0.70; y0.72; RV 0.71; y0.66; 0.71; IC y0.66; 0.65; y0.72;1
respectively. The data indicate that measurement of reactance and FRes may reflect
the degree of airway obstruction. IOS is an effort independent measurement that
could be used more often in clinical routine especially in patients with more severe
lung disease.
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Lung function tests in infants with cystic fibrosis (cf): influence of
bacterial colonisation
G. Tancredi, F. Scalercio, F. Midulla, S. Bertasi, S. Cingolani, G. Cimino, L. Narzi,
A.D. Grzejdziak, S. Quattrucci
Cystic Fibrosis Centre, Pediatrics Department, University of Rome La Sapienza,
Rome, Italy
The role of bacterial colonisation on the lung function in CF infants is not clear.
Aim of our study was to evaluate the usefulness of t yt (%), VmaxFRC andPTEF E
FRC in CF infants colonised and not colonised by pathogens respect to healthy
infants, eterozygous for the CFTR gene mutations, by an infant respiratory function
testing device (Exhalizer EcoMedics). We measured, in 12 CF infants colonised,
nine CF infants not colonised and 16 heterozygous t yt with tidal flow- volumePTEF E
loop, VmaxFRC by squeezing technique and FRC with sulfur-hexafluoride (SF6)
washin-washout technique. Results are reported in table.
Subjects n CF colonised CF not colonised Heterozygous P
Mean"S.D. Mean"S.D. Mean"S.D.
12 (males 7) 9 (males 9) 16 (males 8)
Age weeks 44.4"25.9 34.6"20.1 29.2"14.1 n.s.
Weight g 7865"2988 7453"2819 7461"1823 n.s
Height cm 67.2"9.2 65.8"8.7 66.5"5.7 n.s
FRC mlykg 28.4"8.6 32.4"14.5 21.7"5.43 0.026
V9 FRCmax ml*sy1 143.1"101.5 132.9"97.0 180.8"68.6 n.s.
t ytPTEF E % 32.5"10.5 34.5"13.6 28.3"15.1 n.s
We observed that mean value of FRCykg was significantly higher in CF patients
not colonised respect to other subjects. The mean values of VmaxFRC are lower
in CF patients respect to heterozygous infants even if aren’t statistically different.
The mean value of t yt are similar in all subjects. Our data seems demonstratePTEF E
that air trapping and early airways obstruction are present in CF infants and the
bacterial colonisation not influence lung function in early stages of pulmonary
disease in CF. In conclusion the FRCykg and in lower degree V9 FRC, but notmax
t yt (%) appear to offer a useful objective means of identifying diminishedPTEF E
airways function in infants newly diagnosed with cystic fibrosis.
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Exhaled nitric oxide is reduced in children with cystic fibrosis and does
not correlate with disease severity
E. Hatziagorou , F. Kirvasilis , P. Savopoulou , J. Tsanakas1 1 2 1
Pediatric Pulmonology Unit, Hippokration Hospital, Thessaloniki, Greece, 1st1 2
Paediatric Department, Thessaloniki, Greece
Background: Exhaled nitric oxide (eNO) is increased in inflammatory diseases of
the airways such as asthma. In patients with bronchiectasis that is not associated
with either CF or disorders of ciliary motility, elevated levels of exhaled NO have
been related to the extent of bronchiectasis. In view of the airway inflammation
and bronchiectasis that occur in CF, there has been an interest in the measurement
of exhaled NO in this disorder. Aim: To establish the effect of CF on exhaled NO
in young patients and investigate the relation of lung function and infection status
and exhaled NO. Methods: The levels of exhaled nitric oxide were measured using
a chemiluminescence analyser (NIOX, Aerocrine, Sweeden), in 30 children with
CF and 28 healthy age-matched control subjects (mean age 15.57"5.6 years).
Spirometry (FEV1 and FVC) and bacterial colonization were also recorded. Results:
The mean FEV1 was 66.7"23.97% predicted and the mean FVC was
74.44"20.16% predicted. Mean levels of exhaled nitric oxide were significantly
lower in children with CF than in the control group (10"5.35 ppb v 15.45"4.07
ppb; Ps0.01). FEV1 did not correlate with exhaled NO. No association was
observed between NO values and colonization with Pseudomonas aeruginosa. Con-
clusions: Despite the airway inflammation that is characteristic of CF, exhaled. NO
was reduced. There was no association with lung function or infection status. As
NO has bacteriostatic effects and may augment mucociliary clearance, this obser-
vation may be of clinical importance.
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Composition of airway surface liquid in cystic fibrosis and other airway
diseases
V. Vanthanouvong , I. Kozlova , E. Naas , M. Johannesson , G. Roomans1 1 2 2 1¨ ¨
Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden, Upp-1 2
sala CF center, Uppsala University Hospital, Uppsala, Sweden
The airway epithelium is coated by a thin liquid layer, the airway surface liquid
(ASL). ASL is composed of two fractions, namely mucus and watery layers. The
ionic composition of ASL under normal and pathological conditions has been debat-
ed. Dysfunction of ion transport, mainly of sodium and chloride, may cause volume
and composition changes of the ASL. Imbalance in mucous secretion and water
secretion is characteristic for a number of airway diseases. Nasal fluid is a form of
ASL that can be easily accessed. Sephadex G-25 ion-exchange beads mounted on
a piece of filter paper were equilibrated with nasal fluid from healthy subjects (7),
subjects with a common cold or rhinitis (6), cystic fibrosis (CF) patients (16) and
patients with primary ciliary dyskinesia (PCD) (12). The beads were isolated under
volatile silicon oil, rinsed free of adhering mucus and air-dried. The elemental con-
tent of the beads was analyzed by X-ray microanalysis in the scanning electron
microscope. Analysis of nasal fluid showed that Na, K and Cl concentrations in
nasal fluid from normal subjects were approximately isotonic (Na: 143 mM, Cl:
154 mM, K: 62 mM). In persons suffering from common cold or rhinitis, CF-
patients and PCD-patients, the salt concentration was significantly higher than nor-
mal. In CF patients (average Na: 251 mM, Cl: 298 mM, K: 90 mM) the salt
concentration appeared to depend on the clinical status of the patient, with severely
affected patients having a higher salt concentration. Possibly, the common factor is
inflammation-induced epithelial damage, which leads to an abnormality in ion
transport.
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The use of Palivizumab (Synagis) to prevent RSV bronchiolitis in
infants with CF in Northern Ireland
C.A. Kavanagh, A.J.M. Reid
Royal Belfast Hospital for Sick Children, Belfast, UK
Acute exacerbations of the chronic respiratory disease in CF children are caused by
respiratory viruses in up to 10% of cases. Palivizumab, a humanised immunoglob-
ulin G-1 (IgG-1) monoclonal antibody has been shown as a safe and effective
preventative measure of RSV illness in high-risk infants. We reviewed all infants
with CF in the last four years who were given Palivizumab during the winter
months. Methods: We retrospectively reviewed all of the infants given Palivizumab
in our CF population. All infants were given doses of 15 mgykg by intramuscular
injection. We examined the age of infant given Palivizumab, the dosing regime, the
rate and severity of RSV infection and complication rate. Results: 18 children were
in the study group (Fs11, Ms7) The median age at first vaccination was 3 months
(R, 1–9 months). Two infants were given one dose after they had contracted RSV
illness. Of the remaining 16 infants: The median number of doses given was 4.5
(R, 2–5 doses). One child (6%) contracted RSV infection after two doses of Paliv-
izumab but did not require admission to hospital. No infant reported any adverse
reaction to the Palivizumab. Conclusions: Palivizumab appears to be a safe and
effective way of preventing both acquisition and severity of RSV infection in infants
with CF. Further randomised-controlled studies would be required to provide true
evidence of efficacy in CF infants.
214
Does the diagnosis of pulmonary exacerbations in adult CF patients
meet the US CF Foundation criteria?
T. Jeffcote, J. Lentaigne, M. Price, K. Wathen, N.A. Jarad
Adult CF Centre, Bristol Royal Infirmary, Bristol, United Kingdom
Background: Diagnosis of pulmonary exacerbation differs between centres. The
USCF Foundation devised a set of criteria for diagnosis of exacerbation. The aim
of this project is to assess whether diagnosis of infective exacerbation in our centre
agrees with the US CF criteria. Patients and methods: Eighty two patients were
reviewed. Thirty-nine patients, (20 female), mean age: 26.2 years, had at least one
exacerbation. We considered an adult patient to have had an exacerbation if they
had at least three of the following criteria: increased cough, excessive sputum,
abnormal chest examination, reduced FEV1 by )10% compared with best FEV1
during the previous 3 months, increased respiratory rate, reduced exercise tolerance,
fever, weight loss, abnormal CXR suggestive of infection, reduced O saturation by2
more than 5% and absence from work of school due to chest symptoms. Results:
A total of 77 exacerbations occurred. Cough, sputum breathlessness and reduced
FEV1 were the most frequent symptoms and signs. Fever and changes on the chest
radiograph were seldom present. A total of 59 exacerbations (76.6%) met the USCF
criteria (group 1) and the rest did not (group 2). Patients in group 1 were younger
(mean age"S.E.M. is 25"0.8 year) than patients in group 2 (mean age 29.5q
1.41), Ps0.0047. There was no difference in pulmonary disease severity as esti-
mated by baseline FEV1 and FEV1 at the point of exacerbation between the two
groups. Conclusion: Cough, Sputum, breathlessness were the commonest features
for exacerbations. Clinicians had a tendency to consider exacerbations by symptoms
in younger group of patients. Older group of patients were given antibiotics on
more tenuous grounds.
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Number of exacerbations and days of IV antibiotics are associated with
accelerated decline in lung function in a cohort of adult CF patients
J. De Jaeger, J. Burt, N.A. Jarad
Adult CF Centre, Bristol Royal Infirmary, Bristol, United Kingdom
Aim of research: The aim of this research is to investigate the association between
the number of exacerbation and the change of lung function tests over three years
in a cohort of adult patients with cystic fibrosis. Patients and methods: All patients
treated for at least one severe exacerbation annually over a period of 3 years were
included in this research. Annual change in FEV1, FVC and body weight was
calculated by subtracting the last post IV measurement from the first post IV meas-
urement and divided by time in years. Results: Thirty two patients, 13 female, mean
age 23.4, range 16.4-41.2 years who were followed up from January 2000 to
December 2002 were included. The number of infected exacerbation was twice as
many in patients with CF-related diabetes than those without, Ps0.009. Patients
with allergic bronco-pulmonary aspergillosis had greater number of exacerbations
than those without although this did not reach statistical significance. Number of
pulmonary exacerbations correlated with change in FEV1 (rsq0.55, Ps0.001)
and FVC (rsq0.60, Ps0.002), but not in body weight. Similar correlation was
found between change in FEV1, FVC and body weight with the number of days
of IV antibiotics. Conclusions: Number of exacerbations is higher in patients with
CF-related diabetes than in non-diabetic patients. Number of pulmonary exacerba-
tions and number of IV treatment days correlate with changes in FEV1 and FVC,
but not with change in body weight.
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Frequency of sensitization to Aspergillus fumigatus and its influence to
the patients with cystic fibrosis (CF)
I. Loukou, V. Talanti, M. Liatsis, M. Kanariou, S. Doudounakis
CF Centre, Aghia Sophia Children’s Hospital, Athens, Greece
Introduction : Patients with CF present high percentage of sensitization to Asper-
gillus fumigatus (AF) in comparison with other aeroallergens (house dust mite,
grasses). Aim: The purpose of this study was to determine the frequency of sensi-
tization to AF and detect its association with the serum levels of total IgE, FEV1
values, as well as the permanent (chronic) colonization of bronchial tree with Pseu-
domonas aeruginosa. Material and methods: 159 CF patients were studied (88 boys
and 71 girls), aged 6 to 18 years. IgE, Rast to AF, FEV and colonization or not1
with Ps. aeruginosa were recorded. Results: In CF patients the frequency of sen-
sitization to AF was 20% (32y159). The mean serum levels of total IgE was 226
IUyml in AF positive (sensitized) patients and 77 IUyml in AF negative (non
sensitized) patients, difference that is statistically significant (P-0.001). Mean
FEV was 95% of predicted values in sensitized and 108% in non sensitized patients1
(Ps0.11). Chronic colonization with Ps. aeruginosa was 62.5% in AF positive
patients and 40% in AF negative patients (P-0.05). Conclusion: The frequency of
sensitization to AF in patients with CF, aged 6 to 18 years, is 20%. This sensitization
is associated with elevated serum total IgE levels and seems to be a risk factor for
chronic colonization with Ps. aeruginosa.
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Aspergillus fumigatus an airway pathogen in CF – not only ABPA
K.G. Brownlee , M. Denton , S. Conway1 2 1
Regional Paediatric Cystic Fibrosis Centre, St. James’s University Hospital, Leeds,1
United Kingdom, Department of Microbiology, Leeds Teaching Hospitals, Leeds,2
United Kingdom
Aspergillus fumigatus (AF) is frequently found in the sputum of patients with cystic
fibrosis (9–57%). It is thought that its presence in the absence of ABPA is not
associated with a worse outcome. ABPA is said to be common and yet it is a
difficult diagnosis to make. We believe that airway infection with Aspergillus is a
separate entity to ABPA and requires a different therapeutic approach. Case 1: A
10-year-old boy (homozygous DF508) developed a chronic productive cough,
severe exercise restriction, lethargy and weight loss. FEV1 fell from 79% to 47%
of predicted. HRCT showed increased nodulation and extensive mucous plugging.
AF was cultured from the majority of sputum specimens. Total IgE, Aspergillus
specific IgE, Aspergillus precipitins, EIA and eosinophil count were all normal.
There was no significant clinical improvement with intravenous antibiotics but a
marked improvement after prolonged itraconazole treatment. Case 2: A 12-year-old
boy (DF508 Y1898q1) became increasingly unwell with chest pain, breathless-
ness, a chronic productive cough, lethargy and weight loss. FEV1 fell from 80%
to 47% of predicted. HRCT showed central bronchiectasis affecting all lobes and
numerous nodular densities in keeping with plugged bronchi. An area of ground
glass appearance was present in the left upper lobe. He failed to improve with broad
spectrum intravenous antibiotics. Sputum was repeatedly positive for AF. IgE was
123, Aspergillus specific IgE and eosinophil count were normal, Aspergillus EIA
and precipitins became weakly positive. He improved after prolonged treatment with
voriconazole. Neither patient satisfied the diagnostic criteria of ABPA yet both
patients improved with prolonged treatment with targeted anti-fungal therapy. Fur-
ther studies are needed.
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A long-stay program in a rehabilitation centre is beneficial for CF-lung
transplantation (LTP) candidates
H. Franckx , S. Lampmann , V. Van Loocke , C. Knoop , F. De Baets , I. Dab , R.1 2 3 4 3 2
Hauspie5
Zeepreventorium, CF-rehabilitationcentre, De Haan, Belgium, Academisch Ziek-1 2
enhuis VUB, Brussels, Belgium, Universitair Ziekenhuis UG, Ghent, Belgium,3
Universitair Ziekenhuis ULB, Brussels, Belgium, Vrije Universiteit VUB, Lab.4 5
Anthropogenetics, Brussels, Belgium
Aim: Comparison of FEV and BMI between LTP candidates staying in a Long-1
Stay Rehabilitation Centre (LSR) and patients staying at home (nLSR). Subjects:
Retrospective data of all patients admitted on the waiting list for LTP in the ULB
Brussels (1194–2003) were collected. The LSR (ns13) stayed for a median time
of 1130 non-consecutive days (P10-P90: 175–2155 days) in the LSR centre, receiv-
ing intensive physiotherapy (min 4hyday), nutritional education and psychosocial
guidance. The nLSR (ns41) had min hyday assisted physiotherapy at home12
and regular visits to their CF centre. Both groups had intravenous antibiotic treat-
ment courses as needed. Methods: FEV and BMI from four occasions were record-1
ed: the day of admission on the waiting list, before LTP, 1 month and 1 year after
LTP. Depending on the degree of asymmetry in the distribution of the considered
variables, the Mann-Whitney, Wilcoxon’s signed rank and t-Student tests were used
for unpaired and paired comparisons of the central tendencies. Results: Median age
(LSR 23.5 years, nLSR 24.4 years), FEV (LSR 21.7%pred, nLSR 19.4%pred)1
and BMI (LSR 16.4, nLSR 16.6) upon registration on the LTP-waiting list were
comparable between both groups. However, median waiting time was significantly
longer for the LSR (439 days) than for the nLSR (209 days), Ps0.004. Nine out
of 13 LSR (69%) achieved LTP while only 22 out of 41 nLSR (54%) did. There
were no significant differences as to FEV in both groups at the four measurement1
occasions. Before LTP, median FEV varied between 19 and 23%pred, but signif-1
icantly raised to 66%pred at 1 month after LTP, and to 90% at 1 year after LTP in
both groups (P-0.05 Wilcoxon’s and P-0.001 t-Student test). In contrast with
this similarity, the median% FEV1 values for all LSR stayed above those for the
nLSR during the first 500 days on the waiting list. The BMI for the LSR in relation
to the time on the waiting list was positive for the first 650 days, for the nLSR for
120 days. Conclusion: A long-stay program in a rehabilitation centre permits to
survive longer and in better condition on the waiting list in terms of FEV and1
BMI.
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Delivering a concentrated dose of colistin using AAD reduces
treatment time
H. Langman, A. Orr, R. McVean, D. Riley, J. Redfern, A.K. Webb, A. Jones, M.E.
Dodd
Wythenshawe hospital, Manchester, United Kingdom
Conventional nebuliser systems require an increased volume for drug efficacy. Tra-
ditionally a 4 ml volume is used to provide an acceptable treatment time of 10 min.
Adaptive aerosol delivery (AAD) device permits the use of a concentrated dose to
shorten treatment time without compromising drug delivery. Nebulised colistin caus-
es chest tightness and it is recommended practice to precede inhalation with a
bronchodilator. We were concerned that patients would be intolerant of a concen-
trated dose but wished to shorten treatment time. We report a retrospective survey
of the outcome of our change in practice to delivering 2MU colistin reconstituted
with 2 ml of diluent via AAD in relation to chest tightness. Before prescription the
patients received a supervised dose through the AAD device with measurement of
FEV at pre and 0, 15 and 30 min post inhalation. All patients inhaled 2MU colistin1
reconstituted with either a bronchodilator respule or 2 ml of NaCl or H O. Patients2
mixing with NaCl or H O preceded inhalation with a bronchodilator inhaler. Data2
was reviewed for 47 patients; mean (S.D.) age 26.8 (7.9) years and mean FEV1
2.07 (0.97) l. Forty patients used a bronchodilator diluent. There was a mean (95%
CI) change in FEV ; from pre-0, y3.3 ml (y37.3, 30.7), pre-15 (ns45) 34 ml1
(y7.2, 76.1), and pre-30 (ns33) 55 ml (4, 106.3) These results represent a mean
(S.E.)% fall in FEV 0.13% (1.0) at 0 min, an improvement of 3.5% (1.7) at 151
min, and an improvement of 5.3% (2.1) at 30 min. The concentrated dose was
prescribed for 45y47 patients (1 patient experienced palpitations and the other chest
tightness). The mean (S.E.) inhalation time was 5.8 (0.32) min (ns28). The con-
centrated dose was well tolerated by patients, demonstrating improvement in
FEV without chest tightness. This change in practice reduces the time required for1
the patient to administer nebulised colistin.
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Most cystic fibrosis patients are able to use dry powder inhalers: the
effect of varying resistance on inspiratory volumes and flows
H.A.W. Tiddens , T. Standaert , P. Challoner , R.J. Speirs , K.C. Kesser , S.E.1 2 2 2 3
Overbeek , D. Humble , S. Shrewsbury , D.E. Geller1 2 2 3
ErasmusMCySophia Childrens Hospital, Rotterdam, Netherlands, Chiron Corp,1 2
Seattle, United States, Nemours Childrens Clinic, Orlando, United States3
The time burden for daily aerosolizing dornase alfa and tobramycin for inhalation
(TOBI) and cleaning the nebulizers is significant for CF patients. Dry Powder
Inhalers (DPI) are increasingly used for asthma drugs and may be a more time-
efficient and effective alternative for inhaling CF drugs. Inhalation flow rate and
device resistance (R ) interact to disperse drug from a DPI. Aim: To assess thed
feasibility of CF patients to use DPIs effectively. Methods: 96 stable CF patients
were enrolled, ages 6–54 years with FEV % predicted from 19 to 126%. Subjects1
inhaled forcefully through four different R (0.05, 0.07, 0.12, 0.17 cmH O yLy0.5d 2
min) while inspiratory time (IT), peak inspiratory flow (PIF), and volumes (V)
were measured. Results: For any R , inspired V and IT increased with higher aged
groups; PIF was similar between adults and adolescents but lower in children. As
R increased, PIF decreased and IT increased; V decreased only in older healthierd
subjects. At the lowest R , the mean PIF was 112 LPM (range 75–162) in adultsd
and 89 LPM (45–126) in children; mean inspired V was 2.2 l (0.8 to 3.7) in adults
and 1.2 l (0.5–1.8) in children. At the highest R , mean PIF was 55 LPM (40–70)d
in adults and 47 LPM (22–62) in children; mean inspired V was 1.9 l (0.9–3.5)
in adults and 1.1 l (0.5–2.3) in children. Conclusion: CF patients down to 6 years
of age are capable of effectively using DPIs that have typical resistances; some
young children and adults with low lung function may not be able to use high
resistance devices effectively.
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Pulmonary exacerbation in adult CF patients: outcome of home
management versus hospital management
J. Burt, J. De Jaeger, K. Wathen, N.A. Jarad
Adult CF Centre, Bristol Royal Infirmary, Bristol, United Kingdom
Aim of research: Home management for infective exacerbation of CF is favoured
by patients and have the advantage of obviating hospital admission and minimising
cross infection between CF patients. The outcome of home management has been
shown in some studies run over a short period of time to be inferior to hospital
management. The aim of this study is to examine the change in lung function and
in body weight in patients who were predominantly treated at home and to compare
those in patients who either treated predominantly in hospital or at both home and
in hospital. Patients and methods: All patients treated for at least one severe exac-
erbation annually over a period of 3 years were included in this research. Patients
were considered to have been treated in hospital or at home if over 60% of treatment
days were given in hospital or at home respectively. Patients were considered to
have treatment at both when 40–60% of treatment was given at either site. Annual
change in FEV1, FVC and body weight was calculated by subtracting the last post
IV measurement from the first post IV measurement and divided by time in years.
Results: Thirty-two patients, 13 female, mean age 23.4, range 16.4–41.2 years who
were followed up from January 2000 to December 2002 were included. There were
no differences between those who were treated at hospital, home or both with
respect to age, gender differences or baseline spirometric measures. Patients who
were treated at home tended to be younger than those treated in hospital or at both
sites (Ps0.07). Annual change in FEV1, FVC and in body weight did not differ
in home treatment compared with either hospital treatment or treatment in both.
There was no correlation between the change in FEV1 or in FVC with the change
achieved after each individual course of antibiotics. Conclusions: There was no
difference in annual decline in FEV1, FVC or in body weight between patients
treated predominantly at home, in hospital or both.
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Effects of inhaled tobramycin on lung function in CF patients
G.L. Grzincich , A. Miano , G. Pisi , C. Spaggiari , M. Ambroni , G. Attanasi1 2 1 1 2 1
Cystic Fibrosis Center-University of Parma, Parma, Italy, Cystic Fibrosis Center-1 2
H.M. Bufalini, Cesena, Italy
Aim: To evaluate the changes of lung function after 2 years treatment with inhaled
tobramycin (IT) in CF patients, chronically infected by Pseudomonas aeruginosa
(PA). Method: 35 patients (18 males), median age 23.8 years, were studied. IT
therapy (300 mg bid, every other months) was used for 2 years, replacing a prior
inhaled antibiotic therapy. We compared the trend of FVC, FEV and FEF1 25–75
(mean values) in 3 years before and 2 years with IT therapy and we calculated the
annual lost of pulmonary parameters. For the statistical analysis we used paired t
test. P value less than 0.05 was considered as significant. Results: For all the spi-
rometric variables we observed a lower annual decline after IT therapy, moreover
for FVC and FEV was not significant. The table shows the annual trend of the1
decline with and without therapy:
Annual D 1998y1999 1999y2000 2000y2001 2001y2002
FVC y1.8 y2.5 0.8 y1.7
FEV1 y3.2 y3.2 0.02 y2.2
FEF25–75 y5.7 y5.8 y2.04 y2.4 (*P-0.05)
No IT therapy IT therapy
Conclusion: Our results suggest that IT therapy can control the progression of the
pulmonary damage trough a slower decline of the pulmonary function in CF patients
with chronic PA infection. In particular we noted that the annual decline of the lung
function significantly decrease after the first year of the treatment (Ps0.009).
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Short oral course of ciprofloxacin and azithromycin can improve FEV1
and reduce the need for intravenous antibiotics in patients with
exacerbations in cystic fibrosis
D. Campbell, N.A. Jarad
Adult Cystic Fibrosis Centre, Bristol Royal Infirmary, Bristol, United Kingdom
Background: Evidence suggests that long-term use of azithromycin can prevent
exacerbation rates. This study examines the efficacy of a 2 weeks course of cip-
rofloxacin and azithromycin in preventing the need for intravenous (IV) antibiotics.
Patients and Methods: This is a retrospective study. Patients with pulmonary exac-
erbation who were offered a combination of oral ciprofloxacin 750 mg–1000 mg
twice daily and azithromycin 500 mg daily were reviewed. Clinical improvement
was deemed to have occurred if there was 10% increase in FEV1 after 2 weeks.
Obviation of IV antibiotics was considered if there was no clinical need for intra-
venous antibiotics for at least 8 weeks after the initial presentation. Results: Sixty-
five courses were prescribed for 39 patients. An improvement in FEV1 occurred in
18 (46%) episodes. This was independent from gender and disease severity, but
those who improved were younger, Ps0.02. Growth of pseudomonas aeroginosa
but not Staphylococcus aureus was associated with a more favourable outcome in
terms of FEV1 improvement Ps0.01. Thirty-six (55%) of courses of IV antibiotics
were prevented. There was no difference in outcome according to age, gender and
growth of PA or SA. Those in whom the oral regime prevented IV antibiotics had
higher baseline FEV1 (2.28) than those in whom the oral regime did not, FEV1
(1.71), Ps0.016. Conclusion: Oral courses of ciprofloxacin and Azithromycin
improve lung function tests in young adult CF patients and obviate the need of IV
antibiotics in those with mild to moderate disease.
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The role of fibreoptic bronchoscopy and rhDNase in lobar atelectasis in
CF
S. Sriram, P. Henderson, S.R. Bicknell
West of Scotland Adult Cystic Fibrosis Centre, Glasgow, United Kingdom
Introduction: Recombinant human deoxyribonuclease (rhDNase), an agent which
reduces the viscoelasticity of purulent secretions has been used intrabronchially in
the management of lobar atelectasis in bronchiectasis and in CF in children but its
use has not been reported in adult patients with CF. Methods: Between 2002 and
2003, five patients in our adult CF clinic had New or worsening radiological fea-
tures of lobar atelectasisqyy. Persistence of symptoms of cough or breathlessness
despite conventional antibiotic therapy for a pulmonary exacerbation. Age range
22–42 years, maless2, baseline FEV1 range 1.15–2.57 L, FVC range 1.19–3.55
L. Chest radiograph showed right upper lobe atelectasis (ns4) or right middle lobe
atelectasisyconsolidation (ns1). None had features of acute allergic bronchopul-
monary aspergillosis. One patient was on regular inhaled rhDNase. All underwent
fibreoptic bronchoscopy(FB) as a day case procedure under sedation. The bronchial
tree was inspected for the presence of mucus plugging and obstructing secretions
were cleared, followed by instillation of 2.5–5 mg of rhDNase. Results: (1) FB
identified mucus plugging in two patients. (2) All tolerated FB well and reported
good resolution of symptoms. (3) Clinical response did not correlate with radio-
logical resolution. Conclusion: FB was a useful diagnostic as well as therapeutic
tool in managing pulmonary exacerbations due to lobar atelectasis in CF and
allowed for local instillation of rhDNase to facilitate rapid clinical resolution. There
is scope to develop its application in the adult CF population.
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Benefit of aerosol therapy with Pulmozyme for children with cystic
fibrosis (CF)
S. Dumcius, A. Valiulis
Kaunas University of Medicine, Kaunas, Lithuania
Objective: Treatment with aerosol mucolytic drugs is part of therapy for CF patients.
Clinical trials have shown that Pulmozyme may improve pulmonary functions,
reduce infective episodes and change life style. The aim of our study was to evaluate
effect of dornase alfa treatment on quality of life and pulmonary functions in CF
patiens. Medical records of 17 children (mean age 9.5 years, FVC)40%) were
revised. All patients received 2.5 mg dornase alfa daily for 3 months by nebulisa-
tion. Recordings of FVC and FEV1 were taken at the start and end of Pulmozyme
therapy. The number of respiratory exacerbation episodes was compared during last
12 months before and after treatment. Results: Prior to every-day dornase alfa treat-
ment our patients were hospitalised averagely 2.2 yearly, as compared to 0.9 times
after it (P-0.05). Improvement of FEV1 after 3 months by mean was 9.84%, FVC
by 6.27%. This improvement was maintained during 12 months after treatment.
Conclusion: Pulmozyme treatment significantly reduced the number of infections
and hospitalisation rate among our patients. Inhalation therapy has a positive impact
on pulmonary functions and children’s well being. This treatment reduces hospital
cost of CF patients’ treatment.
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Breathing pattern during exercise in adult patients with cystic fibrosis
G. Perpati , E. Pouliou , E. Armeniakou , V. Dionyssopoulou , E. Stefanatou , P.1 1 2 2 2
Rhoditis , P. Founta , A. Papamichalopoulos , S. Nanas , Ch. Roussos2 2 2 2 2
Cystic fibrosis Outpatient clinic, Athens Chest Hospital, Department of Pulmonary1 2
and Critical Care Medicine, National and Kapodistrian University, Athens, Greece
Introduction: There is only limited information on exercise tolerance of patients
with cystic fibrosis (CF). Aim: The aim of this study was to determine the breathing
pattern during exercise in adult patients with CF. Patients-methods: Eighteen
patients (9 maley9 female, aged 21"11) and eleven healthy subjects (3 maley8
female, aged 29"4) underwent a cardiopulmonary exercise testing (CPET) on a
treadmill.Minute ventilation (V ), tidal volume (V ), breathing frequency (f ) andE T b
inspiratory time (T ) were measured at baseline, maximal exercise and recovery.I
Disease’s severity was estimated by FEV , body mass index (BMI) and Schwach-1
man score (SS). Results: There is an increase of V from the rest to maximalE
exercise and a decrease to normal level at recovery for both groups (12,5 ltymin
vs. 57,2 vs. 14,39, P-0,0001 and 11,29 vs. 81,34 ltymin vs. 20,5, P-0,001). For
CF group the ability to increase minute ventilation is limited in comparison with
healthy (Fs12,863, P-0,001). Similary V increased at peak exercise but in lowert
levels (CF: 0,56 vs. 1,53 vs. 0,72 lt, P-0,0001 and controls: 0,57 vs. 1,88 vs. 1,20
lt, P-0,032). There is no difference in frb from rest to peak (for CF: 23 per minute
to 38 vs. 19 to 44 for controls, P-0,098) but there is significant difference at
recovery (from 38 to 32 vs. 44 to 22 respectively, P-0,001). V and V are founde t
to have a positive correlation with disease’s severity (V vs. FEV : rs0.793, P-e 1
0,0001, V vs. BMI: rs0,802, P-0,0001, V vs. SS: rs0,531, P-0,009). Con-e e
clusion: Exercise performance in adult patients with CF is characterized by
limitation in V and V increase and presentation of tachypnea at recovery on a trye t
to satisfy requirements. These changes are related to disease severity.
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Pseudomonas sepsis after lung transplantation with rare complications
(case study)
K. Czebe , K. Fuzesi , Gy. Lang , A. Molnar , Zs. Monostori , P. Jaksch , W.1 1 1 1 3 2´ ´¨
Klepetko , E. Csiszer2 1´
Koranyi National Institute of Pulmonology, Budapest, Hungary, Universiti of1 2´
Vienna, Department of Cardiothoracic Surgery, Vienna, Austria, National Cancer3
Institute, Budapest, Hungary
A 24-years-old woman with cystic fibrosis had a double lung transplantation. Sepsis
caused by Pseudomonas aeruginosa developed in the 4th post-operative month.
Multiple pulmonary infiltrates occured on the right side with mediastino-hilar lym-
phadenomegaly imitated lymphoma. Endophthalmitis of the left eye was regarded
as the consequence of pansinusitis. The endoscopish sinus surgery, the enucleation
of left eyes, the systemic, adequate, combined, prolonged antibiotic therapy
improved the clinical symptoms only temporarily. By performing MR-angiography
the diagnosis of a septic thrombosis was established in the anastomosis of the right
pulmonal artery that could cause the sepsis. Septic thromboembolism from this
unusual localisation caused not only the pulmonal infiltrates and endophthalmitis,
but further intrapulmonal and suprarenal abscesses as well. Anticoagulant medica-
tion and the use of a new antibiotic combination (fosfomicin and tasobactam), the
CT-guided punction, drainage and local antibiotic lavage of both abscesses resulted
in complete healing. The patient has been symptomless for 13 months. Conclusion:
The healing process of the post-transplantation period needs further careful study,
this is best done in a multidisciplinary approach, new therapeutic interventions may
help the healing of unexpected complications.
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Outcomes of cystic fibrosis patients after spontaneous pneumothorax
C.J. Lopes, M.P. Azevedo, E. Carrilho, C. Barreto, A. Bugalho de Almeida
Pulmonology Department, Hospital de Santa Maria, Lisbon, Portugal
Spontaneous Pneumothorax (SP) is a frequent complication of Cystic Fibrosis
(CF). It is thought to occur more frequently in advanced disease. In our Adult
Cystic Fibrosis Unit 3 from the 29 patients had SP (nearly 10%). Age of occurrence:
23 years, 29 years and 32 years. Two females and one male patient. All patients
had acute onset of symptoms, three with dyspnea and two with chest pain. In all
cases the diagnosis was obtained by chest radiograph. The methods of SP manage-
ment used were: closed thoracotomy using a chest tube only, in one patient; chest
drainage followed by chemical pleurodesis with talc in another patient; chest drain-
age followed by surgical pleurodesis in the last patient. This patient did not have
CF diagnosis before surgery. The choice of therapy was based on the severity of
symptoms and response to therapy. At this time the follow-up periods are: 4 years
for surgical pleurodesis, 2 years for chest drainage and 1 year for chemical pleu-
rodesis. During this period no SP occurred (ipsilateral or contralateral). All patients
have severe disease with global respiratory failure, FEV 14%–16%–25%. Bron-1
chiectactic cysts in Thoracic CT scan, colonized by multiresistent Pseudomonas
aeruginosa. Inspite of the poor prognosis of CF patients after SP, we obtained long
survivals without recurrence in these patients with severe lung disease, using dif-
ferent management methods.
230
Autologous blood pleurodesis in the management of pneumothorax in
cystic fibrosis
R. Rabbani, S. Rajan, D. Honeybourne, D.E. Stableforth, R.S. Steyn
Birmingham Heartlands Hospital, Birmingham, United Kingdom
Pneumothorax is a relatively common complication in cystic fibrosis and recurrence
rates are high. Surgical pleurodesis may be associated with lower risks of recurrence
but the procedure has significant risks and may lead to difficulties during future
lung transplantation. Autologous blood pleurodesis has been described in the man-
agement of pneumothorax in the postoperative period following lung resections with
success (Andres et al 2001), but has not been reported in the management of
pneumothorax in cystic fibrosis. We report on our own experience of 4 patients
with cystic fibrosis who developed spontaneous pneumothoraces and were managed
by autologous blood pleurodesis. The patients were 21–30 years old; all of them
had severe lung disease with 3 of them having already undergone assessments for
a heart-lung transplantation and the 4th being in the process of referral. Aspiration
was initially attempted in two but was unsuccessful and eventually all were man-
aged with an intercostal drain and subsequent blood pleurodesis because of a per-
sistent air leak. Between 50 ml and 120 ml of the patients’ own non-heparinised
blood was taken and then instilled into the intercostal tube. No complications
occurred. Two of the four patients are still alive and have not had a recurrence 7
months and 17 months since having a blood pleurodesis. The remaining two died
of unrelated events 7 months and 11 months following their pneumothorax but no
recurrences were reported before their death. This pilot study suggests that pleu-
rodesis with autologous blood is safe and effective. A larger study is required.
231
Cardiac tamponade in end-stage cystic fibrosis
R.I. Ketchell, R. Badawi, M.E. Hodson, M.Y. Henein
Department of Cystic Fibrosis and Cardiology, Royal Brompton and Harefield NHS
Trust, London, United Kingdom
Introduction: Exaggeration of the normal physiological, respiratory variation in car-
diac filling velocities is characteristic of cardiac tamponade, usually consequent to
the presence of a significant pericardial effusion or less commonly a large pleural
effusion. We present 10 patients with end-stage cystic fibrosis (CF) with haemo-
dynamic evidence of cardiac tamponade on Doppler echocardiography but no evi-
dence of either a pericardial or pleural effusion. Methods: Prospective study of
patients with end-stage cystic fibrosis in a tertiary CF centre using Doppler echo-
cardiography over a 4 year period. Results: Ten patients were identified, mean age
("S.D.) 28"12 years. Each had extensive bronchiectasis on CT with a tendency
to cystic destruction and marked small airways disease. All patients had an FEV -1
1.0 l, mean% predicted FEV ("S.D.) 18"4%, FVC 36"13%, TLC 104"17%1
and RV 281"80% predicted. Six were identified during routine echocardiography
as a part of a heart lungydouble lung transplant assessment, two as a consequence
of clinical evidence of respiratory failure and cor pulmonale and two as a conse-
quence of sudden increased shortness of breath and presyncope on exertion.Doppler
echocardiography: Significant compromise to right sided filling was demonstrated
in each patient during expiration. In contrast an increase in SVC flow and right-
sided filling and ejection velocities was observed during inspiration with reciprocal
decreases in left sided filling and ejection velocities. Three patients had a mildly
dilated right ventricle, including the two with clinical evidence of cor pulmonale.
All patients had a resting tachycardia (mean 115 bpm) but demonstrated normal
LV systolic function. Conclusion: In end-stage CF the exaggerated increase in intra-
thoracic pressure results in compromised expiratory right heart function. This may
add to the clinical deterioration and marked morbidity known in these patients.
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Is gastro-oesophageal reflux (symptomatic and silent) a problem in
patients with CF on the transplant waiting list and after lung
transplantation?
B.M. Button , S. Roberts , T. Kotsimbos , J. Wilson , G. Snell , T. Williams2 1 1 1 1 1
Allergy, Immunology and Respiratory Medicine, The Alfred Hospital, Melbourne,1
Australia, The University of Melbourne, Melbourne, Australia2
Symptomatic and silent gastro-oesophageal reflux (GOR) and tracheal aspiration
are reported in CF. We hypothesise that GOR contributes to declining lung function
before and after lung transplant (LTx). Aims: Establish whether patients on the
waiting list andyor after LTx have GOR; (2) Determine whether GOR is sympto-
matic or silent. Method: Adults with CF on the waiting list and following LTx were
recruited prospectively. A structured symptom questionnaire was followed by ambu-
latory dual probe 24 h oesophageal pH monitoring. Results: Twenty three studies
have been undertaken: nine pre- (Group 1) and 14 post-LTx (Group 2). Mean age
of patients: 28 (19–40) years. Results are reported as medians with interquartile
ranges for proximal (prox) and distal (dist) oesophagus together with normal val-
ues. Reflux index: Group 1: Proxs1.5 (0.7, 4.4)% wnormal-0.1%x; Dists8.6 (4.9,
11.7)% w-4.5%x. Group 2: Proxs1.40 (0.6, 5.0)% w-0.1%x; Dists8.5 (3.5, 12.7)
-4.5x%. Number reflux episodes: Group 1: Proxs56(38, 78) w-4x; Dists180
(122, 239) w-50x. Group 2: Proxs43 (22, 126) w-4x; Dists213 (114, 293) w-
50x. DeMeester Score: Group 1: 38.7 (22.9, 3.0); Group 2: 32.45 (9.9, 54.6) w-
14.72x. There were no significant differences between Groups 1 and 2, however,
there was a significant difference between groups and normal values (P-0.05)
Symptom score: Group 1:6 (0, 9); Group 2:9 (3, 11) w-4y18x. Three of nine
subjects (33.3%) in Group 1 and 3 of 14 (21.4%) in Group 2 had silent GOR w-
4y18x. Conclusion: Symptomatic and silent GOR are significant problems and may
contribute to lung function decline before and after LTx in CF.
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Improved outcome in 80 adult patients referred for lung transplant from
a regional CF centre
M.R. Ratcliffe, H.E. Steele, C. Etherington, S.P. Conway, D.G. Peckham
Seacroft Hospital, Leeds, United Kingdom
The aim of this study was to assess the outcome of adult patients referred for lung
transplant from the CF centre. The case notes of 80 patients from 1st referral in
1991 through to December 2002 were retrospectively reviewed. Mean values at
referral were: age 25 years; FEV1 25% predicted normal; BMI 19.1; Northern CXR
score 16. Survival in transplanted patients was compared to results from a previous
evaluation in 1998. Eighty patients were referred (44 women). The median annual
number of referrals was eight. Seventy-one were assessed at the transplant centre
(four patients decided not to proceed, four died before assessment, one improved
with intensified medical therapy). Fifty-seven patients were listed for transplant.
The median annual number of transplants was two. Twenty (35%) died on the
waiting list, (mean time from listing to death 16 months). Thirty-one (54%)
received a transplant, (mean time listing to surgery 12 months). Nineteen (61%)
of the 31 lung recipients are alive. The commonest cause of post-operative death
was OB, (six patients at a mean 1475 days). Survival figures at 31y12y2003 v. 31y
12y1998 at 1 year – 87% vs. 85%; at 2 years – 76% vs. 75%; at 6 years 58% vs.
30%; at 10 years 47% vs. no data available. Mean BMI improved from 19.1 pre
transplant to 20.6 kgym at 1 year, 21.3 at 5 years, and 23.4 at 7 years. Mean2
FEV1% predicted improved from 25% pre transplant to 71% at 1 year, 64% at 5
years and 55% at 7 years. There has been no closing of the gap between the number
of patients referred for and receiving a lung transplant. A significant minority dies
on the waiting list within 16 months of referral. Optimal timing for referral is still
ill defined. Survival figures for patients in receipt of a lung transplant are improving
with almost 50% alive 10 years post-surgery. (Data to 31y12y2003 will be available
at the conference).
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An evaluation of patientycarer satisfaction with cystic fibrosis (CF)
services in Peninsula
A. Prendiville , C. Pritchard , S. Elworthy , D. Woolley , J. Spinks , R. Holding ,1 1 2 3 1 1
B. Castell , N. Parker , J. Williams3 4 5
RCH Treliske, Truro, United Kingdom, Royal Devon and Exeter Hospital, Exeter,1 2
United Kingdom, Plymouth Health Care Trust, Plymouth, United Kingdom, Torbay3 4
District General Hospital, Torbay, United Kingdom, North Devon District Hospi-5
tal, Barnstable, United Kingdom
The Peninsula CF network is a CF service in rural South West England delivering
care to 200 CF patients at five locations across Devon and Cornwall. Patient and
carer involvement has played a key role in the development of the service. To help
determine whether the increased resources allocated to medical and nursing services
were associated with increasing patient satisfaction and whether there were contin-
uing patient perceived service deficits an anonymised questionnaire was sent to
each CF household in 2002 and 2003. Patients or their carers were asked to score
the medical, nursing, physiotherapy, dietetic and psychology services in terms of
ease of access for advice, clinic support, inpatient and home support. There were
88 and 83 replies in 2002 and 2003 respectively. In 2002 more than 75% of
responses rated the services to be good to excellent. Services provided at home
were rated significantly worse than clinic services (P-0.001)* or inpatient services
(Ps0.010)*. Medical services and nursing services rated significantly better than
physiotherapy (P-0.001)*, dietetic (P-0.001)*, or psychology services (Ps
0.014)*. Ratings for medical and nursing services improved from 2002 to 2003.
Ratings for other aspects of the service remained the same. *Wilcoxon signed Rank
Test. This study reveals that patients or their carers are more satisfied with the better
resourced aspects of the Peninsula CF service (medical and nursing) and that these
services are perceived by patients to continue to improve with time.
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Unusual respiratory bacterial pathogens in a cystic fibrosis adult
patients unit
E. Inglezos, P. Boura, M. Kanellopoulou, M. Skarmoutsou, E. Papafrangas, F.
Apostolopoulou
Sismanoglio General Hospital, Maroussi-Athens, Greece
Chronic pulmonary infection and progressive lung injury are the major causes of
morbidity and mortality in cystic fibrosis.The main bacteria that affect the lung
change with age. S. aureus, S. pneumoniae, and H. influenzae are the predominant
pathogens in children. In adolescents and adults Pseudomonas aeruginosa
approaches a prevalence rate of 85%. In recent years, the emergence of unusual
pathogens such as Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and
Nocardia asteroides isolated from the sputum of CF patients has been increasingly
reported from CF centers data. The aim of this study was to discuss the isolation
and susceptibility testing of these unusual pathogens isolated from the sputum cul-
tures in our adults CF unit. From 1998 to 2002 year we examined 965 sputum
samples in a group of 68 patients aged )18 years and we transiently isolated
unusual pathogens during this period in 19 patients (28%) with an order of fre-
quency S.maltophilia, A. xylosoxidans, and Nocardia asteroides. All these 19
patients were chronically colonised with P. aeruginosa receiving chronic mainte-
nance antibiotic therapy. No obvious deterioration on pulmonary function tests was
noted over this 5-year period. Isolation of Nocardia was clinically correlated with
fever that subsided after a 2 weeks period of treatment with co-trimoxazole.
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Report of a case of Paecilomyces lilacinus (P. lilacinus) infection in a
CF patient
G.A. Loeuille , F. Delepoulle , I. Joly-Durand , V. Montagne1 1 2 1
Cystic fibrosis center, Dunkerque, France, Laboratory of parasitology and mycol-1 2
ogy, Lille, France
Aspergillus is responsible for the majority of the different clinical manifestations
of fungi infections in CF. P. species are ubiquitous and saprophytic fungi which,
rarely, can cause severe and difficult to treat infections in human. The purpose of
our study is to describe the clinical manifestations of P. lilacinus infection in a
patient with CF. The patient was a 16 year and 3-month-old-adolescent who had
CF diagnosed after neonatal screening (genotype: G 542 Xy2161 del A). During
the following years, he developed a chronic bacterial infection with P.A. (at 7 years
and 10 months of age) then a resistant strain of S.A. (at 14 and an half years of
age) and also a long allergic aspergillosis with signs of atopy (at 12 years of age).
A symptomatic diabetes mellitus (DM) appeared at the age of 15 and an half years
and was correctly controlled. Although his medications included itraconazole, he
developed a severe pulmonary infection: fungal culture of sputum showed evidence
of P. lilacinus infection, which was confirmed by serology (5 precipitins). He started
a daily inhalation of amphotericin B and capsules of voriconazole (200 mg po bid),
which is a new triazole. After 5 weeks of therapy, we decided to stop the ampho-
tericin B aerosol and we used intra venous antibiotics and corticosteroids: the
patient’s condition slowly improved. We continued with the treatment of voricon-
azole (250 mg po bid). Most cases of P. lilacinus infection occur in patients with
impaired immune defenses or following surgical procedures. P. lilacinus infection
is unheard of as a pathogen in CF. D.M. and repeated bathings in a lake of the
South of France might have been the main causes.
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Reversal of the CFTR knockout mouse lung phenotype by in utero gene
therapy
J.E. Larson , M. Levitzky , L.K.A. Lindblad , J.H.T. Bates , J.C. Cohen1 3 2 2 1
Ochsner Clinic Foundation, New Orleans, United States, University of Vermont,1 2
School of Medicine, Burlington, United States, Louisiana St. University of Health3
Sciences Center, New Orleans, United States
In utero gene transfer is a highly effective method for delivery to the developing
lung and intestines. Previous studies using this method in the CFTR knockout
mouse showed that the lethal intestinal phenotype could be reversed following tran-
sient infection with a CFTR-adenovirus recombinant. Lack of a pulmonary phe-
notype in the mouse, however, precluded evaluation of any effect on the lung.
Pulmonary mechanic studies employing pressure-volume (PV) curves and variable
impedance with the constant-phase model were used to demonstrate a lung phe-
notype in the cftryyy mouse. Knockout mice exhibited an altered static compli-
ance and PV curve shift. Increased tissue elastance (H) and tissue damping (G)
were noted in the knockout mouse following variable impedance studies. Knockout
mice (S489X) were treated in utero with Av1CF2, a adenovirus-CFTR recombinant,
at 15–16 days gestation. At 30–60 days of age pulmonary function tests were
performed. The in utero CFTR treated cftryyy mice exhibited a lung phenotype
different from that of untreated knockout mice. The rescued knockout mice showed
a phenotype that was not statistically different than that of the cftrqyq animals.
Thus, in utero CFTR gene therapy reverses both the intestinal and lung phenotype
in the CFTR knockout mouse.
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Controlled clinical trials (CCTs) in cystic fibrosis (CF) – are we doing
better?
T.A. Briggs , M. Bryant , R.L. Smyth1 2 3
Alder Hey Children’s Hospital, Liverpool, United Kingdom, Cochrane Cystic1 2
Fibrosis and Genetic Disorders Review Group, Liverpool, United Kingdom,
Department of Child Health, University of Liverpool, Liverpool, United Kingdom3
Introduction: We have previously reported the time trends, design and interventions
in randomised controlled trials (RCTs) in CF until 1997. We maintain an ongoing1( )
register of all RCTs and CCTs in CF and have noted that in the 5 years since 1997
there has been an approximately 50% increase in published RCTs and CCTs. We
aimed to assess whether this exponential increase in the number of published clin-
ical trials in CF has been associated with a similar improvement in their quality.
Methods: From the published report of each trial we recorded details about the
design, numbers of participants and type(s) of intervention. Results: Two hundred
and sixty one trials in 1998–2002 were compared with 544 trials in 1961–1997.
Comparing the two epochs a similar proportion of trials were parallel, doubleysingle
blind and placebo controlled. Twenty-five percentage of trials were multicentre in
the later epoch, compared with 11% previously. Median number of participants were
similar (21 compared with 18). In both epochs the two main types of interventions
were antibiotics and physiotherapy. Conclusion: While the large increase in clinical
trials in CF in recent years is welcome, this has not been associated with improve-
ments in quality. The trend for an increasing proportion of trials to be multicentre
is encouraging. Cheng K., Smyth R.L., Motley J., O’Hea U., Ashby D. Random-1( )
ised Controlled Trials in Cystic Fibrosis (1966–1997) categorised by time, design
and intervention. Paediatric Pulmonary, 2000. 29, 1–7.
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Cancer in transplanted cystic fibrosis patients
M.L. Furnari , L. Termini , M. Arico , L. Mandala , M. Rolla , P. Vitulo1 1 2 3 4 5` `
Centro Regionale Fibrosi Cistica Ospedale dei Bambini ‘‘Di Cristina’’ ARNAS,1
Palermo, Italy, U.O. Oncoematologia Pediatrica Ospedale dei Bambini ‘‘Di Cris-2
tina’’ ARNAS, Palermo, Italy, ISMETT, Palermo, Italy, Centro Regionale Fibrosi3 4
Cistica Universita La Sapienza, Roma, Italy, Clinica Apparato Malattie Respira-5`
torie Universita di Pavia, Pavia, Italy`
Lung transplantation is now a good and acceptable therapy for patients with end-
stage lung disease in Cystic Fibrosis (CF). Between 1997 and 2003, four of 210
patients followed at the CF Center of Palermo underwent lung transplantation; one
of them underwent heart transplantation too. All patients received post-transplant
immunosuppressive therapy with either azathioprine, or cyclosporine or tacrolimus.
We describe the onset of cancer in two of them. Case 1. Female, CF genotype
DF508yW1282X, developed colon adenocarcinoma with liver metastases at the age
of 29 years, 4 years after second transplant, performed because of bronchiolitis
obliterans syndrome (BOS) and CMV infection 1 year after first transplant. Case
2, Male, CF genotype G542XyG542X, developed Hodgkin lymphoma (mediastinal
and right cervical lymphnodes) at the age of 30 years, 4 years after heart-lung
transplantation. Seven months after the diagnosis, following treatment with che-
motherapy (ABVD=3) and radiotherapy of involved field, he developed acute
respiratory distress due to lung rejection. Cancer is a rare event in the CF population
but the risk is markedly increased after transplant in keeping with literature reports.
Balance between cancer therapy and immune-suppression may be very difficult due
to risk of organ rejection or cancer progression.
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Cardiomyopathy as a rare complication: experience of the Czech
National Cystic Fibrosis Centre
V. Vavrova , V. Hrobonova , J. Bartosova , D. Zemkova , M. Macek Jr.1 1 1 1 2
Paediatric Dept, 2nd Medical School, Prague, Czech Republic, Institute of Biol-1 2
ogy and Medical Genetics, 2nd Medical School, Prague, Czech Republic
Cardiomyopathy (CMP), often leading to sudden death, has occasionally been
described in CF patients under 3 years of age. The aim of this study was to evaluate
the incidence and course of CMP in our patient cohort. CMP was diagnosed in the
total of 18 patients (3% from 602 patients), of which 14 have already died. In
deceased patients only 4 cases were diagnosed during their lives, while the remain-
der progressed undetected. All cases were confirmed at autopsy. CMP was the
underlying cause of sudden death in 4 cases with respiratory infections and in 3
patients with a rather severe disease (at 10.7, 12.0 and 20.6 years). Contrary to the
literature reports 6 of these patients were older than 2 years at the time of their
death. Mean age of the clinical diagnosis of CMP was 4.7 years (range 0.4–17.0)
in the deceased and 1.3 years (0.8–2.1) in living patients (the actual mean age was
13 years, the overall course of CF was mild, with mean FEV 80 % p.v.). CMP1
manifested itself by cardiomegaly andyor heart failure. All patients with CMP were
pancreatic insufficient. Clinical diagnosis was confirmed by ECG, ultrasound andy
or chest X-ray exams. Class I-III CFTR gene mutations were predominant: 4x
F508delyF508del, 2x F508delyCFTRdel2,3 (21kb), 1x F508delyG551D and 1x
F508dely1898q1G-)A. Although, the overall numbers are small for statistical
analysis, we have observed that diagnosis of CMP during early infancy markedly
prolonged life expectancy in patients with this potentially lethal complication. Due
to the improvement of diagnosis and care sudden death related to CMP did not
occur during the last 6 years at our CF Centre. Supported by MSMT- 111300003
and MZCR-00000064203.
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Encouraging results of lung transplantation for CF in Belgium
C. Knoop , L. Dupont , P. Evrard , M. Antoine , Y. Sokolow , G. Verleden , D.1 2 3 1 1 2
VanRaemdonck , P. Eucher , D. Van Ranst , M. Estenne2 3 4 1
Hopital Erasme, Brussels, Belgium, UZ Gasthuisberg, Leuven, Belgium, Cli-1 2 3ˆ
niques UCL Mont-Godinne, Mont-Godinne, Belgium, UZ Antwerpen, Antwerpen,4
Belgium
We conducted a retrospective survey of all CF lung transplant recipients in Belgium
in order to assess overall survival, results and complications. Since 1988, 100 CF
patients (59 malesy41 females, mean age ("S.D.) 26"8 years) received a lung
transplant in four Belgian lung transplant centers. Thirty-one patients received a
heart-lung transplant, 67 received a double lung transplant, one received a single
lung transplant and one received a combined double-lung liver transplant. Actuarial
survival was 91, 82, 67, 59, 47 and 25% at 3 months, 1, 3, 5, 7 and 10 years,
respectively; it was 45% at 5 years for patients transplanted from 1988 to 1995 and
65% for those transplanted from 1996 to 2003 (Ps0.005). Forty-three patients died
(surgical complications ns5, infection ns9, chronic rejectionyinfection ns21,
various causes ns8). At present (January, 2004) 57 CF lung transplants recipients
are alive after a median of 36 months (range: 1–150) after surgery. All patients
receive immunosuppression with a calcineurin inhibitor (cyclosporine A ns16,
FK506 ns41) and steroids. The mean ("S.D.) forced vital capacity is 83 ("19)%
predicted and the mean ("S.D.) forced expiratory volume in 1 s is 83 ("23)%
predicted. In conclusion, this multi-center collaborative survey shows that (1) up
to the present date, 100 CF patients have received a lung transplant in Belgium;
(2) actuarial survival data compare favorably to survival data reported by the Reg-
istry of the ISHLT; and (3) relevant lung function parameters in the patients, who
are alive at present, are excellent.
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Additional inspiratory muscle training intensifies the beneficial effects
of cycle ergometer training in patients with cystic fibrosis
S. Albinni, R. Rath, S. Renner, I. Eichler
University Children’s Hospital, Vienna, Austria
The aim of our study was to evaluate the effects of inspiratory muscle training
(IMT) combined with cycle ergometer training (CET) on lung function, exercise
capacity, inspiratory muscle performance and quality of live in patients with CF.
Patients and Methods: Subjects, age 6–18 years, with a FEV1 )30% were ran-
domly allocated to IMT in addition to CET (training group) or CET (control group)
alone. Both groups (total ns27) had a 12 week aerobic endurance CET three times
a week; the training group (ns16) received additional IMT with Respifit 1000 (E.
Biegler, Austria) daily. At the beginning and at the end of the training period
pulmonary function, inspiratory muscle strength (IMS) and endurance (IME) as
well as maximal exercise capacity (MEC) were assessed. IMS was determined as
maximal inspiratory pressure against an occluded airway (Pimax), IME was meas-
ured by the maximal sustained ventilatory capacity. MEC was defined as maximal
oxygen uptake (VO max). Results: Both, IMS (Ps0.0001) and IME (Ps0.0002)2
improved significantly in the training group. VO max improved significantly in the2
training group, but not in the control group (Ps0.01). There was no change of
FEV1 and FVC in both groups. However, MEF 50%VC (Ps0.003) and MEF
25%VC (Ps0.04) improved significantly only in the training group. During the
training period there was a significant reduction of antibiotic use, compared to 3
months prior to the study. Patients in the IMT group reported of markedly improved
expectoration and reduced sensation of breathlessness. Conclusion: IMT appears to
add beneficial effects on exercise performance and quality of life due to improved
inspiratory muscle strength and endurance.
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Performance characteristics of colistimethate sodium solution
(Colistin) nebulised by a novel electronic inhaler (eFlow)
M. Keller, R. Waldner, M. Knoch
PARI Aerosol Research Institute, Munich, Germany
Dissolution of 1 mega unit Colistinmethate-sodium (Gruenenthal GmbH) in 3 ml
isotonic saline gives a solution with physico–chemical properties different from
isotonic saline especially with respect to surface tension (48.9 vs. 72.8 mNym).
The sensitivity of novel electronic inhaler systems to surface tension and dynamic
viscosity requires thorough investigation of relevant in-vitro parameters to give an
indication for the clinical benefit and safety. This study was undertaken to obtain
preliminary information on the aerosol characteristics with respect to Respirable
Fraction (RFspercentage of droplet mass below 5 mm), Mass Median Diameter
(MMD) and Total Output Rate (TOR) when using Colistin nebulised by eFlow
(PARI GmbH), a novel electronic inhaler. Three eFlow devices were tested with 3
ml Colistin solution and compared to isotonic saline. Laser diffraction measure-
ments were carried out at an inspiratory flow rate of 20 lymin with following results:
RFs74.5% vs. 66%, MMDs3.5 vs. 4.1 mm, TORs325 vs. 620 mgymin. These
data indicate that eFlow generates a finer aerosol mist with Colistin vs. saline,
yet at a reduced output rate. For the final product further assessment of the delivered
dose and drug contained in droplets below 5 mm (respirable dose) will be necessary.
Custom adaptation of drug formulation and device may provide benefits with
respect to droplet size and treatment time for an optimized administration of Colistin
to the lungs. The study also shows that the relevant drug formulation rather than a
surrogate must be used in order to assess and compare the performance of different
drug and nebuliser products. A characterisation of nebulisers according to the CEN-
standard EN 13544-1 solely by a 2% sodium-fluoride solution is therefore
inappropriate.
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A review of the management issues for a patient with massive superior
vena cava obstruction
D. Kastner-Cole, I. Zealley, J. Dick, S. Mukhopadhyay
Tayside University Hospitals Trust, Dundee, United Kingdom
It is known that vascuports have a risk of superior vena cava thrombosis. However,
the management of a child with cystic fibrosis (CF) and superior vena cava obstruc-
tion has not been discussed. A now 14-year-old male was diagnosed with CF at the
age of 3 years. He was chronically colonised with Pseudomonas aeruginosa at
diagnosis and was commenced on 3 monthly intravenous antibiotics as well as
nebulised antibiotics. The intravenous antibiotics were initially administered through
short long lines for 14-day courses. At the age of 4 years he received his first
vascuport. This was replaced due to blockage in 1996, 1997 and 2001. MRI angi-
ography following the last, difficult insertion showed superior vena cava obstruction
as well as bilateral subclavian vein obstruction. He had well-established collateral
drainage via the epidural veins and azygous vein. The line blocked shortly after-
wards and was removed. Extensive investigation to rule out thrombophilia was
negative. His FEV1 was 60% of mean predicted at that time. For the past 2 years
he has been treated with oral Azithromycin and intermittent courses of oral Cip-
rofloxacin and he has not received intravenous antibiotics. His lung function has
remained stable. There has been no deterioration in his clinical status or his chest
X-ray findings. An issue of concern is the possible future need of permanent vas-
cular access. It has been suggested to percutaneously access the azygous vein and
to prevent further thrombosis with low dose warfarin. It is uncertain if this patient
can be offered heartylung transplantation when he deteriorates. We will address
these issues in detail.
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Comparison of tobramycin serum plasma levels in 5 CF patients after
inhalation of TOBI via a PARI LC PLUS nebuliser and via eFlow , a  
novel electronic inhaler
F. Friedrichs , M. Keller , H. Dohmen , C. Pfannenstiel , R. Ledermuller1 2 1 1 3¨ ¨
CF-Ambulanz Aachen, Aachen, Germany, Aerosol Research Institute, Munchen,1 2 ¨
Germany, PARI GmbH, Starnberg, Germany3
The current study was undertaken to investigate the usefulness and acceptance of
the novel electronic inhaler eFlow by CF patients. eFlow is designed for a more
rapid, economic and efficient nebulisation of medication due to a lower drug wast-
age and a higher percentage of drug available as delivered and respirable dose
compared to jet nebulisers. Based on in-vitro equivalence test lower doses and
volumes were used for this in-vivo investigation. 5 CF patients (11–29 years) with
a FEV of 12.1% to 95.9% predicted inhaled via a PARI LC PLUS powered by a1
BOY N compressor 2.5 ml Sultanol forte (2.5 mg salbutamol) and afterwards 5 ml
TOBI (300 mg tobramycin) and one week later via eFlow 1.1 ml Sultanol forte
(1.1 mg) and 3.3 ml TOBI (200 mg). Lung function, heart frequency and oxygen
saturation were measured after each medication, venous blood samples were taken
after 1 h. In-vitro data showed a slightly higher mass median diameter (MMD) for
TOBI in the PARI LC PLUS compared to eFlow (4.0 vs. 3.8 mm, GSD 2 vs 1.6
). There were no differences in FEV , heart frequency and oxygen saturation com-1
pared to baseline between the two treatment regimes. Blood drug levels in mgyl
for the LC PLUS vs eFlow in the 5 CF patients were as follows: 2.1:1.6, 2.8:0.9,
0.4:0.4, 0.4:0.4, 0.8:0.6. Mean inhalation times were 4.4 vs 1.6 min for salbutamol
(2.5 vs. 1.1 ml) and 17.4 vs 4.7 mins for tobramycin (5 ml vs 3.3 ml) comparing
the LC PLUS and eFlow, respectively. Conclusion: In-vitro equivalence data are
useful to predict in-vivo performance. Patients liked the eFlow due to its compact-
ness, mobility and faster drug application. Most probably, eFlow will improve com-
pliance and quality of life of CF patients.
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Radiological expression of cystic fibrosis at the moment of diagnosis
T.W. Folescu, I.R. Sad, R.F. D’Amoed, M. Boechat, E.N. Santos, P.A. Daltro, L.Y.S.
Higa
Instituto Fernandes Figueira-Fiocruz, Rio de Janeiro, Brazil
Although CF is a genetic disorder affecting epithelial cells of multiple organs, it is
the respiratory tract that is associated with the most significant morbidity. Chest
image techniques have been used as one of the methods for assessing pulmonary
disease. The radiological scores, Brasfield for X-ray and Bhalla for CT scan, are
able to measure the radiographic changes that result from clinical progression of
the disease. The aim of this study is to describe the radiological abnormalities at
the moment of the diagnosis. From Januaryy2001 to Decembery2003, the Pediatric
CF Center of Rio de Janeiro-Brazil had 29 new diagnosis of CF. Radiological exams
of 23 patients (median age 11 mo) were available and analyzed by three radiologists
according to standard forms of the previously mentioned scores. Brasfield score
ranged from 13 to 25, where two patients received the total score-25, 10 had scores
of 20–24, 8 from 15–19, and 3 from 13–14. The most prominent radiological
features were: air trapping (70%), linear densities due to bronchial prominence
(82.6%), cystic nodular lesions (34%), and lesions that suggested atelectasis or
pulmonary consolidation (52.2%). Due to the severity of clinical and radiological
features of these patients, 18 were submitted to a CT scan at the moment of the
diagnosis. The Bhalla score ranged from 2 to 13, and the main findings were:
peribronchial thickening (94.4%), mosaic perfusion (83.3%), emphysema (61%)
and bronchiectasis (55.4%). Less than 10% of the patients had normal exams. The
severity of radiological changes, demonstrated by such scores, confirms the great
morbidity already in CF diagnosis process, reassuring the importance of including
CF in the differential diagnosis of respiratory disease. Ref: Radilogy 1991;179:783–
788; Pediatrics, vol 63, No 1, Jan 1979.
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Respiratory viruses in cystic fibrosis
D.S. Wat , C.M. Gelder , S. Hibbitts , I. Bowler , R. Evans , M. Pierrepoint , I.J.1 2 1 3 4 3
Doull5
University of Wales College of Medicine, Cardiff, United Kingdom, Llandough1 2
Hospital, Penarth, United Kingdom, Royal Gwent Hospital, Newport, United King-3
dom, Singleton Hospital, Swansea, United Kingdom, University Hospital of Wales,4 5
Cardiff, United Kingdom
Respiratory viruses have been suggested to have a role in the pathogenesis of pul-
monary exacerbation in Cystic Fibrosis (CF). Previous studies on viral detection in
CF relied heavily on tissue cultures and serology, which take 1 to 2 weeks to
process, and they have achieved a detection rate of around 30%. These methods
are relatively insensitive, and more recent studies have used Polymerase Chain
Reaction (PCR), albeit only to Picornaviruses. Nucleic Acid Sequence Based
Amplification (NASBA) is much more sensitive and involves incubating nucleic
acids at 41 8C, using reaction mixture containing oligonucleotide primers and
enzymes. This results in the exponential amplification of products in 90 minutes.
NASBA products can then be detected in ‘real-time’ using molecular beacon or by
probe hybridisation and electrochemiluminescence (ECL). We have tested the appli-
cation of NASBA in the detection of respiratory viruses in CF patients. Nasal swabs
were taken from 10 CF patients with pulmonary exacerbations and were put into
lysis buffer. Viral RNA was extracted using silica slurry and was then amplified
using NASBA. Respiratory viruses were detected in four out of 10 exacerbation
samples; two of which were rhinoviruses, one was influenza A and one was par-
ainfluenza type 4 virus. NASBA has the potential to provide a rapid turn-around
of results allowing diagnostic virology to have a direct impact on patient manage-
ment. With the advent of newer antiviral agents, this may significantly change CF
management in the future and further prolong the life expectancy of the sufferers.
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Use of sirolimus after lung transplantation in patients with cystic
fibrosis
G. Cimino , A.D. Grzejdziak , S. Cingolani , G. Tancredi , F. Venuta , E.1 1 1 1 2
Mercadante , S. Quattrucci2 1
Cystic Fibrosis Centre, Department of Pediatrics, University of Rome, Rome, Italy,1
Department of Thoracic Surgery, University of Rome La Sapienza, Rome, Italy2
Immunosuppressive therapy after lung transplantation in patients with cystic fibrosis
(CF) consists of cyclosporine A (CsA) or tacrolimus, azathioprine and steroids.
CsA and tacrolimus are associated with renal toxicity and long-term treatment may
lead to renal impairment. Sirolimus is a new immunosuppressive drug without renal
toxicity administered in lung transplant recipients (LTR) with chronic renal impair-
ment. An increase rate of infectious complications compared to CsA and tacrolimus
was reported among adverse effects of sirolimus. In LTR with CF who develop
infections related to microorganisms that colonize the respiratory tract and sinuses
the use of sirolimus has not been assessed. In September 2001 we started to admin-
ister sirolimus in LTR with severe chronic renal impairment related to CsA or
tacrolimus in order to assess the effect on renal function. We enrolled eight CF
patients (five males, mean age 26.8 years) with the mean baseline serum creatinine
of 2.68 mgydl (normal range of 0.5–1.4 mgydl) persistent for G6 months. Three
patients presented with obliterative bronchiolitis syndrome (BOS) at enrolment. All
patients were monitored for renal and lung function, and infectious complications.
We observed improvement in renal function in all patients, unchanged lung function
in five patients (one patient with BOS at enrolment). One patient presented with
an increase in the number of infections that responded to dose reduction of siroli-
mus. One patient developed BOS after enrolment and died intraoperatively during
retransplantation. Two patients died for respiratory failure due to BOS (two patients
with BOS at enrolment). Sirolimus is a useful alternative immunosuppressive drug
in LTR with CF who present with chronic renal impairment.
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Superior vena cava (SVC) stenosis: a rare complication of a totally
implantable venous access device (TIVAD) in cystic fibrosis
S. De , M.J. Pierrepoint , A. Wood , I.J. Doull , I.M. Bowler1 1 2 2 1
Royal Gwent Hospital, Newport, United Kingdom, University Hospital of Wales,1 2
Cardiff, United Kingdom
A 16-year-old female presented with a 10-day history of face and neck swelling
with engorged conjunctivae. A Portacath had been sited via her right subclavian
vein 4 years previously. It had been resistant to flushing, but a venogram performed
18 months previously had been normal. Examination revealed signs of SVC
obstruction. A venogram showed thrombotic occlusion of the superior vena cava
at the level of the catheter tip. She received thrombolytic therapy with tissue plas-
minogen activator. Her thrombotic screen was normal. She was not receiving the
oral contraceptive pill but had been on the parenteral progestogen-only contracep-
tive. Repeat venography showed resolution of the SVC thrombus and revealed a
tight stenosis at the level of the catheter tip, along with longstanding occlusion of
the left subclavian and brachiocephalic veins probably secondary to previous periph-
erally inserted central venous catheters (PICC) on this side. The TIVAD was
exposed and the catheter cannulated with a guidewire over which a balloon catheter
was introduced to dilate the SVC stenosis. A new Portacath was sited via the
guidewire. TIVAD are associated with lower complication rates than other central
venous lines. While up to 4% of patients with central venous catheters may have
symptomatic superior vena cava obstruction, most have been associated with malig-
nancy, parenteral nutrition etc; it is rare in patients receiving intravenous antibiotics
alone unless there is an underlying thrombotic diathesis. We are unaware of any
reports of stenosis of a large vein contributing to SVC obstruction due to use of a
TIVAD.
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A pilot study to investigate the lung deposition of aerosol nebulised
solutions using two different nebuliser systems in to the lungs of cystic
fibrosis (CF) patients
C.M. Coldham , S A Mulrennan , G Wright , T Davies , J D Seymour , A H3 2 1 1 3
Morice 2
Hull Royal Infirmary Department of Nuclear Medicine, Hull, United Kingdom,1 2
Castle Hill Hospital Division of Academic Medicine, Hull, United Kingdom, Uni-3
versity of Hull Department of Comparative and Applied Social Sciences, Hull, Unit-
ed Kingdom
Background: Many nebulisers used in the treatment of CF waste between 95–98%
of the medication placed in the chamber. They are often prescribed on a one size
fits all principle. This study uses gamma scintigraphy to assess the reproducibility
of nebuliser deposition and individual nebuliser output in order to tailor the choice
of nebuliser to an individual patient. Primary end point was the relative proportion
of lung deposition. Method: Eight CF patients were enrolled on the trial. Two nebu-
lisers were compared, Pari LC Plus using Turbo boy compressor and Pro-dose
utilising adaptive aerosol delivery technology. FEV1 was measured before and after
5mg of Salbutamol was inhaled. 150 MBq of Tc99m DTPA was placed in the
nebuliser chamber and nebulised for six minutes. Immediately after nebulization
the patients were imaged using ADAC (Phillips) Forte gamma camera with low
energy general purpose collimator. Anterior and Posterior images of the lungs were
taken simultaneously; images of the nebuliser chamber, mouthpiece and filter were
also taken. Results: Mean FEV1 pre and post nebulised Salbutamol was
56.1"21.0% and 58.7"21.1% predicted. In patients completing the study: the
mean total dose delivered to the lungs was 3.31"5%, (Pari) and 5.12% (Pro-dose)
and mean reproducibility of the technique was 13.4%. The mean total dose remain-
ing in the Pari versus Pro-dose was 59.6% and 84.5% respectively. Conclusion:
Gamma scintigraphy offers the clinician a means of assessing nebuliser deposition
in individual patients and allows treatment optimisation. We have confirmed poor
drug delivery with nebuliser systems.
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Inhalation therapy can be improved in CF patients by controlling the
breathing pattern during inspiration
B. Mullinger, K. Sommerer, C. Herpich, T. Meyer, G. Scheuch¨
Inamed GmbH, Gauting, Germany
Inhalation therapy is a central part in the life of CF patients. Therefore Inhalation
systems should be able to target a drug in reproducible dosages into specific regions
of the lung efficiently. To reach this aim particle size and patient’s breathing pattern
need to be optimised. Nevertheless, for most inhalation systems the breathing pat-
tern is neglected and not controlled by the devices itself. But if only the particle
size is optimised, the efficiency and variability of lung deposition are highly influ-
enced by patient’s breathing pattern and could easily vary from 10–50%. In 5 CF
patients with the AKITA inhalation system intrathoracic deposition was deter-
mined with Fe O aerosol particles labelled with Tc. Lung deposition was meas-99m3 4
ured using a gamma camera and a whole body scintillation counter. Patients inhaled
an individualized inhalation volume (75% of inspiratory capacity, max. 1.75 litre)
at a flow rate of 200 mlys. The intrathoracic deposition of 5 CF patients was
86.3"1.5% of the delivered aerosol dose. Peripheral lung deposition was
77.8"4.7%. It can be concluded that the controlled inhalation with the AKITA
delivery system of particles in the size range of 2–5 mm in CF patients results in
high intrathoracic deposition with extremely low intersubject variability. This is an
opportunity to reduce the needed drug amount as well as the therapy time for the
patients.
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Lung deposition following electronically breath controlled inhalation
and manually triggered conventional inhalation in CF patients
E. Kohler, V. Sollich, R. Schuster, V. Wonka, G. Jorch¨
Clinic for General Paediatrics and Neonatology, Otto von Guericke University,
Magdeburg, Germany
Using nebulisation only a small proportion of the initial dose reaches the lungs
while the remainder is swallowed, exhaled or remains in the nebuliser. It was the
purpose of this study to investigate whether lung deposition can be improved by
using a device, which controls the breathing pattern. Relative lung deposition was
estimated by inhalation of the marker substance, sodium cromoglycate (SCG), and
measurement of urinary excretion of SCG. Thirteen CF patients (aged 8–20 years)
received SCG (2 ml 1% Intal nebuliser solution) by means of (a) conventional
inhalation (Parimaster, LC Star jet nebuliser with manual interrupter, slow and
deep breathing) and (b) electronically breath controlled inhalation (AKITA, LC
Star jet nebuliser, optimised breathing). Inhalations were trained and supervised
by a physiotherapist. Urine was collected in 5 fractions until 12 h p.a., and the
excreted SCG was determined by means of HPLC. Prior to each inhalation, the
patients’ pulmonary function was measured using a Pneumoscope. Following
breath controlled inhalation, the amount of SCG excreted in urine was significantly
greater than after conventional inhalation (2.22 mg"0.61 mg vs. 1.63 mg" 0.59
mg, P-0.001), being equivalent to an average improvement of 46%. The absorp-
tion half-life for SCG following breath controlled inhalation was significantly short-
er when compared with conventional inhalation (78"23 min vs. 107"29 min; P-
0.01), being suggestive of a more peripheral deposition. In conclusion, inhalation
with controlled breathing pattern yields a greater and more peripheral lung depo-
sition of SCG compared to manually triggered conventional nebuliser technique,
even in CF patients with several years of inhalation experience and supervised by
a physiotherapist.
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Hypertonic saline X recombinant human DNase: a randomised cross-
over study in 18 cystic fibrosis patients
F.V. Adde , K.T.L. Borges , A.C.F. Hatanaka , C.M.A. Nakaie , J.M.A. Cardieri ,1 1 1 1 1
R.C. Oliveira , G. Lorenzi-Filho , P.H.N. Saldiva , J.C. Rodrigues2 2 2 1
Unidade de Pneumologia, Instituto da Crianca - Hospital das Clinicas, Sao Paulo,1 ¸ ˜
Brazil, Laboratorio de Poluicao Atmosferica Experimental, University of Sao2 ¸´ ˜ ´ ˜
Paulo, Sao Paulo, Brazil˜
Recombinant human DNase (DNase) and hypertonic saline (HS) have been used
in CF patients to improve sputum rheology and lung function. Objectives: compare
the efficacy of nebulised DNase vs HS, the acceptance of each therapy and monitor
the sputum bacterial growth during each treatment in a group of CF patients. Meth-
ods: open label, randomised, crossover study, with a 2 week washout period, where
DNase 2.5mg od was compared with 10 ml 6%HS bid for 4 weeks. Outcome
measures, pre and post each treatment were: FEV , semiquantitative sputum cultures1
(bacterial growth graded as 0 to 4), symptom score (0–12; worsening - improve-
ment) and in vitro studies of mucus wmucociliary transport in a frog palate model
(MCT), cough clearance (CC), contact angle and viscosityx. The acceptance of
each treatment was scored by the patients (very goods 1 to unacceptables5).
Results: 18 patients, 13 Fy5 M, age range 8.7–25.8 y were investigated. The out-
come measures are shown in the table:
Pre HS Post HS Pre DNase Post DNase P*
FEV (%predicted)1 47"18 46"18 49"15 50"21 NS
P. aeruginosa growth 2.4"1.5 2.5"1.6 2.2"1.4 2.4"1.6 NS
S. aureus growth 1.8"1.9 1.5"1.9 1.2"1.8 1.6"2.0 NS
Symtom score 6.1"1.9 7.8"2.8 6.9"2.3 6.7"3.1 NS
Values expressed as mean"S.D.; * paired Student ‘‘t’’ test. DNase promoted a
higher variation in MCT (Ps0.005) and CC (Ps0.019) (Wilcoxon test). Contact
angle and mucus viscosity changed equally after both therapies. No difference was
observed in the score of acceptance of each treatment. Conclusions: no significant
changes in FEV , bacterial growth and symptom score were observed with both1
interventions. Mucus transportability improved with nebulised DNase only. The
acceptance of the two treatments by the patients was similar.
Gastroenterology
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Prenatal diagnosis and postnatal complications of meconium ileus in a
neonate with cystic fibrosis. Case report
F. Karpati, S. Ek, T. Granholm, L. Hjelte
Karolinska University Hospital, Stockholm, Sweden
Meconium ileus (MI) is the presenting symptom in 10–15% of patients with CF.
It may be revealed by targeted ultrasound examination already in utero. In our case,
CF was diagnosed by chorion villus sampling in the late first trimester. The kary-
otype was normal but displayed the same CF mutations (394delTTy621q1T) as
those of an elder brother with CF. The pregnancy was continued. From the 16th
week, subsequent ultrasonic scans showed a progressive intestinal dilatation up to
25 mm. The labour was induced in the 36th week because of signs of foetal bowel
obstruction. The newborn girl was vital with a BW of 3 kg. She developed abdom-
inal distension and surgery was performed at the age of two days. The operation
revealed ileal atresia, a short-segment volvulus and MI. After resection of the
necrotic volvulus segment, an end-to-end anastomosis was performed. Pancreatic
enzyme substitution and supporting therapy of CF airway symptoms was initiated.
Due to rupture of the anastomosis, probably secondary to persistent MI, an ileos-
tomy was performed at the age of 8 days. Combined antibiotic treatment was given
postoperatively for peritonitis and pneumonia. Parenteral nutrition was replaced by
oral feeding. UDCA treatment was initiated when signs of liver affection were seen.
The course was further complicated by general and repeated seizures due to epi-
lepsy. The ileostomy was closed after two and a half months. On follow up, this
two and a half year old patient has been in good general condition, without gastro-
intestinal or pulmonary problems. In this case, careful prenatal follow up resulted
in preterm delivery for optimal timing of abdominal surgery. The management of
MI demands a multidisciplinary approach with close collaboration between obste-
trician, paediatrician and surgeon.
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Trends in the management of meconium ileus: a 15-year review
S. Shah, C.J. Taylor
Sheffield Children’s Hospital, Sheffield, United Kingdom
Background: Meconium ileus (MI) affects 10–15% of children with cystic fibrosis
(CF). The management of MI has evolved over the last few decades. Methods:
Between August 1988 and 2003, 27 neonates presented to the Sheffield Children’s
Hospital with a diagnosis of MI and subsequently were confirmed to have CF. A
retrospective review was carried out in an attempt to define trends in the manage-
ment and outcome of these neonates. The parameters of outcome were analysed in
cohorts: Group 1 1988–1993 (ns7), Group 2 1993–1998 (ns5) and Group 3
1998–2003 (ns14). Results: Eleven neonates (42.4%) had simple meconium ileus
of which 4 were successfully treated with gastrograffin and 1 with N-acetyl cysteine,
with no complications. The remainder required a laparotomy. 15 cases had com-
plicated MI (57.6%). The management included resection with primary anastamosis
(ns4), stoma formation (ns6) and Bishop-Koop enterostomy (ns5). For patients
with simple MI comparison between the groups showed more were treated by gas-
trograffin in group 3 (66.6%) and group 2 (100%) compared to group 1 (0%). For
complicated MI, resection with primary anastamosis was more frequent in group 3
(37.5%) compared to group 2 (25%) and 1 (0%). The median days for hospital
stay and time to establish full enteral feeds was significantly shorter in cases treated
with gastrograffin compared to laparotomy, Ps0.05 and Ps0.01 respectively. The
overall survival was 92%. Conclusion: Our review reveals that neonates with CF
and MI would have a better outcome. Usage of gastrograffin enema has increased
in the management of simple MI, resulting in a significantly shorter hospital stay
and time to establish enteral feeding. Resection with primary anastamosis provides
a single operation alternative for selected cases.
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Transient pancreatic sufficiency in Cystic Fibrosis infants, selected by
neonatal screening, revealed by stool Elastase-1 dosage
L. Narzi , F. Narzi , S. Zullo , S. Bertasi , S. Cingolani , E. Soldi , M. Lucarelli ,1 1 1 1 1 1 2
R. Strom , S. Quattrucci2 1
Centro Fibrosi Cistica, Universita di Roma La Sapienza, Rome, Italy, Dip. di1 2`
Biotecnologie Cellulari ed Ematologia, Universita di Roma La Sapienza, Rome,`
Italy
Cystic Fibrosis (CF) is a severe autosomal recessive disease characterised by anom-
alous transport of ions by the apical membrane of the epithelial cells, with esocrin
glands disfunction. In Lazio region, from September 1998 to 2002, by means of
IRTyDNAyIRT neonatal screening, including genetic test for CFTR mutations,
were selected 52 CF children. On these CF children the esocrin pancreatic function
was evaluated at diagnosis (about 1 month of life) and during the first year. By
dosage of stool chymotrypsin (CH) realised at birth, 22 affected on 47 examined
subjects (47%), resulted with pancreatic insufficiency (PI) while by stool elastase-
1 dosage (E-1), 32 affected showed almost a moderate PI (68%). The 10 CF infants
that showed discrepancy between the results of E-1 and CH, not undergoing therapy
with pancreatic extract, showed a reduction of growth although steatorrhea was
absent. Eight of these CF infants showed a progressively reduction of stool CH to
pathological values during the first year of life. The other two children showed the
same stool CH reduction, although between 3–6 years of age. These results suggest
that a partial PS condition can be temporary because in 32 % of CF children with
PS at birth there is a decline of pancreatic function during the first year of life
while in 8% PS is maintained for more years and that E-1 assay is a more sensitive
test for moderate PI. Genetic analysis for 31 mutations of CFTR gene (Celera
Diagnostics), realised on 10 CF children with transitory PS, showed 4 compound
heterozygous for severe mutations and 6 patients with only one mutation found.
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Fibrosing rectopathy in 2 cystic fibrosis neonates
C. Chalouhi, M. Elkouri, V. Abadie, F. Jaubert, P. De Villartay, I. Sermet-Gaudelus,
G. Lenoir
Hopital Necker-Enfants Malades, Paris, Franceˆ
We present 2 cases of CF newborns presenting with intestinal obstruction and micro-
scopical appearance of Fibrosing Rectopathy (FRP). The first patient was an homo-
zygous DF508 patient diagnosed at neonatal screening. He referred at our CF center
when he was 2 months old for failure to thrive and abdominal distension. Pancreatic
enzyme therapy was initiated but stopped after 15 days because of subocclusion.
The gastrografin enema and the anal manometry showed anal stenosis and micro-
rectum. Deep rectal biopsy showed a thickened fibrous submucosa with plexus
hyperplasia but without disruption of the muscularis mucosa or inflammatory cells.
The patient was treated with exclusive parenteral nutrition during 1 month and
underwent anal dilatation. The patient is now 13 months old and has no problem
of abdominal distension and a good tolerance of pancreatic extracts. The second
patient (DF508y1811q1,6kb A-)G) presented for neonatal meconium ileus. The
gastrografin enema showed an entire colon of thin calibre (microcolon) and the
presence of dilated loops of the jejunum. Resection of 40 cm of jejunum was
performed with jejunostomy. Inspissated mucous with dilated crypts were found in
the resected area. The rectal biopsy showed enlarged submucosa with fibrous con-
nective tissue and scattered hyperplastic submucosa ganglia. After 2 months of
parenteral feeding, surgical anastomosis was performed and the patient’s recovery
was uneventful. These 2 cases report pathological submucosa findings similar to
those found in the colon in the observations of Fibrosing Colonopathy (FCP). These
observations despite the absence of any enzyme treatment (or a very short period)
suggest that the mechanism of FCP could be linked to antenatal events primarily
linked to CF.
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Distal intestinal obstruction syndrome, a childhood illness now seen in
adults
A. Ben-Sassi, T.R.M. Raju, D. Ionscu, D.J. Shale, J. Torkington
University Hospital of Wales, Cardiff, United Kingdom
Introduction: Distal intestinal obstruction syndrome (DIOS) is a well known com-
plication in cystic fibrosis patients after early childhood. Advances in the care of
CF patients mean that patients are now being seen as adults by general surgeons.
Aim and Method: This retrospective study examines the presentations, diagnosis
and management of all patients admitted in the CF unit over the period between
Aug 1997 and July 2003, with the diagnosis DIOS (Meocuniom illius equivalent).
Results: The majority of patients presented complaining of abdominal pain (9y10);
abdominal distension (9y10), and constipation (8y10), Four patients were reported
to have abdominal masses on presentation. There were 6 males and 4 females, with
the age of first presentation varying from 7 to 37 years with a mean age of 24
years. Four patients self presented with these symptoms, whilst the rest were
referred from other health care services. The diagnosis was supported by plain
abdominal X-ray in (8y10), and three patients required further radiological inves-
tigations to confirm the diagnosis. Most cases were managed conservatively with
oral Gastrografin and careful medical and nursing care. Two patients required sur-
gical interventions. Recurrent attacks were seen in over half of the patients (7y10),
with some patients presenting as frequently as six times, all recurrences were man-
aged conservatively. Conclusions: The majority of cases of DIOS in children and
adults can be managed conservatively. Patients with Cystic Fibrosis have a much
extended life expectancy and general surgeons will be seeing these patients with
diseases formally considered as these of childhood.
260*
Xerophthalmia in a patient with cystic fibrosis (CF), short bowel
syndrome and compliance issues
D. Jyothish, M. Desai, J.R. Ainsworth, C. Patchell, J.R. Clarke, P.H. Weller
Birmingham Children’s Hospital, Birmingham, United Kingdom
Xerophthalmia in a patient with cystic fibrosis (CF), short bowel syndrome and
compliance issues. Background: Patients with CF may have Vitamin A deficiency
due to fat malabsorption secondary to pancreatic insufficiency, short bowel syn-
drome following meconium ileus surgery, recurrent pulmonary exacerbations, zinc
deficiency, liver disease and poor compliance with vitamin supplementation. Case
description: A 7 year old girl with CF, short bowel syndrome, poor compliance and
frequent pulmonary exacerbations developed arthritis. Ophthalmology assessment
as part of her arthritis workup revealed Bitot spots and extensive epitheliopathy
consistent with Xerophthalmia. There was a retrospective history of longstanding
impaired night vision. She had been on standard dose vitamin supplementation
(4000 U) and low vitamin A levels were attributed to non-compliance. Zinc levels
were normal. High dose vitamin A supplementation and rigorous measures to ensure
compliance including home visits by the CF liaison team plus frequent monitoring
resulted in complete resolution of eye signs and symptoms within 6 months. Dis-
cussion: Poor compliance and frequent respiratory exacerbations superimposed on
short bowel syndrome led to severe vitamin A deficiency in this patient. Vitamin
A deficiency is still reported in CF patients on vitamin supplements (1, 2) although
recent studies suggest that this is essentially preventable. (3) Regular monitoring,
adequate supplementation, high index of clinical suspicion and prompt action on
low levels is necessary especially in patients with additional risk factors such as
short bowel syndrome to avoid co morbidity due to vitamin A deficiency. Refer-
ences: 1. Neugebauer et al. Eye 1989; 3:360–4; 2. Feranchak et al. J Pediatr. 1999
Nov; 135(5):601–10; 3. Ansari et al. Br J Ophthalmol 1999; 83:688–91.
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Iliopsoas abscess in cystic fibrosis: an unusual presentation
E.F. Moya, L.A. Elliott
Bradford Teaching Hospitals, Bradford, United Kingdom
An 8-year old boy with cystic fibrosis (Delta 508 Homozygous) presented acutely
with fever, pain on the right hip with a limp and pain in the right lower abdominal
quadrant. For the last four years had been complaining intermittently of similar
symptoms. X-rays and ultrasounds of his hips showed no abnormalities. His white
cell count and C-reactive protein were intermittently elevated. He was thought to
have recurrent episodes of Distal Intestinal Obstruction Syndrome (D.I.O.S.)
because of his tendency to constipation and palpable masses in the right lower
quadrant of his abdomen. He seemed to respond to several courses of acetylcysteine,
but after a while the symptoms will reappear. Finally, seven months prior to his
acute presentation, he had a C.T. scan of his abdomen and pelvis, which was report-
ed as being normal. On examination he was pyrexial and had a scoliotic posture
with his right leg held in semi-flexion. A palpable mass was noticed in the right
lumbar region. A repeat C.T. scan with contrast revealed a cystic mass representing
a large right iliopsoas abscess. It was successfully drained showing pus and scanty
growth of gram-positive cocci. He made an uneventful recovery and remains asymp-
tomatic. This report of a right iliopsoas abscess with acute-on-chronic symptoms is
an unusual presentation in C.F. It was difficult to make a diagnosis at an earlier
stage because of the intermittent nature of the symptoms and the partial response
to acetylcysteine. We can only speculate that the original focus of infection was his
bowel, spreading to the retro peritoneum and being partially treated by his regular
prophylactic flucloxacillin and intermittent courses of ciprofloxacin for intercurrent
respiratory exacerbations. We recommend early imaging of the abdomen and pelvis
(C.T. scan with contrast or M.R.I.) if such symptoms persist or return after initial
treatment.
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Dehydration among an adult population of a CF centre during the
august 2003 heat wave in France
N. Desmazes-Dufeu , D. Hubert , D. Dusser
Service de Pneumologie, Hopital Cochin, Paris, France
Adults with CF can develop, less than in infancy, hyponatremic hypochloremic
dehydration with metabolic alkalosis when they sweat excessively. We investigated
the incidence, clinical features, biochemical parameters and complication of dehy-
dration in an adult CF population during the August 2003 heat wave. We reviewed
the admissions and the phone calls to the CF centre during august. 250 CF adults
are regularly followed in the CF centre (mean age 28.7 years - range 17 to 60;
mean FEV1 48.6 %predicted). 6 patients developed acute dehydration. 2 diagnoses
were made via phone call and were rapidly solved via hydration phone advices. 4
were admitted at hospital. Physical exertion in hot exposure was reported for one
patient. Two patients were taken oral NaCl supplementation (3 gyday). They had
fatigue (6), nausea (5), vomiting (5), rapid lost of weight (5), cramps (4), lost of
thirst feeling (4), headache (3), hypotension (2) and high fever (1).Serum con-
centrations at admission are in the table:
1 2 3 4
Na mmolyl (136–143) 118 120 133 134
K mmolyl (3.5–4.5) 2 2.8 2.8 2.7
Cl mmolyl (97–105) 61 50 72 92
Total CO2 mmolyl (22–28) 37 25 20 35
Proteins gyl (63–78) 97 129 119 67
Creatinine mmolyl (50–115) 190 428 700 145
Length of hospital stay (days) 2 5 3
FEV1 before dehydration
(% predicted) 30 23 48 73
Patient 2 died 10 hours after admission of heat stroke. These patients are particularly
at risk of dehydration even in adulthood and should take adequate precautions
during summer months.
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Upper gastrointestinal endoscopy in adult cystic fibrosis: a 23-year
experience in a single CF centre
H. Chaun, P. Zetler
St. Paul’s Hospital, University of British Columbia, Vancouver, Canada
Upper gastrointestinal (UGI) disorders are common in cystic fibrosis (CF) patients,
and are recognized as a significant cause of morbidity. The aim of this study is to
determine the indications, and the frequency of abnormal findings in adult CF
patients who had UGI endoscopy and biopsies for dyspepsia and other disorders.
Methods: Of 289 patients seen in the Adult CF Clinic since 1980, 112 have been
referred to Gastroenterology. This is a retrospective chart review of 37 patients in
whom UGI endoscopy was performed. There were 18 females, 19 males, age range
14–43 years, (mean 26.2). The prime indication was heartburn 11, epigastric pain
11, nausea or vomiting 5, melena or hematemesis 3, iron deficiency anemia 3,
esophageal varices 1, other abdominal pain 1, gluten enteropathy 1, abnormal bar-
ium meal 1. Results: Endoscopic findings were abnormal in 31 patients. 13 had
reflux esophagitis – mild 10, grade C 3, Barrett’s 1; 17 sliding hiatus hernia, 1
with Cameron’s erosions; 1 gastric erosions; 2 duodenal ulcer (NSAID-related 1,
nonspecific 1), 1 possible; 4 large folds or duodenitis in duodenum; 2 esophageal
varices complicating multinodular cirrhosis (1 had sclerotherapy); 1 PEG in place.
All patients had gastric and duodenal biopsies. No patients had H. pylori (Hp).
Duodenal biopsies were abnormal in 10 (duodenitis 9, celiac disease 1). Barrett’s
was histologically confirmed in 1 patient. There were no complications.Conclusion:
36y37 patients (97%) had abnormal endoscopic andyor biopsy findings. Reflux
esophagitis is common in adult CF patients. Hp was absent in all patients. Endos-
copy is safe and useful in the investigation of adult CF patients with UGI disorders.
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Gastro-oesophageal reflux in relation to nutritional status and
pulmonary function in children with cystic fibrosis
D. Tjesic-D. , V. Rozmanic , D. T.-Drinkovic , V. Ahel , A. Votava-Raic , M.1 2 1 2 1
Persic2
Dept. of Pediatrics, University Hospital Centre Zagreb, Zagreb, Croatia
Aim: To evaluate the lung function and growth status of CF patients with or without
gastro-oesophageal reflux (GOR). 27 CF children (age 3 month to 18 years, mean
7 years, 10 girls and 17 boys) were included. Nutritional status was evaluated based
on anthropometrical assessments (weight, height and weight-for-height-index). All
children underwent 24-h oesophageal pH monitoring and 14 (51%) of them were
found to have GOR, defined as reflux index (RI) )10% for infants and RI)5%
for other age groups. FEV was measured in 15 subjects old enough to perform the1
test. Severe pulmonary illness (FEV -40% of predicted value) was found in 31
patients (20%), moderate illness (FEV 40–70% of predicted value) was found in1
4 children (27%), and the rest had mild pulmonary affection (8 or 53%). Results
for children with spirometry findings:
Mean S.D. Range
Age (years) 11.7 4.4 5–18
Weightyheight index (%) 77.8 18.5 49.6–108.7
Mean pH 5,39 0,71 3.8–6.45
RI (%) 11.42 13.42 2–54.1
DeMeester score (normal -14,71) 40.68 45.9 11–189.3
FEV1 (%) 67.4 24.65 21–101
Parameters describing GOR correlated well with patients’ age: a negative correlation
between age and mean pH was observed (P-0.001), as well as a positive
correlation between age and RI, and age in relation to DeMeester score (P-0.002).
This was not true for GOR and weightyheight index, or for any parameter
describing GOR in relation to FEV values. However, when only children with1
deteriorated lung function were evaluated (FEV -70%), a negative correlation to1
RI was determined (P-0,05). These data indicate that GOR is partially age
dependent and worsens with time, possibly contributing to more pronounced lung
deterioration. Correlation was also proven between pulmonary function measured
as FEV and growth expressed as weightyheight index (P-0,005).1
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The use of nasal potential difference measurements in recurrent
pancreatitis
M. Wilschanski , Y. Yaakov , S. Adler , E. Broide , H. Blau , H. Bibi , R.1 1 2 3 4 5
Arnon , A. Klar , N. Vaisman , O. Kolker , Y. Yahav , N. Arad-Chohen , E.6 2 6 6 7 8
Karem1
Hadassah University Hospital, Jerusalem, Israel, Bikur Cholim Hospital, Jeru-1 2
salem, Israel, Assaf Harofe Hospital, Zriffin, Israel, Schneider Medical Center,3 4
Petach Tiqvah, Israel, Barzilai Hospital, Ashkelon, Israel, Souraski Medical Cen-5 6
ter, Tel Aviv, Israel, Sheba Medical Center, Tel Hashomer, Israel, Carmel Medical7 8
Center, Haifa, Israel, Afula Medical Center, Afula, Israel9
Introduction: An emerging number of patients present with an atypical phenotype
of cystic fibrosis (CF) expressing only partial features or single-organ disease only.
The association between the phenotype of recurrent pancreatitis and cystic fibrosis
transmembrane conductance regulator (CFTR) dysfunction is unclear. Methods:
Patients with idiopathic recurrent pancreatitis were referred for electrophysiological
investigation. Results: 18 patients (10 males) aged 22"11 years (9 below the age
of 18 years) with recurrent pancreatitis were studied. 1 patient had mild asthma
and one patient had Crohn’s disease. There was no family history of CF. All patients
had normal spirometry and negative sputum cultures. Most patients had imaging of
the pancreatic duct (ERCPyMRCP) and in 2 patients mild pancreatic duct stenosis
was found. No patient was Pancreatic Insufficient. Mean sweat chloride values were
41"13 meqyl (range 20–66). Nasal potental difference (NPD) was pathological
and diagnostic for CF in 4 patients (sweat chloride 44,60,43,45 meqyl). Mean basal
potential difference (PD) in these 4 patients was -32.5"13 mV and there was an
abnormal response to chloride-free and isoproterenol solutions. In the other 14
patients the mean sweat chloride concentration was 38"14 meqyl. Basal PD was
in the normal range (y15"5 mV) and the chloride transport was normal. Mutation
analysis revealed W1282Xy5T and W1282Xy-- in 2 patients with abnormal NPD
and one W1282X allele was found in one patient with normal NPD. Conclusion:
In this series, a fifth of patients with recurrent pancreatitis have abnormalities of
CFTR function. Larger studies are warranted to firmly establish the role of NPD
as an aid to diagnosis of CF in otherwise idiopathic recurrent pancreatitis.
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Heat wave and acute pancreatitis: very unusual cystic fibrosis
presentation
A. Munck, M. Gerardin, B. Delaisi, G. d’Acremont, J.F. Segura
Hospital Robert debre, Paris, France´
Pancreatitis experienced by 10% of pancreatic sufficient CF patients is rare as
revealing symptom. During the French dramatic 2003 sweltering summer, we diag-
nosed three CF cases with dehydration and acute pancreatitis. Two girls (I, II), one
boy (III) (11, 5, 9 years old) had identical presentation at hospitalisation: dehy-
dration (y13%, y7%, y5%) without diarrhoea, but hypersudation, vomiting,
severe epigastric pain. Pancreatitis was confirmed by amylase and lipase (I:1996y
357, II:763y357, III:353y350). The etiologic procedure included a sweat test (ST).
Cases I (at 2 months), II (at 2 years) had had previous normal ST because of
familial CF history; III’s parents are cousins. Gibson and Cooke (meqyl Cl ) madey
CF diagnosis (I: 80, II: 69, III: 80). CFTR genotyping identified the familial CF
mutations; case I: R552Qy1812q1GA, case II: F508yS545L, screening is under
process for III. Pancreatic status (elastase mgyg) showed PS for case I (500) and
moderate PI for cases II and III (162, 102). The occurrence within a few weeks of
three new CF cases diagnosed through an acute pancreatitis is very unusual. Heat
wave played the trigger role: in the presence of CFTR mutations, dehydration and
hypovolemia led to the pancreatitis episode. Furthermore an initial negative ST may
not exclude CF; CF compatible symptoms should be carefully re-evaluated in order
to reestablish the diagnosis. Heatwave allowed an earlier CF diagnosis and sup-
portive care improving the overall prognosis for these patients.
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A complicated pancreatic pseudocyst
C. Etherington, D.G. Peckham, S.P. Conway
Seacroft Hospital, Leeds, United Kingdom
A 27year old female presented in November 2002 with a six month history of
intermittent LUQ pain radiating to the back. Examination revealed a tender palpable
mass in the LUQ. General health was good wFEV1 80% predicted, BMI 22.7x. She
was homozygous DF508, pancreatic insufficient and chronically colonised with
Pseudomonas aeruginosa. She had presented 2 years prior to this with a similar
history with a diagnosis of pancreatic pseudocyst w12=8 cmx. Radiological aspi-
ration was incomplete due its multilocular nature wculture negativex. Repeat CT
w12y02x demonstrated increased size of the pseudocyst w12.5=7.5=13 cmx. She
was referred for a surgical opinion and a cystojejunostomy was performed w8y03x.
Histology was negative. 2 weeks following surgery she presented with 7 kg weight
loss and pyrexia with an elevated CRP w81.9x. Despite treatment she continued to
deteriorate with persistent pyrexia, abdominal pains and further weight loss. CT
scan w9y03x revealed multiple liver lesions w1–2 cmx diagnosed radiologically as
abscesses. Despite several weeks of appropriate antibiotic treatment, the liver lesions
increased in size with persistently elevated CRP. CT guided drainage of the pseu-
docyst was performed w10y03x and left on free drainage with subsequent aspiration
of 150 ml every other day. By 11y03 liver lesions had increased to 4cm and biopsies
revealed poorly differentiated carcinoma. Clinical picture was consistent with a
primary pancreatic tumour with liver metastases. She has been commenced on che-
motherapy with Epirubicin, Cisplatin and Capecitabine in an attempt to slow pro-
gression of the liver lesions. This case highlights a rare complication of CF and
should make physicians aware of the possibility of underlying malignancy.
268*
Single stage percutaneous gastrostomy button insertion for adults with
cystic fibrosis
H. Watson , J. Dunning , C.S. Haworth , D. Bilton1 2 1 1
Adult CF Centre, Papworth Hospital, Cambridge, United Kingdom, Department1 2
of Cardiothoracic Surgery, Papworth Hospital, Cambridge, United Kingdom
Gastrostomy tubes and buttons are widely used in adolescents and adults with cystic
fibrosis, for supplementary enteral feeding. Percutaneous endoscopic gastrostomy
(PEG) was developed by Gauderer, (Gauderer 1991), and more recently balloon
buttons have been developed, which have traditionally required a two-stage pro-
cedure. A PEG tube was inserted and replaced after 3–6 months with a button,
once the tract had formed. The single stage percutaneous gastrostomy (SSPG) inser-
tion technique reduces the potential morbidity of a second procedure (Griffiths
1996). For the SSPG procedure, gastroscopy is undertaken and a site selected on
the greater curve. The button is inserted using a modified Seldinger technique, and
Cope tags to secure stomach to the abdominal wall. Five patients (aged 18–31)
have had a single stage button inserted at our centre. The procedure was uncom-
plicated and was not associated with any adverse events. There was no difference
in postoperative pain and duration of stay between the SSPG and initial insertion
of a PEG. Early displacement and failure to replace the button immediately can be
associated with loss of the tract. The insertion of an invasive feeding tube can be
a physically and emotionally painful process. The aesthetics of the tube are vital;
many patients favour a button gastrostomy for cosmetic purposes. This method of
insertion is a substantial advance because it allows primary percutaneous insertion
of a gastrostomy button and avoids a second procedure.
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The selective use of creon 40 000 in a specialist adult cystic fibrosis
unit
R. Hartley, H. Watson, C.S. Haworth, D. Bilton
Adult CF Centre, Papworth Hospital, Cambridge, United Kingdom
In pancreatic insufficient patients, adequate pancreatic enzyme replacement therapy
(PERT) is necessary to avoid high faecal energy losses. Despite recommendations
of an upper limit of 10 000 units lipaseykgybody weight (CSM 1995), some adult
patients exceeding this dose continue to display symptoms of steatorrhoea. Creon
40 000 was commenced in strictly selected patients taking high doses of Creon
25 000, who reported symptoms of malabsorption and had a positive faecal fat
microscopy despite receiving maximal antacid therapy. An equivalent lipase dose
was initially started and once dose had been established, patients were recommended
to reduce the number capsules to determine at which point steatorrhoea returned
and therefore the optimal dose of PERT. A baseline and 6 month review question-
naire were completed. Since November 2002, nine patients have changed to Creon
40 000 All patients’ bowel symptoms improved on Creon 40 000. Fat microscopy
is being monitored. Comments received from patients on the new preparation were
all positive. Six out of 9 patients have reduced the overall units of lipaseykg body
weightyday. This could indicate improved mixing properties and efficacy of Creon
40 000. Three out 9 patients have increased the overall units of lipaseykg body
weightyday. There have been no adverse reactions to Creon 40 000 at 6 month
follow up.
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The ultrasound characterisation and long term evaluation of cystic
fibrosis liver disease (CFLD): preliminary results of work in progress
L. Stewart, H. Alton, I. Van Mourik, M. Desai, J. Clarke, P. Weller
Birmingham Children’s Hospital, Birmingham, United Kingdom
Introduction: CFLD has a long latent period before symptomatic presentation.
Despite much research there is currently no single proven test available to facilitate
the earlier detection of CFLD. Aim: To characterise the longitudinal ultrasound (US)
appearances of CFLD in order to devise an objective evaluation tool for the earlier
diagnosis and long term monitoring of CFLD. Methods: 160 patients with known
CFLD had serial US scans over a 10 year period. The scans were assessed and
scored by a single observer according to a preliminary scoring system currently
under test. Results: There are 3 categories of US appearance in CFLD, with a range
of scores in each category. These will be discussed in detail. Detailed assessment
of the score range in each category may facilitate a more personalised approach to
clinical management of CFLD. Conclusions: US appearances must be correlated
against respiratory function, liver function, liver biopsy, nutritional status and clin-
ical examination in order to determine the true value of US when evaluating CFLD.
The validation of a simple, consistent and reproducible US scoring system should
encourage widespread routine use in the management of patients known to, or
suspected of having CFLD. It may also prove helpful as a screening tool for all CF
patients.
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Rapid fatal outcome of early liver disease in a young CF patient – case
report
L.L. Dracea , E. Fanciali , E. Ciofu , L. Petrescu , S. Buzinschi1 1 2 1 1
Children’s Hospital, Brasov, Romania, Emergency Children’s Hospital, Bucha-1 2
rest, Romania
Cystic fibrosis related liver disease (CFRLD), even clinically ill-defined, is an
important cause of morbidity and mortality. A 3 year old girl diagnosed with CF
(delta F505yR1162X) at birth who underwent surgery for MI was admitted with
abdominal pain and distension, intermittent constipation and poor appetite. She
underwent surgery at the age of 2 years for a suboclusive syndrome. Physical exam-
ination revealed pallor, no respiratory symptoms, soft stools and an enlarged abdo-
men with diffuse tenderness. Laboratory indicated a normal blood count and
chemistry, except for slightly increased liver aminotransferases (1.5 fold), increased
GGT, mild hepatomegaly on ultrasound with reduced ascites. She was started on
restrictive salt diet, UDCA and supplementary tube feeding along iv antibiotics.
She seemed to improve the following week, till a sudden deterioration with acute
renal failure, generalised oedema and increase of ascites. Intensive medical therapy
partially stopped massive gastro-oesophageal bleeding which developed the follow-
ing days. The abdominal CT scan revealed portal hypertension, massive ascites,
and extensive foci of liver fibrosis. Progression of ascites, which worsened her
respiratory status, led to death after 1 month from admission. Discussion: Even
known that CFRLD has a slow progression and a great variability in terms of
severity, we consider that the onset in this patient was very early and severe, leading
to rapid fatal outcome. The association of MI, severe mutations, extensive surgery
and poor weight gain during infancy may have had influenced the outcome. Early
identification of patients at risk for the development of CFRLD and close moni-
toring might allow the timely introduction of preventive measures.
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Liver cirrhosis in children with cystic fibrosis in Russia
T.J. Kapustina , N.J. Kashirskaia , N.I. Kapranov , M.N. Sukhov1 2 3 4
Russian State Medical University, Moskow, Russia, Research Centre for Medical1 2
Genetics, Moskow, Russia, Research Centre for Medical, Moskow, Russia, The3 4
Russian children’s clinical hospital, Moskow, Russia
Aim: to reveal features of the clinical and laboratory tests and to consider variants
of treatment liver cirrhosis at children with cystic fibrosis (CF).Results: among
observed in our CF-centre 585 children with CF 45(8%) suffer from liver cirrhosis
(age from 5 to 16.7 years, 26 males, 19 female). The mean age of CF diagnosis
was 6.8 years. The mean age of diagnosis liver cirrhosis (CFLC) was 8.6 years.
All patients have pancreatic insufficiency. 39% patients with CFLC are dF508
homozygotes and 17% heterozygotes for this mutation. Abnormal liver function
tests have 18% patients. On ultrasound we noticed small gall bladder (27%), hepa-
tomegaly (100%), increased echogenicity of liver parenhime (100%). 54% patients
with CFLC have portal hypertension with oesophageal varices. Age of diagnosis
portal hypertension was from 4.1 to 14.5 years. 33% patients with CFLC have
gastro-esophageal reflux, 55% gastroduodenitis. 5 patients have chronic liver failure.
Now all methods of treatment CFLC are only palliative. All our patients with CFLC
receive UDCA (20–30 mgykgyday) because of its choleretic and cytoprotective
effects. 30% of them for more than 10 years (1994–2004 years). At our CF-centre
to the patients with complications of portal hypertension were performed the fol-
lowing operations: 5 portacaval shunts and 1 partial splenectomy (4 patients are
alive today). 6 patients had their oesophageal varices sclerosed (all still alive).
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Ursodeoxycholic acid may protect cystic fibrosis patients from
developing cholelithiasis
M. Fotoulaki, M. Kouyoumtzidou, L. Gerakaris, S. Nousia-Arvanitakis
Aristotle University, Thessaloniki, Greece
A decline in the incidence of cholelithiasis has been reported in CF patients over
the past decade, probably, as a result of the improvement in the management of
malabsorption. The aim of this prospective study was to estimate the prevalence of
cholelithiasis in our CF population. Seventy-one CF individuals, ranging in age and
clinical scores from 1 to 38 and 45 to 97, respectively, were followed-up for a
period of 15 years. They all had adequate pancreatic enzyme replacement therapy
and well-controlled steatorrhea. Pancreatic sufficient patients were excluded. They
were divided into Group A: 29 CF patients (1.5 to 29, 18.68q7.85 years) receiving
ursodeoxycholic acid for focal or nodular biliary cirrhosis and Group B: 42 CF
patients (5 to 36, 16.28q8.11 years) having no liver disease, who received no
ursodeoxycholic acid. All patients were submitted to yearly hepatobiliary ultraso-
nography scoring liver parenchyma irregularities, gallbladder size and contents.
Evaluation included serum aminotransferases, gamma-glutamyltransferase, alkaline
phosphatase, albumin, bilirubin and prothrombin time. Six CF patients, 3 males and
3 females (5 to 20, 12.5q7.17 years) were found to have cholelithiasis. They all
belonged to Group B, who did not have liver involvement and received no urso-
deoxycholic acid. Conclusion: the etiology of cholelithiasis may be multifactorial.
In addition to the improvement of pancreatic replacement therapy, ursodeoxycholic
acid may have contributed to the decline in the occurrence of cholelithiasis in CF.
Further studies are needed to elucidate the possible protective role of ursodeoxy-
cholic acid.
274
The effect of cystic fibrosis liver involvement on mortality, lung
function and nutritional status in cystic fibrosis (CF) patients over 6
years
K.M. Giles , R. Scott-Jupp1 2
South and West Cystic Fibrosis Database, Bath, United Kingdom, Salisbury Dis-1 2
trict Hospital, Salisbury, United Kingdom
CF-related liver involvement (CFLI) occurs at a range of severities from subclinical
to severe disease requiring transplant. Prevalence studies have demonstrated a teen-
age peak and an excess of male cases. As patients age, prevalence falls. Possible
reasons include a cohort effect, differential recognitionydiagnosis, differential mor-
tality and true regression of disease. This study aims to test the differential mortality
hypothesis. CF patients in the south west of England have data collected prospec-
tively for a regional database. A cohort of patients was selected from this database
and classified as CFLIynon-CFLI using 1995y6 records: CFLI: oesophageal varices
present by 1y1y97, andyor referred for liver transplant by 1y1y97, andyor )s3
cm palpable liver; andyor palpable spleen. Non-CFLI: none of the above, and no
reported palpable enlargement of liver or spleen. Patients who did not fit in either
group were excluded from the cohort. Data for 490 patients were analysed, 63 with
CFLI and 427 without. Mortality within the two groups did not differ. Lung function
and heightyweight results were:
Mean FEV1% Mean BMI Mean Height Mean Weight
predicted (adult) Z-score Z-score
LD 72.8 20.7 y0.7 y0.7
Non-LD 72.9 21.4 y0.7 y0.5
Difference y0.08 (y1.34–1.49), y0.66 (0.09–1.24), y0.08 (y0.24–0.40), y0.15 (y0.18–0.49),
(95% CI) Ps0.92 Ps0.02 Ps0.63 Ps0.38
Indicators of pulmonary and nutritional status do not differ significantly between
the groups. We conclude that the fall in prevalence of CFLI in adults compared to
children is probably not the result of excess mortality either directly or in
consequence of increased severity of patients’ underlying CF.
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Fat malabsorption in CF mice reveals phenotypic differences between
DF508 mutants and knockouts
M.J.C. Bijvelds , H.J. Verkade , M. Sinaasappel , H.R. De Jonge1 3 2 1
Department of Biochemistry Erasmus MC, Rotterdam, Netherlands, Department1 2
of Pediatric Gastroenterology Erasmus MC, Rotterdam, Netherlands, Department3
of Pediatrics Academic Hospital Groningen, Groningen, Netherlands
Background & Aims: Fat malabsorption in cystic fibrosis (CF) patients is only
partially corrected by lipase supplementation, indicating that factors other than lip-
ase shortage limit fat absorption. We searched for such modulators of fat absorption
in CF mice. Methods: Fecal fat and bile salt excretion, lipolysis, fatty acid absorp-
tion, and biliary and pancreatic secretion were assessed in homozygous DF508 mice
and cftr null mice. Results: Both CF models showed enhanced fecal bile salt excre-
tion, but bile flow and total biliary bile salt output were unaffected. Fat excretion
was increased only in null mice. Although fat excretion was not enhanced in DF508
mice, the rate of plasma triglyceride accumulation after olive oil gavage was
reduced to a similar extent as in null mice. However, lipolytic capacity, assessed
by measuring triolein-derived lipid absorption relative to oleate uptake, was reduced
only in null mice. Lipase activity, chloride levels, and pH values of pancreatic
secretions were unaffected. Lipolytic activity was partially restored by suppression
of gastric acid. Conclusions: As pancreatic and biliary secretion are not impaired
in these CF mice, defective fat absorption could be studied in the absence of lipase
or bile salt deficiency. Absorption of fatty acids is delayed in both DF508 mice and
null mice, but only in the latter does protracted fatty acid uptake concur with defec-
tive lipolysis, leading to high fat loss. To our knowledge, this is the first study
documenting distinct effects of the CF condition (null mice vs. DF508 mutants) on
fat handling. Our data suggest that incomplete neutralization of gastric acid plays
a key role in fat malabsorption.
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Assessment of enzyme activity following nebulization with the eFlow
electronic nebulizer
M. Tservistas , R. Lichtinghagen , N. Boden , A. Schmitt , S. Seemann , M.1 2 3 1 1
Keller1
PARI GmbH, Munich, Germany, Medizinische Hochschule, Hannover, Germany,1 2
Roche GmbH, Grenzach, Germany3
Introduction: The eFlow is a novel inhaler whose nebulization efficiency was
found to exceed that of many conventional jet nebulizers. Its application for the
deilvery of Dornase alfa (DNase) for cystic fibrosis treatment is attractive, since
an increased delivered dose can result in an improvement of the therapy. A prereq-
uisite is the stability of the enzyme during nebulization. The aim of this study is
to determine the residual activity in Pulmozyme and compare it to the activities
obtained with conventional jet nebulizers and an ultrasonic nebulizer. Methods: 2.5
ml of DNase solution (Pulmozyme, Roche) were aerosolized using the nebulizers
eFlow, PARI LC PLUS, PARI LC STAR (PARI GmbH) and multisonic
infracontrol (Schill). The aerosol was collected and control samples were prepared
to account for activity loss due to aerosol trapping and storage. Enzyme activity
was determined by kinetic measurement of the reaction with a DNA-methyl green
substrate using an automated analysis system (Cobas Mira). Results: The residual
activities for the electronic inhaler eFlow as well as for the jet nebulizers LC
STAR and LC PLUS were between 80 and 90%. The highest activity value
was found for the eFlow (89%), but data obtained from the eFlow and the jet
nebulizers were similar within the variability of the experiment. The ultrasonic
nebulizer showed a residual activity of 59%. Conclusion: The eFow is suitable
for the application of DNase in cystic fibrosis treatment. The good safety profile
of Pulmozyme offers the potential to improve treatment by increased delivery
with a high-efficiency nebulizer.
Nutrition
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Weight and energy: parents’ and children’s perspectives on cystic
fibrosis diet
E. Savage, P. Callery
University College Cork, Cork, Ireland
Aim: The aim of this study was to explore school aged children’s and their parents’
perspectives on dietary management of cystic fibrosis (CF). Children’s dietary
intakes are consistently reported as falling short of nutritional requirements for a
high fat, high calorie diet for CF (Stark et al. 1995, Scott et al. 2003). The effect-
iveness of behavioural intervention programmes in managing feeding problems in
pre-school children has been investigated (Crist et al. 1994, Stark et al, 1994).
There has been less investigation of school aged children’s and parents’ experiences
of implementing dietary advice in CF. Methods: Data were collected by in-depth
interviews with 32 children with CF (aged 6 to 14 years) and their parents, and
participant observations during visits to CF clinics with a sub-group of 21 children.
Data were analysed using principles and procedures of grounded theory (Strauss
and Corbin, 1998) involving the constant comparative method and theoretical sam-
pling to further explore and develop emergent themes. Results: Priorities differed
between parents and children in managing diet. A priority for parents in feeding
was to protect their children’s long-term physical health and survival by keeping
their weight up. A challenge for parents was to gain their children’s co-operation
with eating because children did not always eat a high fat high calorie diet to
maintain weight gain. Children attached little meaning to weight gain as a goal of
dietary management. A priority for children in being healthy was to have energy
for activities and so energy rather than weight was of immediate relevance to their
daily lives. Conclusion: The findings highlight the need for health care professionals
to understand children’s and their parents’ perspectives because the meanings they
attach to food and eating can influence their decisions about implementing dietary
advice in CF.
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Pilot study to evaluate a home based behavioural nutrition education
programme for adults
H. Watson , H. Truby , C.S. Haworth , D. Bilton1 2 1 1
Adult CF Centre, Papworth Hospital, Cambridge, United Kingdom, University of1 2
Surrey, Guildford, United Kingdom
Meta analyses of nutrition intervention methods for weight gain in CF reveal behav-
ioural interventions to be as effective as more invasive methods. The aim of this
pilot study was to evaluate the effectiveness of a new nutrition education pro-
gramme, ‘Eat Well with CF, in improving measures of nutritional status, dietary
intake, and psychosocial factors, including the stages of change model (Prochaska,
DiClemente et al. 1992). 20 patients were randomised to the nutrition education
programme, or a control group, who receive standard dietary management. (10 in
the active group, 10 control). 9 patients completed the 10 week home based pro-
gramme, which included 3 half-day workshops, to explain the process, help with
motivation and answer specific questions. Following the intervention, the active
group showed significant changes in nutrition knowledge, 4.2 points (95% CI
1.4,7.0) and self-efficacy 8 points (95% CI 0.9–6.7), compared to baseline meas-
ures. There was also an increase in reported dietary fat intake, 6.7 points (95% CI
6,9.8). There was no change in general nutrition knowledge, weight or quality of
life. However it was possible to move subjects through stages of change, with 4
(44%) moving from pre-contemplation to action, and 1 (9%) from action to main-
tenance. The remaining 4 (44%) had not changed. These data provide evidence of
the value of this method of nutrition education; a large Randomized Controlled trial
is in progress.
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Relative validity of a food-frequency questionnaire to estimate energy
and fat intake in adolescents with Cystic Fibrosis
J.W. Woestenenk, N.M. de Roos, C.K. van der Ent, W.A. van Staveren
Cystic Fibrosis Center Utrecht, University Medical Center Utrecht, Utrecht,
Netherlands
Cystic Fibrosis is commonly associated with chronic undernutrition and therefor
evaluation of dietary intake is important. A 3-day dietary record (3-d-DR) is a valid
assessment method but it is time-consuming and burdensome for patient and die-
tician. We assessed the relative validity of a food frequency questionnaire (FFQ),
which might be a more acceptable alternative for the 3-d-DR. Eighteen adolescents
with CF (9my9f) aged 11–18 y, filled out both a 74-item FFQ and a 3-d-DR.
Pearson correlation coefficients for energy and fat were calculated. The estimates
obtained with the two methods were plotted according to Bland and Altman. Pear-
sons correlation coefficients were 0.88 (P-0.01) for energy intake and 0.89 (P-
0.01) for fat intake. The FFQ overestimated energy intake by 26"306 kcalyd
(1.6%"12.0%) and underestimated fat intake by 4.2"12.0 gyd (5.6%"11.9%)
compared to the 3-d-DR. These data indicate an good relative validity of the FFQ.
Thus, the FFQ can be used for measuring usual energy and fat intake in adolescents
with CF.
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Decreased Coenzyme Q10 concentration in plasma of children with
cystic fibrosis
A.L.Y. Lecluse , W.H.J. Vaes , R. VandenBerg , J. VanderLaag , R.J.H. Houwen ,1 2 2 1 1
J.H. Oudshoorn1
Wilhelmina Children’s Hospital, Utrecht, Netherlands, TNO Nutrition and Food1 2
Research, Zeist, Netherlands
Coenzyme Q10 (Q10) has an important function in protecting against oxidative
damage by regenerating alpha-tocopherol (vitamin E), the most important fat-sol-
uble antioxidant in humans w1x. Cystic fibrosis (CF) patients have a high demand
for antioxidants, due to the increased oxidative stress resulting from chronic pul-
monary inflammation. In addition, CF patients have low levels of fat-soluble vita-
mins, including alpha-tocopherol, as result of fat malabsorption. To obtain normal
serum levels these patients are routinely supplemented with vitamin E. Besides,
patients with CF have diminished maximal muscle force and work capacity due to
decreased efficiency of mitochondrial oxidative ATP synthesis. Q10 has its function
at this mitochondrial level w2x. Numerous studies have been devoted to vitamin E
in CF w3x, but so far none has addressed Q10 levels. Therefore the aim of the
present study was to assess the Q10 level in plasma of children with cystic fibrosis
and controls as well as alpha-tocopherol levels for comparison. Using a newly
developed HPLC method we measured plasma Q10 and alpha-tocopherol levels in
30 children with cystic fibrosis and 38 age-matched controls (mean age 12,3 years).
Total Q10 levels were significantly lower in the cystic fibrosis group compared to
the control group (resp. 0,82"0,41 mgyl and 1,32"0,39 mgyl, P-0,00001). No
significant differences were seen in the alpha-tocopherol levels. Conclusions: Our
findings show that total Coenzyme Q10 concentration is diminished in pediatric
cystic fibrosis patients, despite normal alpha-tocopherol levels. As suboptimal con-
centrations of Q10 will reduce the protection against oxidative damage these results
might provide a rationale for its supplementation.
1. Crane FL, Navas P. The diversity of coenzyme Q function. Molec Aspects Med
1997; 18S: s1–s6.
2. Meer de K, Gulmans VA, van Der Laag J. Peripheral muscle weakness and
exercise capacity in children with cystic fibrosis. Am J Respir Crit Care Med. 1999;
159(3): 748–54.
3. Winklhofer-Roob BM. Antioxidant status in cystic fibrosis patients. Am J Clin
Nutr. 1996 Jan; 63(1): 138–9.
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Alleviating antioxidant deficits in cystic fibrosis patients – can
innovative galenics provide a cure?
E.I. Back , C. Frindt , D. Nohr , M. Stern , H.K. Biesalski1 2 1 2 1
University of Hohenheim, Stuttgart, Germany, Children’s University Hospital,1 2
Tuebingen, Germany
Background: Conventional oral vitamin supplements are often not efficient in cor-
recting fat soluble vitamin deficits in cystic fibrosis patients as functioning fat diges-
tion is a prerequisite for the absorption of fat soluble vitamins. We thus developed
and tested a complementary balanced diet (CBD) in the form of vitaminised jelly
babies (micellised water-soluble a-tocopheryl acetate (100 IU) and b-carotene (2
mg), 400 mg crystalline vitamin C) in healthy adult volunteers. We assessed the
bioavailability of the CBD in comparison to supplements with ‘regular’ vitamins.
Methods: The trial consisted of three study days (d0: CBD sucked; d10: CBD
swallowed; d20: reference products swallowed). The volunteers had blood samples
drawn after fasting forG12 hours and then at 1, 5, 15, 30, 60, 120, 180, 240, 300,
320 minutes after ingesting the respective supplement. HPLC and a colorimetric
method were used for determination of fat soluble vitamins and vitamin C respec-
tively. Areas under the curve (AUC ) were calculated to assess bioavaila-0–320 min
bility. Results are given as median (min–max). Results: 14 healthy volunteers (6
my8 f), aged 26.8"3.8 years, BMI 24.3"3.7 kgym participated in the study. The2
AUCs of a-tocopherol and b-carotene from d0 were significantly larger (Ps0.016)
when compared to d20 (a-tocopherol: 20.1 (10.9–58.1) vs. 13.5 (6.9–30.6)
w(mmolyl)*hx; b-carotene: 20.5 (4.2–86.7) vs. 4.4 (0.38–25.0) w(mmolyl)*minx).
Discussion: Solubilized fat soluble vitamins from our CBD are obviously faster and
more easily absorbed than regular fat soluble vitamins—probably because they are
already micellised. The CBD will now be tested for its clinical efficacy in a ran-
domized double-blind controlled intervention trial with CF patients.
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Maximising nutritional support. Minimising dietary conflict
J.M. Barrett, Y. Bradburn, D. Honeybourne, D.E. Stableforth
West Midlands Adult CF Centre, Heartlands Hospital, Birmingham, United
Kingdom
Post transplantation renal failure can occur due to long term immunosuppressant
therapy in cystic fibrosis (CF). We have 5 patients (4 male) who have required
renal dialysis post heart–lung (ns3), heart–lung and liver (ns1), and second liver
transplantation (ns1) due to long term cyclosporin therapy. Haemodialysis (ns4)
or CAPD (ns1) commenced 8.5 mean years (3.6–14.25 years) after transplanta-
tion. Undernutrition is common in cystic fibrosis and renal failure, having both of1
these complex diseases increases the degree of undernutrition. Conflicting dietary
advice given by individual specialists can lead to patient confusion, poor dietary
management and may compromise nutritional status further. The dietary advice
given to patients with cystic fibrosis encourages high protein and high calorie foods,
a high intake of dairy products, salt added to food, additional salt supplements and
fat soluble vitamins. This contradicts the usual advice given to patients on renal
dialysis and the dietary changes required can be especially difficult for the CF
patient. Close liaison between specialist renal and CF dietitians is essential for the
successful management of the CF patient with renal failure. It allows the most
important aspects of the patients diet to be prioritised, minimises dietary restriction
and prevents conflicting advice being given to the patient. Increased liaison between
the specialities has improved renal and CF knowledge of the health care profes-
sionals. M. Sinaasappel, M. Stern, J. Littlewood, S. Wolfe, G. Steinkamp, H.G.M.1
Heijerman, E. Robberecht, G. Doring, Nutrition in patients with cystic fibrosis: a
European Consensus. Journal of Cystic Fibrosis 1(2002) 51–75.
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Recruitment of children to the CALICO trial of oral calorie supplements
for cystic fibrosis
V.J. Poustie , J.E. Russell , R.M. Watling , D. Ashby , R.L. Smyth1 1 2 3 1
University of Liverpool, Liverpool, United Kingdom, Royal Liverpool Children’s1 2
Hospital, Liverpool, United Kingdom, Queen Mary, University of London, London,3
United Kingdom
Introduction: The CALICO Trial is a multi-centre, randomised controlled trial of
calorie supplements for children with cystic fibrosis (CF), funded by the CF Trust.
It was designed to assess efficacy of supplements for improving growth & nutri-
tional status. The trial is ongoing, with results expected in October 2004. This
abstract discusses recruitment of children to the trial. Methods: Children requiring
dietary supplementation were recruited from 30 CF clinics. Anonymised data were
collected on eligible children who did not participate in the trial. Children who
found supplements palatable were randomised into the trial. Those children willing
to participate but who found supplements unpalatable were not randomised into the
trial. This report presents data on trial participants, those recruited but not random-
ised and those eligible but not recruited. Results: 165 eligible children were iden-
tified, of which 163 were invited to participate. 31 (group A) refused (reasons
included parental dissatisfaction with randomisation (8) and a dislike of supple-
ments (6)). 131 agreed to participate, of which 30 (group B) found the supplements
unpalatable at initial tasting. The remaining 102 (group C) were randomised into
the trial. Baseline characteristics of these children are provided in the table below.
Group Median age Maleyfemale BMI centile
(inter-quartile range) (standard deviation)
A (ns31) 10 yrs (6.3–12.3) 22y9 31 (25.7)
B (ns30) 10 yrs (6.6–12.2) 20y10 26 (19.9)
C (ns102) 9 yrs (5.7–12.1) 54y48 33 (24.7)
Conclusions: There were no significant differences in age or nutritional status
between the three groups eligible for recruitment to the CALICO trial. This suggests
that the findings of the trial will be generalisable to all children with CF who meet
the criteria for nutritional supplementation.
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Vitamin supplements in cystic fibrosis: assessing adherence of the
ADEK vitamin supplement in adults with CF
R.S. Chinuck
Nottingham City Hospital, Nottingham, United Kingdom
Background: Adherence to vitamin therapy in adult CF is as low as 40–55% (Ket-
tler et al 2002) For the past 5 years the ADEK tablet has been the most commonly
prescribed vitamin supplement amongst adult CF patients at Nottingham city Hos-
pital. It is a multi-vitamin preparation formulated specifically for CF patients.
Adherence to this therapy is not known. Aim: To assess adherence to the ADEK
vitamin supplement in adults with CF. Method: During 2003 a short questionnaire
was piloted on 5 adult CF patients at Nottingham City Hospital. During a 11 month
study period this questionnaire was then subsequently used within the Dietetic
Annual Assessment for the adults at the Nottingham City Hospital clinic. Both
qualitative and quantitative information was collected from 55 patients (30 male),
mean age 23.7 years (16–50 years). Results: 85% Response Rate. 56% of patients
reported not taking ADEK, 42% of patients were fully adherent, 17% of patients
who were adherent disliked the taste and the size of the tablet. The most common
reason for non-adherence: (a) Dislike of the taste, (b) Forgetting, (c) Tablets were
too big, (d) Dislike of the shape, (e) Delay in the prescription because the tablet
is named patient prescribed. Conclusion: There are some undesirable physical char-
acteristics of ADEK which may contribute to adult CF patients not taking the
ADEK vitamin supplement. Recommendation: From patient’s perspective a change
in the product characteristics of the ADEK tablet may improve adherence.
References
1. Kettler LJ, Sawyer SM, Winefield HR, Greville HW 2002. Determinants of
Cystic Fibrosis Adherence in Adults with Cystic Fibrosis. Thorax, 57, 5: 459–469.
2. Leonard CH, Ross-Wilson C, Smyth AR, Polnay J, Range SP, Knox AJ 1998.
Study of a Single High Potency Multi-Vitamin Preparation in the Management of
Cystic Fibrosis. J of Human Nutr and Dietetics, 11, 493–500.
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Vitamin C status in a Cystic Fibrosis paediatric population: any
correlation with the inflammatory parameters
A. Lezo , B. Santini , E. Bignamini , J. Baussano , T. Palmas , E. Montanari1 1 2 2 1 2
Department of Paediatric Sciences-Turin University, Turin, Italy, Cystic Fibrosis1 2
Centre of & quot;Regina Margherita & quot; Hospital, Turin, Italy
Introduction: There is a wide evidence of increased oxidative stress and inflam-
matory process in CF patients. The ascorbicydehydroascorbic acid status and pos-
sible correlations with clinical and haematological parameters of inflammation were
examined. Method: 32 CF patients attending the CF paediatric centre of Turin for
periodic control visit were randomly selected; mean age 119.5"65.4 months; 18
My14 F; 22y32 taking pancreatic enzymes and low-dose vitamin C supplementation
with multivitamin products. Results: Plasma dehydroascorbic acid concentrations
resulted significantly elevated (mean value 0.32"0.41 mgyl, Ps0.034, CI 95%
0.18–0.48) vs. local range of normality. The multiple regression analysis did not
evidence significant correlations between plasma ascorbic and dehydroascorbic con-
centrations with the WBC count, CRP value and the pulmonary function parameters
performed contemporarily. Plasma ascorbic acid concentrations resulted within the
normal range and correlated significantly with the oral vitamin C supplementation
doses (P-0.05) after normalisation for weight. The oral vitamin C supplementation
provided 20% of the total body pool (r2s0.2). Nutritional data revealed reduced
weight for age and height for age (P-0.02), mean Z-score respectively y
0.46"1.07 and y0.51"0.82. No differences were observed in plasma ascorbicy
dehydroascorbic concentrations between the two groups in presence or absence of
pancreatic insufficiency. Conclusion: our data suggest increased levels of ascorbic
acid oxidation in clinically stable CF patients. Further studies are need to validate
the correlation between vitamin C status, inflamation and oxidative stress in clini-
cally distinct cohorts during a long-term observation period.
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Low 25-hydroxy-vitamin D concentrations are common in children with
cystic fibrosis
C.J. Patchell, M. Desai, A. MacDonald, J. Clarke
Birmingham Children’s Hospital, Birmingham, United Kingdom
Background: It is generally accepted that children with CF require additional vita-
min A, D and E supplementation and that levels are monitored annually. In our
own clinic, it has been routine practice to give all patient 8000iu Vit A and 800iu
Vitamin D daily and to monitor vitamin A and E concentrations only. Individual
patient identification of high serum vitamin A concentrations, has led to a reduction
in their vitamin A supplementation by at least 50% in 38 patients. As vitamin A
and D are given together in the same supplement, a reduction in vitamin A will
automatically reduce the intake of vitamin D. Methods and results: The vitamin D
status of 89 subjects with CF with a median age of 8.75 yrs (range 0.6–17.38 yrs)
was determined. They were all white Caucasian children except 3 children of Asian
origin. 25-OH vitamin D (reference range 8–60 mgyl) and parathormone concen-
trations (PTH) (reference range 10–60 ngyl) were measured between the months
of December to May. The median 25-OH vitamin D concentration was 15.2 mgyl
(range 3.1–38 mgyl). 10.1% (ns9) had a concentration below the lower reference
range, and 44% (ns13)-15 ngyl. PTH concentrations were above upper reference
ranges in 10.1% (median 30; range 6.1–141). Vitamin D concentrations-15 mgy
l were significantly correlated with a rise in PTH (rsy0.283, Ps0.016). Conclu-
sions: We confirm that a lower reference range of 15 mgyl is appropriate to reduce
the risk of bone disease in CF. Consideration should be given to the use of separate
fat soluble vitamin supplements.
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An audit of the fat soluble vitamin status of an adult cystic fibrosis
population before and after changing to an all-in-one preparation
E.J. Franks
Ninewells Hospital, Dundee, United Kingdom
This audit was carried out to establish the presumed improvement in fat soluble
vitamin serum levels in CF patients when changing from vitamin A&D tablets and
Vitamin E capsules, to an all-in-one preparation. In Britain it is common practice
for all CF patients to be prescribed fat-soluble vitamins (Sinaasappel et al, 2002).
Evidence exists that many patients ‘‘forget’’ to take up to a half of their prescribed
medication (Borowitz et al, 1994). Published data has shown that serum fat soluble
vitamin levels improve when CF patients are prescribed ADEKs (Wilson et al,
2001), an all-in-one fat soluble vitamin preparation. Anecdotally many CF centres
have reported that patients find ADEKs easier to remember to take than their pre-
vious vitamin preparations as they only have to take 2 ADEKs once a day, and
therefore vitamin status should improve as intake increases. During 2003 the CF
Dietitian discussed the ADEKs product with all adult patients in Tayside attending
the Dundee CF clinic, each patient deciding whether or not they would like to try
these tablets, in place of their current Vitamin A&D and E preparations. If they
agreed to change, serum Vitamin levels were measured when the patient started
their ADEKs prescription and then 6 months after this change. Levels were recorded
as usual and any changes noted. Patients were also asked whether they tolerated
ADEKs, if they found it easier to remember to take, and if they took them more
often than their previous Vitamin preparations. Results to date show an improve-
ment in 70% of patients’ serum vitamin A, D & E levels and, other than 2 patients,
the remaining 20 who have changed prefer the ADEKs to their previous preparation.
The audit continues and will be completed in May 2004.
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Relationship between anthropological measurements and variables of
surviving in CF patients
H. Kayserova , L. Kadasi , E. Nescakova , S. Katina , M. Brezina , M.1 2 3 3 1
Berankova4
National Institute for TB and Respiratory Diseases, Bratislava, Slovakia, Institute1 2
of molecular Biology and Genetics, SAS, Bratislava, Slovakia, Commenius Uni-3
versity, Fac.of Biology, Bratislava, Slovakia, St. Cyril and Metod Hosp., Childrens4
Clin., Bratislava, Slovakia
The objective of this paper is to determine statistically the most important anthro-
pological variables (measures) in relationship to statistically significant variables
of surviving (Katina, Kayserova, 2002): genotype (with estimated risk for death:´
14.9 for 2 severe mutations), meconium illeus (4.1), ABPA (2.5), hyper IgG (1.2),
hypoalbuminaemia (5.9), CFRDM (2.3), rectal prolaps (2.2) and lung functions
(FEV1; estimated risk for each 1% change of predict. value is 5.5). By regular
anthropological examination in our CF patients 16 parameters are investigated. We
concluded that Waring index (WI) and circumferences of upper arm (ArmC), thigh
(ThC) and calf (CC) are the most important measurements in analysis of overall
status. Disease progression is accompanied with typical changes in shape of chest-
increased thoracic index (TI), chest circumference (ChC), decrease of ArmC, ThC
and CC. There where no significant important differences in body weight, height
and body mass index (BMI) according to surviving of CF patients. That is why
the complete anthropological examination has to be made regularly once a year.
Literature: Katina S., Kayserova H.,: Survival analysis of patients with CF in Slo-´
vakia. 23 Annual Conference of the International society for clinical biostatistics.rd
Abstracts book, p79; Dijon – France, September 9–13, 2002
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‘Peeling paint’, dermatitis as a presenting sign of cystic fibrosis(CF)
G.J. Canny, G. O’Regan, A. Irvine
Our Lady’s Hospital for Sick Children, Dublin, Ireland
A five-month-old male infant was referred for assessment of a rash. He was born
at term weighing 4 kg and was exclusively breast fed. His parents had declined
administration of postnatal vitamin K. He had a history of passing 5–8 unformed
greenish stools for the first six weeks of life, which then normalised. Laboratory
investigations at six and twelve weeks revealed normal liver function and full blood
counts. A rash appeared at 4 months of age, initially in the napkin area, and was
resistant to treatment with topical anti-fungal, antibacterial and steroid preparations.
At the time of presentation the rash was extensive, mostly around the mouth and
perineum. The marked eruption consisted of an erosive desquamating dermatitis
with classic ‘painted-on’ scale—the so-called ‘Peeling paint’ sign. Mucous mem-
branes, nails and hair were normal. He had generalised oedema. At 5.5 kgs his
weight had fallen to below the third centile. Laboratory abnormalities included
haemoglobin 7.3 gydl, albumin 1.2 gydl, total protein 2.8 gydl, ALT 93, AST
112iuyl. Vitamin A and Vitamin E levels were low. He had a profound coagulo-
pathy-PT 70.2 secs, APTT 57.8 secs, with marked deficiency of vitamin K depend-
ent clotting factors. Serum zinc levels were normal. Sweat Chloride was 93 mEqy
l and he was homozygous delta F 508 genotype, confirming CF. The rash was
nutritionally responsive and resolved within two weeks of commencing pancreatic
enzyme supplementation. ‘Peeling Paint’ dermatitis an extremely rare presentation
of CF, and is likely due to multiple nutritional deficiencies.
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Study of the effect on energy turnover and body composition in
patients with cystic fibrosis during intensified support by
physiotherapist and dietician
R. Olsson , A. Forslund , J. Stalhammar , M. Andersson , M. Johannesson1 1 2 2 2˚
Nutritional Unit, Dept.of Medical Science, Uppsala University Hospital, Uppsala,1
Sweden, Uppsala CF Center, Dept. of Women’s and Childrens Health, Uppsala2
University, Uppsala, Sweden
It is well known that patients with cystic fibros (CF) have increased energy demand.
This has to be taken into account when patients with CF are asked to do physical
exercise as part of their physiotherapy. For some CF patients with very high resting
energy expenditure, exercise might be detrimental as it further increases energy
demand which lead to a catabolic state. The aim of our pilot study was to see if
differences in energy turnover and body composition could be measured in CF
patients during intensified support by physiotherapist and dietician. Three patients
were followed over 4 months concerning energy turnover and body composition
during intensified support by physiotherapist and dietician. At times the intensified
support from the physiotherapist ment that the patient was not allowed to do phys-
ical exercise. As the patient improved in nutritional status, physical exercise was
restarted. Nutritional status was evaluated by: Body composition: by multicom-
partment model (skin caliper, bioimpedans analyser and dual energy x-ray absorp-
tiometry) and antropometry. Energy turnover; resting energy expenditure and
working capacity: by indirect calorimetry. Energy balance; total energy intake and
total energy expenditure: by 3 days food record, heart rate monitoring and activity
list. Our results indicate that intensified support by physiotherapist and dietician
affect energy turnover and body composition in a positive direction with improve-
ments in working capacity and nutritional status. Our study shows the importance
of an individualised physical exercise program in connection with dietary support
for each patient with CF.
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The relation between pseudomonas aeruginosa colonization stage and
nutritional status in patients with cystic fibrosis
S.F. Fustik, N.S. Slaveska, L.S. Spirevska, T.J. Jakovska
Clinical Center, Skopje, Macedonia, FYR
Pseudomonas aeruginosa (PA) is the most common pathogen causing chronic
infection in patients with cystic fibrosis (CF). The aim of the study was to define
the influence of chronic PA lung infection on nutritional status of patients with CF.
60 patients, regularly attended the CF centre at the Pediatric Clinic in Skopje, were
included in the study. Patients were divided according to the results of regular
sputum cultures into the three groups: group1 with chronic PA infection (ns9);
group2 with intermittent PA infection (ns26); and group3 free of PA infection
(ns25). Nutritional status was estimated using the anthropometric indexes such as
z score for weight (zW), z score for height (zH), z score for weight for height
(zWyH), and body mass index (BMI). Mean values of the anthropometric indexes
and standard deviation (in parenthesis) of three studied groups of CF patients were
respectively: zWsy1.72("0.62), y0.96("1.49), y0.53("1.07); zHsy
1.02("0.87), y0.59("1.49), y0.53("1.13); zWyHsy0.50("1.34), y
0.50("1.01), y0.20("1.09); and BMIs16.06("2.10), 17.1("1.1.85),
18.14("3.34). Besides lower mean values of all anthropometric indexes in group
with chronic PA infection, only zW score was significantly lower in first group in
comparison with second and third group (P-0.05). No significant difference in
anthropometric indexes was found between second and third group. In conclusion,
the results from the study suggest the deleterious effects the chronic infection and
chronic inflammation has on nutritional status of patients with CF. Since chronic
PA infection is associated with worse prognosis, one of the priority of CF treatment
is to prevent or to delay the onset of chronic PA infection.
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Change in nutritional status of children with Cystic Fibrosis in Moscow
over a ten year period
R.M.G. Wellesley , A. Rider , N.J. Kashirskaya , N.I. Kapranov2 2 1 1
Research Centre for Medical Genetics RAMS, Moscow, Russia, University College1 2
London Medical School, London, United Kingdom
Introduction: The study was to follow up the introduction in 1993 of Pancreatic
enzymes into the treatment regimen of the Muscovite CF patients (Southamptony
Moscow collaboration) w1x. Nutritional status had been examined prior to the pan-
creatic enzyme introduction (1993), and one year thereafter (1994) but no follow
up data had since been obtained. Method: The data (weight, height, sex and age)
was collected from all the current patients. A total of 75 Muscovite patients (2
months–18 yrs) had their weightyheight% calculated. Results: The comparison of
the mean weightyheight% in 2003 (mean 92.3% S.E. 1.41) with 1993 (mean
85.7%, S.E. 1.53) results in a P value of 0.0033 indicating considerable improve-
ment in physical status of the average patient. There is some evidence to suggest
an improvement since 1994 but it does not reach the standard 5% critical value.
Graphs splitting the data into age groups show that the most impressive improve-
ment in weightyheight% since 1994 is in the cohort of patients)10 yrs. This is
backed by the increased life expectancy (25.2 yrs in 2003 vs. 14.1 yrs in 1993)
and the number of transfers made to the Moscow Adult Clinic. Currently this stands
at 4–5 referrals p.a. (with a total of 30 patients). This may reflect the benefits of
long term pancreatic enzyme replacement therapy and the effect of a broader diet
on the nutritional health of the patient. Furthermore since 1999 the patients receive
all their medications free. Other changes include regular four times yearly outpatient
visits and treatment of some lung exacerbations with home iv. antibiotic therapy.
Conclusion: This increase in the nutritional status of the Muscovite CF patients has
multiple aetiologies but reflects an encouraging trend. w1. J R Soc Med 1996; 89
(Suppl. 27):48–50x
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Energy intake, body composition and pulmonary function in cystic
fibrosis
T. Moudiou, A. Galli-Tsinopoulou, P. Panagopoulou, S. Nousia-Arvanitakis
Aristotle University, Thessaloniki, Greece
Respiratory insufficiency may be associated with poor nutritional status. The aim
of this study was to investigate energy intake and body composition in relation to
lung function. Thirty CF individuals (9 to 34, 19.98"1.0 years) were examined.
Energy intake (Nutribase software analysis) was 2558.91"120.57 kcalyday. The
difference from the RDA requirements was 5.21"4.59%. The proportion derived
from fat, carbohydrates and proteins was 36.5"0.75, 46.26"0.74 and
15.7"0.33%, respectively. Bioelectrical impedance analysis demonstrated body fat
19.24"1.3, water 59.5"0.98 and lean mass 81.7"3.1%. Body fat correlated with
triceps (rs0.49, P-0.006), biceps (rs0.59, P-0.001) and subscapular skin fold
(rs0.78, P-0.0001). FEV1 had negative correlation with the intake of energy
(rsy0.53, P-0.0001), lipids (rsy0.52, P-0.0001), carbohydrates (rsy0.52,
P-0.0001), proteins (rsy0.56, P-0.0001) and% body lean mass (rsy0.45,
P-0.003). FEV1 had positive correlation with% body fat (rs0.63, P-0.004) and
Shwachman score (rs0.739, P-0.0001). Shwachman score also had negative cor-
relation with the intake of energy (rsy0.41, P-0.007), lipids (rsy0.46, P-
0.002), carbohydrates (rsy0.4, P-0.008), proteins (rsy0.429, P-0.004)
and% body lean mass (rsy0.298, P-0.04) and positive correlation with body
fat (rs0.32, P-0.03). It is concluded that energy intake of CF patients barely
reaches normal requirements. Due to variable energy needs, patients in good clinical
condition consume less as opposed to those in poor clinical status, who may have
increased requirements. Nutritional status, indicated by the proportion of body fat,
affects both lung function and clinical condition.
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Baseline characteristics of children participating in the CALICO trial of
oral calorie supplements for cystic fibrosis
V.J. Poustie , J.E. Russell , R.M. Watling , D. Ashby , R.L. Smyth1 1 2 3 1
University of Liverpool, Liverpool, United Kingdom, Royal Liverpool Children’s1 2
Hospital, Liverpool, United Kingdom, Queen Mary, University of London, London,3
United Kingdom
Introduction: The CALICO Trial is a multi-centre, randomised controlled trial of
calorie supplements for children with cystic fibrosis (CF), funded by the CF Trust.
The trial is designed to assess efficacy of supplements for improving growth and
nutritional status. The trial is ongoing, with results expected in October 2004. This
report presents baseline characteristics of children participating in the trial.Methods:
Children who required dietary supplementation were recruited from 30 UK CF
clinics. 102 of these were randomised to receive calorie supplements with dietetic
advice (treatment group) or dietetic advice alone (control group), for one year.
Anthropometric, nutritional & respiratory outcomes were assessed at baseline, 3, 6
& 12 months. Final results will be presented as mean difference in change in out-
come over 12 months between groups. In this report, relationships between dietary
intake, nutritional status, & respiratory function at baseline are explored. Results:
The median age of the 102 children (54 male) was 9 years (range 2–16), and mean
FEV (% predicted) was 66% (standard deviation 31.9). Mean weight, height &1
BMI centiles were 25th (S.D. 21.7), 27th (S.D. 25.7) & 33 rd (S.D. 24.7) respec-
tively. No associations were found between dietary intake and either nutritional
status or respiratory function. However, there was a weak association between BMI
z score and FEV (%predicted) (Pearson’s correlation coefficient 0.27, P-0.05).1
Conclusions: Analysis of the baseline characteristics of the CALICO trial provides
further evidence that poor respiratory function is associated with sub-optimal nutri-
tional status. However, in this patient group, dietary intake was not associated with
either nutritional status or respiratory function.
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Lung function and body composition in 8 to 12 year-old children with
cystic fibrosis
C. Benden , A. Jaffe , J.E. Williams , C. Wilson , N.J. Fuller , J.C.K. Wells , M.S.1 1 2 2 2 2
Fewtrell2
Portex Respiratory Medicine Unit, Great Ormond Street Hospital for Children,1
London, United Kingdom, MRC Childhood Nutrition Research Centre, London,2
United Kingdom
Background: Although lung function (LF) in children with cystic fibrosis (CF) is
known to be related to their nutritional status, particularly body fat, the latter has
usually been assumed from anthropometric measurements and not measured using
an appropriate reference method. Methods: LF was assessed in twenty-six pre-
pubertal CF subjects, aged 8 to 12 years, using forced expiratory volume (FEV1%
predicted) and a chest radiograph scoring system (Chrispin-Norman Score (CNS)).
Body composition was measured using a reference four-component model . Strength1
of relationship was assessed using Pearson’s correlation coefficient (r). Results:
Body fat (as kg, %fat and fat mass index (fat massyht )) was strongly positively2
related to FEV1 (rs0.47 to 0.51) and strongly negatively related to CNS (rsy
0.48 to y0.52). Although fat free mass (FFM) was not significantly related to
either FEV1 or CNS, hydration fraction of FFM was positively related to FEV1
(rs0.62) and negatively to CNS (rsy0.82). Bone mass was not related to lung
function. All given correlations were statistically significant (P-0.05). Conclusion:
Our results confirm that body fat, but not FFM or bone mass, are related to the
severity of impaired LF in these CF subjects. This preliminary study also suggests
that impaired LF is associated with lower hydration status of the FFM. The clinical
implication of this finding requires further evaluation. Fuller NJ et al. Four-com-1
ponent model for the assessment of body composition in humans: comparison with
alternative methods and evaluation of the density and hydration of fat-free mass.
Clin Sci 1992; 82: 687-93
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Impaired growth velocity in patients with CF is not influenced by Liver
Transplantation
C.J. Patchell, M. Desai, A. MacDonald, I. Van Mourik, J. Clarke
Birmingham Children’s Hospital, Birmingham, United Kingdom
CF related liver disease (CFLD) is a significant cause of morbidity and mortality.
It affects 20%–30% of patients. Of these 5% will require liver transplantation
(OLT). There is little documented about the long-term growth of CF patients post
OLT. Aim: To assess the nutritional status of CF patients requiring OLT up to 24
months post transplant. Methods: Sequential height and weight standard deviation
scores (SDS) were determined pre and post OLT. Main indications for OLT included
hypersplenism and GI bleeding, and worsening nutritional status. Results: The medi-
an age at OLT was 11.52 y (range 2–16.5 y). 8 subjects had CF related diabetes
prior to OLT, and 2 developed an insulin requirement post OLT but this later
resolved, 8 required enteral feeding pre transplant, and 2 were able to stop post
transplant. Pre and Post OLT Height and Weight SDS
Median Pre OLT–6 At OLT Post OLTq12 Post OLTq24
(range) month ns16 ns17 month ns17 month ns12
Weight SDS y0.76 (y1.83 to 1.35) y0.45 (y2.15 to 1.21) y1.1 (y2.96 to 0.43) y0.9 (y4.09 to 0.62)
Height SDS y1.45 (y2.66 to 1.23) y1.33 (y3.18 to 0.96) y1.62 (y3.69 to 0.96) y1.37 (y3.96 toy0.66)
Conclusions: In contrast to OLT for other conditions, there was no improvement in
nutritional status, possibly due to ongoing anorexia and lung disease. Nutritional
Support in CF after OLT remains essential and should be made explicit to candidates
when being assessed. Confounding factors such as change in body fluid retention,
the onset of Diabetes and the role of systemic immunosuppression need further
elucidation.
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Increased resting energy expenditure in CF patients correlated to
genotype but not to gender
K. Nilsson, S. Stalberg, S. Salomonsson, L. Hjelte˚
Stockholm CF center, Karolinska Institutet, Karolinska Univ hospital, Huddinge,
Stockholm, Sweden
Previous studies have shown increased resting energy expenditure (REE) in patients
with CF. It remains unclear which factors are most important for the increased REE.
Aim of the study was to evaluate the results from measurements of REE in ado-
lescent and adult patients at Stockholm CF center in relation to parameters that
might affect REE. REE was measured by open circuit indirect calorimetry using a
Vmax 29n Calorimeter (Sensor Medics Corporation, Yorba Linda, California) in
clinically stable CF patients with no overt signs of infection. Measurements were
completed in the morning after 12 h of fasting. Subjects were measured for approx-
imately 40 min. Fluctuations from steady state were edited out. REE was related
to sex, genotype, bacterial colonization, pulmonary function, BMI, IgG, and essen-
tial fatty acids in s-phospholipids (s-PL). Patients: 41 subjects (maless21), median
18.0 (range 11–38) years, 20 homozygous and 13 heterozygous for DF , 38 were508
pancreatic insufficient, 25 colonized with P aeruginosa, BMI mean 21 (in
thoseG18 yrs), FEV1: mean 78%, FVC: mean 93% predicted. Mean LA: 17, AA:
8, EPA: 0.7, DHA: 2 mole%. Mean REE was increased compared to predicted
values, approximately 11% (Harris–Benedict equation) (P-0.0001). There was no
difference between the sexes. Carriers of DF had a significant increased REE508
compared to those with other mutations (P-0.05). There were no correlations
between REE and pulmonary function, bacterial colonization, BMI nor IgG. A weak
positive correlation between REE and EPA in s-PL was seen (Ps0.042). REE was
increased in the patients studied, especially in carriers for DF . The positive cor-508
relation between REE and EPA in s-PL needs further investigation. No other cor-
relations were found.
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Evaluation of educational program for teaching staff of cystic fibrosis
(CF) patients
A. Van de Sompel, E. Cooreman, C. De Smet, A. Deprettere, M. Lequesne, K.
Desager
University Hospital Antwerp, Pediatrics, Antwerp, Belgium
School plays an important role in the education of children. The aim of this study
was to inform the teaching staff of CF patients about CF disease and test their
knowledge, especially on gastro-intestinal (GI) and nutritional aspects. From may
2002 until may 2003, schools of 20 patients (mean age: 8.2"4.6 years) were
visited. A trained nurse and dietician informed the teaching staff, using slides. Each
teacher was asked to fill out the same questionnaire, before and after the presen-
tation. Questions were grouped to report results on main issues. In total 90 ques-
tionnaires were filled out, 70 were acceptable. Before the presentation 67% knew
that CF is a chronic respiratory disease, but the frequent association with pancreatic
malfunction was known in 8% before and 77% after education. Nearly half recog-
nised diarrhoea as a symptom before, and 89% afterwards. On the issue that general
principles of healthy food are not applicable, 33% agreed before and 82% after
presentation. The knowledge on the increased requirements for fat grew from 17%
before to 76%, and for sodium from 37% to 93%. Only 14% recognised the impor-
tance of a snack, rich on calories before, and after education 94%. This is an
important result since snacks are used during school time. The knowledge of correct
use of pancreatic enzymes improved with 13% (3% before–16% after). Only 4%
of the teachers obtained)70% of correct answers, whereas after the presentation it
was 74%. All differences were statistically significant (P-0.001). In conclusion:
Efforts towards the education of the teaching staff of patients enhances their knowl-
edge on GI and nutritional aspects of CF. This will result in a better understanding
of, and the support towards, our patients.
302*
Normal bone mineral density in Swedish young men with cystic fibrosis
E. Gronowitz, B. Strandvik , M. Lorentzon, C. Ohlsson, D. Mellstrom¨
Dept of Pediatrics, Dept of Internal Medicine, Dept of Geriatrics, Sahlgrenska1 2 3
Academy, Goteborg University, Goteborg, Sweden¨ ¨
Decreased bone mineral density (BMD) is common in patients with cystic fibrosis
(CF), and we have previously found a decreased BMD in 35% of our normal
growing patients with CF but a normal annual increase of BMD. In this study we
have investigated cortical and trabeculare bone in relation to diet in young adult
men with CF and compared with age- and sex matched healthy men. Fourteen men
with CF, aged (mean (SD)) 21.6 (2.2) and 42 healthy controls aged 19.5 (0.2)
were included. The study was performed with dual energy X-ray absorptiometry
(DXA, Lunar Prodigy) and computerized tomography at 4 and 25% of bone length
(Stratec XCT 2000 at), and the nutrition data was obtained by a questionnaire.
Eleven of the CF patients were pancreatic insufficient, ten were homozygous for
dF508 and three compound heterozygous of the same mutation. One patient had
one unknown mutation. FVC and FEV were 103(22)% and 94(24)% of predicted1.0
in the CF patients, respectively. Mean (S.D.) for weight (kg), height (cm) and BMI
(kgym2) in the CF patients were 70.6(10.5), 181.1(5.5), 21.5 (2.9) and for controls
73.6(11.1), 181.7(6.5) and 22.3(2.7), respectively. There were no significant dif-
ferences between the two groups and neither for lean body mass or fat mass. Total
bone mineral content (BMC) and BMD and lumbar and femoral BMD did not
differ. In the radius cortical BMC and BMD and peri- and endostal circumpherences
did not differ but there was a tendency to difference in tibial BMD (Ps0.04),
which disappeared after correction for age and weight. The CF patients consumed
more vitamin supplementation and more diary products than the controls. Conclu-
sion: Young men with CF and with normal anthropometric data had normal cortical
and trabeculare bone mass.
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Oral etidronate therapy of bone mineralization disturbances in patients
with cystic fibrosis
B. Ringuier , B. Leboucher , M. Leblanc , F. Troussier , E. Duveau , M. Audran ,1 1 1 1 1 2
J.L. Ginies1`
Departement de Pediatrie CHU, Angers, France, Service de Rhumatologie CHU,1 2´ ´
Angers, France
Disturbances in bone mineralization are frequent in cystic fibrosis but little work
has focused on the use of biphosphonates in this indication, and none on the use
of oral etidronate. We report our experience using this latter treatment. The study
was retrospective and included 5 children and 3 adults with cystic fibrosis (6 males
and 2 females) and ages ranging from 7 to 30 years and Z-scores for lumbar bone
density lower than y2 S.D. after 1 year of calcium (1 gyd) and vitamin D (900
UIyd and 300 000 UIy6 m) supplementation. All were treated for 1 year with
etidronate: 4 courses of 15 days (1 course per trimester) with doses ranging from
4 to 8 mgykgyd. Calcium and vitamin D supplementation was continued between
the etidronate treatment course. Total body and lumbar bone mineral density were
measured 3 times: at the beginning and the end of the year of calcium and vitamin
D supplementation and at the end of the year of supplementation plus the 4 courses
of etidronate treatment. The increase in bone mineral density in absolute value (gy
cm ) and in Z-score was significantly higher (P-0.05) after the year of combined2
supplementation and etidronate treatment (total body gycm : 3"1%, Z-score:2
2"1% and lumbar spine gycm : 6"5%, Z-score: 3"4%) than after supplemen-2
tation alone (total body gycm : y1"3%, Z-score: y4"3% and lumbar spine gy2
cm : y1"3%, Z-score:y4"4%). None of the patients presented with side effects2
that could be attributed to the treatment. Oral etidronate treatment is well-tolerated
and capable of improving bone mineralization in patients with cystic fibrosis. Fur-
ther work will be necessary to determine the optimal dosage and the optimal fre-
quency for the treatment series.
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Describing the relationship between HbA1c and mean plasma glucose
in people with cystic fibrosis
A.L. Brennan , M.E. Hodson , D.M. Geddes , K.M. Gyi , E.H. Baker1, 2 2 2 2 1
St George’s Hospital Medical School, London, United Kingdom, Royal Brompton1 2
Hospital, London, United Kingdom
Background: Glycosylated haemoglobin (HbA1c) is the standard method for assess-
ing long term glycaemic control in diabetes mellitus (DM). In type 1 DM a 1.98
mM increase in mean 24 hour plasma glucose (MPG) is associated with an increase
of 1% in HbA1c wRohlfing CL 2003x. However as red cell turnover may be
increased in people with CF wFarrell PM 1977, Wagener J 1983, Moran A 1999x,
it is not known whether HbA1c is as accurate a measure of glycaemic control in
cystic fibrosis-related diabetes (CFRD). Methods: 10 people with CFRD underwent
measurement of MPG using a continuous glucose monitoring system (CGMS). A
glucose sensor placed subcutaneously measured interstitial glucose every 10 sec-
onds, recording an averaged reading every 5 minutes. The monitor was calibrated
G3 times daily to blood glucose values obtained by capillary sampling. 24 hour
mean sensor glucose and area under the curve (AUC) were calculated using CGMS
software and sensor glucose values were converted to MPG by adding 11%. HbA1c
was measured in venous samples taken on the first day of monitoring. Results:
HbA1c was strongly correlated with MPG (rs0.814, Ps0.002) and AUC (rs
0.837, Ps0.001). A 1.3 mM change in mean plasma glucose was associated with
an increase in HbA1c of 1%. Conclusion: HbA1c is strongly correlated with 24
hour MPG and AUC in people with CFRD. HbA1c therefore appears to be as good
at determining glycaemic control in people with CFRD as it is in people with type
1 and type 2 diabetes mellitus. Only about 10% of HbA1C is determined by red
blood cells surviving 80–120 days wTahara Y 1993, Goldstein D 1993x. Increased
red cell turnover therefore does not seem to impair the usefulness of HbA1c in
monitoring long term glucose control in patients with CFRD.
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Contribution of serum Insulin-like Growth Factor (IGF) binding protein-
3 and IGF-I levels for the management of patients with cystic fibrosis
D. Caldari , B. Leboucher , M. Leblanc , F. Troussier , R. Coutant , F. Boux de1 1 1 1 1
Casson , J.L. Ginies2 1`
Departement de Pediatrie CHU, Angers, France, Laboratoire de Medecine1 2´ ´ ´
Nucleaire, Angers, France´
In cystic fibrosis, nutritional management improves survival. IGF-I is a sensitive
marker of nutritional status. The aim of this study was to evaluate the variations of
IGF-I and IGFBP-3 in cystic fibrosis according to the chronologic age, the bone
age and the stage of pubertal development, and to seek a relationship between
nutritional status, development of the disease and IGF-I and IGFBP-3 levels. Serum
concentrations of IGF-I and IGFBP-3 were measured in 53 patients with cystic
fibrosis (26 females, 27 males; mean age 11.8"7.6 years) each year between 1996
and 2001. These data were analysed with respect to nutritional status as assessed
by BMI, weight for height (WyH) and height for age (HyA) Z-scores, and the
development of the disease as assessed by Shwachman score and FEV . BMI, Wy1
H, HyA Z scores were respectively lowered toy0.83,y0.8,y0.58. IGF-I Z score
calculated according to the sex, the age and the pubertal development was normal,
Z score of IGFBP-3 calculated according to the age and the sex was reduced to y
1.64. By simple linear regression IGF-I Z score was correlated with BMI, WyH Z
scores and with Shwachman score. By multiple linear regression it remained cor-
related with WyH Z score. IGFBP-3 Z score was correlated only with HyA Z score.
Patients who had IGF-I Z score-y0.5 were in worse nutritional status, and had a
Shwachman score and IGFBP-3 Z score reduced, but were not older. The variation
of IGF-I Z score over one year was associated with WyH variation of the same
year and HyA variation of the following year. In cystic fibrosis IGF-I could have
a direct action on the level of growth. Its measure could be used as prognostic
factor, a reduced concentration having to result in intensifying the treatment, and
to be an additional argument to treat in certain cases subjects with cystic fibrosis
by growth hormone.
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Sex distribution and nutritional state at onset of Cystic Fibrosis related
Diabetes (CFRD): results of an European Prospective Multicenter
Study
R. Holl , C. Mueller-Brandes , M. Nastoll , M. Ballmann1 2 1 1
University, Ulm, Germany, Medical School, Hannover, Germany1 2
The factors effecting the onset of CFRD are still not entirely clear. Female gender
has been discussed as a risk factor for the onset of CFRD. Up to now data are
often based on different diagnostic criteria as well as on small cohorts or retro-
spective analysis combining data from many years. As part of a prospective study,
an annual oral glucose tolerance test (OGTT) was conducted as a screening test in
order to identify patients (G10 years) with CFRD. As an age-independent param-
eter of nutritional status we used body-mass-index (BMI)-Z-scores. Up to now 1734
OGTT from 1099 patients (53% males, 47% females aged 10–64 years, median
age 17 years with no age difference between males and females) were available for
analysis. If the first OGT-test for each patient was evaluated, 100 patients (9.1%)
showed a diabetic glucose profile. Lifetable analysis revealed an earlier onset of
CFRD in female patients (ns53, median age 18.5 years compared to 19.9 years
in male patients (ns47), P-0.05). The nutritional status, as reflected by BMI, did
not differ between male and female subjects, neither in the whole population nor
in the group with CFRD. In the subgroup of CF-patients aged 15–20 years, female
patients (ns129) had even a better nutritional status compared to the male patients
(Ns157) (BMI-Z-scores"S.D.: y0.56"1.01 versus y0.97"1.27, P-0.005).
For patients with CFRD, a significant sex-difference for BMI was present only in
the age-group 20–25 years—again with higher BMI-values in female patients (7
patients, y0.63"0.45 versus y1.55"1.41). In Conclusion, female patients tend
to develop CFRD earlier than males—especially in the age group 25–35 years.
However, the nutritional status in female patients is the same or even better com-
pared to male CF-patients.
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Does diabetes mellitus andyor liver cirrhosis influence the nutritional
status of cystic fibrosis patients?
B. Hauser, J. De Schepper, A. Hansaert, K. De Langhe, A. Malfroot, Y. Vandenplas
AZ-VUB Department of Paediatrics, Brussels, Belgium
Introduction: Cystic fibrosis (CF) is a multi-systemic disease initially characterised
by exocrine pancreatic insufficiency and chronic respiratory tract infections. Dia-
betes mellitus and liver cirrhosis can develop later. A good nutritional status of CF-
patients contributes to a better survival. Few studies with contradictory results were
performed concerning the nutritional status of CF-patients with diabetes mellitus or
liver cirrhosis. Aim of the study: Compare the nutritional status of CF-patients with
or without liver cirrhosis (clinical, laboratory and ultrasonography findings com-
patible with liver cirrhosis) and with or without diabetes mellitus (fasting glycaemia
)126 mgydl andyor glycaemia)200 mgydl 2 hours after an oral glucose tolerance
test). Methods: Retrospective analysis of anthropometric parameters, laboratory
nutritional parameters, and bone mineral density in 69 CF-patients. Results: In com-
parison with CF-patients without liver cirrhosis, CF-patients with liver cirrhosis
have a comparable nutritional intake and pancreatic enzyme replacement therapy,
but show a trend towards a lower weight (y1 S.D.), height (y1 S.D.), body mass
index, arm circumference and skin-fold thickness. Albumin, cholesterol, protrombin
time, somatomedine C, vitamin A and bone mineral density are significantly lower.
In comparison with CF-patients without diabetes mellitus, CF-patients with diabetes
mellitus adequately treated with insulin show no significant difference in anthro-
pometric parameters, laboratory nutritional parameters and bone mineral density.
Conclusions: Nutritional status is not altered by insulin treated diabetes mellitus,
but is slightly impaired in liver cirrhosis.
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Improving diagnosis and treatment of impaired glucose tolerance (IGT)
and Cystic Fibrosis related Diabetes (CFRD) in an adult Cystic Fibrosis
unit
S.L. Williams, F. King, D. Honeybourne, D. Stableforth
Birmingham Heartlands Hospital, Birmingham, United Kingdom
Annual Glucose tolerance testing (GTT) is carried out at our adult Cystic Fibrosis
(CF) centre. This has increased numbers of patients diagnosed with CFRD or IGT.
We are left with the dilemma of how to treat asymptomatic patients with no previous
history of hyperglycaemia. Successful management of CFRD and IGT requires an
individualised approach to advice. A joint CF diabetic clinic was established where
doctors, nurses and dietitians from both specialities assess patients. All Patients
diagnosed with CFRD or IGT were referred to this clinic. Prior to clinic attendance
they were advised to record a food diary with pre and post meal blood sugar levels
over a two week period. This diary was used to assess whether insulin was required
and help select the most appropriate regime for the patient. Since the clinic was
established 106 patients received GTTs; 21 were diagnosed with CFRD,10 were
treated with insulin. 33 were diagnosed with IGT, 5 were treated with insulin. All
patients received dietary advice. The remaining patients (11 diagnosed with CRDM
and 28 with IGT did not require any treatment). This multidisciplinary clinic has
improved patient care for CFRD .The use of a food and blood sugar diary gives a
true picture of daily blood sugar control enabling us to decide whether insulin is
required. If insulin is required the regime is tailored to their individual needs and
lifestyle. The presence of a diabetic team, has increased patient knowledge of dia-
betes, emphasised the importance of regular blood sugar monitoring and raised
awareness of insulin treatments and equipment available. We now have closer links
with the diabetic team and knowledge of Cystic fibrosis and Diabetes has improved
between health care professionals.
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Nutritional status in patients with or without CF related diabetes
mellitus
F.M. Hollander, N. de Roos
Cystic Fibrosis Center, Utrecht, Netherlands
Introduction: In 2002 an evidence-based Consensus Report was published on nutri-
tion in patients with cystic fibrosis (CF). Malnutrition is defined as having a body
mass index (BMI) -18.5 kgym , which is lower than for healthy adults (BMI-2
20). Risk factors are CF related diabetes mellitus (CFRD), pancreatic insufficiency
(PI) and a high energy requirement. Aim of the study: To investigate whether CFRD
and PI deteriorate nutritional status in our patient population. Subjects and Methods:
BMI and the prevalence of CFRD and PI were assessed in 42 out-clinic patients
aged 18–46 y (28 males). Dietary intake was estimated from a food frequency
questionnaire. Results: Mean BMI of all patients was 21.0 kgym (range 14.7–2
28.7). Mean energy intake was 14.3"5.8 MJyd, which was 114% of the estimated
average requirement (12.5 MJyd). Mean fat intake was 148"82 gyd or 39% of
energy. CFRD was found in 10 (24%) patients; PI in 39 (93%) patients. Patients
with CFRD all had PI and their mean BMI was 20.7 kgym (range 18.3–24.1).2
Their was a weak but not significant inverse association between BMI and energy
intake (rsy0.2, Ps0.22). Discussion: In our population CFRD and PI were not
associated with malnutrition. Malnutrition (BMI-18.5) was not associated with a
low energy intake but probably due to increased energy requirement caused by
chronic inflammation. Conclusion: We conclude that the majority of our study pop-
ulation has a normal nutritional status and an adequate dietary intake. In the future
the incidence of CFRD-related malnutrition should be investigated in a larger
population.
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Effects of enteral tube feeding on clinical and nutritional status in
adults with CF
A.M. Morton, H. White, D.G. Peckham, S.P. Conway
Seacroft Hospital, Leeds, United Kingdom
Enteral tube feeding (ETF) is often required to maintainyimprove nutritional status.
Patients may resist the initiation of ETF. The aim of the study was to determine if
nocturnal ETF in malnourished patients with CF improves nutritional status and
slows clinical decline. Patients aged 16q years attending for )1 year, with body
mass index (BMI) -19 kgym for)6 months were divided by acceptance of ETF2
(of )6 months duration) (TF) or non-acceptance (NTF). BMI, FEV , courses IV1
therapy, incidence CFRD, transplantation and death were collected at 1year pre, 0,
1, 2, 3 years post ETF. Data are available for 13 TF (4 male) and 19 NTF (11
male). Median age (TF) 20.9 years (range 18–34.8), (NTF) 20.5 years (17–32)
(NS). In the TF group median BMI at yr 0 was17.5 (14–18.5), NTF 17.8 (14.4–
18.8) (NS). Median BMI increased to 18.8 at 1 year (Mann Whit. P-0.01) and
)19 at year 2 and 3. The NTF group did not achieve BMI)19 or any change
over time. Cumulative survival at 1, 2, 3 years was 100, 92, 77%, (TF) and 95,
89, 79% (NTF) (NS). FEV at 1year pre 0, 1, 2, 3 years was 49, 36, 32, 29, 31%1
(TF) and 53, 47, 47, 43 and 43% (NTF). There was no significant difference in
mean FEV at onset or end of study but a sig. differences at yr 1 (diffs14.7 CI1
2.8 to 26.7 Ps0.017) and year 2 (diffs13.9 CI 0.75 to 27.1 Ps0.04).TF had
increased incidence of CFRD from year 0 (diff.s19.8% CI 19.4 to 20.2, P-0.01)
to year 3 (diff.s27%, CI 26.5 to 27.5, P-0.01) and greater number of courses
IVs at each time point compared to NTF (Mann Whit. P-0.01). Conclusion: ETF
significantly improves nutritional status in malnourished adults with CF. It contrib-
utes to stabilization of lung function despite greater disease severity and incidence
of CFRD in those who tube feed.
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Successful results of overnight supplementary feeding in cystic
fibrosis patients depend on psychosocial factors and compliance to
previous treatment
A.M. Olesen, H.V. Olesen, P.O. Schiotz
CF-center West, Aarhus University Hospital, Skejby Sygehus, Aarhus, Denmark
Starting from may 2001, 11 patients from the Cystic Fibrosis Centre West at Skejby
Hospital in Denmark received overnight supplementary feeding via percutaneous
endoscopic gastrostomy (PEG). By January 2004 time of feeding varies from 1
month to 2 years. All patients received a nutritionally complete elemental formula12
designed specifically for patients with CF (Emsogen; SHS). Emsogen is given
without pancreatic enzymes. Amount, volume and concentration was adjusted to
individual tolerance. Patients: Eleven patients with CF-2 males, 9 females; age
range 9–30 years. Three patients stopped the supplementary feeding during the
period. One died, one had a lung transplantation after having improved her nutri-
tional status and one changed to a social environment that made her able to have
a sufficient oral intake. Results: Eight of the patients improved their weight con-
siderably, were able to take part in more social activities and the children and
adolescents could be more active at school. The average weight gain was 854 g per
month (340–2650 g), the average total weight gain was 26% of the initial weight
(3–56%) and the BMI increased by one to five steps. Three of the patients, two
children and one adult, did not improve their weight considerably due to lack of
compliance and support from relatives. When considering the means of feeding a
malnourished CF patient, it is important to take into account the psychosocial factors
and compliance to previous treatment. It is our experience that support from rela-
tives is necessary, or the patient must be very motivated himself to have a successful
result of the supplementary feeding.
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Is pancreatic enzyme replacement therapy routinely indicated for
pancreatic insufficiency in cystic fibrosis?
J. Gavin, T. Hannan, G.J. Connett
Southampton University Hospital, Southampton, United Kingdom
Pancreatic enzyme replacement therapy (PERT) is routinely prescribed for cystic
fibrosis (CF) individuals with biochemical evidence of pancreatic insufficiency (PI)
causing significant fat malabsorption. We report two boys diagnosed with CF aged
5 years 2 months (Case 1) and 10 years 3 months (Case 2) and found to be PI
but who have been successfully managed without PERT for 1 year 9 months and
6 years 8 months. Both have maintained excellent nutritional status: 104% and
131% weight for height and mid arm circumferences between the 50–75 centileth
throughout this time. Case 1 presented with chronic cough and is heterozygous for
DeltaF508 and 1154insTC mutations with sweat Cl 119 mmolyl. Repeat faecal
elastases were below the lower limit of detection. Three day faecal fat analysis
revealed 39% fat content of stool and a coefficient of fat absorption of-95%. PERT
treatment was associated with symptoms suggestive of DIOS and a palpable faecal
mass in the right iliac fossa. Symptoms resolved after discontinuing PERT and have
not recurred after regular Omeprazole. Case 2 had been diagnosed as poorly con-
trolled asthma but was investigated for clubbing. He is homozygous for the V520F
mutation with sweat Cl 115 mmolyl. Faecal elastase was undetectable and there
was 30% fat content of a 3 day stool collection giving a coefficient of fat absorption
of-95%. Given his excellent nutritional status and lack of GI symptoms PERT
was not given. Both individuals have had low fat-soluble vitamin levels corrected
with supplements. Both describe their stools as normal passing only 1–2 per day.
PERT is not essential for all CF individuals with severe PI. Carefully selected
individuals can do well with appropriate dietary advice and correction of micro-
nutrient deficiencies alone.
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Long-chain polyinsaturated fatty acid modulate inflammatory response
to acute infection induced by Pseudomonas aeruginosa in mice
S. Auvin , F. Collet , F. Gottrand , M.O. Husson , X. Leroy , C. Beermann , D.1 2 1 3 4 5
Turck , B. Guery6 2
Gastroenterology, hepatology and nutition pediatric department, Lille, France, EA1 2
2689 Faculty of medecine, Lille, France, Bacteriology department, Lille, France,3
Anatomopathology department, Lille, France, Head of Lipids research Numico,4 5
Frederickdorff, Germany, Cystic fibrosis care center-Children’s hospital’, Lille,6
France
Objectives: Polyunsaturated fatty acids (PUFA) immuno-modulatory properties
have been extensively studied in chronic infections. However, few studies focused
on acute infection, we therefore decided to evaluate PUFA effects on inflammatory
response and lung physiology in a mice model of Pseudomonas aeruginosa (PA)
induced lung injury. Methods: C57 BLy6 mice were fed for 3 weeks with either an
eicosapentaenoic acid (EPA) rich diet, an arachidonic acid (AA) rich diet, or a
normal fatty acid balanced diet. The study was performed blindly. Lung injury was
induced by endotracheal instillation of 10 CFU of PA (PAO1 strain) per mouse.7
Evaluation criteria were (24 hours after infection): mortality, inflammatory response
assessed with TNFa, IL1b, IL6 and IL10 levels in broncho-alveolar lavage, lung
injury evaluation and extravascular lung water. Results: After PA induced lung
injury, no difference in mortality was observed among the 3 diet groups (20%, 27%
and 13% in AA, EPA and control group, respectively). TNFa level was significantly
higher in the EPA diet than in the other two diet groups. (EPA group: 1752 pgy
ml, AA group: 1171 pgyml, control diet group: 578 pgyml; Ps0.01). No difference
in the other cytokins were found among groups. Lung oedema was also more impor-
tant in EPA diet, consistent with the variation of TNFa level, WyD ratios being
respectively: 7.19, 6.2 and 6.53 (Ps0.03). Conclusion: Our study clearly shows
that, in high acute inflammatory and infectious condition, PUFA induces differences
in the inflammatory response with a higher level of lung oedema. Modulation of
the inflammatory response with PUFA can therefore influence the response to a
bacterial challenge, the host consequences remain however to be precisely evalu-
ated. Acknowledgement: this study was supported by a grant from Numico.
314
Role of oral hypoglycaemics in the prediabetic stage of Cystic Fibrosis
Related Diabetes (CFRD)
A.J. Hannam, U. Das, A.S. Ahuja
Royal Albert Edward Infirmary, Wigan, United Kingdom
The prevalence of CFRD ranges between 5% and 10%. The condition results from
both insulin deficiency and insulin resistance. It has been associated with increased
morbidity and mortality In patients with CF, progressive destruction of the pancre-
atic tissue leads to loss of islet cells. This results in varying degrees of glucose
metabolism abnormalities. We describe a patient who was born full term weighing
8lb 10oz. He was admitted aged 15 months with failure to thrive. He continued to
have poor weight gain and was diagnosed with CF following a sweat test Na 112.
Following introduction of routine medication, his weight was steady on the 50th
centile, height at the 25 centile, until age 11, when his weight gradually fell toth
below the 25 centile and height to the 10 centile by the age of 15. His FEV1th th
fell from)90% predicted to 60–80% predicted over the same time. At age 15 a
routine Hba1c was 6.1 mmol. An OGTT showed fasting sugar at 5.9 mmol, and
4.3 mmol at 2 hours. He was commenced on oral glibenclamide 40 mg twice daily.
His weight improved to reach just below the 75 centile by age 17, his heightth
improved to minus 0.6 sds and his FEV1 also increased within 4 months to)90%
predicted. He remained in this range until his transfer to adult services. His Hba1c
remained-6.0 mmol. Conclusion: It has been suggested that an insidious decline
in lung function takes place years before the diagnosis of diabetes in CF. Gliben-
clamide causes additional secretion of insulin from islet cells of Langerhans. We
propose that a trial of sulphonylurea treatment be considered in patients with declin-
ing lung function and increasing HBA1c levels.
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Cross-sectional study of bone mineral density in french cystic fibrosis
adult patients: correlation with phenotype and with CFTR genotype
I. Durieu , L. Laforest , G. Bellon , E. Van Ganse , D. Vital Durand , R. Nove1 2 2 2 1
Josserand1
CFadult center. Department of Internal Medicine. Centre Hospitalier Lyon-Sud. H,1
Lyon, France, Equipe D’Accueil 3091. Universite Claude-Bernard Lyon1, Lyon,2 ´
France
Various studies have highlighted the high frequency of low bone mineral density
(BMD) in adult patients with cystic fibrosis (CF). We presented here, a cross-
sectional study in an adult French CF population, and a correlation between BMD
and CFTR genotype, disease phenotype and corticosteroid treatment. Sixty two CF
adult patients attending the Lyon CF center were screened for BMD. The association
between BMD status with CFTR genotype, FEV1, analysis of sputum, body mass
index (BMI), diabetes, and chronic corticosteroid treatment were tested (Kruskal-
Wallis and Chi-Squared tests). The mean age was 28 years (range: 18–47). 46%
were homozygous for DF508 mutation, 44% compound heterozygous for DF508
and other mutation, 10% compound heterozygous for other mutations. Mean BMI
was 19.15; mean FEV1 48%; 50 patients had a chronic colonization with Pseu-
domona aeruginosa; 14 patients had diabetes. Twenty patients were treated with
inhaled and 8 with oral corticosteroids. 26% had normal BMD, 40% osteopenia,
and 34% osteoporosis. There was no association between BMD and CFTR geno-
type, age, diabetes, corticosteroid treatment. FEV1 differed significantly across
BMD levels (Ps0.009); lower FEV1 measures were observed in patients with
osteoporosis. The association between, respectively BMI, presence of Pseudomonas
aeruginosa in sputum with BMD did not reach significant P value. Our study
confirms the high frequency of BMD modifications in adults with CF, since only
26% of patients had normal BMD. As demonstrated in other studies, the severity
of osteoporosis seems to be correlated with the severity of pulmonary disease. Our
study suggests that the survey of BMD is necessary in adult patients with CF early
in the course of the disease when severe pulmonary involvement. Further studies
are necessary to investigate the direct effect of chronic inflammation and oxidative
stress associated with pulmonary disease on BMD in CF patients.
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*Severe osteoporosis in CFTR-null mice
F. DIF , C. Marty , M.C. de Vernejoul , G. Levi1 2 2 1
UMR5166 CNRS-MNHN Evolution des Regulations Endocriniennes 7,rue Cuvier,1 ´
Paris, France, INSERM U349, Centre Viggo Petersen, Hopital Lariboisiere, Paris,2 ˆ `
France
Aim: Osteoporosis is a common complication in cystic fibrosis patients, its etio-
pathogenesis is thought to be multifactorial. The purpose of this study was to deter-
mine if there is direct relation between the genetic defect in the CF transmembrane
conductance regulator (CFTR) and osteoporosis. Methods: In this study we have
analyzed the bones of a mouse genetic model of human CF in which both copies
of the CFTR gene have been inactivated. We first used dual energy X-ray absorp-
tiometry to measure the bone mineral density of the femur, the vertebrae and the
total body of these animals. We then performed a complete histomorphometric
analysis of their bones including measures of the number and distribution of active
osteoblasts and osteoclasts as well as the rates of bone deposition and resorption.
Results: We find that even in the absence of obvious nutritional and therapeutic
differences the CFTR mutation is associated to severe osteoporosis. Bone mineral
density of total body and of individual bones is significantly diminished. CFTR
mutants display a striking reduction of cortical bone width and thinner trabecules.
Analysis of dynamic parameters indicates a significant reduction of bone formation
and a concomitant strong increase in bone resorption. Active osteoclasts where
found mostly associated with cortical bone. Conclusions: Our data support the
notion that CF-associated osteoporosis is part of the syndromic symptoms associated
with the CFTR mutation. Models to explain the effect of the CFTR mutation on
bone will be presented.
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Pregnancy outcome in women with cystic fibrosis related diabetes
H. Mosnier-Pudar, S. Epelboin, D. Hubert
Groupe Hospitalier Cochin, Paris, France
Between 1997 and 2001, 22 CF women consulted for consideration of pregnancy.
We retrospectively analysed the impact of cystic fibrosis related diabetes (CFRD)
in the decision and outcome of pregnancy in 6 of them. Among 5 women with pre-
pregnancy CFRD, 2 were discouraged for having a pregnancy, one because of a
rapid worsening of her clinical status, the other one because of renal insufficiency
7 years after lung transplantation. For the 3 remaining women, insulin was initiated
before pregnancy in 2, and at the beginning of pregnancy in 1. Another CF woman
developed gestational diabetes, and needed insulin treatment at 10 weeks gestation.
Insulin treatment included rapid onset insulin 3 to 4 times daily, before main meals;
1 patient also needed NPH insulin at bedtime. One patient had an early pregnancy
loss at 12 weeks, and she was the only one with a bad glucose control (HbA1c
8.8%). A caesarean section was done in the 3 other patients. The median gestational
age was 38.3 weeks, and the birth weights were normal (median: 3200 g). No
perinatal complications were observed. The median weight gain was 8.3 kg. During
pregnancy all the patients were hospitalised for pulmonary exacerbation, one for
poor weight gain, and one for severe hypoglycaemia. After delivery the pulmonary
status was stable. All 3 children are healthy. Screening for diabetes is mandatory
in CF women before and during pregnancy. A good diabetic control seems to be
important for the pregnancy outcome, and insulin treatment is usually required.
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Clinical features and treatment approaches in cystic fibrosis with
pseudo-Bartter’s syndrome
E. Yalcin, N. Kiper, D. Dogru, U. Ozcelik, A. Gocmen, A. Aslan
Hacettepe University, Faculty of Medicine, Ankara, Turkey
Introduction: Infants with CF are prone to develop episodes of hyponatremic
hypochloremic dehydration with metabolic alkalosis, which are biochemical hall-
marks of the pseudo-Bartter’s syndrome (PB). The aim of this study was to deter-
mine the clinical, laboratory features and treatment aproaches in PB seen in CF.
Methods: We reviewed the medical records of 29 children with CF and PB who
were under follow-up in our institution from May 1992 to November 2003. Results:
Of 241 patients with CF, PB was detected in 29 (12%) cases with a mean age of
5 months at the time of first attack (age range 1–18 months; maleyfemale: 14y15).
Most patients experienced vomiting, loss of appetite and dehydratation during PB
episodes. Mean plasma Na, K, Cl, pH and HCO levels were 126 mEqyl, 3.2 mEqy3
l, 79 mEqyl, 7.53, 35 mmolyl, respectively. F508 mutation was the most common
mutation with a frequency of allel 34%. All patients were managed with iv fluids
and NaCl solutions. Mean duration of improvement in days were 2.3 for Na, 2.2
for K, 2.6 for Cl, 3.6 for HCO and pH levels. During follow-up, 12y29 cases3
required hospital admissions due to recurrent PB attacks. The age at the time of
latest attack was 48 months. Conclusions: CF should be considered in the differ-
ential diagnosis of metabolic alkalosis in young children. Vomiting and loss of
appetite are important alerting signs to be suspicious for the development of PB in
CF patients particularly before 4 years age. Early awareness of families and local
physicians regarding warning signs and symptoms for PB is crucial in order to
prevent chronic alkalosis, seizures and malnutrition.
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High prevalence of insulin-requiring diabetes five years after lung
transplantation for cystic fibrosis (CF): experience of the Brussels
Lung Transplant Group
C. Knoop , F. Fery , L. Crenier , Y. Sokolow , G. Casimir , M. Estenne1 1 2 3 2 1´
Hopital Erasme, Department of Chest Medicine, Brussels, Belgium, Hopital Eras-1 2ˆ ˆ
me, Department of Endocrinology, Brussels, Belgium, Hopital Erasme, Department3 ˆ
of Thoracic Surgery, Brussels, Belgium
CF lung transplant recipients are particularly predisposed to developing post-trans-
plant diabetes, which is a serious medical complication. Most CF lung transplant
candidates specifically inquire about the risk of developing this condition. However,
at present, the literature does not provide data. We reviewed the charts of all 63
CF lung transplant recipients (34 malesy29 females; 26"8 years) transplanted at
our institution to provide an answer to this question. Diabetes was defined according
to international guidelines. Actuarial survival was 91, 82, 65, 59 and 47 % at 3
months, 1, 3, 5 and 7 years. Among the 63 patients, 21 (33 %) presented insulin-
requiring diabetes before transplantation. Among the 38 remaining evaluable
patients, 13 (34%) developed diabetes within 3 months, 2 between 3 and 12 months,
2 between 1 and 3 years and 1 patient each after 3, 5 and 7 years. All but 2 patients
required immediate insulin therapy. For patients, who did not present diabetes at
the time of surgery, actuarial freedom from insulin-requiring diabetes was thus 64,
60, 54, 50 and 45 % at 3 months, 1, 3, 5 and 7 years after transplantation. For the
whole group, 6 of 19 (32%) surviving patients were free from insulin-requiring
diabetes at 5 years. This compares unfavorably to the 75% freedom of insulin-
requiring diabetes in the global lung transplant population as reported by the Reg-
istry of the ISHLT. In conclusion, in our experience, 1) 1 out of 3 CF-lung transplant
candidates presents insulin-requiring diabetes before transplantation, 2) 1 out of 2
non-diabetic CF lung transplant recipients will develop insulin-requiring diabetes
by 5 years after transplantation and 3) this population could benefit from the devel-
opment of non-diabetogenic immunosuppressants
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Bone mass density in CF adults: dependence on the overall clinical
status at peak bone mass
L. Fila , D. Zemkova , R. Pipkova , Z. Sumnik , V. Vavrova , M. Macek Jr.1 2 1 2 2 3
Adult Pulmonology Dept, University Hospital Motol, Prague, Czech Republic,1
Paediatric Dept, 2nd Medical School, Prague, Czech Republic, Institute of Biol-2 3
ogy and Medical Genetics, 2nd Medical School, Prague, Czech Republic
Osteoporosis in CF is usually asymptomatic and if untreated may result in severe
complications. Importantly it may become a contraindication for lung transplanta-
tion. Thus, early screening of osteoporosis is important. Forty patients (22 females,
18 males) aged 19–40 years (median 23.7) were screened for osteoporosis by
quantitative CT of their lumbar spine. These results were correlated with longitu-
dinal clinical data. Osteoporosis (T-score -2.5 S.D.) was found in 10%, while
osteopenia (-y1,)y2.5) in 17.5% (mean value:y0.7; S.D.s1.3) in CF adults.
Correlation between bone mass density (BMD) and age rs0.31 (Ps0.05) was
proved. However, correlation between BMD and parameters of current clinical stat-
us did not reach significance at Ps0.05. The influence of CFTR genotype was
negative. When we excluded the outlying case (the oldest patient), in patients aged
19–33 years we observed correlation between BMD and nutritional status (weighty
height; rs0.37, P-0.05). Significant correlation was found between BMD in
adulthood and clinical status at the age of 18 years, i.e. at the peak bone mass (with
body weight: rs0.41, Ps0.01; weightyheight: rs0.44, P-0.01; mid-arm circum-
ference: rs0.5, P-0.01 and FEV : rs0.51, Ps0.001). We also proved the neg-1
ative influence of delayed puberty on BMD, in that correlation between BMD and
the age at menarche (rsy0.47, P-0.05) was significant. In conclusion, correlation
between the current clinical status and BMD in adulthood is weak. On the other
hand we proved correlation between lung function and nutritional status at the age
of peak bone mass with occurrence of BMD in adulthood, including the negative
influence of delayed puberty. Supported by MSMT- 111300003 and MZCR-
00000064203.
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Osteoporosis in patients with Cystic Fibrosis in Rep.of Macedonia
T. Jakovska-Maretti , S. Fustik , J. Gavrilovski , K. Jakovski1 1 2 3
Pediatric Clinic, Skopje, Macedonia, FYR, Orthopedic Clinic, Skopje, Macedonia,1 2
FYR, Institute for pharmacology, Skopje, Macedonia, FYR3
Cystic Fibrosis (CF) is frequently associated with osteoporosis. A lot of factors are
supposed to increase risk of osteoporosis like severe respiratory disease, steroid
therapy, hypogonadism and deficiency of vitamin D. Aim:(a) to investigate osteo-
porosis in our patients and (b) to evaluate its appearance in correlation with 25
OHD deficiency. We studied 30 CF patients (16 boys) aged 6–21 year and 15
healthy children at the same age. We used the method of quantitative ultrasound
(QUS) for determination of the bone status. Speed of sound (SOS), transmission
index (TI) and osteosono-assessment (OSI) were measured by calcaneal ultrasound.
All patients were receiving 800 I.U. vitamin D per day. Results: The mean values
of Z score in patients with CF were for SOS (y0.2"1.4); for TI (y0.6"1.1) and
for OSI (y0.5"1.2). The mean values of Z score in the controled group were: for
SOS (1.3"0.9), for TI (0.9"0.5) and for OSI (0.9"0.4). Patients with CF had
significantly worse bone status (P-0.0001) compared with that of the control
group. We found 10 patients (33%) with osteoporosis. The levels of 25 OHD in
patients with CF(25.6"14.4 ngyml) were significantly lower (P-0.001) compared
to the levels in control group (43.4"14.9 ngyml).Correlations between parameters
of bone status with level of 25 OHD were(Rs0.48). Conclusions: (1) Significant
percentage (33%) of CF patients have osteoporosis. (2) The daily dose of 800 IU
vitamin D is insufficient for some of CF patients. (3) There is a high correlation
(Rs0.9) between low levels of 25 OHD (-10 ngyml) and osteoporosis in patients
with CF.
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An audit of investigation and management of bone disease in patients
with cystic fibrosis
J.C. Morgan, F.P. Edenborough
Northern General Hospital, Sheffield, United Kingdom
Introduction: Bone disease is prevalent in adults with cystic fibrosis. It increases
the likelihood of thoracic vertebral fractures, causing pain, which may hinder spu-
tum clearance and impair pulmonary function. Bone density and risk factors of
osteoporosis are monitored and treated according to protocols based on annual
review. This study assesses the adherence to protocol and appropriateness of treat-
ments. Methods: Notes of all patients attending the Sheffield Adult Cystic Fibrosis
Unit were reviewed and an assessment of current practice against a previously
agreed protocol was performed. Results: 88% of patients had had a DEXA scan,
and annual assessment of PTH, Vitamin D and Calcium was done 40%, 46% and
65% of the time. 81% of patients were receiving an adequate intake of Vitamin D
according to CF Trust guidelines and 75% of patients were receiving a recom-
mended intake of Calcium. Risk factors were regularly documented. However,
appropriate treatment was infrequently prescribed. Conclusions: Appropriate inves-
tigation of bone disease in CF was carried out regularly, but once found, was not
appropriately treated.
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Blood and airways glucose concentrations in people with cystic
fibrosis
A.L. Brennan , D.M. Wood , M.E. Hodson , D.M. Geddes , K.M. Gyi , E.H.1, 2 1 2 2 2
Baker1
St George’s Hospital Medical School, London, United Kingdom, Royal Brompton1 2
Hospital, London, United Kingdom
Background: Diabetes mellitus (DM) is associated with pulmonary decline in cystic
fibrosis (CF), although mechanisms are poorly understood. Glucose is not normally
present in human airway secretions, but appears when the blood glucose exceeds a
threshold of 8.0"1 mM wWood Diab Med 2003x. Glucose in airways secretions is
associated with positive bacterial cultures wRedman Critical Care 2003x. Aims: To
determine (a) the glucose concentration of nasal secretions in people with CF and
(b) the proportion of the day spent by people with and without CF with blood
glucose above the airways glucose threshold. Methods: Subjects were 6 healthy
volunteers (HV, no CF, normal glucose tolerance (NGT)), 9 CF with NGT con-
firmed by oral glucose tolerance test and 10 CF with DM (CFRD). Nasal glucose
was measured using glucose oxidase sticks and blood glucose determined from
capillary samples. 48 hour blood glucose profiles were measured using a subcuta-
neous glucose monitoring system (CGMS). Results: Glucose was not detected in
nasal secretions from HV or CF-NGT, all of whom had blood glucose F5.6 mM.
Nasal glucose was detected in 6y10 people with CFRD who had mean blood glu-
cose 7.9"1.9 mM. Patients with CFRD spent a greater proportion of the day with
blood glucose )8.0 mM (48(30–69)%, mean (interquartile range)) than CF-NGT
(5.3(2–11)%) or HV (1.8(0–1)%) (P-0.0001, ANOVA). Conclusion: People
with CFRD spend considerable periods of the day with blood glucose above the
airways glucose threshold. Glucose is present in nasal secretions from people with
CF when blood glucose is raised and may therefore be present in airways of patients
with CFRD throughout the day. Glucose in airways secretions may promote bac-
terial growth, and this could contribute to pulmonary decline in CFRD by increasing
bacterial load.
s86 Journal of Cystic Fibrosis 3 (2004) S75–S86
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The impact of a future diagnosis of cystic fibrosis-related diabetes
mellitus (CFRD) on disease severity in patients with cystic fibrosis (CF)
in the South West of England
K.M. Giles , G. Connett , P. Ilangovan , A. Cade , A.T. Prendiville1 2 3 4 5
South & West Cystic Fibrosis Database, Bath, United Kingdom, Southampton1 2
University Hospital Trust, Southampton, United Kingdom, North Hampshire Dis-3
trict Hospital, Basingstoke, United Kingdom, Derriford Hospital, Plymouth, United4
Kingdom, Royal Cornwall Hospital Trust, Truro, United Kingdom5
The onset of insulinopenia in CF is insidious. Statistical differences have been found
in heightyweight (6 mths–4 yrs) and in lung function (6 mths–3 yrs) prior to
CFRD diagnosis. We studied our regional CF population of 853 patients (whose
clinical data are collected prospectively and entered on a regional database), to
determine whether any significant difference andyor deterioration in body weight,
height, BMI, FEV or FVC could be detected in the 4 year period prior to the1
diagnosis of CFRD compared to controls frequency-matched for age and sex dis-
tribution. Subjects and controls were extracted from the database if they were)10
years of age at diagnosis of CFRD (cases) or at the end of the study period (con-
trols). Exclusion criteria included prior diagnosis with CFRD, isolation of Burk-
holderia cepacia and type 1 diabetes. Data for 31 CFRD patients and 62 controls
were analysed. Significant differences in FEV % predicted (cases 75.4 vs controls1
79.9, P-0.0001), FVC% predicted (86.5 vs 88.6, Ps0.04), adult BMI (20.5 versus
22.0, Ps0.04) and paediatric weight Z-score (y1.1 vs y0.4, Ps0.01) were seen
4 years prior to CFRD diagnosis. Cases and controls did not differ significantly for
paediatric height Z-score until 1 year prior to CFRD diagnosis. Differences in
FEV , FVC and weight Z-score increased with time. In the year prior to CFRD1
diagnosis there was a 17% difference in% predicted FEV , an 11% difference in%1
predicted FVC and a difference of y1.12 in paediatric weight Z-score. These data
support the hypothesis that increasing insulinopenia in the years prior to the diag-
nosis of CFRD is associated with a significant deterioration in clinical status. Meth-
ods need to be developed to aid the early recognition and treatment of glucose
intolerance in CF patients.
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Factors influencing the development and progression of cystic fibrosis
related bone disease in the adult population
C.R. Parker, P.M. Hockey, M.P. Carroll
Southampton Adult Cystic Fibrosis Unit, Southampton, United Kingdom
Rationale: Patients are at risk of developing cystic fibrosis related bone disease
from a variety of interacting factors, the consequences of which can adversely affect
long-term prognosis. Methods: Case records from the adult cystic fibrosis clinic
were reviewed to identify the appropriateness of investigation, management and
follow up of patients with previously documented cystic fibrosis related bone dis-
ease. Results: A screening sample of 18 records was reviewed. Mean age 26.6 years,
range 18–49. 10 patients had an FEV -60% suggesting at least moderate or severe1
lung disease. Body mass index, mean 19.6, range 17.2–27. All patients had under-
gone an initial and at least one follow up bone density scan. 12 (66.6%) patients
were receiving regular bisphosphonate therapy, 10 taking either a daily or weekly
oral preparation. Two patients required three monthly admission for intravenous
bisphosphonate therapy. Baseline bone density scans showed 15y18 patients as
osteopenic and 3y18 frankly osteoporotic, according to predefined criteria. The
range of Z-scores being y3.8 to y0.1 at the hip and y4.1 to q1.1 at the lumbar
spine. Despite treatment, follow up scans demonstrated 4 further patients had
become osteoporotic with risk of associated complications. Conclusions: Cystic
Fibrosis related bone disease is common. Once established it is difficult to reverse
and despite best available treatment progresses. It is important to emphasise the role
of both nutrition and weight bearing exercise to minimise occurrence and impli-
cations of bone disease in addition to standard pharmacological measures.
Physiotherapy
s88 Journal of Cystic Fibrosis 3 (2004) S88–S94
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Acute effects of chest physiotherapy on gas exchange and wellbeing in
severe cystic fibrosis
R. Soni , R. Dentice , G. Marks , I.H. Young , P.T.P. Bye1 2 2 2 2
Department Respiratory Medicine, Gosford Hospital, Gosford NSW, Australia,1
Department Respiratory Medicine, Royal Prince Alfred Hospital, Sydney NSW,2
Australia
Evidence based conclusions on the acute efficacy of Chest Physiotherapy (CPT)
historically focus on sputum quantification. The acute effects of CPT on the phys-
iological variables of: spirometry, oximetry, ABG and ventilation-perfusion (V yA
Q) distribution as measured by the multiple inert gas elimination technique
(MIGET) were studied in 24 stable adult cystic fibrosis patients. Perception of
wellbeing following CPT and any correlation between wellbeing and physiological
changes were investigated. Spirometry, oximetry, ABG, detailed V yQ (in 11), andA
perception of wellbeing, were measured prior to and 90 mins following CPT. Results
– group data. The effect of a CPT session on FEV , FVC and oximetry was small.1
The effect on mean values of PaO , PaCO , Log SDQ and Log SDV were small.2 2
Individual perception of wellbeing ranged from much worse to much better. Results
– correlations. Large changes in PaO were not correlated with subjective wellbeing,2
(Spearman’s rs0.33, 95% CI y0.08 to 0.65). No correlation between wellbeing
and changes in PaCO , %FEV or FVC was identified. The effect of CPT acutely2 1
on Log SDQ was highly variable ranging from a marked broadening (e.g. 0.29 to
1.03) in a subject who felt much worse to a marked narrowing (e.g. 1.07 to 0.73)
where the subject felt much better. There was a strong correlation between the acute
effects of CPT on subjective wellbeing and changes in V yQ inequality, as meas-A
ured by Log SDQ, (Spearman’s rs0.97, 95% CI 0.89–0.99, P-0.0001). The acute
effects of CPT on gas exchange were present for at least two hours after its com-
pletion and may have implications for treatment adherence.
331
Respiratory muscle strength in patients with cystic fibrosis
B.U. Tugay , H. Arikan , S. Savci , D. Inal Ince , M. Ozturk , U. Ozcelik , N.1 1 1 1 1 2
Kiper2
Hacettepe University School of Physical Therapy and Rehabilitation, Ankara, Tur-1
key, Hacettepe University Ihsan Dogramaci Childrens Hospital Pediatric Pulmon-2
ology, Ankara, Turkey
There is little information and controversy about the maximal inspiratory and expi-
ratory (MIP and MEP respectively) pressures in patients with cystic fibrosis (CF).
The affect of pulmonary disease process on the respiratory muscle strength is not
clear in the literature. Therefore the purpose of this prospective study was to inves-
tigate the status of respiratory muscle strength in patients with CF and to compare
maximal respiratory pressures in patients with different stages of the disease. Forces
generated by respiratory muscles between mild and moderately effected CF patients
(mean age 11.64"3.33 years) were compared. 15 patients were mildly and 9
patients were moderately affected according to the FEV %. MIP values were sta-1
tistically significant between mild and moderately affected CF patients (P-0.05).
The difference between the expected and observed MIP and MEP values were
statistically different in both groups (P-0.05). It was concluded that, routine meas-
urement of MIP and MEP values should be included in the physiotherapy evaluation
process for both CF patients since these values are significantly reduced in both
groups and these values were significantly correlated with clinical scores.
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Comparison of respiratory muscle strength in patients with cystic
fibrosis and non – cystic fibrosis bronchiectasis
B.U. Tugay , H. Arikan , S. Savci , M. Ozturk , D. Inal Ince , U. Ozcelik , N.1 1 1 1 1 2
Kiper2
Hacettepe University School of Physical Therapy and Rehabilitation, Ankara, Tur-1
key, Hacettepe University Ihsan Dogramaci Childrens Hospital, Ankara, Turkey2
Changes in the respiratory muscle strength during the pulmonary disease process
in patients with cystic fibrosis (CF) are unclear in the literature. It is also not known,
whether the changes in respiratory muscle pressures are attributable to the multis-
ystemic nature of the CF disease or only to the pulmonary pathology. Therefore the
purpose of this prospective study was to investigate the status of, and the factors
that are suspected to have influence on respiratory muscle strength in patients with
CF. Forces generated by respiratory muscles between CF patients (mean age
11.64"3.33years) and patients with non CF bronchiectasis (mean age 13.18"3.39
years) were compared. There were 24 patients in either group. The mean FEV %1
were 72.18"21.24 in CF and 67.25"17.78 in non – CF bronchiectasis group (P)
0.05). When MIP and MEP values were compared, no statistically significant dif-
ference was found between CF patients and patients with non CF bronchiectasis
(P)0.05). The difference between the expected and observed MIP and MEP values
were statistically different in both groups (P-0.05). It was concluded that, routine
measurement of MIP and MEP values should be included in the physiotherapy
evaluation process for both CF patients and patients with chronic airflow since these
values are significantly reduced in both groups.
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Rinte measurement before and after chest physiotherapy
L.J. van der Giessen , P.F.M. Merkus , J.C. de Jongste , R. Gosselink , H.A.W.M.1 2 2 3
Tiddens2
Department of Pediatric Physiotherapy, Erasmus MC-Sophia, Rotterdam, Neth-1
erlands, Department of Pediatrics-Respiratory Medicine and Allergology, Erasmus2
MC-Soph, Rotterdam, Netherlands, Department of Pulmonary Rehabilitation, Uni-3
versity Hospital, Leuven, Belgium
Background: Chronic airway inflammation in cystic fibrosis (CF) leads to an
increase in airway resistance early in life. Resistance of the respiratory system can
be measured with Interrupter Resistance Measurement (Rint ). Rint is sensitive toe e
changes in airway caliber in children with mild respiratory tract infections and can
be carried out quickly So far no golden standard is available to evaluate the efficacy
of chest physiotherapy treatment (CPT) in children with CF. Rint may be a usefule
tool. Objective: To assess the feasibility and sensitivity of Rint measurementse
before and after CPT. Methods: Rint was performed directly before and after cheste
physiotherapy treatment. The difference in RINT (DRINT ) was calculated as fol-e e
lows RINT RINT . Sputum production during CPT and daily sputume before - e after( ) ( )
production was estimated with a semi quantitative scoring system. Sputum produc-
tion during CPT and daily sputum production were correlated to DRINT usinge
Spearman rank correlation coefficient (r ). Results: Sixteen children participated.s
Mean age (range) was 15 (7–19) years. Rint measurement could be performede
without difficulty in all patients. DRINT varied between y0.13 and 0.26 kPayLye
s. DRINT correlated significantly with the sputum production score during CPTe
(r s0.63, Ps0.009) and with the daily sputum production score (r s0.55, Pss s
0.026). Conclusion: Rint measurement is a feasible method to evaluate the effect-e
iveness of CPT in CF. The decrease in Rint is positively correlated to the sputume
production during CPT and with the daily sputum production. Based on these results
Rint could be a useful outcome measure in CPT studies in CF. The within ande
between subject variability should be investigated in a larger scale study.
s89Journal of Cystic Fibrosis 3 (2004) S88–S94
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Evaluation of lung clearance index as an outcome measure for airway
clearance intervention studies
E. Main , E.-L. Tannenbaum , P. Aurora , E. Scrase , A. Prasad1 2 3 3 4
CNAHPR, Institute of Child, London, United Kingdom, Physiotherapy Depart-1 2
ment, Great Ormond Street Hospital for Children NHS Trust, London, United King-
dom, Portex Anaesthesia and Respiratory Physiology Unit, Institute of Child3
Health, London, United Kingdom, Cystic Fibrosis Unit, Great Ormond Street Hos-4
pital for Children NHS Trust, London, United Kingdom
Introduction: There are few reliable or sensitive tools for measuring efficacy of
airway clearance techniques. FEV has been shown to be insensitive in early lung1
disease, does not demonstrate subtle changes in short term studies and is dependent
on patient capability and effort. The aim of this study was to evaluate the sensitivity
of lung clearance index (LCI) from multiple breath inert gas washout (1) in meas-
uring the effects of a single airway clearance treatment. Methods: A subgroup of
patients participating in a long-term airway clearance study had three measurements
of LCI before and again immediately after a single physiotherapy session using
either PEP or Cornet. Results: Eleven participants with a median age: 12.9 years
(range 10–15 years) and median FEV : 74% predicted (range 42%–112%), had a1
baseline median LCI of 13.5 (range: 7.2–17.1, normal range: 5.4–7.2). Mean COV
for the three baseline and post-treatment measurements were 8% and 8.9% respec-
tively. There were no significant group changes in LCI following a single treatment.
However, four patients demonstrated an increase in mean LCI of more than two
standard deviations from their baseline values. No patients had a fall in LCI after
treatment. No relationship between FEV or physiotherapy technique and LCI1
response to a single treatment was observed. Conclusion: In this subgroup analysis,
LCI was sensitive enough to expose within-subject increases in LCI following a
single treatment – suggesting an increase in overall ventilation inhomogeneity. Fur-
ther work is required to assess the value of this tool in longer-term interventional
studies but it appears that LCI has potential to be a sensitive outcome measure in
physiotherapy studies.
1. Gustafsson P.M. et al, ERJ, 2003, 22, (6). 972-979.
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The effect of a hospital based intravenous antibiotic course on
Modified Shuttle Test (MST) performance and lung function in children
with CF
N.S. Cox , J. Follett , K. McKay
The Children’s Hospital at Westmead, Sydney, Australia
The 10 m MST is a valid and sensitive measure of exercise capacity in adult CF
patients (Bradley et al 1999 & 2000). Recently, its validity in children has been
established (Rogers et al 2002). Objectives: To identify in children with CF the
usefulness of the MST as an indicator of response to IV antibiotic therapy. Addi-
tionally, to establish the relationship between shuttle test performance and measures
of lung function over a course of IV antibiotics. Subjects and Methods: 24 children
(5 male) admitted requiring IV antibiotics for G10 days performed a MST and
lung function within 48 hours of commencement and cessation of IV antibiotics,
according to standard protocols. Results: Mean age of subjects was 12.6 years
(range 7.4–17.6) and mean length of IV antibiotic course 14.7 days (range 10–
21). Mean FEV %predicted at commencement of antibiotics was 65.9% ("20.7)1
and mean MST distance 750 m ("268). FEV increased by 7.3% predicted (95%1
CI: 3.33 y11.34; PF0.001 paired two-tailed Students’ t-test), FEF by 7.8%25-75
predicted (95% CI: 0.2–15.5; PF0.05) and MST distance by 81.2 m (95% CI:
26.7–135.8; PF0.005). In two cases, there was a greater than 5% improvement in
FEV but a decrease in distance covered during the shuttle test by more than 5%1
from admission. Significant correlation exists between exercise test results and
FEV % predicted at admission (rs0.41:Ps0.05) and discharge (rs0.6; Ps1
0.002) Conclusion: This study demonstrated improvement in both MST and lung
function results. The MST is a sensitive and objective measure of improvement in
exercise tolerance following hospital IV antibiotic therapy in children with CF.
Further, there is a correlation between MST and FEV % at admission and dis-1
charge, however there is no correlation between the degree of improvement in these
measures.
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Exercise tolerance in children with cystic fibrosis and healthy children
using the modified shuttle walk test
G. Beal , B.A. Howe , J. McGaw , A.S. Rigby , C.J. Taylor1 1 2 3 2
Sheffield Childrens Hospital NHS Trust, Sheffield, United Kingdom, University of1 2
Sheffield, Sheffield, United Kingdom, University of Hull, Hull, United Kingdom3
We report the preliminary findings of a two-group study assessing exercise tolerance
by the modified Shuttle Walk test (1). This may be a useful tool in cystic fibrosis
(CF) patients to identify functional respiratory limitations that impact on activities
of daily living and quality of life. A group of healthy children performed the test
to establish a normal range. Results were compared with data from CF children
attending the Sheffield Childrens Hospital CF clinic. Eighty eight healthy volunteers
(45 M: 43 F) age 6.17–15.58 years completed the test. Shuttle Walk annual review
data from 218 CF patients (137 M: 81 F) age 6.00–15.92 years was retrospectively
retrieved. Data was stratified by age and sex. Median values and range (metres)
are shown (Summary data only).
CF Males Healthy Males CF Females Healthy Females
883 (270–1500) 1003 (370–1500) 768 (190–1500) 898 (520–1500)
CF children significantly underachieved compared to their healthy peers (median
difference y120 (95% CIsy225, y51) Ps0.036). They achieved distances
better than or equal to controls in only 4 of 20 age bands. Compared to controls
CF males produced better performances (median difference y102 (95% CIsy
300, 65) Ps0.32) than CF females (median difference y130 (95% CIsy270,
y0) Ps0.045). A prospective study is underway to expand the healthy control
database. Data collection also continues from CF patients annually. Correlates
between Shuttle Test performance and other variables will be sought.
(1). Rogers D et al J Cystic Fibrosis 2002; 1: 139.
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The Modified Shuttle Test (MST): towards prediction of exercise
capacity in adult patients with Cystic Fibrosis
W.R. Doeleman
CF Centre Utrecht, University Medical Center Utrecht, Utrecht, Netherlands
Introduction: Measuring exercise capacity is widely accepted as an instrument in
predicting prognosis and evaluating treatment of patients with Cystic Fibrosis (CF).
A functional approach to measure this capacity is to use an instrument that closely
relates to every day life. The Modified Shuttle Test (MST) is a field test for adult
patients with CF with proven reliability, repeatability and sensitivity in this patient
group. The aim of this study is to describe the relationship between the MST and
other factors within the Disablement Process in order to make a preliminary attempt
in predicting exercise capacity. Methods: Currently, 73 patients (41 male; mean age
26 years, range 17–47) are included in this study. Measures of ‘Body Functions’
were expressed by lung function (percentage of predicted 1-second forced expira-
tory volume (FEV )), muscle strength, body mass index, and oxyhemoglobin1-%pred
saturation before and during exercise. ‘Activities’ were measured using the MST.
‘Participation’ was assessed using the Cystic Fibrosis Questionnaire for teenagers
and adults (CFQ 14 ). Multiple measurements per patient were considered only ifq
the separate measurements were over 6 months apart. Results: Preliminary data
indicate that MST outcome correlates highly (rs0.76; P-0.01) with FEV1-%pred
and moderately (rs0.68; P-0.01) with self-reported physical functioning (CFQ
14 ). When assessing data of male and female patients separately, associationsq
become even more apparent. Conclusion: A relationship exists between ‘Activities’
as measured by the MST and ‘Body Functions’ as measured by the FEV on the1
one hand and ‘Participation’-level on the other. These relationships are of paramount
importance in future research to develop predictive models of prognosis in patients
with CF.
s90 Journal of Cystic Fibrosis 3 (2004) S88–S94
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Increased pH of exhaled breath condensate following physiotherapy in
children with cystic fibrosis
M.K. Aniruddhan , G. MacGregor , E. Green , A. Innes , A.P. Greening , S.1 2 1 2 1
Cunningham1
Royal Hospital for Sick Children, Edinburgh, United Kingdom, Western General1 2
Hospital, Edinburgh, United Kingdom
Introduction: The benefit of physiotherapy in patients with cystic fibrosis is poorly
demonstrated. Low pH in exhaled breath condensate (EBC) is found in CF adults
(compared with controls) and CF adults and children during a respiratory exacer-
bation. It is suggested that low pH reflects airway inflammation. We assessed the
effect of physiotherapy on EBC pH. Methods: 19 children (age 13.0 years, S.D.
2.8; 9 male, 10 female) performed spirometry and EBC, before, and 60 and 120
minutes post physiotherapy. pH was assessed immediately post collection of EBC
by pH microelectrode (Camlab, UK), and frozen at –80 C for later measuremento
of ammonium and nitrite. Results: pH progressively increased from pre physio val-
ues (pH 5.2, S.D. 0.33) at 60 (5.5*, S.D 0.46) and 120 minutes (6.0*, S.D 0.46),
*P-0.001 compared to pre value. An increase in pH was seen in 18 of 19 patients
studied. No similar pattern seen in ammonia or nitrite values. No significant cor-
relation between age or bmi and pH or change in pH with time. Lower FEV % pre1
physio was associated with significantly lower pH pre physio and also at 60 and
120 minutes post (all P-0.05). No correlation between changes in pH with time
and FEV %. No association seen between Pseudomonas aeruginosa colonisation1
(10 patients) and pre pH or changes in pH with time. Conclusions: Physiotherapy
in CF children is associated with a progressive rise in EBC pH over 120 minutes.
Lower pH is seen in those with lower initial FEV %. If (as proposed by others)1
low pH is representative of airway inflammation, then physiotherapy may be effec-
tive in reducing the inflammatory load in the lung.
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Aerosol therapy: creating a charter and therapy protocol for multi-
professional use and management in CF patients
C. Lejosne, G. Rault, S. Ramel, V. Storni, F. Jezequel, J. Thubert, N. Perez, V.
Troadec, J. Le Mouellic, M. Le Guen, T. Gouillou, A. Caroff, R. Kerleroux, S.
Farandeau, D. Marquet, D. Brodziak, P. Noyer
CRCM of Perharidy, ROSCOFF, France
We report on an action to improve aerosol therapy (over one year) in response to
complains of CF patients. Six meetings took place including medical doctors, nurs-
es, pharmacists, physiotherapists and representatives of private enterprises renting
out medical equipment. Using ‘Problem Resolving Method’, we described our work
methods and highlighted any weak points which were then resolved by small multi-
professional working groups. Finally we validated: A consensual teaching method
so as to enable each CF patient to receive the same instructions regardless of which
professional is concerned. A charter between ‘expert centre for CF’ and private
renters enterprises (10 businesses signers at time of reporting). A medical prescrip-
tion model for the patient based on national recommendations. A prescription model
for rental businesses to provide material wanted precisely described. These docu-
ments are used by professionals in the western part of Brittany, France, since June
2003. They are to be evaluated in June 2004 so that aerosol therapy amending is
going on.
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Development of a protocol for physiotherapists administering
prescribed bronchodilators and dornase alpha to patients with cystic
fibrosis
E. Bowman, S. Ridley
Scottish Adult Cystic Fibrosis Service, Western General Hospital, Edinburgh, Unit-
ed Kingdom
One of the key elements in efficient and effective airway clearance is the appropriate
timing of prescribed bronchodilators and dornase alpha. In the respiratory unit at
the Western General Hospital, Edinburgh delivery of these drugs, especially for
those unable to self-administer, relied upon the availability of the nursing staff.
Delayed drug administration and subsequent physiotherapy treatment often occurred
if the nursing staff levels were inadequate. A protocol was therefore developed to
enable named physiotherapists to administer prescribed bronchodilators and dornase
alpha to these patients in a timely manner during their stay in hospital. The phys-
iotherapy clinical specialist, pharmacist and ward manager produced the protocol
with approval from the consultant medical staff and in accordance with local pol-
icies. A training programme was set up to ensure that the named physiotherapists
had the relevant knowledge and skills to ensure safe and effective delivery of these
drugs. The pharmacist and medical staff would review their competencies on an
annual basis. The aim of the introduction of this protocol was to reduce the number
of incidences of delayed administration of bronchodilators and dornase alpha and
improve the timely delivery of physiotherapy. A basic audit to establish the number
of incidences of delayedypoorly-coordinated delivery of these drugs was carried
out before the introduction of the protocol and will be repeated once this practice
is established as a measure of effectiveness. A subjective survey of staff and patients
will also be carried out to ascertain if there has been an improvement in patient
care.
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Postural abnormalities in Cystic Fibrosis: a cause for concern?
R.J. McVean, A. Orr, H. Langman, D. Riley, A. Jones, A.K. Webb, M.E. Dodd
Wythenshawe Hospital, Manchester, United Kingdom
The recognition of low bone mineral density (BMD) and musculoskeletal pain has
raised the awareness of postural problems in CF. Currently our service offers treat-
ment and postural advice to patients presenting with symptomatic pain. We are
concerned about pressures on staff resources and the increase to the patient’s burden
of care that routine postural assessment and treatment would entail. We aimed to
assess posture, record symptoms and survey concerns about posture in a pilot study
of 5 patients. The patients posture was observed and abnormalities in spinal cur-
vature were noted by a CF physio (R.M). Posture was classified as normal, sway-
back, kypholordotic or flatback. The area and nature of pain, (BMD) and patients
concerns about their posture and were documented. 3 females and 2 males were
assessed. Median (range) age, FEV1 and BMI were 31(22–38), 44.7 (28.04–
56.29)% predicted and 20.5 (19.6–28.1). BMD was normal in 2 patients, osteo-
penic in 1 and osteoporotic in 2. All had abnormal posture, 3 swayback and 2
kypholordotic. Four patients reported pain in the shoulders, lumbar and thoracic
spine. All patients expressed concern about their posture. None had previously
sought help or advice about their posture although 1 had previously seen muscu-
loskeletal physiotherapist for thoracic pain. All were able to improve their posture
when instructed and were given appropriate exercises and advice to follow. This
group of patients with more severe lung disease all had abnormal posture which
was symptomatic and caused concern. This survey has highlighted the need to be
proactive, addressing patients postural concerns and symptoms and treating appro-
priately. Further work is needed to investigate methods of assessing posture and
outcomes of any intervention.
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Prevention of thoraco-spinal deformities in CF patients by chest
physiotherapy
L. Smolikova , D. Zemkova , J. Bartosova , V. Vavrova1 2 2 2
Clinic of Rehabilitation, Charles University, 2nd Medical School and UH Motol,1
Prague, Czech Republic, Paediatric Clinic, Charles University, 2nd Medical2
School and UH Motol, Prague, Czech Republic
Objectives: Most CF patients sooner or later develop chest deformities, of which
the most frequent is a barrel shape chest, the result of undesirable breathing patterns
combined with obstructive symptoms. The aim of the study was to assess what
effect on the thorax has modern chest therapy. Methods: The patients were divided
into 3 cohorts according to the level of therapy available at the time. I (ns71):
patients born before 1976—insufficient therapy, II (ns118) in late childhood i.v.
ATB, Prolipase, full modern therapy only during puberty, III (ns157)—modern
therapy at least from 4 years. In 1990 our methods of physiotherapy were radically
changed from passive to active ones (ACTs, inhalation, mobilisation and stretching,
physical exercises etc), particularly by using the technique of respiratory handling,
based on modification of Vojta9s principles. Lung function tests and thoracic index
were compared by t-test in separate age categories from 3 to 18 years.Results:
FEV increased significantly already in cohort II in age categories 10–16 years.1
MEF increased gradually, but the difference reaches significance only in cohort25
III compared to I in age categories 10–14 years. Chest shape improved in cohort
III from the age of 8 years yet, it means after 1990. Abnormal thorax (indexG80)
at the age of 8 years was found in 25.8% patients from cohort II and only in 12.8%
of cohort III, at the age of 14 in 33% of cohort II vs 16.7% of cohort III. Conclusion:
Modern chest physiotherapy improves the habits of CF patients and the shape of
the chest; it leads to a lower level of obstruction, particularly of the peripheral
airways. It is of utmost importance to begin therapy in early childhood. Supported
by MSMT-111300003 and MZCR-00000064203
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Retest reliability of thoracic excursion measurement
J.W.H. Custers , B.G.M. Arets , F.T.C. Kooijmans , C.K. Van der Ent , P.J.M.1, 2 2 1 2
Helders1
Dept. Paediatric Physiotherapy, University Medical Centre Utrecht, The Nether-1
lands. CF Centre Utrecht, University Medical Centre Utrecht, Utrecht, The2
Netherlands
Background: A decline in thoracic excursions may be indicative for increased level
of air-trapping in children with Cystic Fibrosis (CF) Thoracic excursion measure-1
ment (TEM) using a tape measure is simple and may be a suitable instrument in
physiotherapy practice for longitudinal assessment of pulmonary status in CF
patients. This study was performed to evaluate the reliability of TEM in children
with CF. Methods: Intra-tester reliability was studied in 30 children (11.8 year, 5.9–
18.0). One observer with a blinded tape measure executed two consecutive meas-
ures. Two observers studied inter-tester reliability in 26 children (12.8 year, 7.4–
17.9). TEM was standardised and expressed as the mean difference (cm) in thoracic
circumference between maximal inspiration and maximal expiration at the axillary
and xiphoid level. Within-subject variation was measured by calculating the typical
error of measurement and limits of agreement (LOA cm). Furthermore, retest cor-
relations (Pearson r) and intraclass correlations (ICC) were calculated. Results: For
the intra-tester reliability study the mean thoracic excursion was 6.2 (S.D.s1.4)
cm, typical error was 0.31 cm (4.9%) and LOA was 0.86 cm. The retest correlation
was 0.96 and ICC was 0.95. For the inter-tester reliability study the mean thoracic
excursion was 6.1 (S.D.s1.5) cm, typical error was 0.58 cm (10.0%) and LOA
was 1.60 cm. Retest correlation and ICC were both 0.86. Conclusion: In thoracic
excursion measurement intra-tester reliability was found to be good, whereas inter-
tester reliability was found to be moderate, but acceptable.
Custers JWH, Laag J van der, Arets BGM, Helders PJM and Ent CK van der (2003)
Maximal thoracic excursion in children with Cystic Fibrosis, a relevant indicator
for air-trapping. Eur Respir J 22 (S45), 331s.
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Thoracic excursions as an effect parameter for in hospital treatment of
pulmonary exacerbations in cystic fibrosis patients
H.G.M. Arets, J.W.H. Custers, I. Prins, J. van der Laag
Cystic Fibrosis Centre Utrecht, Utrecht, Netherlands
Background: In patients with cystic fibrosis pulmonary function parameters are
important indicators of disease control. In our centre we also measure thoracic
excursions, both at regular follow up and at times of pulmonary exacerbations. This
study was performed to evaluate the usefulness of these measurements during treat-
ment of pulmonary exacerbations. Patients and methods: In 16 CF patients (My
Fs8y8, mean age 12.3 (8–17) yrs, FEV %pred s64%(S.D. 24%)) we measured1
pulmonary function (spirometry (FEV1, FVC, PEF, FEV1%FVC, MEF50, MEF25,
MMEF25-75), whole body plethysmography (R0.5, VCmax, ERV, TV, ITGV,
RVbox, TLC, RV%TLC), impulse oscillometry (R5, X5, res freq) and interrupter
resistance (Rint)) and thoracic excursions at both axillary and xiphoid level. These
measurements were performed both at the beginning and at the end of a 2–3 weeks’
hospital treatment of pulmonary exacerbations. We evaluated changes in thoracic
excursions and correlations between these changes and those of pulmonary function
parameters. Results: Thoracic excursions changed significantly after treatment, axil-
lary excursions changing more significantly than xiphoidal excursions (q1.1
("1.6) cm (Ps0.007) and q0.5 (q0.8) cm (Ps0.014) respectively). Changes
in axillary and mean thoracic excursions were significantly correlated with FVC,
PEF, VCmax, TV, ERV and inversely correlated with RV%TLC. No significant
correlations between changes in xiphoidal excursion and pulmonary function par-
ameters were found. Conclusions: Thoracic excursion can be used as a parameter
to evaluate the course of pulmonary exacerbations. This study in only a small group
of CF patients with moderate severe disease shows that axillary excursions are a
more sensitive tool and correlate better with pulmonary function changes than xip-
hoidal excursions.
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Community physiotherapy service for children with cystic fibrosis: a
family satisfaction survey
N. Byrne, L. Hardy
Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, United Kingdom
Physiotherapy for children with cystic fibrosis (CF) is a vital component of disease
management. Traditionally, review has been during hospitalisation and in clinic
settings. Support in the community is now being offered by a growing number of
centres in the UK and has been available in Newcastle upon Tyne for the last four
years. This services aims to offer additional support and minimise disruption to
family life. Appropriate referrals include those with a recent diagnosis, review dur-
ing home intravenous antibiotic therapy, assessment of respiratory exacerbations,
adherence issues, introduction of new treatment techniques and complex social cir-
cumstances. A questionnaire was sent to all families attending the unit for full care
(ns102) to assess the efficacy of this service. This was adapted from a standardised
questionnaire devised by the Chartered Society of Physiotherapy. Information from
the initial 30 returned questionnaires show a high level of satisfaction with the
community physiotherapy service. 97% of respondents were offered a convenient
appointment time, understood the reason for the home visits and felt involved in
the treatment plan for their child. The physiotherapist listened to their views and
they agreed with the advice given. 83% were aware of how to contact the com-
munity physiotherapist. 26% wanted additional visits, 57% were satisfied with the
level of input and 17% were unsure. Overall 91% of families found the input of
the community physiotherapist to be advantageous. These preliminary findings
clearly highlight the benefits of community physiotherapy for children with CF and
their families.
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Respiratory handling-enlarging the scope of physiotherapy
L. Smolikova , I. Zounkova , M. Malkova , V. Skalicka , V. Vavrova1 1 1 2 2
Clinic of Rehabilitation, Charles University, 2nd Medical School and UH Motol,1
Prague, Czech Republic, Paediatric Clinic, Charles University, 2nd Medical2
School and UH Motol, Prague, Czech Republic
Respiratory handling (RH) is a modification of Vojta9s reflex treatment of loco-
motor retardation in infants, which often accompanies CF. RH is a combination of
sensomotoric stimulation and the movement response thus evoked in the thorax and
abdominal muscles. An essential feature of this method is that it is gentle and
unforced, and not rejected by the infant. There are no tears. The physiotherapist
places her hands on specific points on the infant9s body, or strokes a certain area,
to provoke adequate respiratory movement of the thorax and of the abdominal and
back muscles. Pressure and stroking must be integrated to induce spontaneous activ-
ity. We have used this technique since 1993 for the more than 300 patients treated
in the CF Center, and regularly checked by anthropometry. Two thirds of them,
treated since birth or infancy, do not suffer from chest or spinal deformity, dys-
functional abdominal muscles or locomotor retardation. These patients have better
breathing patterns than our child patients before this method was adopted. RH can
be applied daily by every mother together with standard methods (inhalation etc.)
It must be stressed that the method is preventive for MI newborn, renewing normal
activity of the abdominal muscles. In CF retarded infants, RH improves muscular
activity, corrects thoracic deformity and encourages movement of the limbs. Chil-
dren of 3 years are then ready to use Flutter, supplied to all Czech CF children.
Compliance in older children is enhanced by the resulting lack of deformity, while
adult patients whose condition is exacerbated can also be helped. Supported by
MSMT-111300003 and MZCR-00000064203
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A study investigating physiotherapists perception of adherence
amongst patients with cystic fibrosis (CF)
H. Begley , W. Oliver , D. Rogers1 2 3
Department of Physiotherapy Education,UWCM, Cardiff, United Kingdom
Background: CF is the most common lethal genetic disease in the caucasion pop-
ulation. Physiotherapy management is routinely used to treat a number of associated
clinical problems, although patient compliance with physiotherapy treatment can be
poor. Our study asked a group of paediatric physiotherapists, from a number of
hospitals in Wales, if percieved patient adherence to therapy had affected the phys-
iotherapy management of their CF patients. Methodology: 7 physiotherapists par-
ticipated in a semi-structured interview. Staff grades ranged from junior to clinical
specialist. The questions used were developed from issues raised from relevant
literature and from issues identified during the author’s clinical experience. The
transcripts of the interviews were categorised into various themes and issues that
had been addressed, and appropriate conclusions were drawn from the data obtained.
Results: The choice of physiotherapeutic treatment and rationale were similar
between physiotherapists and matched with the literature on the subject. Most cli-
nicians felt that many of the issues related to treatment adherence were patient
dependent. Clinicians described similar mechanisms for dealing with patient non-
adherence. Conclusion: Overall, the opinions of the physiotherapists were similar
and complemented the findings of the research. The main findings were that com-
pliance is very much dependent on the individual patient, although external factors
such as added adolescent issues and time related factors could alter the levels.
Compliance was lowest with physiotherapy as opposed to medication, but exercise
activity was thought to have higher compliance levels. Clinicians responses varied
with the amount of clinical experience and between inpatient and outpatient phy-
siotherapists. Issues over clinically viable outcome measures were also highlighted.
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The self-management physiotherapy programme: shall we take out a
contract?
C. Ireland, M. Carroll
Southampton University Hospitals NHS Trust, Adult CF Unit, Southampton, United
Kingdom
Introduction: As people with cystic fibrosis (C.F.) are living longer more complex
time consuming treatment is necessary. Adherence to physiotherapy is poor in spite
of its recognised benefit of reducing lung damage and increasing exercise tolerance
(Robinson 2000). There is growing evidence that self-management can act as a
means of improving adherence to physiotherapy treatment. Self-management is the
individual’s ability to manage the symptoms, treatment, psycho-social consequences
and life-style changes inherent in living with a chronic condition. Study: Studies
are still in their infancy but evidence shows that patient empowerment, where the
patient and the professional work as partners in setting patient centred goals, has
the potential to improve adherence and outcomes of care (Ireland 2003). A study
has been undertaken into the effectiveness of a physiotherapy self-management
programme, in the form a contract, in a group of adult and adolescent patients in
the Southampton C.F. Unit. A structured self-management contract, which both the
patient and the professional sign, can potentially act as a means of demonstrating
a commitment to adhere to treatment. Findings: Preliminary results show that a self-
management contract can potentially encourage adherence to physiotherapy treat-
ment. Conclusion: The development of a self-management contract, as a means of
improving adherence to physiotherapy treatment, warrants further investigation.
References:
Robinson (2000) Thorax:56;3:237-241. Ireland (2003)
Physiotherapy: 89;7:397-407
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Controversies in exercise referral: Are we putting patients at risk?
R.J. McVean, A. Orr, H. Langman, D. Riley, A. Jones, A.K. Webb, M.E. Dodd
Wythenshawe Hospital, Manchester, United Kingdom
Research has shown that exercise preserves lung function in cystic fibrosis (CF).
Community Exercise Referral Schemes are a useful and economical way of inte-
grating supervised exercise programmes into CF patients’ self care. It is our Centre
policy to actively refer patients onto such schemes. We wish to minimize the pos-
sibility for cross infection of individuals wishing to attend the same gym. As the
referring clinician retains overall clinical responsibility for individuals, this survey
aims to identify the incidence of the number of patients wishing to attend the same
gym and thereby the potential for and rate of cross infection. We surveyed records
of all referrals over 12 months. 12 patients had requested or been referred onto an
exercise scheme. There were 3 cases of patients wishing to attend the same gym;
microbiological status (1) transmissible Pseudomonas aeruginosa (Pa) and sporadic
Pa; (2) non-Pa and sporadic Pa; (3) 2 patients with sporadic Pa. In the first 2 cases
only one patient was referred. We are aware of 21 patients who have self-referred
or are members of private gyms. There are 3 cases of patients who attend the same
gym; microbiological status (1) sporadic and transmissible Pa; (2) sporadic Pa and
Burkholderia gladioli; (3) a sporadic Pa patient who was actively referred to the
same gym which, unknown to us at the time, was already attended by a patient
with Burkholderia mulitvorans. We are not aware of any cases of cross infection
resulting from patients attending the same exercise facilities. This survey has high-
lighted the difficulties active referral to community gyms poses in relation to our
hospital based segregation policy. As a result we have developed Centre guidelines
for active referral alongside our routine microbiological surveillance.
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An investigation into practices employed to reduce cross infection
during airway clearance in patients with cystic fibrosis
L. Hardy, C. Foster, N. Byrne
Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, United Kingdom
Colonisation with pathogens including Pseudomonas aeruginosa and Burkholderia
Cepacia are known to be major causes of morbidity and mortality in cystic fibrosis
(CF). Since pathogens are disseminated throughout the patient’s environment dur-
ing airway clearance techniques (ACT), it is essential that cross contamination is
minimised. In order to identify current infection control practice during performance
of ACT by hospitalised patients, a questionnaire was sent to 18 regional adult and
paediatric CF centres in the UK. The response rate was 84%. Fourty seven per-
centage of centres nursed all their patients in cubicles. On the open ward, 88% of
ACT were at the bedside with curtains drawn. The remaining 12% were seen in a
treatment room. Hand washing was almost universal and 80% of physiotherapists
also used alcohol rub. 47% of respondents wore aprons for non P. aeruginosa,
increasing to 53% for P. aeruginosa and 87% for B. Cepacia patients. A lower
percentage of therapists wore gloves: 20% (non P. aeruginosa), 27% (P. aerugi-
nosa) and 62% (B. cepacia). It was preferred for individual physiotherapists to treat
only patients culturing a specific pathogen group. However, where this was not
possible, patients culturing B. Cepacia were treated after other groups. Physioth-
erapists in regional CF centres have identified protocols for prevention of cross
infection during performance of ACT, although these differ from centre to centre.
Recommendations are made for standardisation throughout the UK.
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Underlying mechanisms for problems of adherence to physiotherapy
among children with cystic fibrosis
J. Coyle , B. Williams , J. Dowell , M. Morison , A. Smith , S. Mukhopadhyay1 1 1 2 3 1
University of Dundee, Dundee, United Kingdom, University of Abertay, Dundee,1 2
United Kingdom, Tayside University Hospitals Trust, Dundee, United Kingdom3
Background: Research shows 50% of children with cystic fibrosis do not fully
adhere to recommended physiotherapy regimes. Although research has examined
the reasons for non-adherence among adults these have limited relevance for chil-
dren. Yet, understanding the beliefs underlying non-adherence is essential for plan-
ning an effective physiotherapy programme. Methods: A qualitative study based on
in-depth interviews with 32 children aged from 7 to 17 years, and their parents
(ns31) was conducted. The children were purposively selected to reflect a range
of age, symptom severity and family structure. Framework analysis and Nvivo
software were used to analyse the data. Results: Children were found to balance
the immediate physical benefits of physiotherapy, andyor their beliefs about it’s
long term efficacy against its’ negative social consequences of being restrictive,
socially isolating and threatening to identity. Perceived lack of immediate physical
benefits (mucus production, symptom lessening), weak beliefs in the long-term
preventive benefits and strong perceptions of social costs challenge adherence in
both child and parent. Conclusion: To plan an effective chest clearance programme
practitioners need to regularly assess beliefs about the benefits of physiotherapy;
strengthen beliefs about the long-term preventive nature of physiotherapy; recognize
social costs and identify social benefits of physiotherapy; develop age appropriate
games and adapt equipment for play; and assist parents to extend their support
network.
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Planning care: patient and physiotherapist priorities
A. Orr, R. McVean, H. Langman, D. Riley, A. Jones, A.K. Webb, M.E. Dodd
Wythenshawe Hospital, Manchester, United Kingdom
Patient centred care involves communication and partnerships with patients focus-
sing on specific problems to plan management. The CF Annual Review provides
an opportunity for the physiotherapist to identify patients treatment goals, highlight
physiotherapy issues and formulate plans tailored to the specific issues highlighted.
The aims of our audit were to categorise patients’goals (PG) and physiotherapy
issues (PTI), to determine if the two areas were in agreement and identify if plans
were predominantly generated by PG or PTI. Annual review records for 125
patients, 67y125 (53.6%) male, mean age 28.1 (S.D 8.02) years, FEV1% predicted
59.4% (S.D. 20.08) were examined over a 9 month period. The most common PG
were around exercise 48y125 (38.4%), maintaining health 37y125 (29.6%) and
weight 22y125 (17.6%). PTI included; exercise 42y125 (33.6%), patients ‘doing
well’ 34y125 (27.2%), and deteriorating objective measures 18y125 (14.4%).
When comparing PG and PTI there was no agreement, some agreement, and total
agreement in 66y125 (52.8%), 23y125 (18.4%) and 20y125 (16%) respectively.
The most common plans included exercise 71y125 (56.8%), nebulised antibiotics
40y125 (32%), and maintaining current treatment 20y125 (16.0%). Plans matched
PTI only in 32y125 (25.6%), PG only in 15y125 (12%), both in 51y125 (40.8%)
and neither in 10y125 (8%). We conclude that often PG do not match PTI. Plans
were mostly generated from both PG and PTI although in 25% of patients they
were from PTI alone. Further work is required to determine whether patients are
more likely to achieve plans formulated from their own goals or from the physioth-
erapists guidance.
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Paediatric physiotherapy: the next service development
E. Dixon, S.E. Pike, P. Stringer, A. Bush
Royal Brompton and Harefield NHS Trust, London, United Kingdom
Aim: A senior physiotherapist accompanies the Royal Brompton Hospital (RBH)
consultants as they attend clinics at the shared-care centres, to increase the physi-
otherapy input to all patients. From this it became apparent that there were marked
differences in the physiotherapy available and there was a need to continue care
and support locally, at homes and in schools. The aim was therefore to extend the
RBH physiotherapy service into the community, thus providing support and spe-
cialist input into the local environment. Patients: 395 CF children, often shared care
with other hospitals. Physiotherapy service provided to these families is variable,
with some patients only seen at annual review. Methods: A senior CF paediatric
physiotherapist post was established to link with the other members of the RBH
and local teams and assess educational, medical and psychosocial requirements.
Results: In the first 6 month period 48 home visits were carried out for assessment,
treatment and education; 17 school visits to review, update and educate school carers
in physiotherapy management on an individual basis; 22 shared care clinics (20
centres in total, 68 visits annually) were achieved providing local teams with sup-
port and education as required. 39% of time was spent on patient education and
49% in direct patient related communication. Conclusions: In the short time that
this new post has been established, the need has been highlighted and role expansion
identified. This is evident in the positive feedback from local medical teams and
the families themselves, as well as objectively through data collected. In the short-
term a preliminary audit to evaluate families’ views formally of the current services
will be undertaken, leading to a qualitative research study in the future.
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Audit of a clinical network providing paediatric physiotherapy services
to cystic fibrosis (CF) patients in Wales
D. Rogers, I.J.M. Doull
Paediatric CFyRespiratory Unit, UHW, Cardiff, United Kingdom
Introduction: The paediatric cystic fibrosis (CF) unit at the University Hospital of
Wales, Cardiff currently has responsibility for the care of 191 children with CF (70
full care, 121 shared care), spread over a geographical area of approximately 4000
square miles. During the past 10 years a clinical network of paediatric physioth-
erapists has been developed to facilitate individual patient management plans and
to provide a seamless physiotherapy service between the specialist CF centre and
shared care CF clinics. At the Cardiff Paediatric Unit we have used the audit process
to examine the structure and process of our shared care pathways. Audit: The current
clinical network is comprised of 21 paediatric physiotherapists working in 11 Dis-
trict General Hospitals throughout South and Mid Wales. An audit questionnaire
which looked at agreed CF standards for: (1) Current physiotherapy service pro-
vision and staffing levels. (2) Network communication priorities was completed by
every physiotherapist within the clinical network in 2003. Results: (1) A number
of hospitals within the clinical network failed to meet accepted standards for CF
physiotherapy service provision and staffing levels. (2) Network communication
priorities were universally accepted but many failed to reach accepted standards,
mainly due to staffing issues previously identified. Conclusion: At both a national
and local level a number of standards have been developed to improve the quality
of physiotherapy care for paediatric patients with CF. Our audit cycle has identified
the strengths and weaknesses of current services within a clinical network of shared
care clinics. Changes in network structure have now been implemented aimed at
improving the quality of physiotherapy care provided to our patients.
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Comprehensive annual assessment at a regional CF centre: the
improvement in physiotherapy provision over a fifteen year period
R. Ball, S.P. Conway, K.G. Brownlee
Regional Paediatric CF Unit, St James’s University Hospital, Leeds, United
Kingdom
The UK CF Trust advise that all patients have access, and regular assessment from
a Regional Specialist CF centre. Such centres offer up to date information to both
to patients and referring centres. We believe that the Comprehensive Annual Assess-
ment (CAA) is an essential part of this process. At St James’s Hospital a CAA is
offered to those who receive the majority of their care at other hospitals. Our aim
was to assess if the level of education of newly referred patients at CAA had
changed over a 15 year period. A comparative retrospective analysis of physio-
therapy practice and management was undertaken. During 1988–92, 113 patients
were assessed-85 were new referrals (median age 6.21yrs, range 1.4–27.1) and in
1999–2003, 132 patients were assessed-39 were new referrals (median age 2.39yrs,
range 0.22–13.31). All parameters measured had improved. Results:Patients having
any local contact with a physiotherapist (79%–100%). Appropriate use of the
Active Cycle of Breathing Technique (25%–65%). Passive physiotherapy regimens
reduced (60%–51%), (low median age in the second sample). Patients using an
assisted regimen (13%–31%). A greater percentage of patients were draining the
middle and upper lobes. Provision of appropriate postural drainage equipment
(53%–82%). Regular respiratory cultures (49%–82%) Regular RFTs w)5 yrsx
(23%–93%). Provision of appropriate nebuliser and compressor equipment
increased to 100%. Patients involved in planned exercise (45%–62%) Conclusion:
Repeated contact with the children, their parents and the feedback to local general
hospitals achieved by CAA is likely to be an important reason for the findings.
Increased physiotherapy contact and improved clinic monitoring leads to an
improved outcome for patients with CF.
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Urinary incontinence and bowel problems in women with CF and
chronic obstructive pulmonary disease (COPD) compared with
controls
B.M. Button , M. Sherburn , J. Chase , Z. McLachlan , T. Kotsimbos , J.1 1 1 1 2
Wilson2
School of Physiotherapy, University of Melbourne, Melbourne, Australia, Depart-1 2
ment of Allergy, Immunology and Respiratory Medicine, The Alfred Hospital, Mel-
bourne, Australia
Women with lung disease report urinary incontinence and bowel symptoms. Aims:
To estimate prevalence and severity of urinary incontinence (UI) and bowel prob-
lems in CF and COPD compared to controls. Methods: Women with CF and COPD
and healthy controls were invited to complete a survey based on the International
Continence Society recommendations regarding bladder and bowel problems in the
last 12 months,1 month and 2 weeks. Results: 125 women completed the survey;
66 controls, 37 CF and 22 COPD. The mean, range, odds ratio (OR) and p value
are reported for controls, CF and COPD. Age: controls 41 years (19–81), CF 31(19-
61) and COPD 62(48-77). Urge UI: OR 1 (controls), 0.286 (CF), 0.187 (COPD);
Ps0.067(CF); 0.732(COPD). Stress UI: 1, 5.768, 2.764; Ps0.001(CF),
0.099(COPD). Faecal incontinence: 1, 1.879, 4.593; Ps0.455(CF), 0.60(COPD).
Faecal urgency: 1, 1.069, 4.617; Ps0.929(CF), 0.24(COPD). The prevalence of
stress UI was 31% for control, 69% for CF, 60% for COPD groups while urge UI
was 38% for control, 11% for CF, 43% for COPD. COPD women were more likely
to have nocturia than CF or controls (P-0.001). Of those with UI, 18% in control,
57% in CF and 43% in COPD groups were not bothered by their symptoms. Bowel
symptoms occurred more frequently in CF than COPD (40% versus 28.6%), COPD
women had more prolapse than CF (24% vs 3%) and voiding difficulties (24% vs
8%). Conclusions: CF and COPD women have more urinary and bowel symptoms
than controls and are surprisingly more symptom tolerant than controls. CF women
have more defaecation difficulty possibly because of CF related gastro-intestinal
pathology.
Nursing
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Client Satisfaction within a Paediatric District General Hospital (DGH)
Cystic Fibrosis (CF) service
A.J. Hannam, A.S. Ahuja
Royal Albert Edward Infirmary, Wigan, United Kingdom
Introduction: At our clinic we have a team of staff caring for 20 families (24
children) with CF. The team consists of, Consultant Paediatrician, Specialist CF
Nurse, Dietician, Physiotherapist and Psychologist. In addition we have ward, clinic,
pharmacy and X-ray support staff all who have a special interest in CF. We have a
shared care system of service with Alder Hey Children’s Hospital, Liverpool, UK.
The views of patients and their carers are of utmost importance within our service
and indeed within the NHS. A questionnaire was developed to assess the level of
satisfaction our clients and their families have of the care they receive within a
DGH. The aim: To allow the team to assess the need for change and improvement
and to ensure that any changes made were appropriate to the needs of the families
we care for. Method: The survey was based on a five point Likert scale with addi-
tional room for comments. 19 questionnaires containing 14 questions were posted
out to families with SAE included to ensure anonymity. Results: We had a return
rate of 73.6%. The results showed a high rate of satisfaction with the services
offered with 100% of returns showing either satisfied or very satisfied with the
overall quality of care. Questions included satisfaction with professional services,
clinic facilities, contact with staff and courtesyyprivacyydignity. Comments received
from clients also reflected the high satisfaction levels reported. Conclusion: The
results allowed the team to understand changes needed to improve the service we
offer and allowed the families we care for to express their views and concerns. The
survey will be done annually to ensure high quality service is maintained.
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Cystic Fibrosis Young Person’s Clinic: The Families Views
M.J. Tabberner, G. Amison, S. Saunders, W. Nixon, P.H. Weller
Birmingham Childrens Hospital, Birmingham, United Kingdom
At Birmingham Children’s Hospital we have approximately 100 young people
between the ages of 10–16 years who attend the Cystic Fibrosis clinic. The majority
of our patients will attend the Transition clinic where their care will be transferred
to the Adult CF centre. We do not have a specific clinic for adolescents, which
could meet our patients changing needs as they become more independent. Gov-
ernment guidelines advocate the involvement of consumers at all stages and levels
of health care. Therefore, before attempting to provide an Adolescent clinic we
sought the opinions of our patients and their parents. A postal survey was con-
ducted, 100 identical questionnaires were sent to parents and patients in the 10–15
year age group. A reminder letter was sent 4 weeks later. There was a 54% response
rate (87% female; 13% male) from the parents and 53% (42% female; 58% male)
from the patients. The quantitative data was analysed and the comments were sum-
marised and reoccurring themes emphasised. The patients were prepared to be seen
in clinic at age 13 years but the parents wanted them to be at least 14 years. Patients
wanted their parents to discuss adolescent issues with them but the parents wanted
the CF Nurse to do this. The information gathered from this survey will be taken
into consideration when establishing guidelines for adolescent care.
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The views of adolescent cystic fibrosis patients
D. Pooley, R.E. Evans
Singleton Hospital, Swansea, United Kingdom
Introduction: Adolescent CF patients have to juggle their health needs with school-
work and they need to develop some independence in their CF care in preparation
for adult CF care. We were interested in their views on ideas to reduce the effect
of CF on their schoolwork and ideas to ease the transition to adult CF care, as well
as their views on the current CF service. Method: An anonymous questionnaire was
sent to all our CF patients age 10 or over in December 2002. Results: 11 of 15
questionnaires were returned. 73% did not want to see the CF team without their
parents and 64% did not want to attend a joint clinic with the adult team. 64%
would prefer an after school clinic but only 50% would be prepared to do school-
work during their hospital stay. 30% thought hospital food was bad, 70% had
enough to keep them occupied during hospital stay and 18% thought written infor-
mation was inadequate. Conclusion: The majority of our adolescents are not pre-
pared for transition to the adult services and are reluctant to trying new ways of
improving this transition. They are more open to the idea of after school clinics.
Since this questionnaire we are encouraging our adolescents to do part of the con-
sultation with various members of the CF team without their parents and transition
clinics are planned. We have improved access to written information and are
attempting to improve the food.
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Patient file and care continuity for coordinating nurses
M. Kerbrat, S. Argouarch, A.M. Grall, M.L. Madec, S. Pichon, G. Rault
Centre de Perharidy, Roscoff, France
In our centre, each coordinating nurse is referent for a group of patients. However,
for various reasons, a referent can be absent on day of admission or exit to com-
munity care, when the outpatient calls in or comes for routine or urgent visit. We
started a team work to define and implement an information tool which would
guarantee care continuity. The team met to define the necessary headings and the
detailed contents of each section: report of consultations and calls, home care for
intravenous antibiotic treatment, diet, therapeutic education and evaluation, school-
ing, specific protocol. We also defined the archiving method of the various com-
ponents of the nursing file. In addition, we agree on recapitulative forms for each
section. During each outpatient visit, the members of the care team fill in these
forms. We have implemented a standardised nursing file adapted to the specific
needs of the CF patient. This type of file allows every coordinating nurse to provide
a personalised follow-up to the patients. The files are at disposal of the multi-
disciplinary care team.
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What factors influence the use of quality of life measures in the clinical
setting in adolescents and adults with cystic fibrosis?
C. Forsyth
Southampton Adult Cystic Fibrosis Unit, Southampton, United Kingdom
The purpose of this evidence based practice project is to demonstrate an under-
standing of the research process using a question posed from a clinically focused
topic, to direct and guide this purpose. The question posed is: What factors influence
the use of quality of life measures in the clinical setting, in adolescents and adults
with cystic fibrosis? The advances in the management and care of patients with
cystic fibrosis have led to the majority surviving into adulthood, with many appear-
ing to be living normal independent lives. This is regardless of the demanding
treatment regimes and impaired lung function. Whether this longevity has added
quality to the lives of these patients is an aspect that needs to be addressed, by
introducing regular use of quality of life measures in the clinical setting, for this
population of patients. Currently, quality of life is not being measured on a regular
basis. It appears that the term quality of life is now used widely in medicine and
its an emerging field of research, even though the term still lacks definition and the
majority of quality of life measures are not developed from any clear conceptual
basis. There has been increased awareness of the potential benefits of including
quality of life measures in the clinical setting in recent years, but it still remains
primarily in the domain of clinical trials. Quality of life as an outcome measure in
the clinical setting represents a new paradigm. It is a patient centred approach and
is therefore, a departure from the more traditional clinical outcome measures such
as lung function. The aim of quality of life measurements in cystic fibrosis should
be to evaluate the impact of both the disease and its treatment burden on the wider
aspects of patient’s lives. However, it is not clear what should be measured and
how it should be measured under the global construct quality of life. It appears that
it can be measured in many different ways.
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Facilitating integrated multi-disciplinary cystic fibrosis (CF) care from
the paediatric centre through adult care to lung transplantation
F.A. Finlayson , N. Weller , J. Glazner , M. Dodman , S. Sutherland , J. Harris ,1 3 2 2 1 1
G.I. Snell , P. Robinson , J. Wilson1 2 1
The Alfred, Melbourne, Australia, RCH, Melbourne, Australia, RDNS, Mel-1 2 3
bourne, Australia
Changing teams from paediatric to adult and from adult to transplant care can have
a major impact on patients and families . Between 10–25 young people per year1, 2
are accepted from their paediatric centre via a transition process and 3–8 adults per
year transfer from CF to Transplant care at this centre. Aim: Development of targeted
resources to facilitate transfer of care from one specialist team to another. Method:
Separate reviews were undertaken. Each involved a literature search and input from
appropriate stakeholders. Results: Access to current information about the new phy-
sician, team and the different processes of care were identified as key factors to aid
adjustment to change of environment and treating team. Strategies included: Iden-
tification of a primary point of contact in both the adult and the transplant teams.
Orientation to the adult centre prior to transfer. Production of an audio-visual guide.
Additional printed resources for parentycarers and patients. Individualised transfer
programs. Early referral to a Transplant physician with experience in CF manage-
ment for an introductory discussion only. Shared-care between CF and Transplant
teams from wait listing until transplantation. Immediate post-transplant visits from
CF care team. Conclusion: Successful transfer of care involves creating opportu-
nities and access to information and clear lines of communication. 1. Webb A.K.,
Jones A.W. and Dodd M.E. J R Soc Med 2001; 94 (Suppl. 40): 8–11; 2. Stotland
P.K., Tsang A. and Tullis E. Ped Pulm 2000; Suppl. 20:338.
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Transition to adult services; the value of clinical audit in service
development
A.J. Dodds, S. McLaughlin, A. Duff, J. Axtell, H. Blythe
St James University Hospital, Leeds, United Kingdom
Introduction: The Children’s and Adult CF Units in Leeds recognise that transition
is a complex process that involves young adults, their families and CF teams. A
structured six-step programme was introduced in 1996, with the concept that a
successful transition programme is a source of ‘patient satisfaction and professional
pride’. A standards audit has been in place since 2001 to determine the relevance,
effectiveness, acceptability, efficiency, accessibility and equity of this programme.
Methods: Questionnaires are given to young adults (minimum age, 14 years) and
their parents, at the beginning of the programme, and also when transition is com-
plete (patients aged 16–18 years). The CF Patient Advocate was also asked her
perspective on transition. Results: Thirty-one pre-programme questionnaires were
completed, with 96% of respondents finding the programme information useful.
However, 63% of mothers reported concerns about transferring compared to 42%
of young adults and 37% of fathers. These included issues about cross infection,
segregation, changes in staff, and loss of parental involvement. The results sup-
ported the CF advocate views, who also suggested more information should be
given regarding fertility issues. Conclusion: This survey data has led to direct chang-
es in a long-established transition programme. Peer group transition and more infor-
mation about cross infection policies at the Adult Unit is given beforehand. A
comprehensive pre-transfer annual assessment is now carried out so that any chang-
es in treatment are associated with the children’s unit. This paper will outline the
current Leeds Transition Programme in more detail and discuss the on-going value
of audit.
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A year of living dangerously?
C. Hockings, S. Madge
Royal Brompton and Harefield NHS Trust, London, United Kingdom
In the UK it is estimated that over 200 000 young people (-26 year old) will pack
their bags and go travelling this year. Young people with CF will join this exodus.
Aim: To produce a concise information leaflet for people with CF travelling between
the United Kingdom and Australia for an extended period of time. It is anticipated
that the leaflet will improve and promote continuity of care during extended holi-
days and contain information including contact details of specialist centres in Aus-
tralia, health advice related to travelling, medical details of the traveller and
information on accessing health care. Method: (1) Interviews were carried out with
young people with CF who have previously travelled and the health care profes-
sionals who had provided health care for this group. (2) Searches were made on
the Internet and in the print media for information relevant to travelling with CF.
(3) Communication was made with the appropriate government departments to
establish the legal situation for funded health care. (4) Discussion with the CF team
of each CF centre at the most common destinations in Australia. Results: Infor-
mation gained included entitlements abroad, average cost of services (from con-
sultations to medications), documentation and referral procedures and specific
health care advice related to the climate. CF centres also highlighted issues asso-
ciated with their individual service. Discussion: This information will be produced
in a leaflet and will be made available on the Internet. It is anticipated that the
ready availability of this information will make planning trips easier and more
realistic. Many people with CF are taking part in the same activities as their peers,
by supporting them in this experience we hope to encourage optimum health along
side a fulfilling and enjoyable adventure. Supported through the Best Care Schol-
arship (International Nurse Specialist Group-CF)
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Supporting patients in decision making about home therapy
E. Bramwell, S. Barton, S. Fleming, S. Madge
Royal Brompton and Harefield NHS Trust, London, United Kingdom
Aim: To seek the views and opinions of patients about the service including self-
administration, education, support and preference. Methods: An independent
researcher carried out confidential, telephone questionnaires. Results: Ns30 (14
male), mean age 27.3 years (18–47).
Hospital Home
Drug administration Self – 47% Self – 90%
Nurse – 10% Other – 10%
Both – 37% Both – 0%
Felt pressurised into carrying out the procedure 3% 10%
Found the procedure stressful 10% 20%
Education and support 83% were given information on discharge, mostly in the
form of a booklet. 80% received a contact number for advice on discharge. 30%
of patients received a visit from the hospital specialist homecare team and 30%
would have liked a visit, however were not in the catchment area of the homecare
team. Preference 90% stated a preference for home IV treatment, with 31% of
patients continuing to work and 57% attending their education whilst on treatment.
Conclusions: Despite reporting an increase in stress and feeling under pressure to
carry out home IV therapy the majority of patients in this survey preferred this
option. However, the CF Team should be aware of such conflicts and check with
the patient at every episode rather than make assumptions. With the young adult
patient population requiring less treatment and a greater percentage working, the
need for outpatient treatment is only likely to increase. As this option of delivering
treatment appears to be more preferable to patients than hospital admissions the CF
Team are currently exploring further ways of offering support to all patients by
involving primary healthcare teams.
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Home intravenous antibiotic training for families
D. Forster, J. Mighten
Nottingham City Hospital, Nottingham, United Kingdom
Regular admissions for IV antibiotics can be disruptive for the child’s education
and all aspects of family life. However, it is not an easy option and the decision
should be made jointly with the multidisciplinary team and family. The aim of using
the teaching programme is to ensure that parents are competent and safe in the
administration of IV medication. They must be able to state the dosages, timings
and reasons for giving the medication and be aware of possible side effects. Training
is carried out initially whilst the child is in the hospital, so that the other profes-
sionals, physiotherapist, pharmacist and infection control nurse, can be involved.
However, training can continue at home as necessary. The respiratory nurses teach
and assess competency. The teaching package, utilises clear written and verbal
instructions, avoids jargon and enhances the consistency and value of the teaching
process. With adequate teaching, support, including contact numbers, parents should
be able to give IV medication at home, thus reducing the negative impact on family
life. This is an ongoing process and requires regular review.
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The CF care coordinator nurse: a bridge between home and hospital for
IV antibiotic courses
L. Agrario, C. Dupont, M.J. Nadaud, N. Desmazes-Dufeu, D. Dusser, D. Hubert
CRCM adultes, Cochin hospital, Paris, France
The CF centre at Cochin hospital, Paris, France, takes care of 250 CF adults. Their
mean age is 28.7 years (range 17–60); 29% are students and 48% are working.
Mean FEV1 is 48.6% predicted, 75% have chronic bronchial colonisation with P.
aeruginosa and 68.3% receive IV antibiotic courses. In order to decrease the risk
of cross infection and to improve the quality of life, the medical team chose to
favour home care. Then in 2003, about 500 IV antibiotic courses have been decided
by the CF centre practitioners and realised at home. The organisation of these
courses is devoted to the 2 CF care coordinator nurses. In the CF centre, they
coordinate paramedical, social and psychological information about patients. This
knowledge facilitates the relationships with patients and families, as well as home
care professionals. The CF care coordinators are in touch with the home care net-
work for every antibiotic course (nurses, medical device providers, chemists and
biochemical laboratories). In order to optimise the antibiotic courses at home, the
team members chose to develop the following tools: written medical and paramed-
ical guidelines for home nurses, organisation chart of the CF centre team members,
paramedical patient’s file, specifications for the medical device providers, visits and
meeting with the home nurses, a patient link notebook between home and hospital.
The computerisation has been achieved for the medical patient’s file and is in
progress for the paramedical one.
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Does the number of intravenous antibiotic courses administered over
one year have an effect on weight gain in Cystic Fibrosis patients
G. Milne , R. Muirhead2 1
Dundee University, Dundee, United Kingdom, Ninewells Hospital, Dundee, United1 2
Kingdom
Introduction: Intravenous antibiotic therapy (IVAT) is the primary treatment in the
prevention of lung infection and deterioration in Cystic Fibrosis patients. Prescribing
regimes are divided into elective or reactive. Elective being 4 courses per year and
reactive being as many as required to control the infection. The combination of the
patients health at time of requiring IVAT and the antibiotics prescribed affect the
gastrointestinal system and eating routine disturbing their nutritional intake having
a direct impact and possibly detrimental effect on weight maintenance. Method: The
computer records and nurse held notes of all patients attending a paediatric CF
clinic were audited to identify weight gain, height velocity, colonisation and courses
of intravenous antibiotics administered. A retrospective review of the year 2002 to
2003 was analysed.
Cohort Number IVAT Number Average Weight Height Time
courses patients age gain (kg) gain (cm) years
1 0 7 9.4 4.48 5.89 0.96
2 4 8 10.5 3.58 4.98 0.99
3 -4 8 12.7 1.56 4.39 0.90
4 )4 5 13.7 3.90 2.86 0.97
Data: Cohort 1 receiving no IVAT gain weight as expected for healthy children.
Cohort 4 had significant weight gain which could be attributed to higher number
of patients with enteral feeding and increased number of admissions to hospital and
therefore dietetic and physiotherapy support. Cohort 3 children presenting with a
chest infection and receiving reactive IVAT have greater effect from symptoms of
a chest infection identified by poor weight gain. Conclusion: Cohort 2 identifies
the benefits of elective intravenous antibiotic therapy as consistent weight gain and
reduced admissions to hospital over a 1 year period.
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Assessment of pain in the adult CF population attending the Ninewells
clinic
M. Pogson, L. MacDougall
Tayside University Hospital Trust, Dundee, United Kingdom
Within our clinic we had anecdotal evidence that patients do suffer from pain, which
can vary in it’s intensity. There is a feeling amongst the team that patients under-
report pain and discomfort and accept it as being normal within the course of the
disease. We decided to use the Brief Pain Inventory (McCaffery 1999) to attempt
to highlight if there is a need for improved pain control within our clinic population
and whether pain is connected to the severity of disease. The questionnaire and
patient information sheet were given out in the clinic by the CF Nurse Specialist.
All patients attending the adult CF clinic were targeted. The brief pain inventory is
a very simple validated tool, which was easy for the patients to complete. The
results were matched with the patients routine pulmonary function and BMI which
are routinely recorded at every clinic visit. Fourty percent of the patients surveyed
did not report any pain at all. Of those patients their pulmonary function, as meas-
ured by their FEV1 ranged from 0.79 litres to 3.5 litres (mean 2.4 litres). The BMI
for this group ranged from 16 to 24.5 (mean 21.1). The remaining 60% of the
group reported pain of varying severity. This groups pulmonary function ranged
from 1.14 litres to 2.97 litres (mean 1.93 litres). The BMI for this group ranged
from 18 to 31.6 (mean 22.1). Of the patients reeporting pain, 33% of them found
that they were able to achieve adequate pain control. The remainder, however found
that in spite of varying analgesics and use of other measures to reduce pain, eg
distraction or relaxation, the pain had a considerable impact on their lives. Subjects
reported sleep and appetite disturbance. Pain was not found to be associated with
severity of illness. We conclude that patients with CF do suffer from pain and often
this is not well controlled. In order to improve the service we have formed closer
links with the hospital palliative care team, we now make a point of asking the
patients about pain and we have involved the psychologist and pharmacist attached
to the team. McCaffery M, Pasero C 1999 Pain: Clinical Manual, p61 Mosby
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Is genital Candida infection a significant problem for young adults with
Cystic Fibrosis?
A. Lyon, E. Gunn, C.S. Haworth, D. Bilton
Adult CF Centre, Papworth Hospital, Cambridge, United Kingdom
In our adult Cystic Fibrosis (CF) clinic the specialist nurse discusses fertility and
sexual health at annual review with each patient. We were concerned that in omitting
a specific discussion of Candida infection at the annual review we may have over-
looked a significant management problem. We set out to establish whether genital
Candida infection was a common difficulty for our adults with CF. We therefore
asked consecutive clinic attenders to complete a questionnaire regarding their anti-
biotic treatment and their associated symptoms of genital Candida infection. 40
patients (19 M) completed the questionnaire. 25 patients were taking oral mainte-
nance antibiotics. 35 patients regularly received intravenous antibiotics, the number
of courses varying from 2 to 12 per year. 25 patients (10 M) had experienced
symptoms of Candida infection including 1 male who had persistent symptoms.
The patients reported varying relationship of symptoms to antibiotic treatment. 15
(7 M) described symptoms related only to an intravenous antibiotic course. 10
patients (3 M) described symptoms related to augmented oral antibiotic therapy. 2
patients also described worsening symptoms related to courses of oral steroids.
When asked about the presence of symptoms in partners all of the patients declined
to comment. When asked if the clinic staff had ever discussed the possibility of
partner infection only 6 patients reported that this had occurred. Of the 25 patients
with Candida related symptoms, 24 had used either topical Canesten or oral Flu-
conazole. 6 patients reported dissatisfaction with the response to treatment. This
pilot study reveals that there is a significant burden of symptoms in our CF adults
related to genital Candida infection and that treatment is not always successful. It
is also clear that discussions with the medical staff about this problem are not
comprehensive. We suggest that at annual review all patients are alerted to the
symptoms of candidal infection and given advice regarding treatment. The specialist
nurse can also discuss the potential difficulty for partners when appropriate.
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The use of photograph albums to explain surgical procedures for
children with CF
I.L. Boyd, A.M. Mallinson, T.G. Marshall
Royal Hospital for Sick Children, Edinburgh, United Kingdom
Introduction: It is vital that children are given timely, understandable and accurate
information when they are having to undergo procedures, especially surgical pro-
cedures such as gastrostomy and insertion of a Port-a-Cath. These procedures are
often carried out on very young children who may lack understanding, resulting in
them becoming confused and frightened. The Cystic Fibrosis (CF) Nurses at the
Royal Hospital for Sick Children have found it beneficial to explain these proce-
dures with the use of a step-by-step visual explanation using a specially prepared
photograph album. Method: The album was produced by taking a series of photo-
graphs following a CF patient undergoing insertion of a Port-a-Cath and another
patient who had a gastrostomy inserted. Each patient had photographs taken at
various stages of the admission, through to discharge and any subsequent follow
up procedures. Conclusion: The albums have not only been beneficial to the chil-
dren but also parents as it enables the CF nurses and ward staff to explain these
procedures carefully.
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Making memories better: the impact of childhood experiences on how
adults with cystic fibrosis cope with medical procedures
A.J. Mill
Royal Aberdeen Children’s Hospital, Aberdeen, United Kingdom1
Children born today with CF have an increased life expectancy but face a longer
lifetime of medical procedures. The aim of this study was to find out if memorable
childhood experiences of these procedures, impact on the way that CF adults cope
with the same procedures. Forty-two adults with CF attending the CF clinic at
Aberdeen Royal Infirmary were sent a postal questionnaire. It asked for quantitative
information regarding current anxieties prior to medical procedures. Quantitative
and qualitative questioning was used to elicit information regarding memorable
experiences from childhood. A response rate of 62% (ns26) was achieved and the
mean age of respondents was 26.4 years of age. A high level of current anxiety
prior to some medical procedures was evident from the results. Memorable expe-
riences from childhood were mostly negative and related to IV line insertion. When
these experiences were related to current anxiety, IV line insertion was significant
with a P values0.0117. Blood sampling was another procedure with a significant
result, P values0.0120. However, this result reflected the lack of memorable expe-
riences from childhood and the minimal amount of anxiety in adults prior to this
procedure currently. Other salient points that emerged from the qualitative data,
centred around being restrained for procedures and staff having multiple attempts
at procedures. It is hoped that from the results of this study we can try to limit
negative experiences of medical procedures in children with CF and help them cope
better with these procedures as adults.
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Patient satisfaction with the use of inhaled Nitrous Oxide for painful
procedures in a local CF unit
V. Williams, A. Riley, K. Richardson, R.J. Rayner
Royal Wolverhampton Hospitals, Wolverhampton, United Kingdom
The management of Cystic Fibrosis (CF) involves repeated invasive procedures,
which may be painful, despite the use of topical anaesthetic creams and distraction.
Fear of needles is consequently very common. Since December 2002, the paediatric
unit of a District General Hospital (DGH) has routinely offered the use of self-
administered inhaled Nitrous Oxide (Entonox), in addition to topical anaesthetic
cream, to all CF patients over the age of 4 years requiring venous cannulation,
insertion of silastic long lines and blood sampling. The Nitrous Oxide was pre-
scribed by the doctor who was performing the procedure, following guidelines
produced by the paediatric consultant and agreed with the pain control team. The
treated group consisted of 14 children and young people. A patient satisfaction
survey was carried out to collect the views and experiences of these individuals
and their families, compared with their previous experiences of such procedures.
Thirteen patients felt their pain control and anxiety had improved. Two patients
experienced minor adverse side effects. Whilst Mills, HL and Redmond, AOB,
introduced the use of Nitrous Oxide in a Regional Paediatric CF unit, this is the
first report of its use in a DGH (Cystic fibrosis patients view of self administered
Nitrous Oxide (Entonox) during insertion of Epicutaneo – Cava catheters: http:yy
www.ecfsoc.orgyViennayabstractsyP291.htm). The next step will be the develop-
ment of a patient group direction to allow the prescription of Nitrous Oxide for CF
patients by appropriately trained specialist nurses.
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The use of Entonox to facilitate line insertion and venepuncture
J.C. Maddison, K.A. Padoa, G.J. Connett
Southampton University Hospitals NHS Trust, Southampton, United Kingdom
Most CF children undergo repeated venous access procedures. Needles phobias are
common. Local anaesthetics reduce pain but do not relieve anxiety. Entonox, a 50%
nitrous oxideyoxygen mix is an analgesic and anxiolytic. We have assessed its
benefit, when administered by the CF Nurse Specialist after extended role training,
in selected individuals apprehensive about venepuncture. Individuals were encour-
aged to self administer entonox using a demand valve system shortly before the
procedure and throughout according to their perceived needs. Over 12 months, 39
children aged 3–16 years were considered. None had specific exclusion criteria
although respiratory exacerbation was not considered a contraindication. Eleven
declined. Ten did not perceive its use as necessary and one parent withheld consent.
All 28 who received entonox reported decreased anxiety compared with previous
procedure. All individuals returned to normal activities immediately afterwards and
there were no adverse events. All stated they would want to use entonox for future
venepunctures. First attempt success improved (85–95%) compared with historical
controls. Four children were able to overcome needle phobias, which have previ-
ously prevented venepuncture for annual assessment blood tests. Entonox is an
effective, well-tolerated drug for overcoming many of the problems encountered
with successful venepuncture in Cystic Fibrosis.
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Parents Views of the Paediatric Cystic Fibrosis Service
R.E. Evans, D. Pooley
Singleton Hospital, Swansea, United Kingdom
Introduction: A new consultant brings ideas for change to a service but with a
chronic illness, patients and parents are resistant to change. Some changes were
made in April 2002 (change of clinic day, infection control policy, inpatient care
pathway, staff teaching) and further changes were planned (psychology input, par-
ents receiving copies of clinic letters). We sought the views of the parents on the
service before making further changes. Method: An anonymous questionnaire cov-
ering community, outpatient and inpatient aspects of CF care was sent to the parents
of all CF children attending our clinic in December 2002. A stamp-addressed enve-
lope was provided to return the questionnaire. Results: 25 of 31 questionnaires were
returned. No parent was dissatisfied with the overall service and the majority (68%)
would call us rather than their family doctor if their child were unwell. No parent
suggested that we needed a psychologist. 88% wanted copies of clinic letters. 12%
thought we could improve on written information, 4% verbal. Views on community
service were generally good and better than we expected. Areas that needed
improvement on ward included out of hours physiotherapy, dietetic input and junior
doctor CF knowledge. Conclusions: Parents views are important to a service and
we have used their views to further develop our service. Parents now get copies of
clinic letters and we have improved the information we provide. Results were fed
back to the parents in a newsletter. Despite not initially wanting a psychologist our
parents now recognise her value.
Psychosocial Issues
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A longitudinal study of coping in mothers and fathers following a new
diagnosis of cystic fibrosis: clinical implications
C.A. Glasscoe , J. Hill , G. Lancaster , R.L. Smyth1 2 3 4
Royal Liverpool Children’s Hospital NHS Trust-Alder Hey, Liverpool, United1
Kingdom, University of Liverpool, Department of Psychiatry, Liverpool, United2
Kingdom, University of Liverpool, Centre for Medical Statistics and Health Eval-3
uation, Liverpool, United Kingdom, University of Liverpool, Institute of Child4
Health, Liverpool, United Kingdom.
Background: Although 95% of families achieve some degree of adaptation within
the first year of the diagnosis of cystic fibrosis (CF), a proportion of parents report
elevated levels of depression and some partner dissatisfaction. The majority of stud-
ies focus on the effect and coping of mothers. A model of parental adaptation
examined differences in beliefs and role allocation as mediators of depression in
both parents. Past unresolved loss and the quality of the couple relationship were
assessed as possible moderators of depression. Methods: A cohort of 45 pairs of
parents, matched for age, sex and position in the family of the affected child,
compared study and control groups soon after the diagnosis (Time A) and nine
months later (Time B). Beliefs were operationalised with the locus of control con-
struct and role allocation was contextualised with division of childcare tasks. The
primary outcome was depression, measured with the Beck Depression Inventory
(BDI) and a clinical cut-off of G13 for dysphoria (mild depression). Emphasis
was placed on the estimation of effect with 95% confidence intervals using a Man-
tel–Haenszel risk-ratio (RR ). Main results: Soon after the diagnosis 22% ofMH
couples in the CF group reported dysphoria in both parents compared with 11.1%
in the control group. Risk of dysphoria where the child was F9 months of age at
baseline was RR s2 (1.04, 3.86) for mothers and RR s5 (1.55, 16.09) forMH MH
fathers at Time A and RR s2.86 (1.29, 6.32) for mothers and RR s7 (0.86,MH MH
56.9) for fathers at Time B. Conclusions: Early diagnosis may increase the likeli-
hood of depression in both parents. Although fewer fathers reported dysphoria than
mothers the increased effect on mothers and fathers in the CF relative to the control
group is an area of concern for clinicians.
383
The New Diagnosis Cystic Fibrosis Group
D. Forster, J. Mighten
Nottingham City Hospital, Nottingham, United Kingdom
The idea of running a group for parents with children newly diagnosed with CF
was initially discussed between the respiratory nurses and social worker in 1996.
It was apparent that home visits and clinic appointments did not provide the support
necessary to enable parents to cope with the complex issues surrounding new diag-
nosis. Aims of the groups are to: Meet together informally; Meet different members
of CF team in a more relaxed atmosphere, away from the hospital; Hear more about
CF and be able to ask questions; Share experiencesyfeelings; A time limited pro-
gramme, with 6 sessions being held in the evenings to accommodate working part-
ners. The programme begins with a session for introductions and discussion about
feelings on diagnosis. The monthly sessions continue with an introduction to genet-
ics, physio, dietetics and an opportunity to talk to a parent of an older child and
an adult. The groups have all evaluated positively. Statements such as, ‘please don’t
stop the sessions they do us all good’ support this. It is hoped that parents will
continue to develop support mechanisms themselves.
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Receiving a CF diagnosis; parental experiences and affect on relatives
I. de Monestrol , A. Bergsten Brucefors , B. Sjoberg , L. Hjelte1 2 1 1¨
Stockholm CF centre, Karolinska Univ. Hospital Huddinge, Karolinska Institutet,1
Stockholm, Sweden, Department of of Public Health Science, Div. of Social Med-2
icine, Karolinska Institutet, Stockholm, Sweden
Introduction: In order to be able to evaluate the psychological impact of a possible
neonatal screening programme in Sweden the parental experiences of receiving a
CF diagnosis of their child alerted on symptoms were investigated. Methods: A
questionnaire was sent to the parents of all the CF children born 1968–2000 (G18
years ns48,-18 years ns95) and attending Stockholm CF centre, with questions
about the implications of the CF diagnosis for the parents, siblings and relatives.
Results: A majority (51%) of the parents described not feeling well after their child
received its CF diagnosis. They experienced anxiety (24%), crisis (18%) and unpro-
fessionally given information (10%). In this study we saw a shift of focus over
time. Parents to adult CF children more often mentioned that their child had been
given a specific life expectancy. Parents to younger CF children more frequently
mentioned that life focused on treatment and care. Some parents described positive
(10%) or mixed (30%) experiences. A majority (82%) of the parents described
that the CF diagnosis had an influence on all relatives. Siblings were affected by
receiving less attention and time (52%), by showing worry (28%) as well as jeal-
ousy (12%). Grandparents showed anxiety (67%), lack of knowledge or under-
standing (17%) but also denial (11%). Other relatives showed anxiety (40%), lack
of knowledge or understanding (30%) but also gave constructive help to the family
(23%). Conclusions: This study shows how revolutionary it is to receive a CF
diagnosis not only for parents but also for siblings and other relatives. Correct
information and tools for adapting to the diagnosis are important for all involved.
A future question is how to help relatives to become as good a support as possible
to the parents.
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Psychosocial adjustment and coping in parents of children with cystic
fibrosis
C. Liossi , R. Evans1 2
Department of Psychology, University of Wales Swansea, Swansea, United King-1
dom, Department of Child Health, Singleton Hospital, Swansea, United Kingdom2
Advances in diagnosis and treatment of CF have resulted in patients living longer
and thus families live with the illness for longer. At the same time treatments are
becoming increasingly demanding and are largely performed in the family home.
Uncertainty about the course of the disease can put much additional pressure on
the family. Caring for a child with CF is stressful and this has implications for the
main carer, the parental relationship, well siblings, family functioning as well as
the affected. However, despite the extent and significance of the problem, limited
information exists about the impact that cystic fibrosis has on the families and the
ways that families cope. This qualitative study explores the impact of cystic fibrosis
and treatment on parents, current stresses experienced and coping strategies used
by them. In total 20 semi-structured interviews will be conducted with parents (10
interviews with mothers and 10 with fathers) of children suffering from cystic
fibrosis. The interviews are tape-recorded, transcribed and analysed with Interpre-
tative Phenomenological Analysis, a qualitative analytic method concerned with an
individual’s personal perception or account of an object or event as opposed to an
attempt to produce an objective statement of the object or event itself. Preliminary
results of this investigation will be available by the time of the conference.
s103Journal of Cystic Fibrosis 3 (2004) S102–S110
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Reproductive attitudes of couples having a child with cystic fibrosis in
Brittany (France)
M. De Braekeleer , G. Rault , G. Bellis1 2 3
Faculte de Medecine & CHU Morvan, Brest, France, Centre de Perharidy, Ros-1 2´ ´
coff, France, Institut National d’Etudes Demographiques, Paris, France3 ´
Cystic fibrosis (CF) has an incidence of 1 in 2636 livebirths and a carrier rate of
1 in 26 inhabitants in Brittany. One objective of a major enquiry among parents
having a CF child, CF adolescents and adults was to evaluate the reproductive
behaviour of those 124 couples attending a CF care center. The knowledge of the
recurrence risk resulted in deciding against further progeny or in reducing the num-
ber of children (average number of children: 1.96; ideal mean number of children:
3.7). 35% adopted or changed method after the birth of their affected child, but the
change was due to the birth of the CF child in only 14.3% of the couples. 95.1%
were in favor of prenatal diagnosis and 41.2% of the couples had used it. 68.6%
were in favor of pregnancy interruption for CF and 76.2% would interrupt the
pregnancy should PD revealed that their fetus had CF. All 123 respondents thought
that genetic counseling was useful but only 87.1% knew of its availability. Our
results are quite different from those previously published. Although they could be
population-specific, one cannot exclude that they reflect a change of attitudes of
parents, the other studies being much older. Supported by grants from the ‘Fon-
dation du Centre Helio-Marin’ in Roscoff and the ‘Programme Hospitalier de´
Recherche Clinique (PHRC)’.
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Coping with Cystic Fibrosis in the family—experiences of healthy
siblings
K. Russo , M. Hogg1 2
Royal Belfast Hospital for Sick Children, Belfast, United Kingdom
Introduction: Cystic Fibrosis (CF) impacts significantly upon families, and coping
methods changes as the disease progresses over time. Bluebond-Langer (1996)
provided a comprehensive model of this process by interviewing families at differ-
ent points along the illness trajectory about their experiences. The aim of this pilot
study was to use a similar methodology to explore the issues that arise for healthy
siblings coping with a CF sibling across different stages of development. Method-
ology: Well siblings of CF children were invited to participate in a structured inter-
view consisting of 5 questions. A total of 9 children were selected, 3 each from the
age groups of -6 years; 7–12 years; and 13–18 years. Interviews were undertaken
in the family home, and took 10 min to complete. Results: Siblings from the younger
group were able to identify simple feelings about CF, with more complex emotions
appearing from age 7 onwards. Feelings of jealousy due to lack of attention were
reported from the middle group. The identification of solutions to difficult feelings
about CF occurred from ages 13 onwards. Younger children simply wished for CF
to go away, whereas acceptance appeared to occur from age 13. Wishing for a cure
appeared in the older group. Conclusions: This small pilot study has highlighted
the natural developmental processes involved in learning to cope with having CF
in the family. A larger study of this nature would indeed provide a useful framework
from which to base responses to commonly asked questions about the experiences
of healthy siblings in families with a chronic illness.
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Living with CF-Comparing the coping strategy in the families with CF-
member and families with ALL-member
G. Petrova, S. Shopova, I. Kalev
Medical University, Sofia, Bulgaria
Our goals: To understand and treat the specific psychological problems in families
with CF-member, and to find the way we can help to improve their quality of life.
And what is the difference in the family reactions when they realize they have a
member with CF or ALL. Our methods: Attitude Questionnaire; Anxiety Scale;
Interview in depth concerning the feelings of the relatives for the patients; Social
support Questionnaire. Patients: 1 group is of the families of 15 diagnosed withst
CF, confirmed with clinical symptoms, the sweat tests and genetic mapping. 2nd
group—the families of 15 diagnosed with ALL, confirmed by clinical symptoms,
bone marrow biopsy and CBC. Conclusions: Decreasing of the abilities in life for
the patients with CF is slower, and is accepted more difficult than the rapid pro-
gress for one in the patients with ALL. The relatives of the children with CF show,
reaction of ‘moan’ long before the real end comes with over-caring and hyper-
protecting the child, without any hope for future sterling life for their child. The
second group of parents is trying to save the life (no matter of it’s quality) of the
child at any cost. These differences are due to the different prognosis, the possi-
bilities for medical treatment and healing and the life expectancy in these two
diseases.
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Parents who have cystic fibrosis—experiences and aspects of
parenthood
M. Frankl, L. Hjelte
Karolinska University Hospital, Huddinge, Stockholm, Sweden
Introduction: Many women with cystic fibrosis have reduced fertility due to thick
mucus in their cervix. Men with CF have a normal testicular function and sperm
production, but 99% of CF males are infertile due to atresiayobstruction of the vas
deferens. Advances in healthcare have increased the possibilities both for men and
women with CF to become parents by means of assisted fertilisation. Today in
Sweden there are 51 known men and women (24 men) with CF who are parents
to approximately 70 children. Methods: 3 questionnaires were sent out: Parenthood
when having CF questionnaire, the Swedish Parenthood Stress Questionnaire
(SPSQ) and the value of children to parents’ questionnaire. Results: 35 (of 51) CF-
patients and 29 partners participated in the study and were compared to 91 (of 153)
healthy controls and their 71 partners. Patients expressed little worry that the fact
that they had CF would affect their children in a negative way and they did not
believe that the disease would influence their possibility of being good parents.
Most parents wished for no extra support from the CF clinic in regard to treatment
or informationysupport to the children. SPSQ: The patient group reported less total
stress (P-0.05). Women within both groups reported higher levels of total stress.
Conclusion: We conclude that the psychosocial situation and family life seem sat-
isfying for parents with cystic fibrosis. This study shows that parents with CF see
themselves as ordinary parents who do not differ from healthy parents in any major
way.
s104 Journal of Cystic Fibrosis 3 (2004) S102–S110
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Cultural differences in coping with cystic fibrosis: the Albanian
minority in Italy
P. Catastini, F. Festini, T. Repetto
Cystic Fibrosis Centre of Tuscany, Meyer Hospital, University of Florence, Flor-
ence, Italy
It has been shown that CF incidence among Albanians is considerably higher than
in other Caucasian populations (Thorax 2003;58:93). In the last decade, Italy wit-
nessed a relevant influx of Albanian immigrants; an increasing number of Albanian
CF newborns have been diagnosed thanks to Italy’s neonatal screening programme
and taken care of in Italian CF Centres. The goal of this study was to evaluate how
the different cultural background affects the parents’ personal experience of the
disease and their coping strategies toward stress generated by the illness and by the
healthcare team. The STAI Test—to assess state and trait anxiety—was administered
to 7 parents (4 M, 3 F, mean age 29.5 years, S.D. 8.1) of Albanian CF newborns
diagnosed by neonatal screening, who also underwent a clinical psychological inter-
view. A control group of 8 parents (4 M, 4 F, mean age 35.8 years, S.D. 3.4) of
Italian CF screening-diagnosed neonates was assessed with the same method. In
both groups the majority of subjects had state and trait anxiety scores higher than
mean values but in the Albanian group the proportion of subjects with trait anxiety
scores over the mean q1 S.D. was higher than among Italians (Fisher test Ps
0.04). The psychological interviews evidenced a different approach of Albanian
parents to CF; in particular, they repeatedly expressed an attitude of defence against
the possibility of increasing their knowledge of CF, going as far as refusing to
receive any information about it, although accepting all the proposed treatments.
Although the examined sample is small, these results raise questions about the
relational and communicational strategies that the CF care team should adopt with
the parents of Albanian infants with CF to achieve the best possible opportunity of
treatment.
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Psychological problems presenting to an adult cystic fibrosis clinical
psychology service over a 5 year period
H. Oxley, A.K. Webb, A.M. Jones, M. Dodd
Manchester Adult Cystic Fibrosis Centre (MACFC), Manchester, United Kingdom
Background: The CF Trust recommends all CF patients have access to a psychol-
ogist. The clinical psychologist (CP) in the MACFC (0.6 wte) spends approx. 35%
of her time in face to face work with referred patients (q10% in annual assess-
ments, q45% in other patient related activity—Oxley et al 2004). The presenting
problems of such patients have not previously been described in detail. Aim: To
determine the extent & range of presenting problems of patients referred to the CP
service of a large adult CF centre. Method: A retrospective review of CP’s records
& medical notes was conducted. Categories of problems were identified & fre-
quency of presentation calculated. Results: 102 of a total 240 patients at MACFC
were referred to the CP for assessmentytherapy, resulting in a total of 156 referrals
(63.5% female) over 5 years. Mean (range) no. of sessions 4.5 (1–46), age 27.7
(17–50) years, FEV1 56.8 (14.9–120.8)% predicted, BMI 20.65 (15.2–37). The
most common presenting problems were depressionylow mood (24.7%) & anxiety
disorders (22.7%). 10 other categories of problems were identified: difficulty coping
with CF(10.8%), problems with health behaviours inc. adherence (6.3%), relation-
ship issues (5.6%), insomnia (4.9%), adjustment to non-health life events (3.8%),
‘end of life’ issues (3.8%), weightyeating problems (3.1%), self harmysuicidal
ideation (2.1%), substance misuse (2.1%), other problems (10.1%). Conclusion:
Referrals to the CP at MACFC identified a large number & range of difficulties
compared with some previous surveys of CF patients. This may reflect several
factors e.g. use of more detailed assessments in this study, and also highlights the
need for appropriate therapy services for this patient group. Oxley et al (2004)
Clinical psychology requirements of an adult CF Centre. ECFS.
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Male fertility-information and knowledge in the CF male population
M. Malmborg , C. Boberg , B. Sjoberg , M. Frankl , H. Wiklund-Weiss , B.1 2 3 3 3¨
Strandvik2
University Hospital, Lund, Sweden, Queen Silvia’s Hospital for Children, Goth-1 2
enburg, Sweden, University Hospital, Huddinge, Stockholm, Sweden, Academic3 4
Hospital for Children, Uppsala, Sweden
Introduction: Men with CF have a normal testicular function and sperm production,
but 99 % are infertile due to atresiayobstruction of the vas deferens. Advances in
healthcare have increased the possibilities for men with CF to become parents by
means of assisted fertilisation. In 1993, the first Swedish man with CF became a
father with the help of assisted fertilisation. In Sweden today 24 men with CF are
parents to approximately 40 children. Aim of study: The aim of this multi centre
study was to find out if, how and when male CF-patients were informed and what
their reactions were on the information given. We also wanted to know how they
would prefer to be informed. Methods: A questionnaire with questions on infor-
mation and knowledge in connection with infertility and fatherhood were sent out
to all (159) registered men with CF over the age of 16 years. Preliminary results:
A majority has had and also wants to have the discussion with the CF-doctor but
a few had had no discussion with a health professional about infertility. Most men
experienced the discussion as very important. A majority recommended information
between 16–19 years. Preliminary conclusion: Most men are satisfied with the
circumstances under which the information has been given. Open comments show
that the centres must improve the work with parents, to encourage them to inform
their sons at an early age, to prevent information ‘by mistake’.
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Using metaphor to communicate with children about CF medications:
Feedback from children and carers on a new information leaflet
J. Hill, J. Hambleton, M. Pierrepoint, I. Bowler
Royal Gwent Hospital, Newport, United Kingdom
Collaboration with patients is increasingly understood as an important component
of high quality effective healthcare. The extension of this philosophy to paediatric
services is now widely regarded as essential (BPS SIG, 2001). Good patient-pro-
fessional communication is key, and it is believed that the early involvement of
children in the management of their chronic illness has good outcomes in later life.
Whilst paediatric Cystic Fibrosis teams endeavour to facilitate the involvement of
children and their parentsycarers in healthcare, there continue to be efforts to find
engaging methods to aid this process. In Gwent (UK) the CF team developed an
information leaflet about commonly used medications, which used simple meta-
phors and cartoons to engage and communicate effectively with children and young
people. The leaflet acted as a concrete prompt to the medical team to communicate
directly with children, whilst being mindful of appropriate language and pace. Feed-
back about the leaflet was gathered from children and their carers via a brief semi-
structured interview incorporating ratings on likert scales. Feedback was generally
positive, and indicated that both paediatric patients and adult family members found
the simple explanations of medications to be very helpful in enhancing understand-
ing. Feedback indicated the need for information to be friendly, simple, and com-
municated using familiar and age-appropriate language and concepts. Families
generally appreciated the information leaflet in its capacity to address childrens’
growing curiosity about their illness, and to facilitate conversations between chil-
dren and their family members, peers and medical staff.
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‘CF, a spelling mistake«’ – a CF kit for primary schools developed in
Belgium
K. De Rijcke, A. Stroobants
Belgian CF Association, Brussels, Belgium
Introduction: The goal of the CF kit is to give teachers and peers of CF kids a better under-
standing of CF:
● appropriate information and open communication about what it means to live with CF
● improve social integration
● prevent mobbing and exclusion.
Teaching and talking about CF in the class also helps children with CF:
● to speak more openly about their disease
● to better cope with CF at school and in their daily life.
Methods and contents: This kit was developed by teachers and educational specialists with
CF experience, together with CF kids and families. The kit is built up around 2 imaginary
figures, Robin, a boy with CF and his friend, the parrot Peps. It was tested by several CF
families and schools before being finalized.The kit (French and Dutch version) consists of:
● brochure for teachers (information about CF; tips to integrate a child with CF in the class)
● manual for teachers (concrete suggestions to teach, work, play around CF for each age
group)
● folders for the pupils (information, exercises and games on CF for each age group)
● children’s books on CF
● CF box (‘backpack’ on wheels with CF care material)
● plastic color plates of Robin & Peps, presenting different aspects of CF
● puppet Peps
● videotape
● letter for parents of classmates
The kit is provided for free by the CF association and can be used independently by the
schools. Results: So far the kit has been used in 50 schools. Some schools used the kit for 1
CF lesson, others set up a whole school project; a couple of CF kids used it for a class
presentation about their disease. Children and parents were very satisfied. The evaluation
forms sent back by most schools were very positive: the information is considered clear, the
material practical, well structured, easy to apply and appropriate for the different age groups.
395
An evaluation of the joint service clinic model for transition from
paediatric to adult CF services
M. Sanchez
CF Team, Great Ormond Street Hospital for Children NHS Trust, London, United
Kingdom
Advances in medicine and increased life-expectancy mean that children diagnosed
with CF today should continue to receive specialist medical care in an adult health
care setting. Transition from paediatric to adult services is essential in providing
developmentally appropriate CF care (Elborn, 1998). Given close relationships with
paediatric teams, transition should be timely and planned. Transition illustrates a
collaborative process between the adolescent, parents, paediatric and adult services.
There are various models of transition around the UK, varying usually as a result
of the resources available rather than needs of patients. It is important that these
models are evaluated so that guidelines for best practice can inform service devel-
opment (Bryon, 2001). The intention here is to describe one model of transition
and evaluate its effectiveness. The joint service clinic model is evaluated here.
Adolescents attend a joint clinic where they meet paediatric and adult multidisci-
plinary teams and share information. This process supports the adolescent taking
increasing amounts of responsibility for their CF care. It allows parents, who must
be involved, to meet the new team caring for their child. Informal visits of the adult
centre are arranged to familiarise the patient and family with the new environment.
Psychosocial stressors and illness factors are considered in planning the transition
and time of transition. To measure outcome, the effectiveness of the clinic is being
evaluated using a questionnaire survey of patients, parents and staff. Findings and
implications for service delivery will be discussed.
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Impact of a specialist cystic fibrosis social worker on a developing
regional centre for adults and adolescents
J.L. Dyer, J.E. Smith, N.A. Jarad
Bristol Cystic Fibrosis Centre, Bristol Royal Infirmary, Bristol, United Kingdom
The psychological, emotional and social impact of cystic fibrosis is well recognised
as an obstacle to optimum well being. In order to address this aspect of patient
health, a part-time specialist social worker (SW) was appointed to join the multi-
disciplinary team (MDT). The remit was to offer confidential, psycho-social and
emotional support through counselling skills and provide skilled advice on practical
issues for adults and adolescents transitioning from the paediatric centre. During
the first year 87 interventions were carried out. A questionnaire was sent to all
patients who regularly attended the CF clinic (ns67). Replies were received from
44 patients (66%). 98% of responders knew of the SW appointment and 90% had
met her. 50% of patients knew about the range of SW support on offer, whilst
others were unsure or knew only about help in obtaining financial health benefits.
All those who had received help considered it helpful. All responders considered
the SW to be a valuable member of the CF team, even those who had not required
SW input. Over half (25) of responders added comments, all positively valuing
help with practical and emotional issues as a non-medical intervention. Although
many of the outcomes have addressed quality of life issues, the intervention of the
specialist CF SW can be directly linked to an improvement in health in at least 3
patients. Adult and adolescent patients have evaluated the role of the SW as integral
to the MDT in achieving optimal health and well being.
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Satisfaction of adult CF patients with multidisciplinary care; Using
patient feedback to set goals to improve CF care in an adult centre
A. Saey, L. Van Schil
Adult CF Centre Sint Vincentiushospital, Antwerp, Belgium
Introduction: Patients’ perception of multidisciplinary care has become an important
tool in the processes of monitoring and improving quality of health care services
(Sitzia J, Wood N, 1998). Methods: Questionnaire 44 items: each discipline for-
mulated 5 items. Answers: 5 step satisfaction scale from ‘‘dissatisfied’’ to ‘‘very
satisfied’’Category: not applicable Inclusion criteria: )16 years and )3 contacts
in 2001 Results: Subjects ns 24 of 63 % of the cf population. Mean age: 32 Ø
Sex: M (11) F (13); Education: university (7) higher education (17); Missing
values: 1.3 % Ø Items not applicable: 21 %;
– Subjects are dissatisfied about67 % parking facilities and cost20 % discharge
policy by nurses
– Subjects are satisfied about:100 % the medical attention pulmonary disease96
% quick intervention by pulmonologist
– Subjects evaluate following items as not applicable88 % information about gas-
trstomy75 % family guidance by psychologist
Conclusion: ns24, small population. No exploration of the concept ‘satisfaction
with subjects’; Retrospective: questionnaire in ‘02 about experiences in ’01; Qual-
itative analysis of quantitative data; Subjects are most dissatisfied about parking
facilities; Discharge at the ward is the most important aspect of care to improve;
Medical care and outpatient care by nurses are the most satisfying aspects in CF
care in our centre.
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Survey on patients’ opinion on the organisation of a French CF centre
M. Breton , M.O. Frattini , N. Desmazes-Dufeu , D. Manach , D. Dusser , D.1 1 2 2 2
Hubert2
DIES (developpement, innovation, evaluation, sante), Paris, France, CRCM adul-1 2´ ´ ´
tes, Cochin hospital, Paris, France
In the aim to improve the quality of care and the quality of life in CF patients,
DIES and the adult CF centre at Cochin Hospital, Paris, have worked on the organ-
isation of the CF centre and its care network in hospital and at home. This work
was done with professionals on one hand and with patients on the other hand. The
patients’ advice was collected through 5 meetings with 9 patients and 73 answers
at a questionnaire (from 250 mailings). 59% of the respondents were female, with
a mean age of 29.6 years and a mean follow-up in the CF centre of 5 years. They
agreed with the professionals on: the modalities of transition from paediatric to
adult care, asking for being introduced to the adult medical team; the possibility of
negotiation for a better compliance and quality of life (75% satisfied); the availa-
bility of the medical team (80% satisfied); the continuous increase in hospital-
hygiene (but 50% of the patients still wished an improvement); the medical and
psychological preparation for lung transplantation. Their spontaneous requests were
of new treatments allowing to spare time in their every day life (50%); of support
to speak of CF with their close-relations (25%) and to live as adults with children
(30%) and with a job (30%); of help in the tasks of their every day life (25%).
Only 44% of the patients wished meetings between patients and the CF team mem-
bers on the following subjects: improvement in treatments (32%), sports and phys-
iotherapy (31%), social regulations (29%), relations with their employer (29%),
fertility and pregnancy (26%) and couple relationships (24%). The expectations of
the adult CF patients rejoin the preoccupations of the professionals to improve care
but also quality of life. Supported by Vaincre la Mucoviscidose.
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Presentation and perceived impact of centre care in patients diagnosed
with CF in adulthood
K.A. McGregor , J.M. Bradley , L.R. Boyle , J. Howard , J.S. Elborn1 2 1 1 1
Regional Adult CF Centre, Belfast, United Kingdom, University of Ulster, Jor-1 2
danstown, United Kingdom
Introduction: Increasing numbers of patients are diagnosed with CF in adulthood.
This survey aimed to review the genotype and phenotype of patients diagnosed with
CF in adulthood ()16 years) and to ascertain their perceptions and views of centre
care. Methods: A retrospective review of hospital notes provided information relat-
ing to genotype and phenotype. A questionnaire was also sent to all patients.
Results: 22y140 patients at our Regional Adult CF Centre were diagnosed with CF
in adulthood. 19y22 patients returned questionnaires: mean(S.D.) age at diagnosis,
32.7(11.6) years; time since diagnosis, 5.3(3.8) years; FEV at diagnosis, 71(27)%.1
12y19 patients had abnormal ()60 mmolyl) sweat chloride at diagnosis. 4y19 were
homozygous and 13y19 were heterozygous for DF508. R117H (8y19) was the most
common other mutation. At diagnosis patients presented with pulmonary (14y19),
ENT (5y19) or gastrointestinal (5y19) symptoms, pancreatic insufficiency (4y19),
diabetes (2y19) and family history of CF (6y19). Pre-diagnosis, patient manage-
ment was mostly by GP andyor hospital (14y19). Late diagnosis was most com-
monly attributed to mild symptoms (11y19) or incorrect diagnosis (8y19).
Post-diagnosis, all patients reported they were reviewed more frequently and were
better informed about their disease. The majority reported increased support from
the multidisciplinary team. Post-diagnosis, patients used a wider range of airway
clearance techniques and spent a significantly greater amount of time on nebulisersy
inhalers and airway clearance (P-0.05). Patients perception of their health signif-
icantly improved post-diagnosis (P-0.05). Conclusion: The genotype and
phenotype of patients diagnosed with CF in adulthood is variable. Centre care has
a positive impact on their management and quality of life.
401
Pseudomonas aeruginosa (PsA) acquisition and infection: 1. What
parents know and how they try to protect the child
G. Ullrich , S. Wiedau , H.J. Bartig , W. Schulz , G. Steinkamp1 2 1 2 3
Hannover Medical School, Dept of Paediatrics, Division of Paediatric Pulmon-1
ology, Hannover, Germany, University of Braunschweig, Psychological Institute,2
Div of Clinical Psychology, Braunschweig, Germany, Clinical Research Hannover3
and CF Centre Hamburg-Altona, Hannover, Germany
There is a growing consensus that early chronic PsA infection should be prevented.
Whilst the focus of the medical debate is on patient segregation and on hospital
hygiene (1), at least in Germany discussion has extended to include measures to
prevent environmental acquisition. These measures are mostly parents’ duties.
Whether or not they engage in respective actions depends on their risk perception
and knowledge.Methods: We conducted a cross-sectional multicentre study with a
standardized questionnaire (parents) designed for the purpose of the study and based
on previous interviews (2). The questionnaire consisted of several parts (knowledge
and precautions, poster 1, and risk perception, poster 2). Participation was voluntary
and irrespective of the child’s PsA status. Inclusion criteria: child’s age below 13y,
diagnosis of CF at least 12months ago, sufficient comprehension of German lan-
guage. Results: Ns130 returned questionnaires (63%), of which )80% were
answered by mothers. Items addressing knowledge were summarized to a global
score. Only 2% of parents correctly answered all 9 items, 36% answered)4items.
Virulence was markedly overestimated, and measures of individual hygiene (envi-
ronmental precautions) were highly valued. Correspondingly, a subset of parents
engaged in preventive measures of questionable rationale, such as prohibition of
jumping into or splashing about in puddles. Conclusions: Lack of parental knowl-
edge about PsA acquisition and infection may trigger unnecessary actions and pro-
hibitions, which undermine the child’s quality of life. Therefore, medical
counselling should also address the possibility of parental over involvement.
(1) for EBM-based guidelines see: enquiries@cftrust.co.uk;
(2) Ullrich et al., J Cystic Fibrosis, 2002(1): 122–30.
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Pseudomonas aeruginosa (PsA) acquisition and infection: 2. Parental
fears and concerns
G. Ullrich , S. Wiedau , H.J. Bartig , W. Schulz , M. Ballmann , G. Steinkamp1 2 1 2 1 3
Hannover Medical School, Dept of Paediatrics, Div of Paediatric Pulmonology,1
Hannover, Germany, University of Braunschweig, Psychological Institute, Div. of2
Clinical Psychology, Braunschweig, Germany, Clinical Research and CF Centre3
Hamburg-Altona, Hannover, Germany
In Germany, many parents consider PsA infection a consequence of environmental
acquisition. Therefore, the majority feels an obligation to assure maximum hygiene.
Yet, the natural omnipresence of the germ may stimulate parental fears, thus influ-
encing risk perception, which may ultimately lead to exaggerated hygienic measures
(1). The target of the present study was to systematically investigate parental fears
and their risk perception. Methods: cross-sectional multicentre study with a stan-
dardized questionnaire (further details see part 1). Emotional impact was assessed
with 12 items on 4-point-likert-scales which we analysed by factor analysis. Results:
Items were grouped to 3 consistent factors explaining 55% of the variance. Two
factors directly referred to PsA infection: one with a focus on the threat of infection,
and the other with a focus on its impact. The third factor only indirectly referred
to infection. Pronounced threat-related fears were correlated with high involvement
in ‘‘preventive’’ measures and low scores on knowledge about PsA infection (see
part 1). Some single item results were remarkable: 46% of parents fully agreed to
have fears about a dramatic decline of the child’s health due to PsA infection, 28%
fully confessed to fear that if their child gets chronically infected, he or she might
live for only a few more years. Conclusions: Corresponding with our pilot study
(1) parents who performed numerous preventive measures were not protected from
having pronounced fears of infection. Furthermore, the threat of infection was dra-
matically overemphasized. Therefore, proactive counselling and education with
respect to the nature and risk of PsA infection seems paramount.
(1) Ullrich et al., J Cystic Fibrosis, 2002(1): 122–30.
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15 years of patient segregation—reflecting upon expected and
unexpected consequences
G. Ullrich, H.J. Bartig
Hannover Medical School, Dep. of Paediatrics, Div. of Paediatric Pulmonology,
Hannover, Germany
Referring to positive reports of the Danish CF centre w1x, who started separating
CF patients according to Pseudomonas aeruginosa (PsA) status as early as 1981,
segregation was implemented at our centre in 1988. From a psychological stand-
point, segregation was expected to have serious adverse effects inasmuch as it
implied: (1) undermining mutual support; and (2) stigmatizing those who are
already burdened. We were also concerned that families might expand the concept
of segregation: those who were ‘‘positive’’ could easily be further differentiated
according to their microbiological strain. Why not keeping off from different strains,
too? Would the CF community break into peaces? At that time, nobody could
anticipate the occurrence of the life-threatening Burkholderia cepacia epidemic (for-
mer Pseudomonas cepacia) which shocked the CF world during the early 90ies.
Evidence for patient-to-patient transmission w2x also influenced the perception of
segregation as a whole. Yet, in retrospect, some of our expectations proved invalid,
others were too short-sighted: (1) at our centre, the psychological impact of seg-
regation (due to PsA!) does not have as great an influence as we had expected at
the outset. Technological advances (mobile phones, Internet) allow to compensate
for ‘unsafe’ personal contact; (2) there was no expansion of the concept of segre-
gation within the ‘positive group’. But, unexpectedly, instead of an expansion of
segregation we observed an expansion of PsA-‘prevention’: nowadays, this appears
to be the family’s duty (precautions against environmental acquisition)! This unex-
pected ‘consequence’ of segregation has evolved to one of the most prominent
concerns. 1. Hoiby & Pedersen. Acta paed. Scand. 1989 (78) 395–404; 2. Govan
et al. Lancet. 1993 (342) 15–19.
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Assessment of adherence to nebulised treatment in cystic fibrosis
patients
S.A. Mulrennan, T.M. Moon, A.H. Morice
Division of Academic Medicine, University of Hull, Castle Hill Hospital, Cottingh-
am, East Yorkshire, United Kingdom
Background: Many cystic fibrosis patients are prescribed nebulised colomycin on
a daily basis. The prodose nebuliser is a new device claimed to improve the
efficiency of nebulised drug delivery. This should result in a decrease in nebulisation
time which may improve adherence.We have tested this hypothesis using the inbuilt
data storage module. Study aim: To assess the effect of the prodose nebuliser on
lung function, daily symptom score, satisfactionypreference and adherence in
patients with cystic fibrosis. Methods: A comparative observational study was per-
formed. Patients were assessed on their usual nebuliser (Halolite or Pari) and the
prodose nebuliser. Dairy record cards assessed respiratory symptoms, time and num-
ber of nebulisations. A questionnaire scored satisfaction with nebuliser treatment,
symptom improvement and length of nebuliser treatment. Adherence data was down
loaded from the prodose nebuliser. Results: 12 patients, mean age 24, mean FEV1
2.6 participated. Nebulisation time was reported to be significantly less with the
prodose nebuliser. Mean 6.47 min compared to 10.58 (Ps0.003). Satisfaction
with the nebuliser treatment and duration was also higher with the prodose nebuliser
(Ps0.03 and Ps0.05 respectively). 92 % of patients preferred the prodose nebu-
liser to their usual device, shorter nebulisation time being the major reasoning for
this. Objective assessment of nebuliser usage was surprisingly disparate from
recorded values. Mean 40% compared to 84% respectively (Ps0.008). Conclu-
sions: The prodose system has significantly shorter nebulisation time and is pre-
ferred because of this. Objective assessment provides useful information of patient
adherence, even in well-known patients. Prescribing can be tailored accordingly.
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Promoting independent respiratory care in patients with Cystic Fibrosis
while maintaining quality of life
S. Wright , P.M. McIlwaine , T. Ho , A.G.F. Davidson1 1 1 2
British Columbia Children’s hospital, Vancouver, Canada, University of British1 2
Columbia, Vancouver, Canada
The purpose of this study was to assess the model of physiotherapy care delivered
by the British Columbia Children’s Hospital CF Clinic to its pediatric patients. Our
purpose was to achieve the ultimate goal of maximum quality of care and inde-
pendence by the age of ‘Graduation’ to an adult facility. At this point we expected
our CF patients to have the ability to self-monitor and adjust their treatment regime.
One hundred and ten patients aged birth to 18 years were assessed and information
collected regarding types of airway clearance technique, quality of treatment, and
numbers of missed treatments. The patients’ understanding of their condition, phys-
iotherapy and medication was also assessed. Information was analysed by age group
(0–2, 2–6, 6–12, and 13–18 years) and disease severity. Results revealed total
dependency of care from birth to two years. During middle childhood the intro-
duction of techniques such as PEP allowed the child to assume greater responsibility
for their treatment and fostered independence. At this age, the parents’ role changed
from deliverer of care, to coach and advocate. By the teenage years the patients
were totally independent in performing their treatments and were adopting the role
of self-advocacy. With increasing age and disease progression, adherence issues rise.
This is due to the complex nature of adolescence with its conflicts between health
care and life-style issues, and the expanding burden of care. In conclusion in order
to complement independence and quality of care, adherence and motivational strat-
egies must be appropriately adhered to. We have the scientific and clinical expertise
but require the wisdom to appreciate its limits.
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Health-related quality of life in children with CF: perceptions of parents
and physicians
A.J. Janse, J. Van der Laag, J.L.L. Kimpen, G. Sinnema
Cystic Fibrosis Center Utrecht, University Medical Center Utrecht, Utrecht,
Netherlands
To explore the differences in perception of quality of life (QOL) between parents
of chronically ill children and physicians, a multi-center cross-sectional study was
performed. QOL was assessed by the Health Utilities Index mark 3 (HUI3). The
physician completed the HUI3, independently from the parents, and blinded for
their answers. Children with CF were either admitted in day-care for a yearly check-
up (CF-day) or hospitalized for a pneumonia (CF-hosp). The parents of 82 children
(CF-day) and 36 children (CF-hosp) participated. Mean age (S.D.) of the children
was 9.9 (3.4) years and 10.7 (3.7) years respectively; FEV1% predicted mean
(S.D.) was 82.2 (22.4) and 59.3 (18.3) respectively. For the objective HUI-domains
(vision, hearing, speech, ambulation, dexterity), physicians and parents highly
agreed on perceived QOL (percentages agreement above 80). However, percentages
agreement on the subjective domains (emotion, painydiscomfort) were below 40.
In comparison to the parents, physicians assessed the patients to have less painy
discomfort, but they assessed more emotional impact of CF on the child than the
parents did. In the parental assessments, patients (both groups) with lower FEV1
predicted values had more painydiscomfort. In the physicians’ assessments patients
(only CF-day) with lower FEV1 predicted values had more painydiscomfort and
more emotional impact of CF. In conclusion, systematic assessment of QOL in
clinical practice may facilitate discussions between parents and physician on per-
ception differences in the impact of the disease. This may contribute to a better
mutual understanding and even enhance compliance and treatment effects.
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Cystic Fibrosis Questionnaire (Dutch version): a health-related quality
of life measure for children with cystic fibrosis (CF) and their parents
J. Grootveld, G. Vercaeren, K.N. Desager
University Hospital Antwerp, Department of Pediatrics, Antwerp, Belgium
Cystic Fibrosis Questionnaire (CFQOL) is a valid tool to measure disease-specific
health-related quality of life in CF children (Quittner, J Pediatr Psychol. 2003). The
aim of this study was to administer CFQOL to parents of 20 CF children, to search
for correlations between items and to relate items to clinical data. The age of patients
ranged between 7 and 20 years with median FEV1 93% of predicted (range: 40–
128). Eleven CFQOL items were evaluated (median score, range): ‘physical’: 89
(44–100), ‘emotion’: 80 (40–100), ‘vitality’: 67 (40–93), ‘school’: 78 (22–100),
‘eating’: 67 (0–100), ‘body image’: 89 (22–100), ‘treatment burden’: 44 (0–100),
‘health’: 67 (33–78), ‘respiratory’: 78 (17–89), ‘digestion’: 67 (33–100), ‘weight’:
67 (33–100). The higher the score, the more successful the child was in that area.
Significant inverse correlations were found between each of the items ‘physical’,
‘vitality’, ‘respiratory’ and age. Each of the items ‘physical’, ‘vitality’, ‘eating’,
‘digestion’ correlated significantly with the item ‘respiratory’. Other correlations
were found between ‘digestion’ and ‘physical’ and ‘weight’ and ‘body image’ (P-
0.05). Item ‘body image’ was significantly lower in the group of patients with
underweight compared to patients with normal weight. The items ‘physical symp-
toms’ and ‘respiratory symptoms’ were significantly lower in the group of patients
who need intravenous antibiotics compared to patients who do not need such treat-
ment. Conclusion: CFQOL in CF patients provides a comprehensive assessment of
how this disease affects daily living in several areas of functioning, including phys-
ical, emotional and social. Significant correlations between items were found and
differences between groups of patients were shown.
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Validation of the Italian version of the Cystic Fibrosis Quality of Life
Questionnaire (CFQoL): pilot study
F. Gobbi , F. Lupi , A. Miano , F. Monti , E. Iacinti , D. Petrolini1 2 1 2 3 3
Centro Regionale Fibrosi Cistica-Ospedale Bufalini, Cesena, Italy, Universita di1 2 `
Bologna-Facolta di Psicologia, Bologna, Italy, Centro Fibrosi Cistica, Parma,3`
Italy
Introduction: Health-related quality of life (HRQoL) measurement is important in
determinating the impact of disease on patients. Generic HRQoL measures have
been employed with patients with cystic fibrosis (CF) in Italy but these may not
be sufficiently specific. The aim of this work was to validate in Italy the Cystic
Fibrosis Quality of Life Questionnaire (CFQoL; Gee, L., Abbott, J. et al., 2000),
a disease-specific HRQoL measure for adults and adolescents with cystic fibrosis.
Method: The CFQoL has been translated into italian and then completed by 76 CF
patients. The factorial structure was assessed by applying two Principal Components
Analysis, with varimax rotation. The test–retest procedure was employed to test the
external reliability and, in order to verify the concurrent validity, the Short Form
36 item (SF-36) Health Related Status questionnaire was administered in parallel.
Results: Averages, standard deviations, item-total correlations, Cronbach Alpha and
Guttman Split-half coefficients were calculated and confirmed a very good internal
reliability (Alphas0.651–0.908). The factorial structure is essentially similar to the
original one even if a few items do not show strong correlation with their factor.
Test-retest reliability was found to be robust (Pearson rs0.691–0.944 at 15 days)
and the concurrent validity demonstrated to be good too (rs0.470–0.860). By
using cluster and discriminatory analysis, the measure was found able to divide
patients with different levels of disease severity into different groups. Conclusions:
In the pilot study the italian CFQoL demonstrated to have good statistical properties
and, when fully validated, it will be useful in clinical trials and longitudinal studies.
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Health related quality of life in children with Cystic Fibrosis:
assessment of agreement between parents and children
T. Havermans, M. Vreys, M. Proesmans, K. De Boeck
University Hospital Gasthuisberg, Leuven, Belgium
Aim: To investigate the degree of agreement between parents and their children with
Cystic Fibrosis (CF) on health related quality of life (HRQoL). Method: 36 parents
and their child completed the Dutch version of the Cystic Fibrosis Questionnaire
Revised (Quittner, 2003, Klijn, 2003). The following dimensions were assessed:
physical condition, emotional state, body image, eating, treatment, respiratory and
digestion. Higher scores indicated a better HRQoL. Paired t-test and intra-class
correlation coefficients (ICC) were presented. Results: Children reported higher
QOL than parents on the dimensions physical condition, emotional state, body
image, eating and treatment, indicating fewer problems in these areas. Moderate
agreement between parents and children was found on the dimensions respiratory,
digestion and body image (rs0.50, rs0.41 and rs0.40 respectively). Agreement
levels between parents and children on physical condition, emotional state and
treatment were low (rsy0.01, rs0.01 and rs0.18 respectively). The agreement
level on the eating dimension was very high (rs0.75). Age and gender analysis
showed that older children (age 11–13) reported better QoL in terms of eating than
younger children (6–10) and girls reported better QoL in terms of eating than boys.
Conclusions: In concordance with previous studies agreement was found on symp-
tom related issues (respiratory and digestion). Parents and children agreed strongly
on the eating dimension and disagreed most on the treatment dimension. The results
support the need for working together with the family to establish treatment sched-
ules that take into account the needs of the illness as well as individual differences
in perceptions of the illness and its impact on QoL.
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The Continuum of Maturation with Cystic Fibrosis: Home and Away
A.R. Landy, E. Chapman, D. Bilton, A. Lyon
Papworth Adult CF Centre, Papworth, Cambs, United Kingdom
How easy is it for young CF adults to attain emotional maturity? We look at physical
and psychological issues and view life as a continuum involving a number of devel-
opmental tasks to be negotiated (Erikson, 1963). CF brings additional factors such
as responsibility for medication, relationships and perhaps parenthood, treatment
decisions, disease progression, transplant, and death. Data on 42 adult patients com-
pleting the CFpsychQ as part of their annual review were collected. Patient files
gave information about living status: alone (grp 1), with partner (grp 2), at home
(grp 3). Groups 1 and 3 differed significantly on age, BMI, and levels of family
involvement. Patients living alone were more likely to be older, have a higher BMI
and lower levels of family involvement. There was no difference between the groups
in their FEV status. We note however that despite parental and patient assertions1
that physical maturity and independence are gained, adult emotional autonomy is
often not fully realised. Young adults with CF are increasingly wishing to take on
the mantel of independence yet expect to be able to return to the parental home for
care and support, regardless of their own responsibilities as a partner or parent
themselves. Our concentration on the physical aspects of care may result in under-
emphasis of the importance of continual staged emotional development. Do the
adult and paediatric sectors need to work together more closely to evolve an inte-
grated physical and psychological model of care over the continuum? We plan to
monitor changes in living status over time and a comparison with a group of healthy
matched individuals is planned.
Erikson, E. (1963) Childhood and Society, New York: Norton.
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Socio-economic profile of the adult cystic fibrosis population of
Quebec
L. de Launiere , F. Paquette , Y. Hebert1 2 1` ´
Adult Cystic Fibrosis Committee of Quebec, Montreal, Canada, Cystic Fibrosis1 2
Clinic of the McGill Uniersity Health Centre, Montreal, Canada, Cystic Fibrosis3
Clinic, University of Montreal Hospital Centre, Montreal, Canada
This study provides a socio-economic profile of the adult cystic fibrosis population
(18q years) of Quebec to better understand this population and to enable the Adult
Cystic Fibrosis Committee of Quebec (ACFCQ) and those who work in hospital
environments to provide more effective services. About 570 adults with cystic fibro-
sis (median life expectancy: 35.9 years) live in Quebec. In the first quarter of 2003,
400 of them (70%) agreed to take part in this survey. The survey revealed, among
other things, that 57% of respondents have a gross annual income under
CAD$15 000 (10 800 euros); 48% have no intimate companion; and 31% are nei-
ther in the labour force nor at school. The study also showed that 68% were gen-
erally ‘satisfied’ or ‘very satisfied’ with their lives, while 8% were generally
‘dissatisfied’ or ‘not very satisfied’. Other interesting findings include the following:
30% of respondents felt that friends and family under- or over-estimated the seri-
ousness of their disease; 20% felt that men and women experience the disease
differently; 32% desire assistance with psychological problems related to the dis-
ease. With respect to ‘knowledge of the disease’, 58% of respondents felt they had
an ‘excellent’ or ‘very good’ understanding of C.F. The demographics of this pop-
ulation, including gender, age and degree of illness (according to respondents’ sub-
jective perceptions), were taken into consideration in analysing the results. These
findings will enable us to develop strategies to foster the integration of this popu-
lation into society and the workforce and meet its needs for information and pro-
fessional support.
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Hemoptysis in cystic fibrosis: Psychological manifestations,
psychodynamics and implications
M.S. Miller, A. Barak, D. Katznelson, A. Augarten, A. Szeinberg, O. Efrati, J.
Yahav
National Center for Cystic Fibrosis, Sheba Medical Center, Tel Hashomer, Israel,1
Tel Aviv University, Sackler School of Medicine, Tel Aviv, Israel2
Events of major hempotysis adversely affected the mental and emotional states of
10 CF adult patients from our centre. Data collected by interviews conducted ret-
rospectively, from observations and follow-up, revealed that these events were
accompanied by acute and sustained anxiety, panic and feelings of helplessness.
While conservative medical treatment, such as hospitalization, bed rest, intensive
intravenous antibiotic treatment, vitamin K therapy, blood transfusion, temporary
discontinuation of physical therapy and bronchial artery embolization, were usually
sufficient to control the symptoms the psychological aftermaths were protracted.
Long-term variable after effects included a variety of anxiety states with concom-
itant depression, elements of post traumatic stress disorder and increased compli-
ance. It appears that the physical experience and accompanying sensations, the
unpredictability of the event onset and their random circumstances, the subjective
meaning attributed sometimes erroneously to their ominous significance together
with the emotional reactions of witnesses and emergency services comprised stres-
sors and traumatizing elements for these patients. The suddenness of these exac-
erbations appeared to upset the precarious psychic equilibrium attained over time
and maintained by these seriously ill patients in view of the gradual deterioration
and increasing severity of their illnesses. Gradual adaptation to decline in health
and effective defense mechanisms particularly denial were undermined by these
events and heightened anxieties, fantasies, dreams and fears of immanent death
intensified, requiring a process of further appraisal and adaptation. These findings
have important implications for initial psychosocial crisis management and
intervention.
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The clinical psychology requirements of an adult cystic fibrosis service
H. Oxley, A.K. Webb, A.M. Jones, M. Dodd
Manchester Adult Cystic Fibrosis Service (MACFC), Manchester, United Kingdom
Background: The CF Trust UK recommends 0.4 wte psychologist staff for every
50 CF patients. The MACFC (240 pts) appointed a clinical psychologist (CP) to
a newly established post in 1996 (now 0.6 wte). This is additional to 2 social
workers in the team. Broad aims of the CP service are to provide an assessment &
therapy service to patients and psychological ‘consultancy’ to the MDT. Priority
has been given to direct work with patients, to give immediate access to the CP.
Aim: To determine how the time of the CP in MACFC is utilised & what roles are
carried out. Method: A retrospective review of CP records was undertaken and time
spent in the various roles of the CP calculated. Results: 35% of CP time is spent
in face to face assessmentytherapy with referred CF patients (Oxley et al. 2004) &
10% in routine psychological contacts i.e. annual and pre-transplant assessments.
45% of time is spent providing psychological adviceyinformation to the MDT on
issues including: adherence problems, managing health professionalypatient con-
sultations, difficult behaviours etc. 10% of time is given to non patient activity i.e.
admin, research, training, supervision, staff issues and development of the CF serv-
ice. Conclusion: The CP (0.6 wte) at MACFC currently spends 45% of time meet-
ing the need to assess and treat patients. This figure would be much higher without
the 1.7 wte social worker input to the unit. Annual surveys of MACFC staff (Oxley
et al. 2003) indicate a need for more access to psychological advice and more
support for the team than is currently provided. Current CP time therefore does not
allow all necessary roles to be completed, and could not support increased numbers
of patients within the service. Oxley et al. (2003) Supporting staff in a CF centre.
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The mosaic of dependence, independence and inter-dependence in CF
C.M. Worby
University of Nevada, Reno, United States
Conceptualizing dependence and independence as polar opposites along a contin-
uum is a false construct that impairs our ability to facilitate growth and development
in persons with CF. More useful is to view dependence, independence and inter-
dependence as a mosaic: aspects of the person’s connectedness to important others
which interact and manifest their expression in different proportions at different
points in the life cycle and illness stages. Several variables influence the mosaic’s
pattern. First is the person’s developmental stage: infancy, childhood, adolescence,
adulthood. Second, is the stage and virulence of the illness as expressed in symp-
toms, signs and quality of life. A third variable is the nature of the social contexts
within which the person lives out her or his daily life. Depending on age, these
contexts include family, school or job, friendship network and spiritualyreligious
community. Fourth, is the nature of the CF care giving team, particularly its attitude
toward adherence issues. Fifth, is the psychological construction the individual with
the illness makes of his or her situation. The clinical implication of the above
perspective is that generalizations about what is the ‘‘appropriate’’ mix of depend-
ence, independence and interdependence are insufficient. Assessment and interven-
tions must be rooted in an intimate knowledge of the particular patient’s
circumstances and self-construction of the illness and its meaning. Three points in
the CF life cycle – childhood, adolescence and adulthood – will be discussed in
detail, with case examples, to illustrate these concepts.
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Improving care of patients with Cystic Fibrosis (CF): a protocol for the
transition from pediatric to adult care
L. Copal-van der Neut, D.v. Elst-Laurijsen, A.C. de Kiviet
Cystic Fibrosis centre, Utrecht, Netherlands
Introduction: The CF-team of the CF-centre UMC-Utrecht in the Netherlands sig-
nalled problems related to transition, both for patients and their parents. Purpose:
To develop a structured transition process for adolescents with CF and his parents.
Methods: We assessed transition related problems by interviewing patients, parents
and concerned caregivers; We performed a literature study; We recruited a multi-
disciplinary study group in which both pediatric and adult caregivers participated
(physicians, CF-nurses, social workers) and a representative of our CF-population;
A protocol for transition, which includes checklists and an evaluative survey for
both patients and parents, was developed by the study group. Preliminary results:
This protocol was implemented in 2002. The first evaluative surveys showed sat-
isfied patients and parents; from the 14 patients who have completed transition, 10
patients participated in the survey, 9 of them experienced no significant problems
with regard to transition and had no negative remarks. One patient had one sug-
gestion to add to the protocol. Conclusion: The evaluative survey shows less tran-
sition-related problems after implementing the protocol; The caregivers experience
fewer problems; We think our protocol is a valuable tool to improve the provided
care of the CF-patients.
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Psychological interventions for cystic fibrosis (Cochrane Review)
C.A. Glasscoe , A.L. Quittner , R.L. Smyth1 2 3
Royal Liverpool Children’s Hospital NHS Trust-Alder Hey, Liverpool, United1
Kingdom, University of Florida, Department of Health & Clinical Psychology,2
Gainesville, United States, University of Liverpool, Institute of Child Health, Liv-3
erpool, United Kingdom
Background: As survival estimates for cystic fibrosis (CF) increase long-term man-
agement has become an important focus for intervention. This review aimed to
describe the extent and quality of effectiveness studies utilising psychological inter-
ventions and whether they provide significant psychosocial and physical benefits in
addition to standard care. Methods: RCTs and quasi-randomised trials were includ-
ed. Study participants were children and adults diagnosed with CF and their imme-
diate family members. Psychological interventions were from a broad range of
modalities and outcomes were primarily psychosocial. Main Results: Findings from
eight studies were reviewed, falling into four main groups: (1) gene pre-test edu-
cation counselling for relatives of those with CF (one study); (2) biofeedback,
massage and music therapy to assist physiotherapy (three studies); (3) behavioural
interventions to improve dietary intake in children up to 12 years (three studies);
and (4) self-administration of treatments to improve quality of life in adults (one
study). Interventions were largely educational or behavioural, targeted at specific
treatment concerns during the chronic phase. There was some evidence that behav-
ioural interventions may improve emotional outcomes in people with CF and their
carers. No consistent effect on lung function was found although one small study
showed that biofeedback assisted breathing retraining was associated with improve-
ment in some measures of spirometric lung function. Insufficient evidence was
available for more complex interventions or those aimed at other aspects of the
disease process. Conclusions: Multicentre approaches are needed to increase the
sample size of these psychosocial studies and to enhance the power and precision
of the findings.
Epidemiology and Screening
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Differences in clinical conditions at age 15 between CF patients
diagnosed by neonatal screening and by symptoms in Tuscany, Italy
F. Festini , G. Taccetti , T. Repetto , A. Negri , G. Pisano , E. Micheletti , M.1 1 1 2 2 2
de Martino 1
CF Centre of Tuscany, Meyer Hospital, University of Florence, Florence, Italy,1
CF Unit, Leghorn City Hospital, Leghorn, Italy2
A neonatal screening program has been carried out in Tuscany,Italy, since 1982. We
studied the entire cohort of 122 patients who were diagnosed before age 15 and
reached that age, followed at the CF Centre of Tuscany since its institution (1975)
up to Dec.31, 2003. The aim was to investigate whether differences exist in clinical
conditions at age 15 between CF patients diagnosed by screening and those diag-
nosed by symptoms. Patients diagnosed due to meconium ileus (ns27)were not
included. Of the 95 patients examined (M 53, F 42), 17 (M 9, F 8) were diagnosed
by screening (mean age at diagnosis: 1.8 months, SD 0.8, range 4-1 mo.) and 78
(M 44, F 34) were diagnosed by symptoms (mean age at diagnosis: 46.1 months,
SD 46.5, range 143-1 mo.). We considered the following outcomes, measured at
age 15 ("4 months): BMI above or below the 10th percentile for sex and age;
mean FEV1; whether or not they were chronically colonized by P.aeruginosa (PA);
mortality rate after 15 years from birth. Results:
Diagnosed by Missing Diagnosed by Missing
symptoms screening
Pts with BMI above the 10th 51.9% 26 60% 2
Percentile
Mean FEV1 % ("SD) 71 ("24.5) 28 67.7 ("23.1) 2
Pts with chronic PA 64.1% 25 37.5% 1
colonization
Mortality at 15 yearth 14.1% 0 5.5% 0
Discussion: In the cohort studied, at age 15 patients diagnosed by screening showed
a better nutritional status than their peers diagnosed by symptoms. Lung function
was similar in the two groups. The prevalence of chronic PA colonizations in the
screening group was notably lower than that of symptoms group. The mortality rate
at 15th year in the symptoms group was 2.5-fold that in the screening group.
Neonatal screening for CF in Tuscany allowed an early start of follow-up which
prevented the worsening of nutritional status, delayed chronic PA colonizations and
reduced the mortality.
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Screening in Tuscany newborn for cystic fibrosis using
immunoreactive trypsinogen test, molecular analysis on blood spot
sample and measurement of lactase activity on meconium
C. Centrone , E. Pelo , B. Minuti , G. Taccetti , N. Ravenni , F. Torricelli1 1 1 2 2 1
U.O.Citogenetica e Genetica A.O.Careeggi, Firenze, Italy, Centro Regionale1 2
Fibrosi Cistica, A.O. Meyer, Firenze, Italy
Newborn screening for cystic fibrosis (CF) is carried out in the region of Tuscany,
since 1991, using trypsin dosage on a spot of blood and lactase dosage on a meco-
nium sample. The present research is designed to study the mutation of the CFTR
gene side by side to the above analyses in order to increase and improve screening
specificity. 43 353 samples from Tuscany’s Neonatal units (covering 99% of all
newborns) have been analyzed. Genetic analysis was made using the Guthrie spot
on samples with IRT values )54 ng. The search for mutations (with informed
consent of parents) was carried out with the PCR-OLA methodology (31 mutations)
together with DHPL (Denaturing High Pressure Liquid Cromatography) for exon
17b. 529 IRT-positive newborns were identified (1.2% of the whole population),
who were all investigated for genetic mutations. Overall, 33 heterozygous subjects
were found, as well as 9 patients with CF (2 homozygous, 7 double heterozygous,
for an incidence of 1:4817). Those found to be either homozygous or double het-
erozygous performed the sweat test. The following mutations were identified:
deltaF508559%, G542X510%, 3849H10kbC-T58%, W1282X54%,
L1065P54%, N1303K54%, 2789HG5-A52%, R117H52%, R347P52%,
deltaI 50752%, S549R52%, G85E52%, R1066C52%. To improve the spec-
ificity of the screening test as well as to identify the largest number of CF newborns,
we decided to have all heterozygous newborns perform the sweat test. This approach
may permit CF diagnosis, can determine an improvement in sensitivity, reduce the
recall rate and detect CF carrier status, making genetic counseling possible. In Italy
where a large number of non-Italian babies are born, the CF gene mutations are
higly diversified, making their use in screening programs more difficult.
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Revisiting the risk of cystic fibrosis following the ultrasound detection
of an echogenic bowel during pregnancy: the 13-year experience of
Brittany (France)
V. Scotet , M.P. Audrezet , J. Creff , I. Quere , M. Blayau , C. Ferec1 1 1 1 2 1´ ´ ´ ´
INSERM EMI 01-15, Laboratoire de genetique moleculaire, CHU Morvan, Brest,1 ´ ´ ´
France, Laboratoire de genetique moleculaire, CHU Pontchaillon, Rennes, France2 ´ ´ ´
This study aimed to revisit the risk of cystic fibrosis (CF) following the detection
of an echogenic bowel during pregnancy from the experience of Brittany, a French
region where CF is frequent. We report our 13 year-experience in this field (1991-
2003). A total of 219 pregnant women were referred for a prenatal diagnosis of CF
based on an initial analysis (87% mutation detection rate) followed by an extended
DHPLC analysis when only one mutation was detected (98.5% detection rate).
Among these diagnoses, we identified 18 CF-fetuses and 15 heterozygous ones.
This led to an incidence of CF of 8.2% and of heterozygosity of 6.8% in this
population, which is significantly higher than in the general population (p-
0.0001). Only severe mutations were identified in CF fetuses (DF508, Q220X,
W1282X, 1248q1G)A, 1717-1G)A, 3129del4). The situation is particularly dif-
ficult when only one mutation is detected and we used Bayesian calculations to
estimate the residual risk of CF. Assuming a carrier rate of 6.8%, the residual risk
was 1y600 when no mutation was detected by our protocol. The complementary
analysis performed when only one mutation is detected, which enabled to reach a
98.5% detection rate, led to a residual risk of 1y30. Combining these data with
those of the newborn screening performed over the same period, we calculated that
ultrasound examination enabled the identification of 10.4% of the CF-fetuses on
the period (18y173). The results of the last three years confirm those observed in
a preliminary study. Our results are of first importance for clinicians who order
testing for CF following the ultrasound diagnosis of echogenic bowel. They also
highlight the importance of efforts made to identify a second mutation in hetero-
zygous fetuses, what enables to reduce the residual risk of CF.
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CF neonatal screening in Poland
D. Sands, A. Nowakowska, R. Piotrowski, K. Zybert, M. Oltarzewski, A.
Milanowski
Institute of Mother and Child, Warsaw, Poland
The aim of the neonatal screening programme is early diagnosis in presymptomatic
period. In Poland the average age of clinical diagnosis is about 4 years of age
(mean 42months). Newborns from 4 regions of Poland have been screened (100000
newborns per year). The existing screening infrastructure and spare blood spots
after screening for PKU and hypothyreosis are used. Different methods have been
tested: ‘‘Joint two stage procedure’’ IRTyIRTyIRTyDNA (DF 508) finally being
preferred. Infants with positive neonatal screening results (second IRT at 4 weeks
andyor one or two mutations) are called to the CF centre at our Institute for clinical
verification. On the same day 2 sweat tests are performed: pilocarpine ionthopho-
resis and a conductometric test. In all diagnosed children complex therapy is intro-
duced. Results: Since 01 January 1999 - 01 August 2003 448.431 newborns were
screened. We diagnosed 71 children with cf. Mean age of cf diagnosis was 6 weeks.
The following genotypes were found: 42 DF 508 homozygotes, 12 DF 508 heter-
ozygotes with a second known mutation, 12 DF 508 with a second unknown muta-
tion, 4 with one known mutation, 1 with unknown mutations. Conclusions: 1. The
joint, two stage protocol for cf screening can be recommended for countries with
low frequency of DF 508 mutation, when DNA analysis must be limited to one
mutation. 2. The joint protocol resulted in low recall rate (0,05%) and high positive
predictive value of 40%. 3. Neonatal screening for cf enabled earlier diagnosis and
the introduction of complex therapy earlier than symptomatic screening.
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Results of a three year pilot programme for CF neonatal screening in
the Piedmont region of Italy
G. Restagno , E. Bignamini , S. Pagliardini , M.P. Forneris , I. Baussano , A.1 2 3 2 2
Gomez , C. Mari , A.M. Sedita , M. Ferraris , E. Cocco , C. De Leo1 1 1 1 1 1
Molecular Genetics Service, A.O. O.I.R.M.-S.Anna, Torino, Italy, Paediatric C. F.1 2
Center, Piemonte and Valle d’Aosta, A.O. O.I.R.M.-S.Anna, Torino, Italy, Neonatal3
Screening Center, A.O. O.I.R.M.-S.Anna, Torino, Italy
The purpose of this work is to assess the performance of a three years pilot pro-
gramme for neonatal screening of CF in the Piedmont and Aosta Valley regions,
north western Italy, in the period from december 2000 to december 2003. The
neonatal screening strategy is a two-step protocol, which combines the assay for
immunoreactive trypsinogen (IRT) with the analysis of 31 mutations in the CFTR
gene using the OLA-PCR-SCS method directly on the Guthrie blood spot. 107167
newborns were screened. 2110 had an IRT level greater than the decisional thresh-
old (1.9%, 1 of 50), and were analysed with OLA-PCR-SCS. 25 newborns with
two mutations in the CFTR gene were directly referred to the CF center at a mean
age of 6 weeks. 169 heterozygous infants were recalled for a sweat test: 10 were
diagnosed as CF, and parents of 132 newborns were identified as carriers and
received a genetic counselling. Between the 35 newborns diagnosed as CF (IRT)
cut off, sweat test positive), 25 presented two mutations and 10 one detectable
mutation (detection rate 85.7%). 34% of patients were F508del homozygotes, 37%
compound heterozygotes and 29% heterozygotes. Incidence of CF was 1y3061,
leading to a carrier frequency of 1y27 (3.7%). The estimated frequency of heter-
ozygotes in children with hypertrypsinaemia was 8.5% (1y11), two times greater
than in the general population (3.7%). Three false negative were ascertained, one
of them bearing the mutations F508del and 3499q2T)C. This strategy results in
early and accurate diagnosis of cystic fibrosis but the identification of an excess of
carriers in CF neonatal screening remains an important matter that can be managed
only with effective counselling strategies in the context of newborn screening.
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Parental depression following the diagnosis of cystic fibrosis:
Implications for screening
C.A. Glasscoe , J. Hill , G. Lancaster , R.L. Smyth1 2 3 4
Royal Liverpool Children’s Hospital NHS Trust-Alder Hey, Liverpool, United1
Kingdom, University of Liverpool, Department of Psychiatry, Liverpool, United2
Kingdom, University of Liverpool, Centre for Medical Statistics & Health Evalu-3
ation, Liverpool, United Kingdom, University of Liverpool, Institute of Child4
Health, Liverpool, United Kingdom
Background: Although 95% of parents achieve a degree of psychosocial adaptation
within the first year of a diagnosis of cystic fibrosis (CF), some parents continue
to report elevated levels of depression. This study aimed to understand what makes
the difference. Method: A cohort study with 45 pairs of parents, matched for age,
sex and position in the family of the affected child compared study and control
groups over a nine-month period at baseline (A) and follow-up (B). Time A was
within three months of the diagnosis and Time B was nine months later. Mothers
and fathers were assessed for depression using the Beck Depression Inventory
(BDI) with a cut-off value of G13 for dysphoria (mild depression). In order to
combine the groups for comparison a stratified analysis was conducted using Man-
tel–Haenszel risk-ratio (RR ) and two strata for each of the matching variables.MH
Emphasis was placed on an estimation of effect with 95% confidence intervals.
Results: There was no main group effect for depression in the whole group of
mothers (RR s1.15(0.58,2.29)) or fathers (RR s1.75(0.58,5.32)). However,MH MH
heterogeneity was found in the matching strata for age. Mothers in the CF group
with a childF9 months of age at the first time-point were more likely to experience
dysphoria nine months later than mothers in the control group (RR sMH
2.86(1.29,6.32)). Although fewer fathers reported, dysphoria than mothers there
was a nonsignificant trend in the same direction with a group difference in the
younger age stratum (RR s7(0.86,56.9)). Conclusion: With screening the major-MH
ity of children with CF will be diagnosed early. Levels of depression in parents of
infants diagnosed by screening need to be monitored longitudinally. Further research
should focus on preventative strategies.
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Diagnosis of CF by newborn screening results in better preservation of
lung function at 15 years of age
K.O. McKay, K.J. Gaskin
The Children’s Hospital at Westmead and University of Sydney, Sydney, Australia
Newborn screening (NBS) for CF remains controversial, as it is a disease for which
there is no cure. Previous studies have shown clinical benefits in childhood. We
now report the influence of diagnosis by NBS on outcomes at 15 years. The
‘screened’ (SG) and ‘non-screened’ (NSG) groups were from the cohort of Aus-
tralian patients studied in childhood (Waters et al., 1999). In this cohort, the NSG
were born in the 3 year immediately before the introduction of NBS in July 1981,
while the SG were born in the first 3yr of the program. For this study, the NSG
and SG were compared at or near the 15th birthday of their subjects. Of the original
57 in the NSG, 2 were lost to follow-up (LTFU) and 7 (2 male) died before their
15th birthday, while of the original 60 in the SG, 4 had died (1 male) and 4 were
LTFU, leaving 48 in the NSG and 52 in the SG. There was no significant difference
in mortality to 15 year (12% NSG, 6.7% SG) but those who died in the NSG were
significantly younger (110"11 mo, mean"S.E.M.) than those in the SG
(158"11mo; PF0.05 Mann–Whitney). The SG was taller (162.7"1.3 cm, z-
score: y0.47"0.19) and heavier (52.5"1.5 kg, z: y0.54"0.15) although not
significantly so compared with the NSG (159.3"1.33 cm, z: y0.83"0.17;
48.6"1.5 kg, z: y0.87"0.16). The Shwachman score was significantly higher in
the SG (82.6"2.2) than the NSG (75.6"2.4, PF0.05 ANOVA). Lung function
parameters were all significantly higher in the SG than the NSG wFEV (SG1
79.4"3.3% predicted, NSG: 67.2"3.4%; PF0.01), FVC (SG 96.9"2.9%, NSG:
84.3"3.4%; PF0.01) and FEF (SG 69.4"5.2%, NSG: 46.1"5.4%;25–75
PF0.005)x. These results suggest that early diagnosis of CF via NBS results in
improved clinical outcomes, including better preservation of lung function, at 15
years.
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Early complications in Czech CF infants
V. Skalicka , A. Holcikova , Z. Vancikova , L. Pelikan , K. Blahova , T.1 2 1 1 1
Kucerova , D. Zemkova , V. Vavrova1 1 1
Paediatric Department, Charles Univ. 2nd Medical Faculty, Univ. Hospital Motol,1
Prague, Czech Republic, Paediatric Infectious Clinic, Masaryk University, Brno,2
Czech Republic
During 1998–2003 46 patients aged 0–3 were observed since they were diagnosed
with CF. 44 (96%) were pancreatic-insufficient, 2 (4%) pancreatic-sufficient. Gen-
otype: deltaF508 homozygous 24 (52%), deltaF508yother 18 (39%), otheryother
4 (9%). Average age at diagnosis: 7 months (range 0–32). Signs that lead to
diagnosis were monitored and symptoms of early complications searched for. Signs
leading to diagnosis: meconium ileus in 13 (28%) patients, respiratory (R) symp-
toms in 8, failure-to-thrive (FT) in 11, RqFT in 3, rectal prolapse in 2, fatty stools
in 1, severe hepatopathy in 1, anemia (Hb below 8 gydl) in 4, isolated disturbance
of electrolyte and acid-base balance in 1. 2 patients were diagnosed prenatally.
Complications at the moment of diagnosis: respiratory insufficiency in 3, hepato-
pathy in 4, severe hypoproteinemia (HP) in 3, hypoelectrolytemia (HE) in 4, com-
bined HPqHE in 2 (leading to hepatorenal failure with signs of myocarditis in one
of them), hypogammaglobulinemia in 14, hyperimmunoglobulinemia with positive
ANCA in 1. After diagnosis of CF, appropriate treatment led to good compensation
and elimination of complications. Conclusion: Even in early infancy unrecognised
CF leads to severe, possibly life-threatening complications. Early diagnosis and
appropriate treatment are essential for avoiding undesirable organ damage. As such,
it is necessary to keep on testing all patients with hypoproteinemia, anemia or
hyponatremia for CF. Supported by MSMT 111300003.
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To be parents in CF: bring up a baby or take care of a patient? An
experience of a psychological support group of CF children parents
S. Di Marco, S. La Fata, L. Iapichino, F. Pardo
Centro Regionale Fibrosi Cistica Ospedale di Bambini &quot;G Di Cristina&quot;-
ARNAS, Palermo, Italy
This paper presents some preliminary results of an action research project about CF
children’ parenthood. For CF affected children’ parents, (diagnosed by neonatal
screening and aged 0–6 years) we prepare a thought-space about role in supporting
the ‘healthy’ growth of the baby. The long-term goal is to favourite an early and
solid relationship between CF child and his parents, as it could improve in the
family emotional experience, coping strategies to CF disease and compliance, and
also relationship with Cf team. We considered that best tool was the focus group,
so it started in October 2002 and carries on until today, proposed to 15 couples of
CF children’ parents, 6 partecipated. The session groups takes place every 15 days,
have a length of 90’ and managed by CF Centre psychologist and dietitian. In first
term of sessions the subjects most frequently discussed were: CF child nutrition in
the first months of growth, psychological and motor development of the child,
availability of constructing adequate family compliance. The most important themes
regard some feelings, as: the ‘painful memory’ of diagnosis announcement, perse-
cutory emotions (as guilt about genetic transmission of CF disease or ambivalent
feelings about the baby), difficulty in distinguishing what is and what is not ‘nor-
mal’ in growth of own baby; difficulty to separate and identify the real baby from
that one idealized of pregnancy and that one ‘darkened’ by CF disease; difficulty
to take a good educational role. We consider these results not regarding only parents
of CF child or CF Centre psychologist (family compliance is matter of the whole
CF team), but involve all CF operators in contact with CF patient and his family.
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Diagnostic algorithm for classic and atypical cystic fibrosis
M. Sinaasappel , K. De Boeck ,1 2
Sophia Children’s Hospital of Erasmus MC, Rotterdam, Netherlands, University Hos-1 2
pital Gasthuisberg, Leuven, Belgium
On behalf of the CF Diagnostic Network
The term cystic fibrosis covers a clinical disease pattern that includes classic as well as
atypical CF. Patients are diagnosed with classic CF if they have one or more phenotypic CF
characteristics and an elevated sweat chloride value. The vast majority of CF patients suffer
from classic CF; usually one established disease causing CFTR-mutation is identified on each
CF chromosome. Atypical CF designates individuals with a CF phenotype in at least one
organ system and a normal or borderline sweat chloride value in whom confirmation of the
diagnosis CF requires CFTR-genotyping and detection of one validated disease causing
CFTR-mutation on each chromosome (at least one of which will usually be a mild mutation)
or direct quantification of CFTR function by nasal potential difference measurement (Boyle,
Curr Opin Pulm Med 9:498-503) andyor by intestinal current measurements. The diagnostic
approach to CF can be initiated by sweat test or by DNA-analysis. In settings where the
reliable Gibson & Cook sweat test is available, the approach starting with sweat test is pre-
ferred. About 98% of CF patients have an elevated sweat chloride where as in many popu-
lations the mutation detection rate will only be 80-85%. A chloride cut-off of 30 mEqyL is
chosen: results between 30 and 60 mEqyL comprise only 4% of tests performed but 23% of
these patients carry two CFTR mutations, as frequently in the range 30-40 as in the range
40-60mEqyL (AJCCM 2002;165:757) (Projectnr QLK3CT9900241)
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Newborn screening of CFTR mutations using liquid chip chemistry
D.J. Marshall , G. Harms , C. Miller , S.C. Johnson , C.B. Sherrill , G.L.3 3 3 3 3
Hoffman , R.H. Laessig , G.J. Kopish , M.W. Baker , P.M. Farrell , J.R. Prudent2 2 2 2 1 3
University of Wisconsin, Madison, Wisconsin, United States, State Hygiene Lab-1 2
oratory of Wisconsin, Madison, Wisconsin, United States, EraGen Biosciences,3
Inc., Madison, Wisconsin, United States
Combining industrial cutting edge science with prominent academia and public
health leaders has led to a new technology which can substantially reduce the time
for Cystic Fibrosis multi-mutation analysis. In collaboration with the State Hygiene
Laboratory of Wisconsin and The Medical School at the University of Wisconsin,
EraGen Biosciences has taken a technology that expands the genetic alphabet from
the research laboratory into the clinic. Objective: To examine the throughput, repro-
ducibility and robustness of a new test called MultiCode CFTR to screen new-
borns for cystic fibrosis mutations using dried blood spots. Study designs:
MultiCode CFTR was compared against a linear array method (CF-Gold ). The
first study focused on mutation identification by analyzing dried blood specimens.
The second study compared side-by-side testing of both methods. The third study
compared the throughput, reproducibility and robustness of both methods. Results:
In the first study of 6750 potential allele assignments (225 specimens times 30
mutations), 99.3% of the assignments were correct. The assay failed to yield assign-
ments for 46 (0.7%) with no incorrect assignments. The second study is ongoing.
The third study shows a 33% reduction in overall assay time with a 50% reduction
in hands-on technician time using the MultiCode method. Conclusion: The study
results indicate that the MultiCode CFTR is superior for mutation analysis on dried
blood spots. Advantages include (1) ease of use; (2) reduction in analytical time
and technician time; (3) automation of allele detection; and (4) flexibility allowing
easy additionycontraction of alleles screened for.
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Cystic fibrosis in the Western Cape province of South Africa:
epidemiology, clinical features and prognosis
A.T.R. Westwood
School of Child and Adolescent Health, University of Cape Town, Cape Town,1
South Africa, Red Cross Children’s Hospital, Cape Town, South Africa2
Between October 1974 and September 2003 181 unscreened cystic fibrosis (CF)
patients were followed through childhood. Demographic data was derived from the
1996 South African census. Clinical and prognostic details were compiled from a
database maintained by the author. CF was commoner in the ‘white’ population
(incidence 1:3003, prevalence 10,8y100 000) than in the ‘coloured ‘ population
(1:10273, 2,5y100 000). Four ‘black African’ patients were seen. Failure to thrive
was the commonest individual presenting feature (28.2%). The anaemiayoedema
presentation was unusually common in the ‘coloured’ patients (8y75). Median age
at diagnosis was 6 months (interquartile range 3–30 months). Ninety five percent
of patients had pancreatic insufficiency (PI). Two thirds of patients had one or more
complications of CF beyond lung disease andyor PI. Median survival was 19.8
years (25th percentile 11.4 years). Thirteen of the 61 deaths occurred in infancy.
Significantly more ‘coloured’ than ‘white’ patients died during the 29 year period
(49.3% vs. 22.8% Chi 14.5, Ps0.00014). CF is common in the ‘white’ and ‘col-2
oured’ populations of this province. It presents typically and in most cases is diag-
nosed early. Death in infancy has been a problem. Survival to adulthood has become
the norm, particularly for ‘white’ patients.
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A CF- specific database as a clinical an epidemiological tool
G. Reychler, V. Godding, P. Mailleux, J. Gigi, T. Leal, P. Lebecque
Cliniques St Luc, Universite Catholique de Louvain, Bruxelles, Belgium´
Thanks to the collaboration between clinicians and I.T specialists, a CF-specific
database system was developed using a Windev licence. We aimed to create a
clinical tool suitable for our daily practice, which would also allow us to automat-
ically extract every year a range of epidemiological data required by the Belgian
Cystic Fibrosis Registry. Individual data are encoded, using different modules (such
as admin, outpatient visits, hospital admissions, complications«). For each patient,
the database automatically generates graphs summarising the evolution of essential
parameters. These include weight (in kg, Pc, Z-score,%IWH), height (Pc, Z-score),
BMI (absolute value, Z-score), FVC and FEV1 (% pred.), bacteriological findings.
In addition, several tables of collective data are generated such as listings of admin-
istrative or basic medical data, warning listings, tables summarising anthropomet-
rical, spirometric or bacteriological characteristics from all the patients, or according
to age or sex. If the database is regularly updated throughout the year, then all the
fields of the Belgian Register Questionnaire, which is closely derived from the CFF
model, will be automatically completed. By default, Cole’s reference values are
used for anthropometry, and Knudson’s for spirometry. Each of the 7 CF Reference
centres in Belgium will be offered the opportunity to use this software, which will
be available in French, Dutch and English. Supported by the Belgian Cystic Fibrosis
Association.
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The frequency and presentation of pancreatitis in cystic fibrosis. A
survey
M. Weren , E. Kerem , M. Proesmans , K. De Boeck1 2 1 1
University Hospital Gasthuisberg, Leuven, Belgium, Hadassah Hospital, Jerusa-1 2
lem, Israel
Pancreatitis is a rare complication of CF. In the present multi-centre survey, we
evaluate the frequency, risk factors, clinical course and outcome of CF patients with
pancreatitis. We recorded a total of 10071 CF patients from 29 different countries.
In this population, there were 125 patients with pancreatitis (1.24%; 95% binomial
confidence intervals wCIx 1.02% to 1.46%). We have received full clinical data on
61 patients with pancreatitis. The majority of patients with pancreatitis have PS:
34y61 patients (56%; CI: 43% to 68%). PI was found in 15 patients (25%; CI 14%
to 35%). Eight patients had PI after an initial period of PS and four patients had a
dubious pancreatic state. The amylase and lipase levels were not significantly dif-
ferent between patients with pancreatitis and PI and patients with pancreatitis and
PS. Relapses of pancreatitis occurred more frequently in PS (21y34) than in PI (5y
15) patients (Ps0.04). Chronic pancreatitis occurred more often in PI (6y15) than
in PS (3y34) patients (Ps0.01). The occurrence of pancreatitis preceded the diag-
nosis of CF in 18y61 cases. Thirty-one out of thirty-four patients with PS carried
at least one mild CFTR mutation; five out of fifteen PI patients carried 2 severe
CFTR mutations. Pancreatitis is a rare complication in CF patients, occurring in
1.24% of a large CF cohort. Pancreatitis is more frequent in CF patients with PS,
but has to be considered in all CF patients with unexplained epigastric abdominal
pain, including those with PI.
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Prediction of 2-year mortality in CF – A comparison of Shwachman
score and percent predicted FEV1
S. Walters , A. Mehta , G. Mehta , P. Tulley1 2 2 1
University of Birmingham, Birmingham, United Kingdom, UK CF Database,1 2
Ninewells Hospital and Medical School, University of Dundee, Dundee, United
Kingdom
Introduction: The Shwachman Score (SS) is perceived to be of low relevance to
adult patients, and does not meet current criteria for a valid clinical scoring sys-
tem.Objective: To determine validity of SS in prediction of 2 year mortality in the
UK, and to compare this with% predicted FEV1 using the UKCF database. Meth-
ods: A retrospective cohort study (transplanted patients excluded). SS from annual
review and average% predicted FEV1 from clinic visits were recorded for 2000.
Mortality was recorded at 1 and 2 year follow-up. Receiver-operator curves (ROC)
were calculated using StatsDirect. Results: 2706 patients were identified of whom
1773 had a SS and 2221 had a% predicted FEV1 recorded. 28 patients died during
2-year follow-up, 7 of which had SS.
Shwachman FEV1
Optimum cut-off 66 47.31
Sensitivity 0.833 (0.359 to 0.996) 0.893 (0.718 to 0.977)
Specificity 0.876 (0.860 to 0.891) 0.803 (0.787 to 0.820)
Positive predictive value 0.0230 0.0581
Area under curve 0.815 (0.198 to 1.00) 0.900 (0.592 to 1.00)
Doubling the weighting given to specificity improved positive predictive value of
FEV1 (0.106 with a cut-off of 33.7 and sensitivity 0.714), but not SS (results same
as above). Conclusion: There appears to be little difference in the validity of
Shwachman and% predicted FEV1 to predict 2 year mortality in patients with CF
however there were few deaths in this cohort and neither has high predictive value.
More SS data is being collected.
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Incidence of cystic fibrosis worldwide
V. Scotet, M.P. Audrezet, C. Ferec´ ´
INSERM EMI 01-15, Laboratoire de genetique moleculaire, CHU Morvan, Brest,´ ´ ´
France
Cystic fibrosis (CF) is defined as the most common inherited disorder that affects
children in Caucasian populations, with an incidence initially estimated to 1y2500
livebirths. The aim of this study was to perform a meta-analysis of the incidence
of CF in the world. CF incidence could be measured by different study design
(epidemiological studies, CF-registries, newborn screening (NS) programs) or esti-
mated by carrier frequency. The different studies dealing with CF incidence were
retrospectively registered by using bibliographic databases but also internet tools in
order to found unpublished data. The incidence of CF is reported by continent. In
Europe, its oscillated between 1y1700 (Irlande, Brittany) and 1y25 000 (Finlande).
In North-America, data of registry and NS showed an incidence of 1y3500. The
same data was observed in Australia where NS is highly practised. Very high inci-
dences were reported in isolated populations, such as 1y377 in an area of North-
Brittany (France), 1y569 in the Amish population (Ohio, USA) or 1y902 in
Saguenay-Lac-Saint-Jean (Quebec). Few data are available in non-Caucasians´
groups, even if several studies have determined the mutation spectrum in those
populations. Incidence is close to 1y9000 in South-America, 1y17 000 in Africa
and around 1y30 000 in Asia. The precise knowledge of CF incidence in different
ethnical groups is crucial for genetic counseling to allow a precise calculation of
residual risk. The implementation of NS programs has constitued a precious help
to estimate this incidence. They generally provide a lower incidence than the epi-
demiologic studies performed at an earlier period where prenatal diagnosis did not
exist.
s116 Journal of Cystic Fibrosis 3 (2004) S112–S118
436*
Lung function in Asians with cystic fibrosis may be worse than in
Caucasian homozygousDF508 controls
J. McCormick, E.J. Sims, A. Mehta
UK CF Database, Tayside Institute of Child Health, Ninewells Hospital, Dundee,
United Kingdom
Background: Using the UK CF Database, we tested the hypothesis that the CF
phenotype in Asian patients is as severe as matched homozygous DF508 Caucasian
controls. Methods: Asian patients were matched with up to 5 controls and analysed
for mean height, weight, BMI Z-scores, FEV yFVC% predicted data and the use1
of inhaled corticosteroids (ICS) and pancreatic enzymes. Controls were Caucasian
homozygous DF508 patients matched for gender, age ("12 months), location (by
CF Centre or clinic) and chronic Pseudomonas aeruginosa status. CF-related dia-
betes patients were excluded. Anthropometric measures and FEV yFVC percent1
predicted were analysed " adjustment for ethnicity. Results: 51 Asian CF patients
(30 male) were matched with 145 controls (93 male). Asian patients had signifi-
cantly lower raw Z scores for weight (males P-0.01, females P-0.05) and BMI
(P-0.01 males, females P-0.01) compared with matched controls which disap-
peared after ethnicity adjustments based on known reference criteria, though the
trend towards lower values persisted. In contrast, lung function remained signifi-
cantly worse in the Asian patients irrespective of corrective factors. Asian maley
female mean difference compared with controls (95% C.I.): FEV % predicted y1
12.5(y23.8 to y1.2)yy21.4(y37.8 to y4.9), FVC% predictedy16.9(y24.9 to
y8.8)yy19.8 (y32.8 toy6.8). There were no differences in ICS use or pancreatic
enzyme dosage between groups. Conclusions: These data suggest that the Asian CF
phenotype is more severe for lung function than the Caucasian homozygous DF508
phenotype, and as severe for anthropometric measures. Socio-cultural factors and
rare CF genotypes may be contributing to the severity of CF in this vulnerable
group.
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Repeated aminoglycoside therapy in cystic fibrosis patients reduces
distortion product otoacoustic emissions in the absence of pure tone
audiometry deficit
M. Mulheran , S. Narayanan , P. Hyman Taylor , K. Tan , A. Smyth , A. Knox ,1 1 2 2 2 2
D. Stableforth3
MRC Toxicology Unit, Leicester, United Kingdom, Nottingham City Hospital, Not-1 2
tingham, United Kingdom, Heartlands Hospital, Birmingham, United Kingdom3
Introduction: Cystic Fibrosis patients require repeated high dosage therapy with
aminoglycoside antibiotics. These drugs have a per course ototoxic risk of 5–10%.
Distortion Product Otoacoustic Emissions (DPOAEs) have been used to detect sub-
tle changes in cochlear outer hair cell (OHC) in the absence of any significant
changes in Pure Tone Audiometry. This study aimed to characterise these changes
in a large group of CF patients (ns138) with normal PTAs, against a group of
audiologically normal controls (ns86) over the age range 12–35. Methods:
DPOAEs were measured in both groups at 2, 4 and 6 kHz using an Otodynamics
ILO 92. Stimulus parameters were: Intensity L1sL dBSPL; f yf s1.22. The f2 2 1 2
level generating a (2f yf ) DPOAE of y10dBSPL provided an isoDP measure1 2
of sensitivity. Aminoglycoside exposure in the CF group was obtained by inspection
of clinical notes:median number of courses 7; median dosage 32 g; plasma levels
within normal limits. Data were analysed by t-test. Results: Both groups were com-
parable by age and sex distribution. There were significant increases (P-0.05–
0.0001) in the y10dBSPL isoDP values at 2 and 4 kHz in the right, and at all
three frequencies in the left ear. Conclusions: These changes provide further evi-
dence of early effects of aminoglycoside on cochlear OHC function preceding
changes in the PTA, providing early warning of ototoxicity. This may present an
objective indicator for the clinician for considering the use of alternative antibiotics.
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Changing patterns of lung function decline in children with cystic
fibrosis
W. Xu, P. Subbarao, M. Corey
The Hospital for Sick Children, Toronto, Canada
This study aimed to describe how the course of lung disease in young CF patients
changed over the past 40 years. Patients in the Toronto CF database were studied
if born between 1960 and 1989 and diagnosed under 10 years of age. Mixed model
regression analysis of FEV % predicted versus age included those with at least 21
pulmonary function tests, starting before age 10. Follow-up was truncated to provide
equivalent periods in each of 6 birth cohorts. The course of FEV was similar in1
the first 3 cohorts, with intercept of 92% predicted at age 5 and decline of approx-
imately 2.5% predicted per year. Rate of decline improved in the last 3 cohorts, to
approximately 1% predicted per year. However the intercept value at age 5 was
markedly lower than in the earlier cohorts, perhaps due to better survival to school
age of severely affected children in later cohorts. These patterns were not altered
when other covariates (sex, age at diagnosis, pancreatic status) were included in
regression models. Models incorporating pulmonary infection status are underway.
Measures of lung function in pre-school children will be necessary for understand-
ing the initial stages of lung dysfunction in CF. Finally, without more sensitive
measures of lung disease, clinical trials will require huge numbers of patients with
the current rate of FEV decline.1
Birth cohort 1960–64 1965–69 1970–74 1975–79 1980–84 1985–89
Follow-up to 1978 1983 1988 1993 1998 2003
Total 207 169 174 140 136 140
Died-5 year, n (%) 17(8.2) 14(8.3) 11(6.3) 2(1.4) 7(5.2) 3(2.1)
Excluded 58 35 49 48 39 29
-2 visits (died or transferred out) or first test after age 10 years (transferred in)
Study n 132 120 114 90 90 108
FEV slope1 y2.1 y2.6 y2.5 y1.8 y1.1 y0.8
Intercept (5 year) 92.4 92.4 92.1 87.4 81.7 82.1
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Genotyping Pseudomonas aeruginosa isolates by pulsed field gel
electrophoresis (PFGE) and randomly amplified polymorphic DNA
(RAPD) techniques
D. Jyothish , M. Desai , N. West , P. Weller , J. Clarke , M. Mehmi , C. Powell ,1 1 1 1 1 2 2
K. Hinton , A. Hilton , P. Lambert2 2 2
Birmingham Children’s Hospital NHS Trust, Birmingham, United Kingdom, Aston1 2
University, Birmingham, United Kingdom
Background: Pseudomonas aeruginosa lung infection causes significant morbidity
and mortality in cystic fibrosis. Identifying the different genotypes is necessary to
understand transmissibility and reach a consensus on segregation policies. PFGE,
the ‘gold standard’ genotyping method is expensive and time consuming while
RAPD, though quicker and economical has been dogged by concerns about repro-
ducibility. Aims: A preliminary study genotyping 50 isolates in 2002 suggested that
under ideal conditions, RAPD gives high discrimination and reproducibility. (1)
Our current aims were 1. Confirm reproducibility by repeating RAPD on these
samples a year later 2. Compare the discriminatory powers of RAPD and PFGE.
Methods: PFGE was done using Xba1 macrorestriction analysis and RAPD using
primers 1254 and Epo15. Digital profiles were analysed using Gel Compar program
and Unweighted Pair Groups using Mathematical Averages (UPGMA) clustering.
Results: RAPD was highly reproducible as shown by similar Simpson’s Index of
Diversity. PFGE showed similar strain profiles but had higher discriminatory power
in distinguishing related strains. Discussion: This agrees with previous studies (2)
showing that RAPD is a robust method for rapid, typing of large numbers of iso-
lates. RAPD could thus be used as an initial screening method, followed by PFGE
on selected samples to increase resolution. In conjunction with epidemiological data,
these methods will help us resolve issues of transmission, cross infection and seg-
regation in cystic fibrosis. References: 1. Hinton.K. Subtyping Pseudomonas aeru-
ginosa isolates using RAPD-Project for B.Sc. Human Biology, University of Aston
2002; 2. Kersulyte et al. J Clinical Microbiology 1995, 33(8), 2216–19.
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Newly acquired Pseudomonas aeruginosa (P.a.) in Belgian CF-
patients: does the patients’ P.a. genotype correlate with environmental
genotypes?
S. Van daele , F. De Baets , P. Schelstraete , L. Van Simaey , G. Claeys , M.1 1 1 2 2
Vaneechoutte2
Pediatric Pulmonology,University Hospital, Gent, Belgium, Microbiolo-1 2
gy,University Hospital, Gent, Belgium
Introduction: Since chronic infection with P.a. in CF-patients is correlated with rapid
decline in lung function and decreased life expectancy, eradication of the organism
has to be attempted, after the first appearance. The means by which P.a. is acquired
are not yet understood. Patient-to-patient-transmission is possible, as well as con-
tamination from the environment. Aim: To examine whether the P.a. genotype, in
patients who grew for the first time P.a. in their sputum, correlates with P.a. gen-
otypes from their close environment. Methods: The 7 Belgian CF-centres send spu-
tum of ‘newly’ infected P.a. patients between Jan. 2003 and Dec. 2003. The
CF-nurse took cultures at the home of the patient (sinks, showers, swimming pools,
nebulizers etc«). The environmental and patients’ strains were genotyped by
RAPD (Random Amplified Polymorphic DNA-fingerprinting)-technique and then
by fAFLP (fluorescent Amplified Fragment Length Polymorphism), which is more
reproducible and easier to compare by computer because of its digitised results.
Results: 29 patients were enrolled. For 18 patients genotyping and environmental
culture could be performed (drop out: no P.a. growth in patient sample (6), patient
sample lostybad quality (5)). For 2y18 patients the genotype could be linked to an
environmental genotype (showertab and nebuliser). For 10y18 patients the envi-
ronmental cultures (at least 6 locations per patient) did not grow P.a. 6y18 Patients
had P.a. positive environmental samples, however with a distinct genotype. Con-
clusion: In 2y18 newly P.a. infected CF-patients we found the same genotype in
the environment. The question remains whether they were infected from this envi-
ronmental source, or whether the patient contaminated hisyher environment.
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Sweat tests in Sweden 2002 – a cross sectional study
B.-M. Jakobsson, S. Salomonsson, L. Hjelte
Stockholm CF Centre, Karolinska University Hospital, Karolinska Institute, Stock-
holm, Sweden.
The sweat test is still the important test for the diagnosis of cystic fibrosis. Two
guidelines for performing the sweat test have recently been published (NCCLS and
UK). Aim of study: To investigate how well these guidelines are observed in Swe-
den. Method: All departments of paediatrics (ns37) were contacted by phone. A
questionnaire was sent to the 27 departments that performed sweat tests as well as
subsequent complementary questions. The questionnaire contained questions regard-
ing methods used, performance, number of sweat testsyyear. The complementary
questions concerned analyses of sweat. Results: All the departments filled in and
returned the questionnaire, 24y27 the complementary questions. Sweat tests were
performed in the paediatric department or in the department of clinical chemistry
by either a nurse (ns25), a lab technician (ns55), an assistant nurse (ns4) or
technical assistant (ns1). The numbers of persons performing sweat tests varied
from one to elevenydepartment. According to the questionnaire 1279 (1–380y
department) sweat tests were performed, only 7 departments performed )50.
Duplicates were performed routinely in 5 departments, otherwise only on specific
indication. Chloride was the most regularly analysed electrolyte with or without
sodium andyor conductivity. Devices used were: Macroduct (ns15), Quantitative
Pilocarpine Iontophoresis according to Gibson Cooke (ns7), Orion skin (ns5),
ABC indicator (ns1), Nanoduct (ns1). Conclusion: Several departments did not
observe the guidelines, which recommend a minimum of 50 sweat tests yyear and
a minimum 10 sweat testsyindividualyyear, as well as that neither sodium nor con-
ductivity should be used alone. What about the future? Should sweat test be more
centralized? External quality control?
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Analysis of CFTR exon 3 in CFTR related diseases
A. Nikolic, A. Divac, J. Kusic, D. Radojkovic
Institute of Molecular Genetics and Genetic Engineering, Belgrade, Yugoslavia
CFTR gene exon 3 is one of the CFTR exons with relatively high frequency of
mutations. This study was undertaken to test the possible involvement of exon 3
mutations and polymorphisms in aetiology of male infertility, chronic pancreatitis
(CP), disseminated bronchiectasis (DB) and chronic obstructive pulmonary disease
(COPD) in Serbian patients. We analyzed 21 infertile men, 39 patients with CP, 19
patients with DB, 31 patients with COPD and 103 healthy individuals. Exon 3 of
the CFTR gene was screened for presence of mutations and polymorphisms by
DGGE method, followed by direct DNA sequencing. In the group of infertile men,
as well as in the group of patients with CP no mutations or polymorphisms were
detected. Among patients with DB two patients were heterozygous for R75Q var-
iant. This variant was also detected in four patients with COPD, three of them being
heterozygous carriers, while one was homozygous for R75Q. In COPD patients,
one was a heterozygous carrier of another variant, R74W. In a group of healthy
individuals, R75Q was present with allelic frequency of 0.97%. Our findings sug-
gest that R75Q variant could be involved in COPD, since its frequency in this
group was significantly higher then in control population (Ps0.002, 95%CI:2.15–
55.63). Additional analysis of CFTR gene in R75Q carriers has shown that another
CFTR variant was also present in each patient. These variants were either mild
mutations or polymorphisms: M470V, V920L and L997F. Therefore, it is also pos-
sible that these mutations might have a synergistic effect on COPD phenotype.
Further research could reveal functional consequences of R75Q mutation, alone or
in combination with other CFTR variants.
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Pseudomonas aeruginosa DNA-fingerprinting register in Belgian CF-
patients:a one year survey
S. Van daele , M. Vaneechoutte , G. Claeys , P. Schelstraete , F. Haerynck , F. De1 2 2 1 1
Baets1
Pedaitric Pulmonology,University Hospital, Gent, Belgium, Microbiolo-1 2
gy,University Hospital, Gent, Belgium
Introduction: In CF-patients chronic Pseudomonas aeruginosa (P.a) infection leads
to a faster decline in lung function and a decreased life expectancy.The means by
which the organism is acquired are not yet understood. A reasonable fear for patient-
to-patient transmission exists, leading to reduced social contact between CF-
patients. Aim: To register P.a. genotypes in all colonized patients of the 7 Belgian
CF-centres, and compare to one another and to epidemic strains from abroad. Meth-
ods: The patients had to fill in a questionnaire, scoring the amount of social contacts.
Sputum samples from P.a. colonized patients, were cultured on Tryptic Soy and
McConkey Agar. Differentely looking colonies were picked, subcultured and again
identified. Random Amplified Polymorphic DNA-fingerprinting (RAPD) technique
was used to differentiate genotypes. One representative of each RAPD-type was
genotyped by fALFP (fluorescent amplified length fragment polymorphism) and
compared to each other and to 4 epidemic types (from UK and the Netherlands).
Results: 455 P.a. strains of 190 patients were genotyped by RAPD.FAFLP-analysis
resulted in 177 different genotypes. There were 20 clusters (sgroups of patients
with the same genotype). 5y13 Two-person-clusters contained a sibling pair. There
were 2 groups of 4 patients, one of 5,6,7,9 and 10 patients.13y20 Clusters contained
patients of multiple centres. In 9y13 multicentre clusters, contact between patients
could be established (stay in the same rehabilitation centre, CF-camp, social con-
tact). The Belgian strains were not related to the epidemic strains, except for the
Manchester-type, carried by 7 patients of a clustergroup. Conclusions: The genetic
diversity among P.a. strains from Belgian CF-centres is large. In most of the mul-
ticentre clusters, social contact between patients could be observed.
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Sweat testing practices in German cystic fibrosis centers
L. Naehrlich
University hospital for children and adolescents, Erlangen, Germany
An accurately performed and analyzed sweat test remains the diagnostic cornerstone
of Cystic fibrosis (CF). To determine whether the current practice of sweat testing
in German CF-ambulances is consistent with the guidelines of the National Com-
mitee for Clinical Laboratory Standards (NCCLS) a survey was performed.Method:
A questionaire was mailed to all 123 German CF-ambulances that join the German
CF register. The results were compared with NCCLS-guidelines. Results: 88 out of
113 responding ambulances perform sweat tests. All centers carried out 30–1100
(median 200) sweat tests by pilocarpine iontophoresis per year. Sweat was collected
into Macroduct collectors in 68 (77%), onto filter or gaze in 9 (10%) and into
different collectors in 11 ambulances (13%). Inconsistent with the recommended
maximal 30 min sample time sweat was collected for maximal 6–90 (median 45)
min. Minimum acceptable sweat volumes were quoted between 100 and 7500
(median 1000) mgym ymin differing from the recommended 1000 mgym ymin.2 2
Osmolality was measured in 3%, sodium in 24% and conductivity in 53% of the
centers. Chloride, the only accepted diagnostic measurement by the NCCLS, was
investigated by only 58% of all ambulances. The recommended chloride CF-ref-
erence value of )60 mmolyl was used in 78% of centers that perform chloride
testing. Conclusion: Major areas of inconsistencies between sweat testing practice
in German CF-ambulances and NCCLS-guidelines are sweat collection, analyzing
method and reference values. Chloride, the only accepted diagnostic measurement
by the NCCLS, was investigated only by 58% of all ambulances. Guidelines should
be discussed to minimize the risk of unnecesary repetition tests, false-negative and
-positive diagnosis.
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Demographic data of the cystic fibrosis population in Estonia
T. Kahre , P. Kool , M. Panov , M. Vasar , M. Parlist , U. Putnik , K. Leito1 2 2 2 3 3 3¨
Molecular Diagnostic Centre, Tartu University Clinics, Tartu, Estonia, Children‘s1 2
Hospital of Tartu University Clinics, Tartu, Estonia, Tallinn Children‘s Hospital,3
Tallinn, Estonia
Our aim was to analyze the demographic data of the CF population in Estonia in
terms of age, gender, age at diagnosis, ethnicity, survival and mortality rates during
last decades and to investigate the clinical manifestation of CF patients in relation
to their genotype. In our survey, we aimed to include all CF patients in Estonia
born between 1974-2003. Altogether 76 CF patients were identified through retro-
and prospective study, but clinical and molecular data was available for 41 patients
from 36 families. The incidence of CF in Estonia by archival data is 1:7750 and
according to the Hardy–Weinberg calculations 1:7450 live-births. In 2003, the mean
age of the living patients known by us was 12 years 3 months (95% CI 113–182
months) and 29% of our patients were over 18 years old. The mean age of estab-
lishing CF diagnosis (without meconium ileus patients) was 2 years 3 months (95%
CI 18.0–36.1 months). Our group did not exhibit significant gender differences
when comparing segregation of CFTR mutations, mean age, mean age at diagnosis,
Kaplan–Meyer survival probabilities or other clinical features. When analyzing the
mortality rates (MR) during the period of 1983–2002 significant decline has been
detected. For the period 1983–1987, the MR was calculated as high as 12.2% per
person-year, but during the period 1998–2002 MR had decreased to 0.7%. Although
there is a tendency of ageing of our CF population, more effort should be made to
diagnose CF in earlier age and to give better treatment and follow-up in specialized
centrums established in Estonia in 1994–1995.
Other
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Why we need a European prospective study on the outcome of
pregnancies in women with Cystic Fibrosis
W.E. Mackenzie
Birmingham Heartlands Hospital, Birmingham, United Kingdom
Modern obstetric practice uses ratified guidelines for the management of common
medical conditions occurring in pregnancy. One example would be the management
of pregnancy in women with diabetes mellitus. Common guidelines exist for this
condition that apply throughout Western obstetric practice and are useful not only
to professionals but also patients themselves. As the number of pregnancies in
women with cystic fibrosis increase the time has come for the development of
similar guidelines. Such guidelines should be developed from robust data for which
only a prospective European study of pregnancy in women with cystic fibrosis could
provide.
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Rheumatological disorders affecting the adult cystic fibrosis (CF)
population attending the West Midlands Adult Cystic Fibrosis Centre,
Birmingham
T. Potter , S. Williams , M. Pugh , D. Stableforth , D. Honeybourne1 2 3 4 4
Dudley Group of Hospitals NHS trust, Dudley, United Kingdom, University Hos-1 2
pitals, Birmingham, NHS trust, Birmingham, United Kingdom, St Mary’s Hospital,3
Isle of Wight, United Kingdom, Birmingham Heartlands and Solihull NHS trust,4
Birmingham, United Kingdom
Introduction: Previous studies identified CF arthritis in up to 8.5% w1x of subjects
but there are no data on long term outcome. Improved survival has led to the greater
recognition of CF complications and we undertook a study to characterise rheu-
matological disorders in a population of CF patients attending our unit. Methods:
Patients were invited to complete a disease specific questionnaire and undergo
examination to identify rheumatological disease. Serology and joint radiographs
were performed as appropriate. Genotype and recent lung function were obtained
from patient records. Radiographs were reported by a blinded Radiologist. Results:
Data was collected on 176 patients, and a rheumatological problem found in 36. 5
patients had a history of CF arthritis lasting 2 days to 2 weeks. Attacks started in
childhood in 3, adulthood in 2. All attacks were decreasing in frequency. All were
ANA and RF negative and there was no radiological evidence of joint damage.
NSAIDS helped 2 patients and oral prednisolone helped 1. 11 patients described
drug induced arthralgia or arthritis: 7 attributed to ciprofloxacin, and 4 ceftazidime.
There was no apparent association between CF genotype and lung function and
either rheumatological problem. In addition 1 patient had HPOA and one patient
had urticarial vasculitis. Other problems were characterised including transplant
related gout and soft tissue disorders. Conclusion: CF arthritis is uncommon in our
unit, and its severity appears to diminish with increasing age. However rheumato-
logical antibiotic side effects do affect the management of over 6% of our popu-
lation. Other disorders which affect the rest of the population do occur and should
be remembered when reviewing CF patients. 1. Bourke S. et al. Q J Med
1987;64:651–659.
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Clinical status and ocular surface changes in patients with cystic
fibrosis
M. Mrugacz , A. Minarowska , M. Kaczmarski , L. Minarowski1 2 2 2
Department of Pediatric Ophtalmology, Medical University of Bialystok, Bialystok,1
Poland, IIIrd Department of Children’s Diseases, Medical Univeristy of Bialystok,2
Bialystok, Poland
Background: Cystic fibrosis is the disease effects all secretory epithelia including
the eye. Ocular changes refer mainly to the dry eye symptoms and pertain to the
tear hyposecretion. The aim this study was tear fluid examination in young cystic
fibrosis patients. Material and methods: We examined 18 cystic fibrosis patients
and 18 controls aged 4–19. The patients were evaluated systemically and examined
for surface changes and Schirmer test. Results: Abnormal Schirmer test was
observed in 81% cystic fibrosis patients. The mean value of Schirmer test was
10.68"5.54 mm in the cystic fibrosis group and 25.0"3.08 mm in the controls.
They were significant correlations. Cystic fibrosis patients showed no statistically
significant increase in the incidence of clinical blepharitis. Conclusion: Schirmer
test may be used in diagnosis dry eye in cystic fibrosis patients. The cystic fibrosis
patients with good systemic prognosis have a low rate of ocular surface changes.
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Does CF patients’ reported adherence to therapy comply with
prescriptions collected?
J. Redfern, A.M. Jones, A.K. Webb
Manchester CF Centre, Manchester, United Kingdom
Introduction: As part of the annual assessment the specialist CF pharmacist asked
adult CF patients to estimate their own level of drug adherence across up to three
drug therapies. A comparison was then made with the level of prescription collec-
tions in primary care. Method: Patients were asked to estimate a score from 0 to
10 on adherence to therapy for Dornase alpha, nebulised colistin and inhaled Ser-
etide, where 10 was complete adherence. A parallel evaluation was carried out for
the same patient’s prescriptions collected from their general practioner. Results: The
differences in the individual self rating results were statistically compared with the
GP scores. The results of the analysis are shown in the table below.
Therapy Dornase alpha Colistin Seretide
Number of patients 23 43 23
Mean Adherence—self 7.78 8.49 7.74
Mean Adherence—GP 6.00 4.29 3.76
Mean Difference 1.78 4.2 3.98
Standard Deviation Adherence—self 2.55 1.72 2.16
Standard Deviation Adherence—GP 3.89 3.88 3.60
P 0.05 0.01 0.01
Analysis: The results indicate a significant difference between self estimate of
adherence to therapy and actual level of prescription take up. There is a wide range
of actual GP prescription take up and some patients do not use some therapies at
all but report that they do when asked. Adherence to therapy for Dornase alpha is
higher than for Colistin or Seretide. Conclusion: Patients’ self estimate of adherence
to therapy differ significantly from the level of actual prescription take up. Whilst
collecting prescriptions is no guarantee of adherence, medical staff should consider
low adherence as a potential reason for a lack of apparent therapy success before
alternative therapies are contemplated.
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Strategic planning: key findings from a Yorkshire wide patient survey
A. Armitage, S. Conway, D. Peckham
Yorkshire Region CF Strategic Planning Group, Leeds, United Kingdom
Introduction: This collaborative venture aimed to develop partnership working
between commissioners, providers and service usersycarers in order to ensure that
good quality, effective services can be maintained for the future. Method: A survey
was distributed via the CF clinics to the homes of all known adults (368) and
parents of children (295) with CF throughout the Yorkshire area. Carer focus groups
and an inter-professional workshop, to which carers were invited, were held. Results:
A single mail out questionnaire gave response rates of adult 30% and paediatric
80%. Parents and children valued access to experts; commitment and continuity;
efficiency. They experienced difficulties obtaining prescriptions from primary care;
lack of CF knowledge in primary care and other hospitals; lack of choiceyinfor-
mation about CF and support. Adults valued experienced ward staff on a specialist
unit; 24 h telephone access to experts; being treated as individuals. They had dif-
ficulties obtaining prescriptions from primary care; delays in commencing IV anti-
biotic therapy; access and equality. A range of improvements that service users
would like to see was documented. Information from the focus groups supplemented
the user survey. Two of the main issues raised were difficult access particularly for
patients in remote rural areas and the value of shared care. Conclusion: The service-
user perspective favoured CF services being based on a clinical network model for
adults and children. This collaborative venture has been positive in acknowledging
that partnership working is essential when assessing and developing CF services.
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What are the Information Requirements of Cystic Fibrosis Patients?
Can the Internet help?
J.M. Evans
University of New England, Armidale, Australia
Traditionally, information to provide an understanding of Cystic Fibrosis (CF) has
been provided by clinicians to either adult patients or the parents of children during
the initial diagnosis of the disease. Information is also provided by Cystic Fibrosis
Associations or Trusts. Consumers are becoming active participants in their own
health care, assisted by the ability to access an increasing amount of relevant health
information on the Internet. Pew reported in July 2003 that 93 million Americans
and 80 percent of Internet users had searched for at least one of 16 major health
topics online. This is a 54% increase since 2000, and makes the act of searching
for health information online the third most popular after email and internet shop-
ping. This paper will provide a summary of the findings of a research project that
has been reviewing the access to and sources of information for CF. A quantitative
methodology has been used to analyse the subject titles of CF bulletin boards in
the USA and in Australia, and to identify themes regarding information needs and
sources. Interviews of patients and carers were carried out to validate the primary
phase. Both methodological approaches of this research explore the information
needs in areas where CF is suspected but not yet diagnosed, in its early stages, and
where sufferers have limited access to specialist care. The overall objective is to
develop a model of information requirements for both adults and carers of children
with CF.
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An investigation of CF prescribing issues in primary care within a UK
specialist services commissioning region
A. Bevan, G. Connett
Southampton University Hospitals NHS Trust, Southampton, United Kingdom
Historically, specialist prescribing was transferred to GPs as a method of cost shift-
ing to enable hospital services to work within finite budgets. With the increased
complexity of treatment for cystic fibrosis (CF), GPs might not be best placed to
undertake this responsibility. In this study, a paediatric pharmacist used a semi-
structured method to interview 20 families and 10 GPs. The aim was to review
current prescribing practice and consider whether this met families’ needs. Families
were accepting of the current system but lack of understanding about CF by GPs,
pharmacists and reception staff was problematic. Some felt it was a ‘‘constant
battle’’ to obtain drugs. Repeat prescriptions were often not updated following
changes in treatment by the specialist team. The process for obtaining drugs was
time consuming. Most received prescriptions monthly. Many admitted to stock pil-
ing because of delays between requesting and receiving drugs. All GPs admitted to
poor disease knowledge and were unfamiliar with many of the drugs used or unsure
of their indication. Some GPs had never engaged with the family abrogating respon-
sibility for all care to the specialist team, except prescribing. Most GPs update their
patient’s repeat prescriptions themselves. GPs relied on clear information about drug
changes but this was inconsistent because of differences in correspondence from
secondary care. Many prescribed unlicensed drugs and felt uncomfortable taking
this responsibility. GPs sometimes had to contact the hospital for clarification about
requests to prescribe acutely. Should specialists be asking GPs to take responsibility
for prescribing drugs about which they have poor knowledge, to treat a disease they
don’t understand and, in some cases, for patients they hardly ever meet?
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A life table estimate of CF survival after age 40 suggests that these
patients will have a 54% chance of surviving to age 60
W.J. Warwick , C.E. Milla , J.A. Dodge1 1 2
University of Minnesota CF Center, Minneapolis, United States, University of1 2
Wales, Swansea, United Kingdom
Last year 11 countries reported 1817 patients age 40 and older to the CF Aging
Project. We used these 5-year groups of CF patients to estimate the survival poten-
tial of CF patients after their 40th birthday. The entry number for each group was
the sum of the number reported for that and all older age groups.We assumed: (1)
Survival for patients after age 40 to be the same for the 11 countries and to be
gender and Center independent. (2) The drop in numbers from group to group was
the same in the 11 countries, i.e., the dropped were either dead or alive censored
(alive and either too young for the next group or lost to follow-up but known to
be alive). (3) The deadyalive censored ration observed for in Minnesota patients
of the same age, 1 dead to 3 censored for each 5 year period, is a fitting estimate
for this study. (4) These assumptions can be used to make a survival curve. That
survival curve suggests that these CF patients age 40 had a 82% survival to age
45, a 73% survival to age 50, a 60% survival to age 55, a 54% survival to age 60
and a 44% survival to age 65. This is consistent with a per year 3% per year
mortality (or 97% survival) is not remarkably different than the 2% annual mortality
rate reported by the US Patient Registry and used to calculate the US 50% survival
age of 33 years. If the US year-by-year mortality rate of 2% per year applies to
these older patients their predicted survival to age 60 would be 67%. The 13%
difference could be due to the contribution of unidentified diseases of aging asso-
ciated with cystic fibrosis. As these estimations are reasonable we expect a remark-
able increase in old CF patients over the next years. We recommend that the ECFS
create a CF Aging study group and provide stronger support for the international
CF Aging Project.
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A Study of Cystic Fibrosis (CF) Associated Diseases of Aging
J.A. Dodge , C.E. Milla , W.J. Warwick2 1 1
University of Minnesota CF Center, Minneapolis, United States, University of1 2
Wales, Swansea, United Kingdom
Aging with CF presentations have been made at 3 International CF meetings empha-
sizing the need for an international study of the risks for CF associated diseases of
aging before clinics are filled with geriatric CF patients who have new or different
responses to diseases of aging. All argued the need for a prospective study of CF
patients’ age 40q to include the course of problems that started before and those
starting after age 40. The study to include annual review of health, nutrition, life
style, physiotherapy, alternative treatments, illnesses, physical health, pulmonary
function, lung and other infections, hospitalizations, surgery, height and weight,
medicines, plus quality of life, new diagnoses and all new symptoms even if no
diagnosis has been made. For privacy individual data will be only birth date, sex,
the first two letters of the first name and the first letter of the city of birth. Data
will be encrypted and kept in a secure computer site with access limited to the CF
Aging Project’s International Committee of CF physicians, database experts and
epidemiologists. Supervision will be by a guiding group consisting of a WHO
observer, at least 1 CF patients, epidemiologists, physicians providing care to CF
adults, and representatives of the ECFS and the NACF groups. Progress will be
reported at the ECFS and the NACF conferences and published in journals related
to CF associated diseases or to diseases of aging. Physicians out side of the CF
Aging Project study groups will be permitted to ask questions of the database with
safeguards for privacy. The CF Aging Project will seek support for the study and
for future projects from governmental and foundation sources as well as pharma-
ceutical organizations. CFW will keep an eye on privacy and assist recruitment.
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Urolithiasis in cystic fibrosis
M. Laurans , M. Guillot , M. Elafi , J. Brouard , Ph. Bottet , D. Kauffmann ,1 1 2 1 3 1
J.F. Duhamel 1
Department of Pediatrics, CAEN, France, Department of Pneumology, CAEN,1 2
France, Department of Urology, CAEN, France3
Introduction: Abnormal CFTR in CF apical epithelium membrane is responsible for
a defect in ion transport. The kidney is an organ most exquisitely adapted for ion
transport. Patients with CF have an increased risk of urolithiasis and nephrocalci-
nosis. We present 2 cases of urolithiasis in our 100 CF patients in Caen. Case 1: a
20 years old patient presented with a severe pyelonephritis with hydronephrosis.
She had left nephrolithiasis with urinary obstruction. Fresh urine samples were
negative for crystals or erythrocytis. Hyperoxaluria was detected in every urine
samples. Case 2: Hyperoxaluria was detected in a 23 years old female. She had
urolithiasis without complication. Discussion and conclusion : Patients with CF
might be predisposed to the development of oxaluria by then high intestinal con-
centration of glycine conjugated bile acids in combination with fat malabsorption.
The etiology of urolithiasis in CF and its relation to the dysfunction of CFTR or
others parameters need elucidation.
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A national inquiry into care in the Cystic Fibrosis Reference Centres in Belgium
K. De Rijcke, C. Sterckx, A. Stroobants, J. Veys
Belgian CF Association, Brussels, Belgium
Introduction: Since 1999, hospital units in Belgium can be officially recognised and financed as
CF Reference Centres (CFRC) by the National Health Insurance Institute (NHI). A convention
defines the conditions. In 2003, the Belgian CF association set up a national inquiry in order to:
● analyse global quality, tendencies, needs«of the CFRC care: perception of patients, families
and team members
● further improve CFRC care
● provide better information to patients
● obtain more accurate support for CFRC
Methods: 3 different questionnaires were sent by post. Questionnaires could be sent back anon-
ymously and for free.
1.1 for patientsyfamilies: 53 questions
1.2 for CF team members: 18 questions
1.3 for CFRC: 38 questions
Results:
1. Questionnaire patients: 325y780 replies (42%)
● representative of Belgian CF population
● 95% go to CFRC
● overall very satisfied about CFRC care (general score 85%)
● strong points: high level of care, specialised, experienced team, regular follow-up and rapid
reaction, warm, personal approach team
● remarks: risk of cross infection, availability CF team, more time for education, adult care
2. Questionnaire team members: 60y85 (70%)
● lack of support by hospital administration and National Health Insurance Institute
● financing not sufficient
● high priority for patient care
● not enough time for research, training, education, team work
● overall: work with patients and CF team very positive, practical conditions more difficult
3. Questionnaire centres: 8y9 - average 100 patients
The CF patientsyfamilies were informed about the results by post, the professionals during a Day
of the CFRC. Conclusion and discussion: The results were discussed with the CFRC and a plan
for further collaboration was set up. The results are further used to lobby with the NHI to improve
the convention and the financing.
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Can Integrated Patient Therapy Management (IPTM) improve the quality of life of
CF patients?
D. Honeybourne , N. Gilday , R. Davies , S. Bryan , P. Spurgeon , E. Frew , B. Kluettgens1 1 1 2 2 2
, D. Doogan3 3
Adult CF Centre, Heartlands Hospital, Birmingham, United Kingdom, Health Services Man-1 2
agement Centre, Birmingham University, Birmingham, United Kingdom, Lloyds Pharmacy, Cov-3
entry, United Kingdom
Introduction: IPTM is a new concept, which links primary and secondary care through medicines
management (MM) consultations by community pharmacists. The study was designed to test the
hypothesis that CF patients’ quality of life and satisfaction with pharmaceutical services can be
improved by providing IPTM. IPTM is characterised by dispensing and home delivery of out-
patient prescriptions and GP prescriptions and MM consultations at home by community phar-
macists. Methods: Seventy patients have been recruited. The study is a Before-After design where
each patient is their own control and last 6 months. During the first 2 months, the patient’s QoL
and satisfaction with pharmacy services are measured by questionnaires. Patients rate different
aspects of satisfaction from 1scompletely disagree to 7scompletely agree. The first MM visit
initiates the second study phase, during which the patient receives several MM consultations,
prescription home delivery and clinical waste collection. At the end of the study period, QoL and
satisfaction with the new pharmacy services are measured and compared to the first results.
Results: Patients’ satisfaction with current pharmacy services is shown in the table. Waiting times
in hospital pharmacy and having to carry outpatient prescriptions home was of particular concern
to patients.
Table 1: Satisfaction with current pharmacy services (ns23)
Statement Score: Mean wMedianx
Wait a long time at hospital pharmacy 6.17 w7x
Wait a long time at community pharmacy 3.39 w4x
GP always gives me prescription I want 5.13 w5x
Understand why I need set of drugs 6.65 w7x
Worry run out of drugs I need 4.48 w5x
Constantly worry about infection 4.7 w4x
Difficulty carrying drugs home after hospital visit 5.26 w6x
Worry about pharmacy not having drugs I need 4.26 w5x
Overall satisfied with way I get drugs 4.35 w5x
Conclusions: Patients’ current satisfaction with regard to pharmacy services indicates that
hospital pharmacy waiting times are of particular concern. Future results will show if IPTM has
improved patients’ QoL and satisfaction with pharmacy services.
